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Abstract
The pathological hallmark of Amyotrophic lateral sclerosis (ALS) is the presence of
ubiquitylated protein inclusions in affected motor neurons, which is indicative of disruption in
the mechanisms that maintain proteome homeostasis (proteostasis) in these cells. Moreover,
many of the genes in which mutations are associated with ALS encode proteins that have
important roles in the maintenance of proteostasis. It is thus hypothesised that dysfunction in
the proteostasis network underlies motor neuron degeneration in ALS. Whilst proteostasis
dysfunction in ALS has been a major focus of research in the past two decades, there is an
urgent need to identify the precise molecular mechanisms that lead to this dysfunction.
Addressing this gap in knowledge is a necessary step towards understanding what causes
neurodegeneration in ALS, and to the identification of novel therapeutic targets to prevent this.
In work presented in Chapter III, yeast were used as a model biological system for highthroughput screening to identify alterations in the proteostasis network caused by expression
of pathological isoforms of TDP-43, FUS and SOD1. Whilst the expression of SOD1A4V in
yeast was not toxic, it was associated with up-regulation of proteins involved in mRNA
metabolism (DCP2 and ASC1), the ubiquitin-proteasome system (UPS) and the endoplasmic
reticulum-associated degradation pathway (ERAD) (UBA1, PRE2 and UFD1). The expression
of FUSWT was moderately toxic to yeast, while TDP-43WT expression markedly reduced yeast
viability. Up-regulation of UFD1, a key protein in maintaining ER proteostasis, correlated with
suppression of SOD1A4V toxicity and increased cellular capacity to manage pathological FUS.
Moreover, changes in abundance of HAC1 (involved in the unfolded protein response), DSK2
(ubiquitin-dependent protein degradation in the ERAD pathway and the UPS) and PBP1
(involved in diverse RNA processing pathways that control gene expression) were key
differences between expression of TDP-43WT versus FUSWT, with these proteins being down-
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regulated in TDP-43WT-expressing yeast and up-regulated in FUSWT-expressing yeast. The
increased abundance of these proteins in FUSWT-expressing yeast may have augmented the
cellular capacity to restore ER proteostasis and UPS activity. Moreover, the decreased
abundance of these proteins in TDP-43WT-expressing yeast, which correlated with higher
toxicity, suggests that disruptions in ubiquitin-dependent protein degradation and ER
proteostasis may be associated with TDP-43 associated pathology. Hence, disruptions in gene
expression regulation, ER proteostasis and UPS activity could underlie different genetic forms
of ALS.
Through work presented in Chapter IV, a key hit from the SOD1A4V yeast screen (the E1
ubiquitin-activating enzyme, UBA1) was validated, demonstrating that increased UBA1
expression suppresses mutant SOD1 toxicity in neuronal cells (NSC-34). The expression of
SOD1A4V in NSC-34 cells caused disruption to UPS activity, and this correlated with cellular
toxicity. SOD1A4V aggregation into large inclusions was a prominent feature in these cells.
Remarkably, increased expression of catalytically-active UBA1, but not a catalytically-inactive
mutant, improved cell viability. Interestingly, the protective mechanism by which increased
UBA1 expression prevented toxicity in these cells did not involve suppression of SOD1A4V
aggregation. It has been previously reported that aggregates formed by SOD1 promote cellular
toxicity by sequestering ubiquitin, causing ubiquitin dyshomeostasis. Hence, increasing the
levels of UBA1 in NSC-34 cells expressing SOD1A4V may have improved cell viability through
amelioration of SOD1A4V-mediated deficiency in the cellular pool of activated ubiquitin.
The work presented in Chapter V involved the use of conformationally-destabilised mutants of
firefly luciferase (Fluc) to develop a high content screening (HCS) assay to examine protein
folding/re-folding capacity in NSC-34 cells expressing SOD1A4V and CCNFS621G. It was
demonstrated that these Fluc isoforms can be used in high-throughput format to report on

ii

reductions in the activity of the chaperone network that result from the expression of SOD1A4V,
providing multiplexed information at single-cell resolution. In addition to SOD1A4V and
CCNFS621G, NSC-34 cell models of ALS-associated mutants of TDP-43, FUS, VAPB, VCP,
OPTN and UBQLN2 were generated that, in future work, can be screened using this assay. For
ALS-associated mutant proteins that do cause reductions in the protein quality control capacity
of neuronal cells, as is the case for SOD1A4V, this assay has potential to be applied in drug
screening studies to identify candidate compounds that are able to ameliorate this deficiency.
In summary, this PhD thesis describes the development and use of two novel high-throughput
methodologies to investigate proteostasis disturbances caused by mutations in ALS-associated
genes. The common alterations identified in the proteostasis network caused by pathological
TDP-43, FUS and SOD1 expression lay the groundwork for further research in this area. In the
future both methodologies can be exploited for drug screening applications. Continued
development of HCS assays capable of measuring deficiencies in the proteostasis network will
be valuable in the search for therapeutic targets and development of drugs to treat ALS. Overall,
the work achieved in this PhD provides substantial foundation for further investigation into the
specific proteostasis components that could be potent targets for therapeutic intervention in
ALS.
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Chapter 1: Introduction
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Introduction
Amyotrophic lateral sclerosis (ALS) is one of the most prevalent forms of motor neuron disease
worldwide (Dormann et al. 2010). Now considered to be a heterogeneous disorder (Robberecht
and Philips 2013), it is typified by the progressive loss of motor neurons of the motor cortex,
brainstem and spinal cord. The muscles served by these motor neurons consequently atrophy,
weaken and become vulnerable to spasticity and fasciculations. Typically, death results within
3-5 years of symptom onset as degeneration progresses to the motor neurons serving the
respiratory muscles and diaphragm, resulting in respiratory failure (Boillee et al. 2006).
However, in some cases disease duration can be quite variable (Strong et al. 2005, Wang et al.
2008).
A significant proportion of patients also suffer cognitive and behavioural impairment. In fact,
ALS and frontotemporal dementia (FTD) are increasingly recognised as being part of a
pathological spectrum (Basso et al. 2009, Robberecht and Philips 2013, van der Zee et al. 2013).
ALS itself is classified as either familial (fALS) or sporadic (sALS). fALS comprises ~10% of
all reported cases, with the remaining ~90% of sALS patients having no apparent family history
of disease (Ilieva et al. 2009). Genetic studies of fALS patients have led to the identification of
a growing list of causative genetic mutations that segregate with disease. The first of these were
discovered in SOD1 (copper/zinc superoxide dismutase) (Rosen et al. 1993), and this list has
grown to include TARDBP (TAR DNA-binding protein 43; TDP-43) (Neumann et al. 2006),
FUS (Fused in Sarcoma) (Kwiatkowski et al. 2009, Vance et al. 2009), C9ORF72 (chromosome
9 open reading frame 72) (DeJesus-Hernandez et al. 2011), VAPB (VAMP (vesicle-associated
membrane protein)-associated protein B) (Nishimura et al. 2004, Nishimura et al. 2004), OPTN
(optineurin) (Maruyama et al. 2010), ANG (angiogenin) (Greenway et al. 2006), SETX
(senataxin) (Chen et al. 2004), VCP (transitional endoplasmic reticulum ATPase/p97) (Johnson
et al. 2010), UBQLN2 (ubiquilin-2) (Deng et al. 2011), hnRNPA1 (heterogeneous nuclear
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ribonucleoprotein A1) (Kim et al. 2013), MATR3 (matrin-3) (Johnson et al. 2014), CCNF
(cyclin F) (Williams et al. 2016), PFN1 (profilin-1) (Wu et al. 2012), SQSTM1 (p62) (Fecto et
al. 2011), TBK1 (TANK-binding kinase 1) (Cirulli et al. 2015), CYLD (CYLD lysine 63
deubiquitinase) (Dobson-Stone et al. 2013), EWSR1 (Ewing sarcoma breakpoint region 1)
(Couthouis et al. 2012) and TAF15 (TATA box-binding protein-associated factor 15) (Ticozzi
et al. 2011), among others. This list is not exhaustive, with more than 50 potential ALS genes
now published. Establishing the causality of many of these mutations, however, has remained
challenging for geneticists.
Mutations in many of the genes associated with fALS have also been detected in sALS patients,
including C9ORF72 (Shatunov et al. 2010), TARDBP (Sreedharan et al. 2008), FUS (Belzil et
al. 2009, Corrado et al. 2010, DeJesus-Hernandez et al. 2010, Lai et al. 2011), ANG (Greenway
et al. 2006), MATR3 (Lin et al. 2015, Leblond et al. 2016), EWSR1 (Couthouis et al. 2012),
OPTN (van Blitterswijk et al. 2012), VCP (Koppers et al. 2012) and SQSTM1 (Fecto et al.
2011, Teyssou et al. 2013). The genetic contribution to sALS is estimated to be ~65% (AlChalabi et al. 2010, Al-Chalabi and Visscher 2014), but current methodologies for genetic
analysis have fallen short in identifying genetic variants in the majority of sALS cases
(Andersen and Al-Chalabi, 2011, Renton et al. 2014, Dharmadasa et al. 2017, Nguyen et al.
2018). In terms of clinical presentation and pathological features, sALS and fALS are largely
indistinguishable. Rather, fALS and sALS are distinguished based on the presence of a recorded
family history of ALS. However, advances in genetic analysis techniques are paving the way
towards the identification of previously unknown familial relatedness between individuals with
sALS carrying identical ALS-associated gene variants (Twine et al. 2019). The hallmark
pathology of ubiquitylated TDP-43-positive inclusions in affected motor neurons is observed
in post-mortem tissue from both individuals with sALS and those with fALS (Leigh et al. 1991,
Neumann et al. 2006). Moreover, while clinical presentation is heterogeneous overall amongst
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individuals with ALS, there is no definitive delineation between those with fALS and those
with sALS. Thus, continued efforts to identify relatedness amongst individuals with sALS and
to identify genetic variants that contribute to sALS risk are warranted to aid diagnosis and
prognosis of individuals with fALS and sALS, improve patient outcomes and provide insight
into the genetic mechanisms that contribute to ALS pathogenesis.
The currently identified ALS-associated genes cover a diverse range of molecular functions and
thus it is becoming increasingly apparent that motor neuron dysfunction and death is unlikely
to be caused by one mechanism alone. The key to understanding ALS will be to discern how
the ALS-associated genes and their respective molecular pathways interconnect. As a starting
point, it is well established that inclusion bodies (inclusions) containing aggregated proteins are
a characteristic feature of the affected motor neurons in post-mortem spinal cord tissue from
ALS patients. The universal presence of inclusions in ALS indicates that there is disruption of
the cellular mechanisms that maintain proteome homeostasis (proteostasis) in motor neurons.
The objective of this introductory chapter is to summarise current evidence for, and
understanding of, the potential roles of ALS-associated mutant proteins in proteostasis
dysfunction in motor neurons and how they contribute to disease.
Proteostasis involves the co-ordination of interacting molecular processes
The primary function of motor neurons is to respond to the binding of neurotransmitters to cell
surface receptors and to generate, propagate and transmit action potentials for rapid information
transfer from the motor areas of the brain to the muscles. This is dependent on homeostasis of
the intra- and extracellular environment (Kanning et al. 2010). Proteostasis is defined as the
maintenance of all proteins in the cellular proteome in a conformation, concentration and
location that is required for their correct function (Balch et al. 2008). It involves stringent
regulation of the processes of transcription, RNA processing and transport, translation, protein
folding, protein trafficking and transport, and protein degradation (Hartl et al. 2011, Yerbury et
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al. 2016) (Figure 1.1). This requires readaptation of the innate biology of the cell in response to
constant intrinsic and extrinsic changes. These processes are intricately connected to each other,
creating a dynamic system in equilibrium, such that disturbances in one component lead to
significant changes in other components.
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Figure 1.1. Summary of the interacting molecular processes that maintain proteome homeostasis
(proteostasis). The maintenance of cellular proteostasis requires stringent regulation of the processes constituting
RNA metabolism and protein quality control. RNA metabolic processes include (A) transcription, (B) mRNA
splicing and processing, (C) mRNA transport into the cytosol or the rough endoplasmic reticulum (rER) and (D)
mRNA decay. From the moment (E) a nascent protein has been translated, it enters the realm of the protein quality
control network. (F) Molecular chaperones (G) mediate folding of nascent proteins into their native conformation.
When molecular chaperones are unable to fold aberrant misfolded proteins into their native conformation, (H)
ubiquitylation can direct the misfolded proteins for proteasomal degradation. The ubiquitin-proteasome system is
also responsible for the regulated degradation of many proteins with key roles in signalling pathways.
Alternatively, (I) ubiquitylation can assist in the active segregation of misfolded proteins from the cytosol into
distinct types of inclusions that function as protein quality control compartments, e.g. aggresomes. (J) In some
instances, misfolded proteins that escape these mechanisms can aggregate. (K) Molecular chaperones can assist in
directing aggregates for proteolytic degradation through the selective macroautophagy pathway, which is also the
primary degradative pathway for the clearance of long-lived proteins, macromolecular structures and old or
damaged organelles.

1.2.1

RNA metabolism

Fundamentally, the appropriate levels of proteins in the cell are maintained through the correct
regulation of transcription, mRNA splicing and processing, transport from the nucleus to
distinct locations in the cytoplasm, and translation into nascent polypeptides. A multitude of
DNA- and RNA-binding proteins (D/RBPs) exist that interact with nascent and mature mRNA
molecules to ensure their proper functioning (Baltz et al. 2012, Castello et al. 2012). Together,
these DBPs and RBPs form an elaborate network crucial to maintaining the appropriate levels
of mRNAs and their encoded proteins (Janssens and Van Broeckhoven 2013). The regulation
of RNA metabolism is crucial in the preservation of a functional cellular environment, and
multiple neurodegenerative diseases have now been linked to dysfunctional RNA metabolism
(Cooper et al. 2009, Todd and Paulson 2010, Belzil et al. 2013). For example, the survival
motor neuron (SMN) protein, genetically linked to the motor neuron disease spinal muscular
atrophy (SMA), is critical for efficient splicing activity (Liu et al. 1997, Pellizzoni et al. 1998).
SMN assists in assembly of the spliceosome, a molecular complex responsible for splicing premRNA transcripts (Liu et al. 1997, Pellizzoni et al. 1998). Loss of SMN function due to SMAcausing mutations leads to impaired spliceosomal activity (Wan et al. 2005). Moreover,
knockdown of SMN in zebrafish and mouse models causes splicing defects and motor neuron
degeneration (Winkler et al. 2005, Zhang et al. 2008). Beyond SMA, mutations causing SMN
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deficiency have also been implicated as a risk factor for sALS (Veldink et al. 2005, Corcia et
al. 2006). Although SMN has multiple functions in cells beyond splicing activity (Rossoll et
al. 2003, Zhang et al. 2003, Carrel et al. 2006, Zhang et al. 2006), these data nevertheless
suggest that there is a crucial role for efficient mRNA splicing in the maintenance of motor
neuron health. Furthermore, dysregulation of proper splicing activity is prevalent in ALS
caused by mutations in TARDBP and FUS (Hoell et al. 2011, Polymenidou et al. 2011, LagierTourenne et al. 2012, Arnold et al. 2013).
Once an mRNA has been translated into a nascent polypeptide, regulation of the fate of the
mRNA is crucial for proper control of gene expression and cellular protein levels (Wang et al.
2002, Yang et al. 2003). Integral in mRNA regulation are mechanisms of mRNA decay, which
are intricately controlled by highly conserved networks of enzymes in eukaryotes (Parker and
Song 2004). Typically, mRNA decay is deadenylation-dependent, initiating through the
removal of the mRNA poly(A) tail by any of several different poly(A)-specific
exoribonucleases (Boeck et al. 1996, Körner et al. 1998, Tucker et al. 2001). Following this,
the deadenylated mRNA is degraded through either a 5’ to 3’ directed pathway or a 3’ to 5’
directed pathway. The 5’ to 3’ pathway proceeds through the action of decapping enzymes,
DCP1 and DCP2, that remove the 5’ cap of the mRNA (Steiger et al. 2003). This then facilitates
completion of the decay pathway by the XRN1 exonuclease (Larimer et al. 1992).
Alternatively, structures comprised of a network of exonucleases, termed exosome complexes,
degrade their mRNA substrates through the 3’ to 5’ direction (Anderson and Parker 1998,
Mukherjee et al. 2002, Wang et al. 2002). As for the nascent polypeptide, it enters the realm of
the protein quality control network. This network encompasses the proteins and pathways that
regulate protein folding and re-folding, trafficking of proteins to their correct cellular location,
and that monitor the efficient compartmentalisation and clearance of misfolded proteins and
those at the end of their functional life cycle in the cell.
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1.2.2

Protein quality control

Mechanisms of protein folding, re-folding and the prevention of protein aggregation are
managed by networks of molecular chaperones and co-chaperones (Balch et al. 2008, Yerbury
and Kumita 2010). These include several systems of ‘heat-shock proteins’ (HSPs); the small
HSP (sHSP), HSP40, HSP60 (chaperonin), HSP70, HSP90 and HSP100 systems. Hartl et al.
(2011) provides an expansive review of the molecular chaperone networks and so this will not
be covered here. The full repertoire of chaperones, co-chaperones, folding enzymes and
adaptors that make up these systems in human cells, the chaperone network (chaperome), has
been quantified to comprise 332 proteins (Brehme et al. 2014). Many proteins of the chaperome
are abundantly expressed in cells and encompass a considerable proportion of the cellular
machinery (Bukau et al. 2006, Ron and Walter 2007). Under normal physiological conditions,
the various proteins of the chaperome have diverse roles in regulating correct protein folding,
preventing protein folding intermediates and aberrant proteins from misfolding, and targeting
stressed or aberrant proteins for degradation (Sherman and Goldberg 2001, Gidalevitz et al.
2006, Douglas and Dillin 2010, Yerbury and Kumita 2010, Gidalevitz et al. 2011, Yerbury et
al. 2013). Extensive evidence indicates that they do this by recognising and binding to exposed
hydrophobic stretches of the target protein’s amino acid sequence, thereby preventing
unfavourable interactions between non-native protein species (Voisine et al. 2010, Hartl et al.
2011, Wyatt et al. 2013).
Abnormal physiological demands on the proteostasis network, such as the overexpression of
proteins above normal concentrations, can alter the chaperone-substrate balance. Mutations that
increase the propensity of a protein to aggregate can also tip this balance to disfavour
proteostasis by exceeding the cellular chaperome capacity (Gidalevitz et al. 2006, Yerbury et
al. 2013). Age itself leads to a decline in the capacity of the chaperome. Gene expression
analysis of human brain tissue has revealed that, during normal brain aging, almost a third of
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chaperone-encoding genes are down-regulated (Brehme et al. 2014). A considerable proportion
of this chaperome deterioration was also detected in post-mortem brain tissue from patients
with Alzheimer’s (AD), Parkinson’s (PD) and Huntington’s disease (HD). Moreover, a subset
of these repressed chaperones was identified to comprise an intricate subnetwork that is critical
in buffering against proteotoxic stress during cellular aging. As with ALS, AD, PD and HD are
age-correlated diseases and are each primarily associated with genetic mutations that introduce
increased proteostatic burden through the production of aggregation-prone proteins. It stands to
reason that a declining capacity of the protective chaperone subnetwork (Brehme et al. 2014)
with increased age may make this system highly vulnerable to genetic mutations that lead to
accumulation of mutant, aggregation-prone proteins.
1.2.2.1 Ubiquitin-dependent protein degradation
When molecular chaperones are unable to fold aberrant proteins into their native conformation,
regulatory components and co-factors of the HSP40, HSP70 and HSP90 systems help to prepare
and direct the substrate proteins for proteolytic degradation through the ubiquitin-proteasome
system (UPS) or through selective macroautophagy (Arndt et al. 2007, Ding and Yin 2008,
Gamerdinger et al. 2009, Arndt et al. 2010, Kampinga and Craig 2010, Jin et al. 2013).
Ubiquitylation of substrate proteins, i.e. the conjugation of ubiquitin molecules to substrate
proteins, is critically important for directing proteins through these proteolytic systems (Tan et
al. 2008, Kraft et al. 2010). The UPS is the main proteolytic system for the degradation of
regulatory proteins and damaged, misfolded proteins. Substrate proteins are ubiquitylated
through the co-ordinated action of E1 ubiquitin-activating, E2 ubiquitin-conjugating and E3
ubiquitin-ligase enzymes in a multistep cascade of enzymatic reactions, and subsequently
targeted to the 19S regulatory particle of the 26S proteasome (Hershko and Ciechanover 1998,
Crews 2003, Kleiger and Mayor 2014). Inside the 20S core particle of the proteasome, substrate
proteins are cleaved into small peptides (Bhattacharyya et al. 2014). Selective macroautophagy
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(referred to as autophagy from hereon) is primarily responsible for the clearance of long-lived
proteins, macromolecular complexes, organelles and aggregates formed by misfolded proteins,
and is a highly conserved pathway among eukaryotes (Hughes and Rusten 2007, Jin et al. 2013).
Ubiquitylation also plays a role in alternative routes of protein quality control, assisting in the
active segregation of misfolded proteins from the cytosol into distinct types of inclusions
(Kawaguchi et al. 2003, Tan et al. 2008, Zhang and Qian 2011). These structures have been
reported to contain high concentrations of quality control machinery. For instance, aggresomes
and the related juxtanuclear quality control compartment (JUNQ) contain ubiquitylated proteins
targeted for proteasomal degradation, active proteasomes, HSP70 and other chaperones
(Johnston et al. 1998, Kopito 2000, Arrasate et al. 2004, Kaganovich et al. 2008, Treusch et al.
2009, Zhang and Qian 2011, Weisberg et al. 2012, Polling et al. 2014). However, in a cell that
has been exposed to excessive protein-folding stress, the capacity of these quality control
mechanisms can be exceeded, enabling misfolded proteins to escape compartmentalisation or
degradation. Critically, rogue misfolded proteins are then able to amplify this initial deficiency
in the proteostasis network. Through their abnormal conformations they can interact aberrantly
with other proteins, including components of the proteostasis network, impairing their normal
functions and further disrupting mechanisms of proteostasis (Matsumoto et al. 2005, Gidalevitz
et al. 2006, Weisberg et al. 2012).
1.2.2.2 Diverse cellular processes are governed by the ubiquitin-proteasome system
The UPS is not only crucial for the clearance of damaged, aberrant proteins that escape the
chaperone network in the cell, but it is also responsible for the turnover of short-lived proteins
and numerous other cellular functions, including cell cycle progression and DNA repair
pathways (Ciechanover 1998, Ciechanover 2006). The UPS plays a key role in cellular
responses to stimuli, including stress, which require the concentrations and localisation of
certain key proteins to be tightly regulated and rapidly increased or decreased (reviewed in
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Ciechanover and Stanhill (2014)). For instance, the UPS is involved in spatiotemporal
regulation of the levels of different transcriptional activators, coactivators and repressors that
are required for the coordination of cellular responses to diverse stimuli. Its role in transcription
regulation extends beyond degradative control of transcriptional activators and repressor
concentrations (Muratani and Tansey 2003) to controlling their localisation (Hoppe et al. 2000)
and proteolytically modulating their structure to convert them into functional states (Palombella
et al. 1994).
At least 38 E2 and > 600 E3 genes have now been identified in the human genome, along with
2 E1 ubiquitin-activating enzymes, UBA1 and UBA6 (Deshaies and Joazeiro 2009, Schulman
and Harper 2009, Ye and Rape 2009, Kaneko et al. 2016). These E1, E2 and E3 enzymes work
in highly organised sequential enzymatic reactions to conjugate ubiquitin to specific protein
substrates and direct their fate. The full repertoire of E1, E2 and E3 enzymes, de-ubiquitylating
enzymes (DUBs), and the total population of ubiquitin molecules at any one time in a human
cell is estimated to account for ~1.3% of the total cellular proteome (Kulak et al. 2014).
Ubiquitin itself is a highly conserved, small 76-amino acid protein that is encoded by four genes
at different loci in the genome; two polyubiquitin precursor genes, UBB, UBC, and two
ribosomal fusion genes, UBA52 and RPS27A (Wiborg et al. 1985). UBB is comprised of headto-tail repeats of three ubiquitin units, UBC of nine ubiquitin units, while UBA52 and
RPS27A/UBA80 encode ribosomal subunits that are each fused to the C terminus of a single
ubiquitin unit. Following translation, various DUBs process the ubiquitin repeats to generate
free ubiquitin (Monia et al. 1989, Wilkinson et al. 1995).
Ubiquitylation serves functions beyond protein degradation via the UPS, and does so by
circulating in different cellular ‘pools’ (Dantuma et al. 2006, Groothuis et al. 2006) at levels
estimated to be ~8 × 107 copies, or 85 µM, in a human cell (Kaiser et al. 2011). In one of these
pools, ubiquitin is conjugated to substrate proteins by an isopeptide bond either as a single
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monomeric entity, monoubiquitin, or as polyubiquitin chains of various topologies
(comprehensively reviewed in Komander and Rape (2012)). ‘Activated’ ubiquitin comprises
another pool, thioester-linked via its carboxyl terminus to a catalytic cysteine residue of an E1
ubiquitin-activating enzyme (Haas and Rose 1982). This forms the initial step of the E1-E2-E3
multistep enzymatic cascade that leads to the conjugation of ubiquitin to substrate proteins.
‘Free’ ubiquitin makes up a third pool. The distribution of ubiquitin in these pools is in a
constant state of flux as competing ubiquitin-dependent processes extract free ubiquitin,
decreasing its availability while replenishment occurs through combinations of de novo
ubiquitin synthesis and the actions of diverse DUBs that release conjugated ubiquitin (Monia
et al. 1989, Wilkinson et al. 1995, Verma et al. 2002, Yao and Cohen 2002, Nijman et al. 2005).
1.2.2.3 Ubiquitin conjugation comprises a versatile cellular signalling system
A huge diversity of molecular processes depend on the signalling specificity provided by the
conjugation of ubiquitin in defined linkage arrangements (Figure 1.2). In human cells,
monoubiquitin-conjugates (Figure 1.2) account for more than 60% of the total cellular ubiquitin
pool, with a majority of this comprised of monoubiquitylated histone H2A (Joo et al. 2007,
Kaiser et al. 2011). Monoubiquitylation of histone H2A is required for gene silencing (de
Napoles et al. 2004, Wang et al. 2004, Baarends et al. 2005) and changes in the ubiquitylation
status of histone H2A are involved in cellular responses to various stressors by modulating
expression of key genes (Carlson et al. 1987, Mimnaugh et al. 1997). Monoubiquitylation can
mediate internalisation of cell surface receptors and regulation of their levels, and further
regulates the activity of proteins involved in different stages of endocytosis (Terrell et al. 1998,
Lucero et al. 2000, Nakatsu et al. 2000, Roth and Davis 2000, Katzmann et al. 2001). In
addition, monoubiquitylation is involved in the process of enveloped viruses budding from the
plasma membrane of infected cells (Ott et al. 1998, Harty et al. 2000, Patnaik et al. 2000, Strack
et al. 2000).
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As well as monoubiquitylation, additional ubiquitin molecules can be progressively added to
the first conjugated ubiquitin of substrate proteins to form an extensive number of defined
polyubiquitin chains. The diversity of polyubiquitin chains that exist are possible due to the
seven internal lysine residues of ubiquitin (Lys6, Lys11, Lys27, Lys29, Lys33, Lys48, Lys63),
and in some cases the Met1 at its amino-terminus, which serve as sites for the carboxyl-terminus
glycine residue of an additional ubiquitin to link to (Chau et al. 1989, Thrower et al. 2000,
Dammer et al. 2011, Walczak et al. 2012). About 11% of the total ubiquitin pool is used for
polyubiquitylation of a vast range of protein substrates (Kaiser et al. 2011). Polyubiquitin
chains can have varying lengths, and linkages that are either homogenous throughout the chain,
or heterogenous with changes in the Lys or Met1 residue used for each successive ubiquitin.
The fates of proteins tagged with homogenous Lys11, Lys48 and Lys63 polyubiquitin linkages
have been studied extensively, whereas Lys6, Lys27, Lys29 and Lys33 are less well understood
and account for less than 1% of total cellular ubiquitin (Figure 1.2) (Peng et al. 2003, Xu et al.
2009, Kaiser et al. 2011). Homogenous Lys48-linked chains are widely understood to be the
main signal for proteasomal degradation, while Lys11-, Lys29- and Lys63- linkages have also
been implicated as proteasome-targeting signals for a lower proportion of protein substrates
(Johnson et al. 1995, Baboshina and Haas 1996, Thrower et al. 2000, Ravid and Hochstrasser
2008, Xu et al. 2009, Kaiser et al. 2011, Kim et al. 2011). As for the targeting of substrates for
lysosomal degradation via the autophagy pathway, both monoubiquitylation and
polyubiquitylation with Lys63-linkages can serve as signals to adaptor proteins that link
substrates to the autophagy machinery (Figure 1.2) (reviewed in Kirkin et al. (2009) and
Korolchuk et al. (2010)).
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Figure 1.2. Schematic representation of the diversity of ubiquitin signals in cells. The conjugation of ubiquitin
in defined linkage arrangements to various substrates in the cell provides unparalleled signalling specificity for
diverse molecular processes. Ubiquitylation is an ATP-dependent process and occurs through the co-ordinated
action of E1, E2 and E3 enzymes. Monoubiquitylation is involved in the regulation of gene silencing and the
expression of genes involved in cellular stress responses. Monoubiquitylation also mediates endocytosis, and can
additionally serve as a signal for selective autophagy. Beyond monoubiquitylation, additional ubiquitin molecules
can be progressively added to form an extensive number of defined polyubiquitin chains. The diversity of
polyubiquitin chains that exist are possible due to the seven internal lysine residues of ubiquitin (Lys6, Lys11,
Lys27, Lys29, Lys33, Lys48, Lys63), and in some cases the Met1 at its amino-terminus. Specificity of
polyubiquitin chain linkages is enabled through the activity of the specific E2 and E3 enzymes involved. At least
38 E2 and > 600 E3 genes have now been identified in the human genome, along with 2 E1 ubiquitin-activating
enzymes, UBA1 and UBA6 (Deshaies and Joazeiro 2009, Schulman and Harper 2009, Ye and Rape 2009, Kaneko
et al. 2016). Lys48-polyubiquitin chains constitute the main signal for proteasomal degradation. Lys11-, Lys29and Lys63-linkages have also been implicated as proteasome-targeting signals for a lower proportion of protein
substrates. Lys63-polyubiquitin chains serve as a major signal to adaptor proteins that link substrates to the
autophagy machinery. Lys6, Lys27, Lys29 and Lys33 are less well understood and account for less than 1% of
total cellular ubiquitin (Peng et al. 2003, Xu et al. 2009, Kaiser et al. 2011).

The stunning diversity of polyubiquitin chain linkages are generated through the coordinated
action of E1, E2 and E3 enzymes in a multistep cascade of enzymatic reactions, with specificity
enabled through the activity of the specific E2 and E3 enzymes involved (Deshaies and Joazeiro
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2009, Rotin and Kumar 2009, Schulman and Harper 2009, Ye and Rape 2009, Zimmerman et
al. 2010, Budhidarmo et al. 2012, Primorac and Musacchio 2013, Berndsen and Wolberger
2014, Spratt et al. 2014, Vittal et al. 2015). The conjugation process begins when the active site
cysteine of an E1 ubiquitin-activating enzyme forms a thioester linkage with the carboxyl
terminus of ubiquitin, activating the ubiquitin molecule (Haas et al. 1982) (Figure 1.2). The
next step involves an E2 ubiquitin-conjugating enzyme with high affinity for the activated
ubiquitin (Hershko et al. 1983, Pickart and Rose 1985). The activated ubiquitin is transferred
to the active site cysteine of the E2 enzyme via trans-thioesterification, in coordination with
relinquishment of the E1 enzyme (Eletr et al. 2005). Finally, linking the activated ubiquitin to
the target substrate protein depends on the specificity provided by the E2 enzyme and its
cognate E3 ubiquitin-ligase. E3 enzymes of the Really Interesting New Gene (RING)/U-box
families (comprising > 600 human genes) link their associated E2 enzyme, charged with
ubiquitin, to their specific substrate protein (Figure 1.3, a) (Deshaies and Joazeiro 2009,
Budhidarmo et al. 2012). In contrast, ubiquitin can be transferred from the E2 enzyme to an
active site cysteine of an E3 enzyme of the Homologous to E6-AP Carboxyl Terminus (HECT)
family (~30 human genes) or of the RING between RING (RBR) family (~12 human genes)
(Figure 1.3, b) (Rotin and Kumar 2009, Smit and Sixma 2014, Spratt et al. 2014).
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Figure 1.3. E3 ubiquitin-ligase enzymes of the RING, HECT and RBR families link ubiquitin to substrate
proteins through different mechanisms. The conjugation of activated ubiquitin to its target substrate depends
on the specificity provided by the E2 ubiquitin-conjugating enzyme and its cognate E3 ubiquitin-ligase enzyme.
(A) E3 enzymes of the Really Interesting New Gene (RING)/U-box families (comprising > 600 human genes) link
their associated E2 enzyme, charged with ubiquitin, to the specific substrate. (B) In contrast, ubiquitin can be
transferred from the E2 enzyme to an active site cysteine of an E3 enzyme of the Homologous to E6-AP Carboxyl
Terminus (HECT) family (~30 human genes) or of the RING between RING (RBR) family (~12 human genes).

Ubiquitin homeostasis and proteostasis in motor neurons: a challenging cellular
environment
As structurally and functionally complex post-mitotic cells, the specialised environments within
different neuron sub-types of the central nervous system (CNS) have uniquely high demands
for efficient ubiquitin homeostasis and overall proteostasis (Yerbury et al. 2016). While exit
from the cell cycle is necessary for the differentiation of neurons (Herrup 2013, Anda et al.
2016), an inherent disadvantage of the post-mitotic state is that damage caused to DNA, proteins
and organelles that is not ameliorated through cellular repair processes accumulates throughout
the aging process, as cells are unable to dilute damaged proteins and organelles through cell
division (Evans et al. 2004, Akbari and Krokan 2008, Barzilai et al. 2008, Martin 2008,
McKinnon 2009, Yerbury et al. 2016). Moreover, there have been several studies
demonstrating that extracellular factors (e.g. chondroitin sulphate proteoglycans (CSPGs) in
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the perineuronal net, a specialised extracellular matrix structure in the CNS) and intrinsic
molecular programs within most neurons largely inhibit any capacity for axon regeneration
following injury and damage accumulation (Dou and Levine 1994, Di Giovanni 2009, Liu et
al. 2011, Schwab and Strittmatter 2014, Carulli et al. 2016, Tedeschi and Bradke 2017).
With their specialised structures and functions, neurons have exceptionally high ATP
requirements (Hall et al. 2012). However, dysfunction of the organelle that drives energy
production, the mitochondria, has been found to increase with age (Kujoth et al. 2005). In
particular, somatic mutations in mitochondrial DNA have been extensively reported to occur in
neurons and contribute to the pathogenesis of several neurodegenerative diseases (Linnane et
al. 1989, Corral-Debrinski et al. 1992, Corral-Debrinski et al. 1992, Corral-Debrinski et al.
1994, Brierley et al. 1998, Michikawa et al. 1999, Lin et al. 2002, Coskun et al. 2004,
Kraytsberg et al. 2006). ATP is crucial for the maintenance of proteostasis and ubiquitin
homeostasis (Yerbury et al. 2016). It is required for protein synthesis, for the activity of most
chaperones in the human chaperome, and for ubiquitylation, thus for all downstream ubiquitindependent molecular processes (Hershko et al. 1980, Haas et al. 1982, Brehme et al. 2014).
These requirements for ATP are higher in motor neurons as these processes need to be carried
out efficiently in the far-reaching locales of the motor neuron, from the soma, along axons
through to synaptic terminals. Hence, an age-related decline in mitochondrial function and
subsequent disruptions in energy metabolism increase the vulnerability of motor neurons to
proteostasis dysfunction with increasing age (Yerbury et al. 2016).
Recently it was discovered that the proteome of spinal motor neurons is supersaturated (i.e. the
concentration of individual proteins is high relative to their solubility) in comparison to
oculomotor neurons, which are resistant to degeneration in ALS (Ciryam et al. 2015, Yerbury
et al. 2019). This suggests that the metastability of the spinal motor neuron proteome may
contribute to a distinct susceptibility to proteostasis dysfunction. As discussed in section 1.2.2,
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the expression of a sub-network of chaperones in the human chaperome, including many ATPdependent chaperones, has been reported to decline with age (Brehme et al. 2014). As cells age
their ability to activate appropriate responses to proteotoxic stress deteriorates (Ben-Zvi et al.
2009). Together, these age-related changes are potently problematic in motor neurons
harbouring genetic mutations, as the proteostasis network is compromised in its ability to
manage any aberrant mutant RNA or protein species that result. Mutant RNA and protein
species are then able to further aggravate dysfunction in the proteostasis network by
overloading key components and disrupting their functions (Matsumoto et al. 2005, Gidalevitz
et al. 2006, Weisberg et al. 2012). For instance, it has been postulated that genetic mutations
that increase protein aggregation-propensity may decrease the ability of the chaperone network
to correctly fold other proteins or direct them to degradative machinery, leading to accumulation
of misfolded proteins (Bruijn et al. 2004).
Deterioration of the proteostasis network in aging neurons is evident in the fact that pathological
protein inclusions are a common feature of several different age-associated neurodegenerative
diseases. Critically, disruption of the functioning of the UPS and of molecular chaperones (e.g.
HSP40, HSP70) is well documented to occur in these diseases, and in some cases increasing the
levels of components of these systems has been reported to suppress pathological protein
aggregation (Bence et al. 2001, Cleveland and Rothstein 2001, Watanabe et al. 2001, Kim et al.
2002, Takeuchi et al. 2002, Urushitani et al. 2002, Bruijn et al. 2004, Holmberg et al. 2004,
Kabashi et al. 2004, Bennett et al. 2005, Yerbury et al. 2013). Indeed, the affected motor neurons
in post-mortem spinal cord tissue from individuals with sALS and fALS universally contain
ubiquitin-positive inclusions, providing strong evidence that the proteostasis network is
dysfunctional in ALS; in particular, the UPS and ubiquitin homeostasis (Leigh et al. 1991). As
will be discussed in the following section, extensive evidence indicates that many of the genetic
mutations that segregate with ALS disrupt the proteostasis network.
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A growing list of genes are associated with ALS
Many of the ALS-associated genes encode proteins with functional roles in the maintenance of
proteostasis in cells, or that are aggregation-prone, or that, in their mutant form, cause
dysfunction of components of proteostasis machinery (Table 1.1). Hence, proteostasis
dysfunction in motor neurons may be an underlying pathogenic link between the different ALSassociated genetic mutations.
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Table 1.1. List of some of the ALS-associated genetic mutations and the potential mechanisms by which they lead to disruptions in cellular proteome homeostasis
(proteostasis).
Gene; Protein

Disease
phenotype

Function

Chromosomal
locus

Examples of ALSassociated mutations

Potential mechanisms of
proteostasis disruption

References

SOD1; Cu/Zn
superoxide
dismutase
(SOD1)

ALS
ALS/FTD

Catalyses the conversion
of superoxide radicals to
molecular oxygen and
hydrogen peroxide.

21q22.11

> 180 mutations.
Most common:
G93A; D90A; A4V; I113T;
L144F

Impaired molecular chaperone
activity and UPS activity.

TARDBP; TAR
DNA binding
protein 43 kDa
(TDP-43)

ALS
ALS/FTD
FTD

1p36.22

G287S; G290A; S292N;
G294A; G298; A315T;
E331K; R361S; D169G;
M337V; G348C; A382T;
N390D; N390S

FUS; Fused in
sarcoma (FUS)

ALS
ALS/FTD
FTD

Predominantly localised
to nucleus; binds DNA
and RNA, regulates
transcription, mRNA
splicing and transport.
Assembly and regulation
of stress granules.
Predominantly localised
to nucleus; binds DNA
and RNA, regulates
transcription, mRNA
splicing and transport.
Assembly and regulation
of stress granules.

16p11.2

H517Q; R521G; insGG;
delGG; R244C; R514S;
G515C; R518K; R521C;
R521G; R521H; R522G;
R524T; R524S; P525L

Cytoplasmic accumulation;
disrupted stress granule
dynamics; disruptions in
transcription, mRNA
processing; disruptions in
expression of TDP-43 and
FUS mRNA targets.

UBQLN2;
Ubiquilin-2
(UBQLN2)

ALS
ALS/FTD

Xp11.21

P497H; P497S; P506T;
P509S; P525S

Impaired UPS activity and
autophagy.

OPTN;
Optineurin
(OPTN)

ALS
ALS/FTD

Member of the ubiquilin
protein family; ubiquitinlike proteins involved in
the UPS and autophagy.
Maintenance of the Golgi
complex; membrane
trafficking; post-Golgi
trafficking to lysosomes;
exocytosis.

Shibata et al. (1996), Bruijn et al.
(1997), Bruening et al. (1999), Johnston
et al. (2000), Kato et al. (2000),
Watanabe et al. (2001), Takeuchi et al.
(2002), Urushitani et al. (2002), Wang
et al. (2002), Cheroni et al. (2005),
Matsumoto et al. (2005), Cheroni et al.
(2009), Crippa et al. (2010), Onesto et
al. (2011).
Neumann et al. (2006), Sreedharan et
al. (2008), Ayala et al. (2008), Belzil et
al. (2009), Johnson et al. (2009),
Kwiatkowski et al. (2009), Ticozzi et
al. (2009), Vance et al. (2009), Blair et
al. (2010), Corrado et al. (2010),
DeJesus-Hernandez et al. (2010), Deng
et al. (2010), Van Langenhove et al.
(2010), Dewey et al. (2011), Lai et al.
(2011), Polymenidou et al. (2011),
Sephton et al. (2011), Tollervey et al.
(2011), Colombrita et al. (2012),
Dichmann and Harland (2012), Ishigaki
et al. (2012), Keller et al. (2012),
Lagier-Tourenne et al. (2012), Rogelj et
al. (2012), Nakaya et al. (2013).
Deng et al. (2011), Fecto et al. (2012),
Teyssou et al. (2017).

10p13

Deletion of exon 5;
R96L; E478G; A481V;
Q398X; Q165X

Golgi dysfunction and
impaired post-Golgi
trafficking; impaired
autophagy; aberrant
accumulation of OPTN.
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Sahlender et al. (2005), del Toro et al.
(2009), Maruyama et al. (2010), Ito et
al. (2011), Keller et al. (2012).

VAPB; Vesicleassociated
membrane
protein
[VAMP]associated
protein B
(VAPB)

ALS
SMA

VCP;
Transitional
endoplasmic
reticulum
ATPase/p97
(VCP)

ALS
ALS/FTD
FTD

SQSTM1;
Sequestosome1 (p62)

ALS
ALS/FTD

C9ORF72;
Chromosome 9
open reading
frame 72
(C9ORF72)

TAF15; TATAbinding protein
associated
factor 15
(TAF15)

Localised to ER
membrane & pre-Golgi
intermediates; regulates
ER-organelle & ERcytoskeleton interactions;
recruits lipid-binding
proteins to cytosolic
surface of ER membranes;
homeostatic and
signalling functions at
neuromuscular synapse.
AAA+-ATPase; regulates
a variety of cellular
functions: cell signalling,
cell cycling, organelle
biogenesis, protein
degradation via
autophagy, UPS & ERassociated degradation
(ERAD).
Multifunctional; roles in
UPS and autophagy.

20q13.3

P56S

ER dysfunction;
oligomerisation and
aggregation; dominantnegative inhibition of wildtype VAPB.

Skehel et al. (2000), Nishimura et al.
(2004a), Nishimura et al. (2004b),
Kaiser et al. (2005), Loewen and
Levine (2005), Teuling et al. (2007),
Ratnaparkhi et al. (2008), Suzuki et al.
(2009), Forrest et al. (2013), Kuijpers et
al. (2013), Qin et al. (2013).

9p13

R191Q; R159G; D592N;
R155H; I151V; I114P

Impaired ERAD, UPS and
autophagy.

Ye et al. (2001), Watts et al. (2004),
Weihl et al. (2007), Ju et al. (2009),
Gitcho et al. (2009), Johnson et al.
(2010), Meyer et al. (2012).

5q35

P392L; A33V; V153I;
S370P; K238E; K344E;
P348L

Impaired UPS activity and
autophagy; aberrant
accumulation and aggregation
of p62.

Fecto et al. (2011), Teyssou et al.
(2013), Rubino et al. (2012).

ALS
ALS/FTD
FTD

Membrane trafficking and
autophagy.

9p21.2

(GGGGCC)n
hexanucleotide repeat
expansion

Todd and Paulson (2010), Hernandez et
al. (2011), Renton et al. (2011), Mori et
al. (2013), May et al. (2014), Peters et
al. (2015), Haeusler et al. (2016),
Webster et al. (2016), Chitiprolu et al.
(2018).

ALS

Predominantly localised
to nucleus; binds DNA
and RNA, regulates
transcription, mRNA
splicing and transport.
Stress granule dynamics.

17q11.1-q11.2

G391E; R408C; G473E;
M368T; D386N; R388H;
R395Q

Loss of function in autophagy;
proteotoxicity through
production and aberrant
activity of dipeptide-repeat
(DPR) proteins; disruption of
RNA metabolism through
production and activity of
RNA foci.
Disrupted stress granule
dynamics; disruptions in
transcription, mRNA
processing.
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Couthouis et al. (2011), Ticozzi et al.
(2011).

1.4.1

SOD1 and C9ORF72; the major genetic players?

Mutations in the gene encoding SOD1 are among the most well studied in fALS, accounting
for a significant proportion (20-25%) of all fALS cases (Bosco et al. 2010, Chen et al. 2013)
and 2% of sALS cases (Pasinelli and Brown 2006). The first reports of an association between
mutant SOD1 and ALS were published in 1993 (Deng et al., 1993; Rosen et al., 1993), and
since then at least 180 different mutations that are associated with ALS have been identified in
this gene, located at chromosomal locus 21q22.11 (Abel et al. 2013). Disease onset and
progression is variable among individuals with different SOD1 mutations, and even between
people with the same SOD1 mutation (Picher-Martel et al. 2016). The propensity of SOD1
mutants to unfold and aggregate correlates with cellular toxicity, and it has been proposed that
this may contribute to variation in disease severity associated with different SOD1 mutations
(McAlary et al. 2016). The Ala4Val mutation in SOD1 (SOD1A4V) has been documented to
present as one of the more severe forms of ALS with rapid disease progression (Cudkowicz et
al. 1997, Juneja et al. 1997). In zebrafish ALS models, it has been found that the disease
phenotype is most aggressive in animals injected with SOD1A4V mRNA compared to SOD1G93A
or SOD1G37R mRNA (Lemmens et al. 2007).
In its wild-type form (SOD1WT), SOD1 is a 32 kDa soluble cytosolic homodimeric protein, with
one copper- and one zinc-binding site per monomer (Crapo et al. 1992, Strong et al. 2005). It
is a highly conserved antioxidant that catalyses the conversion of superoxide radicals to
molecular oxygen and hydrogen peroxide, protecting cells from uncontrolled reactions with
harmful oxygen free radicals (McCord and Fridovich 1969). Of all cell types in the body it is
found in its highest concentration within motor neurons (Bergeron et al. 1996).
Most SOD1 mutations are dominant, and it is now widely recognised that mutations contribute
to neurodegeneration via a toxic gain-of-function mechanism as opposed to a loss of antioxidant
activity (Gurney et al. 1994, Ripps et al. 1995, Wong et al. 1995, Reaume et al. 1996, Bruijn
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et al. 1997, Nagai et al. 2001, Howland et al. 2002, Wang et al. 2003, Jonsson et al. 2004).
Supporting this is the finding that transgenic SOD1 knockout mice do not develop ALS
symptoms (Reaume et al. 1996). Moreover, increased expression of SOD1WT accelerates
disease progression (Jaarsma et al. 2000, Deng et al. 2006). Studies using conformationspecific antibodies that are selective for misfolded SOD1WT with altered post-translational
modifications have detected misfolded SOD1WT in sALS patients, demonstrating that SOD1WT
is able to adopt abnormal conformations (Bosco et al. 2010, Pokrishevsky et al. 2012).
Ubiquitylated intracellular inclusions containing detergent-insoluble protein aggregates
immunoreactive to SOD1 are a characteristic pathological feature observed in post-mortem
spinal cord tissue samples from SOD1-fALS patients (Shibata et al. 1996, Kato et al. 2000) as
well as in mutant SOD1 transgenic mouse models (Bruijn et al. 1997, Johnston 2000, Watanabe
et al. 2001, Wang et al. 2003). Interestingly, Keller et al. (2012) found that SOD1-fALS patients
possess a unique immunohistochemical signature, including the presence of C9ORF72-positive
inclusions. In fact, the TDP-43-positive inclusions that are a hallmark of most genetic variants
of fALS and sALS are not found in SOD1-fALS patients or transgenic mouse models
(Mackenzie et al. 2007).
Beyond the presence of ubiquitin in SOD1 inclusions, there is extensive evidence indicating
that aberrant interactions occur between mutant SOD1 and other proteostasis components. The
first report of an effect of mutant SOD1 in modulating the activity of different molecular
chaperones was published ~20 years ago (Bruening et al. 1999). Numerous studies have since
documented correlations between mutant SOD1 aggregation, modulation of the activity of
chaperones and decreases in UPS activity in neuronal cell culture and in spinal cord motor
neurons in mouse models of SOD1-fALS (Watanabe et al. 2001, Takeuchi et al. 2002, Cheroni
et al. 2005, Matsumoto et al. 2005, Cheroni et al. 2009, Crippa et al. 2010). Critically, the
activity of the UPS is significantly more compromised by mutant SOD1 in spinal cord motor
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neurons of SOD1G93A mice than in non-motor neurons (Urushitani et al. 2002). Corroborating
this evidence that motor neurons have a distinct vulnerability to UPS dysfunction, Onesto et al.
(2011) observed that mutant SOD1 aggregation and UPS dysfunction occurred exclusively in
motor neuron-like NSC-34 cells, and not in C2C12 muscle cells. Given that molecular
chaperones and the UPS are essential for the maintenance of proteostasis and for the regulation
of normal cellular activities, these data indicate that a potential mechanism of mutant SOD1
neurotoxicity is through decreasing the capacity of the UPS and the chaperone network (Figure
1.4). The increased burden on proteostasis machinery likely impairs the ability of the cell to
correctly fold or degrade other proteins, leading to drastic disruptions in diverse molecular
processes, cellular dysfunction and loss of viability.
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Figure 1.4. Potential pathogenic mechanisms of mutant SOD1 on the UPS and chaperone activity in motor
neurons. Compared to other cell types, motor neurons have a distinct vulnerability to mutant SOD1-mediated UPS
dysfunction and disruptions in the activity of molecular chaperones. (A) In motor neurons, (i) misfolded mutant
SOD1 may overload the capacity of molecular chaperone systems, e.g. the HSP70/HSP40 system, thereby
decreasing the capacity of these chaperone systems to fold other proteins in the cell, leading to accumulation of
aberrant protein species. (ii) Evidence indicates that mutant SOD1 may be preferentially targeted for proteasomal
degradation, however, this conversely may cause overloading of the UPS in motor neurons, disrupting the
proteasomal degradation of other substrate proteins in the cell. (B) In other cell types (e.g. muscle cells, non-motor
neurons) the expression of mutant SOD1 does not lead to disruptions in the capacity of the molecular chaperone
systems or of the UPS.

The most common genetic cause of ALS currently identified is a (GGGGCC)n repeat expansion
that occurs either in the first intron or the promoter of the C9ORF72 gene on chromosome 9,
varying depending on the transcript isoform (Beck et al. 2013). In normal, healthy individuals
the GGGGCC hexanucleotide sequence is repeated no more than 33 times, compared to up to
hundreds and even thousands of repeats in patients with ALS, FTD and ALS/FTD (DeJesusHernandez et al. 2011, Beck et al. 2013, van der Zee et al. 2013). Hernandez et al. (2011) first
identified this hexanucleotide expansion in a large cohort of fALS patients also exhibiting a
FTD phenotype, as well as in a smaller percentage of sALS patients. Mutant C9ORF72 accounts
for about 40% of fALS and 7% of sALS (Majounie et al. 2012).
The function of C9ORF72 was elucidated over several studies in the past decade. Initially, two
independent groups identified homology of full-length C9ORF72 with DENN (Differentially
Expressed in Normal and Neoplasia)-domain proteins (Zhang et al. 2012, Levine et al. 2013).
DENN-domain proteins are highly conserved GDP/GTP exchange factors (GEFs) for RabGTPases, which regulate many aspects of membrane trafficking. This implicated a very
important role for C9ORF72 in key cellular processes, including the autophagic protein
degradation pathway. It was through the work of Webster et al. (2016) that the role of C9ORF72
in regulating the first steps of autophagy was demonstrated. One of the major theories regarding
the pathological role of the C9ORF72 mutation in FTD and ALS is that it leads to
haploinsufficiency and thus a loss-of-function mechanism (DeJesus-Hernandez et al. 2011).
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Pathogenicity of C9ORF72 mutation is also believed to result from accumulation of the noncoding repeat expansion mRNA in the cytoplasm and nucleus, forming toxic RNA foci that
sequester RBPs (Todd and Paulson 2010, DeJesus-Hernandez et al. 2011, Renton et al. 2011).
RNA foci are characteristic molecular hallmarks of pathogenesis in myotonic dystrophy and
several other neurological disorders (Wojciechowska and Krzyzosiak 2011). Additionally, ALS
patients with the C9ORF72 mutation exhibit the characteristic intracellular inclusions of
misfolded proteins, particularly phosphorylated TDP-43 aggregates (DeJesus-Hernandez et al.
2011). Cytoplasmic inclusions that are unique to C9ORF72-ALS, C9ORF72-ALS/FTD and
C9ORF72-FTD have also been reported; characteristically TDP-43-negative, p62-, ubiquitinand UBQLN2-positive inclusions that contain poly-(Gly-Ala), -(Gly-Pro) and –(Gly-Arg)
dipeptide-repeat (DPR) proteins (Mori et al. 2013, May et al. 2014).
DPR pathology is a direct consequence of the GGGGCC hexanucleotide repeat expansion,
through repeat-associated non-ATG-initiated (RAN) translation of this intronic repeat from
both the sense and antisense transcripts (Ash et al. 2013, Gendron et al. 2013, Mann et al. 2013,
Mori et al. 2013, Zu et al. 2013, May et al. 2014). Poly-(Gly-Ala) DPRs are the most abundant
DPR species in post-mortem brain tissue from individuals with repeat expansions in C9ORF72
(Mori et al. 2013). Proteomic analysis of poly-(Gly-Ala) aggregates has detected strong
enrichment for p62, the proteasome subunits PSMB4, PSMB5, PSMB6, PSMC6, and PSMD13,
several ubiquitin-related proteins, including UBQLN1 and UBQLN2, and the multifunctional
protein UNC119 (May et al. 2014). UNC119 is required for axon development and maintenance
and has key roles in synaptic functions (Maduro and Pilgrim 1995). UNC119 mutation in
Caenorhabditis elegans leads to motor dysfunction (Knobel et al. 2001). It is thus possible that
DPR aggregates contribute to neuronal dysfunction and degeneration in individuals with
C9ORF72 repeat expansions through sequestering proteins, such as UNC119, with important
functions in neuronal health. Accumulating evidence suggests that it is a combination of
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C9ORF72 haploinsufficiency and the toxic gain-of-function mechanisms of aberrant RNA foci
and DPRs that cause the full spectrum of pathology observed in individuals with C9ORF72
repeat expansions (Peters et al. 2015, Haeusler et al. 2016, Chitiprolu et al. 2018).
1.4.2

Mutations in genes involved in protein degradation pathways

1.4.2.1 UBQLN2 mutations
Several ALS-associated genes function in protein degradation pathways. Mutations in the
UBQLN2 gene (chromosomal locus Xp11.21) cause X-linked fALS and ALS/FTD (Deng et al.
2011). UBQLN2 is a member of the ubiquilin protein family, ubiquitin-like proteins that are
involved in delivering ubiquitylated proteins to the proteasome and have roles in autophagy
(Ko et al. 2004, Rothenberg et al. 2010). UBQLN2 has an N-terminal ubiquitin-like (UBL)
domain that binds to the proteasome and a C-terminal ubiquitin-associated (UBA) domain that
binds to substrate proteins. Interestingly, Deng et al. (2011) found that all the UBQLN2
mutations (P497H, P497S, P506T, P509S and P525S) detected in patients affect proline
residues in a unique PXX repeat region, indicating that these mutations could confer a common
pathogenic property on the UBQLN2 protein. Through work using cell culture models, these
researchers investigated the functional consequence of mutant UBQLN2 on ubiquitin-mediated
protein degradation and found that protein degradation via the UPS was impaired. Moreover,
mutations in UBQLN2 have been found to cause impaired autophagy (Fecto et al. 2012,
Teyssou et al. 2017). Such disruptions to degradative pathways, which are crucial for
proteostasis, could contribute significantly to further proteostasis disruptions and the
accumulation and aggregation of aberrant proteins in the cell.
Examining post-mortem spinal cord sections from two fALS patients with a P497H or P506T
mutation, Deng et al. (2011) observed skein-like inclusions that were immunoreactive to two
types of UBQLN2 antibodies. These same inclusions were also immunoreactive for p62, TDP43, FUS and OPTN, proteins that, as discussed in other sections of this chapter, are found in
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inclusions in other types of ALS. Of note, these inclusions were not found to contain SOD1.
UBQLN2 was also detected in the skein-like inclusions observed in a broad spectrum of ALS
cases; sporadic and familial forms of ALS, including those caused by either SOD1 or TARDBP
mutations, and ALS/FTD (Deng et al. 2011). This common association of UBQLN2 with
inclusions indicates that it could have important roles in ALS and ALS/FTD caused by
mutations in different genes.
1.4.2.2 SQSTM1 mutations
Mutations in SQSTM1, encoding another ubiquitin-binding protein, p62, have been reported in
fALS, sALS and FTD (Fecto et al. 2011, Rubino et al. 2012, Teyssou et al. 2013). P62 is a
multifunctional protein with particularly important roles in proteasomal and autophagic protein
degradation (Seibenhener et al. 2004, Bjorkoy et al. 2006). The involvement of p62 in
neurodegeneration is becoming increasingly apparent, with p62-immunoreactive inclusions a
common pathological feature in many neurodegenerative diseases including AD, PD, HD, FTD
as well as in the motor neurons of ALS patients (Kuusisto et al. 2002, Zatloukal et al. 2002,
Nakaso et al. 2004, Mizuno et al. 2006, Pikkarainen et al. 2008). It is often detected co-localised
with TDP-43 and ubiquitin in the inclusions of ALS and FTD patients (Hiji et al. 2008, Deng
et al. 2010, Keller et al. 2012, Teyssou et al. 2013).
The mutations that have been identified in ALS and FTD patients are distributed throughout
the whole protein, but most affect amino acids that are highly conserved in mammals, and that
are in different functional domains important for protein-protein interactions. For instance,
several mutations have been found in its UBA domain, affecting the binding of p62 to ubiquitin
and ubiquitylated proteins (Fecto et al. 2011, Teyssou et al. 2013). Both proteasomal and
autophagic protein degradation may be severely impeded in such variants. Indeed, some
mutations (e.g. K344E) have been detected in a region of the protein that interacts with LC3, a
key autophagy-related protein, and are therefore likely to interfere with this interaction and thus
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impede the autophagic pathway (Rubino et al. 2012). As well as a loss-of-function mechanism
contributing to disease, mutations may lead to a toxic gain-of-function through dysregulation
of the cell signalling pathways in which p62 has key roles. For example, several mutations
affect the PEST (proline-, glutamic acid-, serine-, threonine-enriched) domain, which forms a
signal peptide important for degradation of p62 and thus for regulating p62 protein levels (Fecto
et al. 2011). Such altered levels of p62 may lead to both accumulation and aggregation of
misfolded p62 and disturbance of the signalling pathways regulated by this protein. Given the
common presence of p62 pathology in several neurodegenerative diseases, it is likely that it is
fundamentally involved in the pathogenesis of these diseases, potentially through disruption of
its functions in proteostasis.
1.4.2.3 VCP mutations
Mutations in VCP have been identified in patients suffering from a spectrum of
neurodegenerative disorders including inclusion body myopathy with Paget disease of bone
(PDB) and/or FTD (IBMPFD) (Weihl et al. 2009). An exome sequencing study revealed that
VCP mutations were causal in a cohort of fALS cases, and that mutations in this gene may
account for ~1-2% of fALS cases (Johnson et al. 2010). Mutations in VCP lead to TDP-43immunoreactive, ubiquitylated cytoplasmic inclusions in muscle and frontal cortex neurons of
patients (Watts et al. 2004, Weihl et al. 2008) and in transgenic mouse models harbouring the
R155H and A232E mutations (Weihl et al. 2007, Badadani et al. 2010, Custer et al. 2010). A
novel mutation in VCP, I114P, has also been detected in sALS (Koppers et al. 2012), though
the pathogenicity of this variant is yet to be confirmed. This same study detected inclusions
positive for p62, ubiquitin and TDP-43, and confirmed the VCP-ALS frequency of ~1-2%
found in the exome sequencing study.
VCP is a highly conserved AAA+-ATPase, involved in the regulation of a variety of cellular
functions. These include cell signalling, the cell cycle, organelle biogenesis, and in particular,
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protein degradation via autophagy, the UPS, and the endoplasmic reticulum-associated
degradation (ERAD) pathway; VCP provides mechanical force for extracting substrates from
the ER membrane (Ye et al. 2001, Johnson et al. 2010, Meyer et al. 2012). In autophagy, VCP
is essential for maturation of ubiquitin-containing autophagosomes. The VCP mutations
identified in ALS and IBMPFD interestingly all occur in the N-terminal region of the protein,
which functions in binding polyubiquitylated proteins (Watts et al. 2004, Johnson et al. 2010).
Studies of mutant VCP using cell culture and transgenic mouse models has shown that loss of
VCP activity impairs autophagy; specifically, autophagosomes fail to mature into
autophagolysosomes, leading to the accumulation of non-degradative autophagosomes and
aggregated proteins (Ju et al. 2009). Moreover, mutations in VCP have been found to lead to
impaired proteasome activity, endoplasmic reticulum (ER) stress and activation of apoptosis
signalling pathways (Gitcho et al. 2009). It is conceivable that the functions of VCP in protein
degradation are disrupted in VCP-fALS, and that these disruptions lead to the accumulation and
aggregation of ubiquitylated proteins in motor neurons.
1.4.2.4 OPTN mutations
Maruyama et al. (2010) reported the first findings of mutations in the OPTN gene in fALS
patients, the product of which has been detected in inclusions within post-mortem spinal cord
tissue from individuals with fALS and sALS, co-localised with ubiquitin, TDP-43, FUS and
SOD1 in different cases (Maruyama et al. 2010, Ito and Suzuki 2011, Keller et al. 2012). OPTN
is a multifunctional protein involved in maintenance of the Golgi apparatus and post-Golgi
trafficking to the cell surface and to lysosomes through its interactions with huntingtin, Rab8
and myosin VI (Sahlender et al. 2005, del Toro et al. 2009). It may also have a role in regulating
its own expression, as an inhibitor of the activation of nuclear factor kappa B (NF-κB), which
mediates upregulation of OPTN (Zhu et al. 2007, Mrowka et al. 2008).
The co-localisation of OPTN in the SOD1-immunoreactive inclusions of SOD1-fALS patients,
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as well as in other fALS variants, such as C9ORF72 repeat expansion carriers and those with
mutations in TARDBP, FUS and in individuals with sALS (Maruyama et al. 2010, Keller et al.
2012), indicates a broad role for OPTN in the pathogenic mechanisms of ALS. Moreover,
OPTN has been detected in the inclusion bodies characteristic of a wide range of
neurodegenerative diseases including AD, PD and Creutzfeldt-Jakob disease (CJD) (Osawa et
al. 2011) and mutations have been implicated in primary open angle glaucoma (POAG), a
neurodegenerative eye disease (Rezaie et al. 2002). This suggests that OPTN could contribute
to neurodegeneration in these diseases via common pathogenic pathways. Two of the mutations
in OPTN, a Q398X nonsense mutation and a homozygous deletion of exon 5 (Ex5del), result
in a loss-of-function phenotype, disturbing Golgi organisation and regulation, and post-Golgi
transport. Indeed, depletion of OPTN through RNA interference has been shown to result in
Golgi disorganisation and reduced post-Golgi transport (Sahlender et al. 2005). As with
SQSTM1-, VCP- and UBQLN2-fALS cases, mutations in OPTN potentially cause impairment
of autophagy; mutations in OPTN and disruptions of its functions would lead to altered
trafficking of lysosomal proteins from the Golgi, causing disruptions in lysosomal function.
The glutamic acid residue substituted in the E478G mutation is highly conserved among OPTN
proteins of a wide range of species and occurs in the ubiquitin-binding domain of the protein
that mediates its interaction with NF-κB (Maruyama et al. 2010). Consistent with the
observation that OPTN-immunoreactivity in tissue from a patient with the E478G mutation is
increased, the E478G mutation potentially causes upregulation of OPTN through overactive
NF-κB activity. While the initial pathological mechanisms caused by these mutations differ,
their downstream effects converge in disrupting proteostasis, through dysfunction of OPTN in
protein degradation, or through increasing the levels of an aberrant mutant form of OPTN. It is
also conceivable that aggregation of OPTN results in loss of soluble protein from the cell, and
consequently causes further loss-of-function and disruption of its roles in proteostasis.
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1.4.2.5 VAPB mutations
In 2004 a new chromosomal locus (20q13.3) was identified for an atypical form of ALS, ALS8
(Nishimura et al. 2004), and subsequently a novel missense mutation, P56S, was found in the
gene encoding VAPB (Nishimura et al. 2004). VAPB belongs to a family of ubiquitously
expressed, type II integral membrane VAP proteins that localise to the ER membrane and preGolgi intermediates (Skehel et al. 2000), and are involved in non-vesicular transfer of lipids,
membrane trafficking, regulating ER-organelle and ER-cytoskeleton interactions, transport and
secretion, as well as homeostatic and signalling functions at the neuromuscular junction
(Soussan et al. 1999, Foster et al. 2000, Amarilio et al. 2005, Lev et al. 2008, De Vos et al.
2012, Han et al. 2012, Manford et al. 2012). The VAP protein family also target lipid-binding
proteins carrying a short motif containing two phenylalanines in an acidic tract (FFAT motif).
Recognising the FFAT motif, VAPs then recruit them to the cytosolic surface of ER membranes
(Kaiser et al. 2005, Loewen and Levine 2005). Mammalian species have two VAP proteins;
VAPA and VAPB (Nishimura et al. 1999).
Several mutations in VAPB have now been identified in people with ALS, however the P56S
mutation is the only one currently known to co-segregate with ALS (Nishimura et al. 2004,
Kabashi et al. 2013). In vitro and in vivo this mutation causes VAPB to oligomerise, aggregate
and accumulate in inclusions (Nishimura et al. 2004, Teuling et al. 2007, Tudor et al. 2010,
Kuijpers et al. 2013, Qiu et al. 2013). Interestingly, Teuling et al. (2007) found that mutant
VAPBP56S aggregates are continuous with the ER, possibly through interactions between the
transmembrane domains of the mutant VAPB proteins with VAPBWT still anchored to the ER
membrane. Furthermore, by trapping endogenous VAPBWT in mutant aggregates and reducing
cytosolic VAPB levels, this interaction impairs the normal function of VAPB. The hypothesis
of a dominant-negative mechanism of action of mutant VAPB in disease is supported by other
work carried out in yeast, mammalian cell culture, Drosophila and in transgenic mice
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(Ratnaparkhi et al. 2008, Suzuki et al. 2009, Forrest et al. 2013, Kuijpers et al. 2013).
Moreover, Teuling et al. (2007) reported that VAPA and VAPB levels are reduced in the spinal
cord motor neurons of ALS patients, in contrast to the normally abundant levels of these
proteins in the CNS of healthy individuals not affected by ALS, particularly in motor neurons.
The relatively high lipid metabolism and lipid transport requirements of large, complex motor
neurons makes them particularly vulnerable to reduced VAP function caused by mutation.
Golgi disassembly has been shown to result from abnormal lipid metabolism (Fukunaga et al.
2000, Gonatas et al. 2006). The disruption of intracellular transport and membrane trafficking
caused by reduced VAPB activity and abnormal lipid metabolism may additionally affect
autophagy.
Strikingly, findings made in work by Kuijpers et al. (2013) suggest a novel mechanism in motor
neurons that may enable them to cope with mutant VAPB levels that exceed the capacity of the
normal quality control pathways. They reported on extensive data that support a hypothesis in
which mutant VAPB inclusions represent a specialised ER-associated protein quality control
compartment, reminiscent of aggresomes, that isolates misfolded and aggregated VAPB from
the rest of the ER. Moreover, these researchers showed that mutant VAPB inclusions in
VAPBP56S transgenic mice were reversible ER-associated structures that were enriched in
factors that operate in the ERAD pathway (VCP, Derlin-1 and BAP31), the presence of which
was not associated with signs of motor neuron degeneration (Kuijpers et al. 2013). The lack of
neuronal pathology in these mice may be due to effective sequestration and clearance of mutant
VAPB in this novel protective compartment, preventing its aberrant accumulation and
interaction with VAPBWT.
1.4.3

DNA/RNA-binding proteins in ALS

The role of aberrant RNA metabolism in ALS pathogenesis first came to light with the
discovery that the D/RBP TDP-43 is one of the major protein constituents of ubiquitylated
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inclusions in sALS, which comprises the majority (~90%) of all ALS cases (Neumann et al.
2006). It was also found to be the major constituent of inclusions in MAPT-negative FTD
patients, providing the first biochemical evidence of a molecular link between ALS and FTD
(Arai et al. 2006, Neumann et al. 2006). Subsequently, mutations were identified in a highly
conserved region of the TARDBP gene in both fALS and sALS patients (Sreedharan et al.
2008), as well as ALS/FTD and FTD patients (Borroni et al. 2009, Gitcho et al. 2009, Andersen
and Al-Chalabi 2011). Shortly following this, mutations in FUS, encoding another D/RBP,
were detected in ~4-5% of fALS patients (Kwiatkowski et al. 2009, Vance et al. 2009).
Mutations in FUS have also been identified in sALS and FTD patients (Belzil et al. 2009,
Ticozzi et al. 2009, Blair et al. 2010, Corrado et al. 2010, DeJesus-Hernandez et al. 2010, Deng
et al. 2010, Van Langenhove et al. 2010, Lai et al. 2011), and intraneuronal inclusions
containing FUS are reported to occur in the brain and spinal cord of both familial and sporadic
ALS and FTD patients (Kwiatkowski et al. 2009, Neumann et al. 2009, Neumann et al. 2009,
Vance et al. 2009, Keller et al. 2012). Moreover, TDP-43 and FUS mislocalisation and
pathology have been observed in several neurodegenerative disorders; both are implicated in
polyglutamine disorders (Schwab et al. 2008, Doi et al. 2010), while TDP-43 pathology is also
observed in AD and other forms of dementia, PD and various myopathies (Forman et al. 2007,
Chen-Plotkin et al. 2010, Lagier-Tourenne et al. 2010).
TDP-43 and FUS are structurally and functionally related heterogeneous nuclear
ribonucleoproteins (hnRNPs), both with roles in transcription regulation, pre-mRNA splicing,
mRNA stabilisation and RNA transport (Buratti et al. 2001, Buratti et al. 2004, Mercado et al.
2005, Strong et al. 2007, Colombrita et al. 2009). Indeed, TDP-43 and FUS each have several
thousand mRNA targets (Hoell et al. 2011, Polymenidou et al. 2011, Tollervey et al. 2011).
Both proteins contain RNA recognition motifs (RRM), a nuclear localisation signal (NLS) and
a glycine-rich region (GRR) that forms part of a yeast prion-like domain (Wang et al. 2004,
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Buratti et al. 2005, Neumann et al. 2006, Lagier-Tourenne and Cleveland 2009, Cushman et al.
2010, Gitler and Shorter 2011, Udan and Baloh 2011). This functional and structural similarity
led Couthouis et al. (2011) to screen for additional prion-like domain-containing D/RBPs that
may contribute to ALS pathogenesis, through which they identified mutations in TAF15 in
fALS patients. A separate study also detected TAF15 mutations in fALS patients (Ticozzi et al.
2011), and TAF15-positive intraneuronal inclusions are present within TAF15-fALS patients
(Couthouis et al. 2011), findings that underscore a role for aberrant RNA metabolism in ALS.
Although predominantly localised to the nucleus, TDP-43 shuttles between the nucleus and
cytoplasm in a transcription-dependent manner (Ayala et al. 2008). In the cytoplasm, TDP-43
has been found to have distinct functions, including mRNA stabilisation and translation (Wang
et al. 2008) and the formation and regulation of stress granules (Colombrita et al. 2009, LiuYesucevitz et al. 2010, Dewey et al. 2011, McDonald et al. 2011, Bentmann et al. 2012). Stress
granules (SGs) are punctate cytoplasmic foci, ranging in size from 0.1 to 2.0 µm, that sequester
mRNA and ribosomal components to regulate translation and prioritise the synthesis of stress
protective proteins in response to stressors, e.g. oxidative stress, heat shock, proteasome
inhibition and other forms of cellular injury (Anderson and Kedersha 2009, Moisse et al. 2009,
Moisse et al. 2009). SGs are transient structures; when the cellular stress has passed, SGs
rapidly disaggregate, enabling their components to return to their normal localisation and
function (Kedersha et al. 1999).
As with TDP-43, both FUS and TAF15 are predominantly nuclear proteins that have additional
cytoplasmic functions, such as mRNA transport, local translation and RNA decay, and they
incorporate into SGs (Fujii et al. 2005, Yoshimura et al. 2006, Andersson et al. 2008,
Blechingberg et al. 2012). FUS and TAF15 are part of the FET (FUS, EWS, TAF15) family of
structurally and functionally related D/RBPs (Tan and Manley 2009). These two proteins
appear to associate with SGs via the same mechanisms, as the RNA-binding C-terminal
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domains of both proteins, which contain RGG repeats and a zinc finger domain, mediate SG
recruitment (Bentmann et al. 2012, Marko et al. 2012).
The key mechanisms by which these D/RBPs contribute to disease are not yet clear, although
the fact that TDP-43 and FUS pathology occur in a wide variety of diseases is strong indication
for an important pathogenic role of altered RNA metabolism. Nuclear import defects and
cytoplasmic accumulation seem to be important events in both FUS- and TARDBP-linked ALS,
and possibly in TAF15-linked disease. Most of the ALS-associated mutations in FUS are
clustered within its C-terminal NLS, and multiple studies have shown a correlation between
mutations that cause a severe cytoplasmic accumulation and a greater disease severity and
progression rate (Kwiatkowski et al. 2009, Dormann et al. 2010, Gal et al. 2011, Niu et al.
2012). Mutations in the GRR of TARDBP, which constitute the majority of disease-linked
mutations, have been shown to cause a progressive shift of TDP-43 localisation to the
cytoplasm (Ayala et al. 2008, Johnson et al. 2009), and the cytoplasmic accumulation of TDP43 has been shown to be toxic to neurons (Barmada et al. 2010). The GRR is also necessary for
its association with SGs, and GRR mutations cause altered SG dynamics (Dewey et al. 2011).
Increased sequestration of TDP-43, FUS, TAF15 and other D/RBPs in cytoplasmic SGs
interferes with their dynamic nucleus-cytoplasm shuttling, reducing levels of these proteins in
the nucleus and their functional availability in the cytoplasm. Furthermore, the accumulation of
TDP-43 into cytoplasmic inclusions that is characteristic of ALS, FTD, AD, PD and various
myopathies (Forman et al. 2007, Schwab et al. 2008, Chen-Plotkin et al. 2010, Doi et al. 2010,
Lagier-Tourenne et al. 2010) further depletes the functional pool of TDP-43 in neurons. The
aggregation of TDP-43 into cytoplasmic inclusions in ALS may be triggered by cellular insult
resulting from defective autophagic or UPS protein degradation, suggested by the recurrent
finding that ubiquitin and p62 are co-localised in TDP-43-positive inclusions (Mizuno et al.
2006, Neumann et al. 2006, Deng et al. 2010, Keller et al. 2012). Moreover, in a Drosophila
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model, disease-causing mutations in VCP were found to cause significant redistribution of
TDP-43 to the cytoplasm, and this redistribution was sufficient to cause cytotoxicity (Ritson et
al. 2010). It is entirely possible that the key roles of VCP in autophagy and ubiquitin-dependent
segregation of substrates from multiprotein complexes, e.g. SGs, would be hindered in cases in
which it is mutated, thus causing impaired recycling of TDP-43 from SGs back to the nucleus.
Many of the mRNA targets of TDP-43 and FUS are crucial for normal neuronal function
(Polymenidou et al. 2011, Sephton et al. 2011, Tollervey et al. 2011, Colombrita et al. 2012,
Dichmann and Harland 2012, Ishigaki et al. 2012, Lagier-Tourenne et al. 2012, Rogelj et al.
2012, Nakaya et al. 2013). Moreover, TDP-43 deficiency has been found to affect the levels of
mRNAs encoding CHMP2B, FIG, OPTN, VAPB and VCP, all of which are implicated in ALS
and have key roles in protein degradation pathways (Polymenidou et al. 2011). Another target
of TDP-43 is the mRNA encoding ATG7, an autophagy-related protein (Bose et al. 2011). FUS
has also been reported to bind to mRNAs encoding ALS-associated OPTN, VAPB, VCP and
UBQLN2, as well as mRNAs encoding other proteins involved in the UPS (Hoell et al. 2011,
Colombrita et al. 2012, Lagier-Tourenne et al. 2012). It is thus conceivable that abnormalities
in mRNA splicing and processing resulting from dysregulation of TDP-43 and/or FUS lead to
innumerable disturbances in neurons. Indeed, both deficiency and overexpression of WT and
mutant forms of TDP-43 promote cytotoxicity, and it is intrinsically aggregation-prone in its
WT form (Johnson et al. 2009, Laird et al. 2010, Liachko et al. 2010, Armakola et al. 2011,
Huang et al. 2012, Uchida et al. 2012). Cytoplasmic accumulations of TDP-43, FUS or TAF15
may aberrantly sequester RNAs and/or other proteins (Voigt et al. 2010, Hoell et al. 2011),
causing further dysfunction in cellular RNA metabolism and disruptions in the activities of the
affected proteins.
The possible role of mutant TDP-43 in the disruption of proteostasis can also be extended to
disturbance of the intracellular trafficking and secretory pathways in motor neurons. Fujita et
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al. (2008) found that abnormal TDP-43 cytoplasmic immunoreactivity was associated with
impaired functioning of the Golgi apparatus, leading to Golgi fragmentation. It is unknown
whether errors in mRNA metabolism are responsible for this impairment. The Golgi apparatus
has numerous important functions in maintaining proteostasis, including post-translational
modification of proteins and protein trafficking.
ALS gene variants may converge in proteostasis dysfunction
Inclusion bodies containing visible accumulations of detergent-insoluble protein aggregates are
a pathological hallmark of many neurodegenerative disorders including AD, PD, HD and CJD
(Leigh et al. 1991, Chiti and Dobson 2006, Ticozzi et al. 2010), and ALS, in both sporadic and
familial cases (Gurney et al. 1994, Wong et al. 1995, Bruijn et al. 1997, Bruijn et al. 1998,
Watanabe et al. 2001, Boillee et al. 2006). Generally, specific aggregating proteins are
implicated in each of these neurodegenerative diseases; α-synuclein in PD, huntingtin in HD,
Aβ and tau in AD (Ilieva et al. 2009). In ALS, however, the situation appears to be more
complex, with a multitude of different proteins being detected in the inclusion bodies inside
affected motor neurons (Migheli et al. 1993, Okamoto et al. 1993, Buee-Scherrer et al. 1995,
Wong et al. 2000, Arai et al. 2006, Mizuno et al. 2006, Neumann et al. 2006, Fujita et al. 2008,
Maruyama et al. 2010, Deng et al. 2011). In fact, a number of morphologically different types
of inclusions are found in ALS motor neurons, including: filamentous skeins, dense hyaline
bodies, and round or conglomerate Lewy body-like forms (Leigh et al. 1991); Bunina bodies
(Okamoto et al. 1993, Strong et al. 2005); basophilic inclusions (Nelson and Prensky 1972,
Oda et al. 1978, Chou 1979); and spheroids (Leigh et al. 1991). Intra- and extraneuronal tauimmunoreactive aggregates have also been detected in a subgroup of ALS patients exhibiting
features of FTD and cognitive decline (Yang et al. 2003), although the exact prevalence of these
aggregates is yet to be determined.
Misfolded proteins aggregate and form inclusions when they accumulate to a concentration that
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exceeds their solubility (Chiti and Dobson 2006). Yet proteins have co-evolved with their
cellular environments to exist at optimal functional concentrations at which their solubility is
near compromised (Tartaglia et al. 2007, Ciryam et al. 2013, Ciryam et al. 2015), seemingly
making them vulnerable to precipitation in the face of changes to their environment. In order
to prevent such changes to protein solubility, the cell must be able to actively maintain
proteostasis, keeping cellular proteins in their correct conformation, concentration and location
(Balch et al. 2008). Proteins can accumulate in the cell and form inclusions when these
mechanisms maintaining proteostasis are compromised, or their capacity is exceeded (Yerbury
and Kumita 2010, Gidalevitz et al. 2011, Yerbury et al. 2013). Conversely, as mentioned in
section 1.2.2.1, aberrant protein species can be sequestered into inclusions that function as
protein quality control compartments when proteostasis is compromised or capacity is
exceeded, in a cellular response to protect against abnormal interactions of aberrant proteins
with other molecules and macromolecular complexes within the cells (Johnston et al. 1998,
Kopito 2000, Arrasate et al. 2004, Kaganovich et al. 2008, Treusch et al. 2009, Zhang and Qian
2011, Weisberg et al. 2012, Polling et al. 2014).
As cells age, the efficacy of proteostasis mechanisms declines (Balch et al. 2008, Ben-Zvi et
al. 2009, Brehme et al. 2014). It is postulated that aging, proteostasis and neurodegenerative
disease are closely linked (Morimoto 2008, Wyatt et al. 2013, Yerbury et al. 2016), explaining
why most neurodegenerative diseases, including ALS, are late-onset, with most forms
developing during middle-age and in later years (Derham and Harding 1997, Zhang et al. 2004,
Erickson et al. 2006, Massey et al. 2006). Importantly, motor neurons have been shown to be
particularly vulnerable to disruptions in proteostasis and to other stressful stimuli, including
proteotoxic stress induced by aggregated proteins, even in comparison with other cells of the
nervous system (Durham et al. 1997, Bruening et al. 1999, Batulan et al. 2003, Yerbury et al.
2019).
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The common occurrence of ubiquitylated protein inclusions inside the diseased motor neurons
of ALS patients harbouring a multitude of different genetic mutations leads to the hypothesis
that altered proteostasis in motor neurons is a critical underlying cause of ALS (Figure 1.5).
Investigating how mutations in the identified ALS-associated genes lead to dysfunction of
proteostasis and the responses of motor neurons to these events will greatly increase our
understanding of how neurodegeneration in ALS proceeds.
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Figure 1.5. Summary of potential mechanisms by which ALS-associated gene variants cause proteostasis
dysfunction in motor neurons. Oligomeric or aggregated mutant SOD1 sequesters molecular chaperones,
ubiquitin and proteasome subunits, interfering with chaperone activity and the UPS. Mutations in C9ORF72 may
lead to haploinsufficiency and thereby disruptions in C9ORF72 function in autophagy. C9ORF72 mutations also
result in the production of toxic RNA foci and dipeptide repeat proteins (DPRs). RNA foci sequester RNA-binding
proteins (RBPs), disrupting their functions while DPRs may aberrantly interact with and sequester different cellular
components, including proteasome subunits. Mutations in UBQLN2 and SQSTM1 (encoding p62) impair their
functions in autophagy and in delivering ubiquitylated proteins to the proteasome for degradation. VCP is involved
in protein degradation via autophagy, the UPS, and the endoplasmic reticulum-associated degradation (ERAD)
pathway. Loss of VCP activity from ALS-associated mutations leads to impaired delivery of ubiquitylated proteins
to the proteasome, disruptions in ERAD and failure of autophagosomes to mature into autophagolysosomes.
Mutations in OPTN impair the functions of OPTN in Golgi organisation and post-Golgi transport, leading to Golgi
disorganisation and fragmentation. Impaired OPTN activity potentially leads to altered delivery of ubiquitylated
cargo to autophagosomes and disrupted trafficking of lysosomal proteins from the Golgi, causing disruptions in
lysosomal function and autophagy. Mutations in VAPB are hypothesised to cause dominant-negative impairment
of wild-type VAPB; aggregates formed by mutant VAPB interact aberrantly with and sequester wild-type VAPB.
Consequently, impaired VAPB activity leads to disruptions in ER function, ER-Golgi transport and membrane
trafficking. Mutations in the DNA/RNA-binding proteins TARDBP (encoding TDP-43), FUS and TAF15 cause
disruptions in transcription, mRNA splicing and processing, mRNA transport and altered stress granule dynamics.
Moreover, mutations in TARDBP and FUS lead to disruptions in the expression of the mRNA targets of TDP-43
and FUS. Figure adapted from Ciryam et al. 2017.
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Studying dysregulation of proteostasis in ALS models: Summary and aims
Amongst the complexity and molecular heterogeneity of ALS, previous studies have identified
disruptions in the proteostasis network that are associated with certain ALS gene variants.
However, there remains a need to identify the exact proteostasis disruptions that are commonly
associated with each of the ALS-causing genetic mutations, and those that are unique to each
gene variant. It is hypothesised that dysfunction of the proteostasis network in motor neurons
may be an underlying link between the different ALS-associated gene variants that contributes
to motor neuron degeneration in ALS. As such, the overall objective of this PhD research was
to develop and employ novel experimental strategies that enable investigation of the effects of
different ALS-associated gene variants on common proteostasis components and processes.
Such approaches may facilitate identification of the proteostasis components that have key roles
in ALS pathogenesis, and thereby lead to the elucidation of potential therapeutic targets. To
achieve this objective, the specific aims of this work were to:
1. Establish a high-throughput screening system using Saccharomyces cerevisiae to model
pathological TDP-43 and FUS aggregation, and ALS-associated mutant SOD1.
2.

Use this S. cerevisiae model to examine the effects of pathological TDP-43, FUS and
SOD1 on common proteostasis components and processes.

3. Validate the relevance of key proteostasis components identified in the S. cerevisiae
screens using neuronal cell culture models of ALS.
4. Establish a high-content screening (HCS) system that can be used to investigate
proteostasis dysfunction in neuronal cell culture models of multiple different ALSassociated gene variants in parallel experiments.
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Ch 2

Chapter 2: General materials and methods
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This chapter outlines the general materials and methods used in the research detailed
throughout this thesis. Additional materials and methods that pertain specifically to the work
detailed in Chapters III – V are provided in the relevant chapters.
Materials and reagents
All media and buffers used in this research were prepared using Milli-Q water (Q-POD®
Ultrapure

Water

Remote

Dispenser,

Millipore,

Billerica,

MA,

USA).

Ethylenediaminetetraacetic acid (EDTA) and tryptone were from Amresco (Solon, USA).
HyperLadder™ I and HyperLadder™ II molecular weight markers were from Bioline
(Alexandria, NSW, Australia). Mini-PROTEAN® TGX™ Precast Protein Gels, Precision Plus
Protein™ Dual Color protein standards and sodium dodecyl sulphate (SDS) were from BioRad (Hercules, CA, USA). Foetal Bovine Serum (heat-inactivated prior to use; FBS) was from
Bovogen Biologicals (East Keilor, VIC, Australia). Sterile cell culture plates were from Greiner
Bio-One (Frickenhausen, Germany). Β-mercaptoethanol, bicinchoninic acid disodium salt
hydrate (bicinchoninic acid, BCA), bovine serum albumin (BSA), Brilliant Blue R concentrate,
copper sulphate pentahydrate (CuSO4.5H2O), dimethyl sulfoxide (DMSO), magnesium
chloride (MgCl2), methanol, paraformaldehyde (PFA), potassium chloride (KCl), sodium
chloride (NaCl), Tris-hydrochloride (Tris-HCl), tris(hydroxymethyl)aminomethane, Triton X100, Tween® 20 (polyethylene glycol sorbitan monolaurate) and yeast extract were from
Sigma-Aldrich (St. Louis, MO, USA). Dulbecco’s Modified Eagles Medium with nutrient
mixture F-12 powder (DMEM/F-12) supplemented with 2.5 mM L-glutamine, DMEM/F-12
without phenol red supplemented with 2.5 mM L-glutamine, Halt™ Protease Inhibitor Cocktail
(100X), Lipofectamine® 2000 and 3000, OptiMEM® I (1X) reduced serum medium,
SuperSignal™ West Pico chemiluminescent substrate, 0.05% trypsin-EDTA were all obtained
from Thermo Fisher Scientific (Waltham, MA, USA). All other reagents were from Amresco,
Astral Scientific (Gymea, NSW, Australia) or Sigma-Aldrich and were endotoxin free.
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Plasmids
The pEGFP-N1 expression vector containing human wild-type SOD1 (SOD1WT-EGFP) and
SOD1 altered by the disease-associated Ala4Val (A4V) mutation (SOD1A4V-EGFP) were
kindly provided by Assoc. Prof. Bradley Turner (The Florey Institute of Neuroscience &
Mental Health, Victoria, Australia) and had been constructed as previously described (Turner
et al. 2005). Both the SOD1-EGFP vectors and the pCMV6-AC-tGFP vector containing human
wild-type TARDBP (TDP-43WT-tGFP) and the disease-associated mutant M337V (TDP43M337V-tGFP) (OriGene, Maryland, USA) had previously been transformed into chemically
competent Escherichia coli (E. coli) DH5-α cells and were stored in glycerol at -80 °C prior to
plasmid DNA purification. The identity of these stocks had been confirmed by sequencing
(Jake Matic, 2012, personal communication). Additional plasmids used in the research
presented in Chapters III – V are detailed in the relevant chapters.
Transformation of E. coli and plasmid DNA purification
The subcloning procedures used throughout the research presented in Chapters III and V used
the DH5-α E. coli strain. Chemically-competent DH5-α cells had kindly been previously
prepared using calcium chloride-treatment by Dr. Luke McAlary (University of Wollongong,
NSW, Australia). To transform cells using the heat-shock protocol, 100 µL of chemicallycompetent DH5-α cells were gently mixed with 10 ng of plasmid DNA and incubated on ice
for 30 min. Cells were then heat-shocked at 42 °C for 45 sec and immediately transferred to
ice to incubate for 5 min. Cells were then diluted with 500 µL of Super Optimal Broth with
Catabolite repression (SOC; 0.5% (w/v) yeast extract, 2% (w/v) tryptone, 10 mM NaCl, 2.5
mM KCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM glucose) and incubated for 1 h at 37 °C with
agitation (190 rpm). Aliquots of 100 µL and 300 µL of transformation cultures were then plated
onto pre-warmed sterile selective Luria-Bertani (LB)-agar plates (LB [1% (w/v) tryptone, 1%
(w/v) NaCl, 0.5% (w/v) yeast extract], containing 15% (w/v) agar and the appropriate
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antibiotic; either 100 µg/mL ampicillin, or 50 µg/mL kanamycin) and incubated overnight at
37 °C. Successfully transformed single bacterial colonies were selected and used to inoculate
sterile selective LB broth containing the appropriate antibiotic, for plasmid purification using
the CompactPrep Plasmid Maxi Kit (Qiagen, Hilden, Germany) as per the manufacturer’s
protocol. To confirm the purity of extracted plasmid DNA following the purification procedure
and measure its concentration, the ratio of absorbance at 260 nm and 280 nm (A260/A280 ratio)
and concentration (A260) were measured using a NanoDrop 2000c dual-mode UV-Vis
Spectrophotometer (Thermo Fisher Scientific, Waltham, USA).
Samples of extracted plasmid DNA were examined using diagnostic restriction enzyme
digestion with the appropriate restriction enzymes. Digested plasmid DNA samples were then
prepared for agarose gel electrophoresis by mixing samples with DNA loading buffer (30%
(v/v) glycerol, 0.25% (w/v) bromophenol blue) and resolved by electrophoresis on 1% (w/v)
agarose gels in tris-acetate-EDTA (TAE) buffer (1 mM EDTA, 40 mM Tris and 20 mM acetic
acid) alongside HyperLadder™ I (200 – 10037 bp) or HyperLadder™ II (50 – 2000 bp)
molecular weight markers, as appropriate for each digested DNA sample. Following
electrophoresis, agarose gels were stained with 0.005% (w/v) ethidium bromide solution for 20
min and destained in dH2O for 20 min. The resulting stained DNA bands within the gels were
visualised using UV light exposure in a Gel Logic 2200 Pro Imaging System (Carestream
Health, Rochester, NY, USA).
Preparation of glycerol stocks of transformed E. coli
Glycerol stocks of successfully transformed DH5-α E. coli were prepared for the long-term
storage of plasmid DNA at -80 °C. Selected single colonies of DH5-α E. coli transformed with
each respective plasmid construct were used to inoculate 5 mL aliquots of LB broth
supplemented with the appropriate antibiotic (either 100 µg/mL ampicillin, or 50 µg/mL
kanamycin) and incubated overnight at 37 °C with agitation (190 rpm). The following day, 1
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mL of each overnight culture was mixed with 1 mL of sterile glycerol in cryovials for storage
at -80 °C.
Mammalian cell culture
The M. musculus neuroblastoma × spinal cord hybrid cell line (NSC-34) was supplied by Prof.
Neil Cashman (University of British Columbia, Vancouver, Canada) (Cashman et al. 1992).
NSC-34 cells were maintained in a routinely serviced 37 °C Heracell 150i incubator with
humidified air containing 5% (v/v) carbon dioxide (CO2). DMEM/F-12 supplemented with
10% (v/v) FBS (DMEM/F-12/FBS) was used for regular culturing of cells. Cells were passaged
once they reached ~80% confluence, usually every 3 days. This involved rinsing the adherent
cells with a small volume of serum-free DMEM/F-12 before incubating them with 0.05%
trypsin-EDTA for 3 min at 37 °C. Cells were then collected by centrifugation at 1,500 rpm for
5 min at room temperature, followed by resuspension in DMEM/F-12/FBS and transfer of a
suitable volume of resuspended cells to a sterile cell culture flask to achieve an appropriate
dilution, usually a 1:6 dilution. Plasmid DNA transfections in NSC-34 cells performed in the
experiments outlined in Chapters III and V are detailed in the relevant sections of each chapter.
Statistics
Results presented throughout Chapters III – V are the mean ± SEM of three independent
experiments, unless otherwise indicated. To analyse and compare differences in means in
experiments involving multiple treatments, one-way analysis of variance (ANOVA) tests were
used, paired with post hoc testing using Tukey’s multiple comparison test. Otherwise, Student’s
t tests were used to evaluate differences in means. Unless stated otherwise, statistical analyses
were performed using GraphPad Prism® (Version 5.00, GraphPad Software, Inc., La Jolla,
CA, USA). A significance level of p < 0.05 was used to define differences between means as
significant for all statistical analyses.
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Chapter 3: Yeast EGFP-fusion library screens
reveal differential levels of ALS-associated proteins
in yeast expressing TDP-43, FUS and SOD1

The research in this chapter was carried out in collaboration with Professor Stephen G.
Oliver and Dr. Giorgio Favrin as part of a 12 month stay in the S. G. Oliver laboratory at
the Department of Biochemistry, University of Cambridge, UK.
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Introduction
The budding yeast Saccharomyces cerevisiae has become an established robust model for
investigating mechanisms involved in several neurodegenerative diseases, including PD, HD,
AD and ALS (Krobitsch and Lindquist 2000, Auluck et al. 2002, Outeiro and Lindquist 2003,
Willingham et al. 2003, Cooper et al. 2006, Johnson et al. 2008, Gitler et al. 2009, Johnson et
al. 2009, Elden et al. 2010, Sun et al. 2011, Treusch et al. 2011, Kim et al. 2014). The yeast
genome is well characterised and many key molecular processes are conserved between yeast
and higher eukaryotic organisms, including humans. Almost a third of yeast genes have a direct
human orthologue (Botstein et al. 1997). Indeed, key pathways that are disrupted in
neurodegenerative diseases, such as protein folding and other protein quality control
mechanisms, are fundamental features of eukaryotic biology that are conserved across the
spectrum of eukaryotic organisms. As such, yeast provide an ideal starting point to screen for
genes and proteins that aberrantly or advantageously interact with neurodegenerative disease
genes, with findings that can then be validated in neurologically relevant cellular and animal
models (Elden et al. 2010, Couthouis et al. 2011, Sun et al. 2011, Kim et al. 2014). Methods
to overexpress or knock out every yeast gene are well established. The development of
Synthetic genetic array (SGA) methodology (Baryshnikova et al. 2010) has facilitated the study
of genes and their associated pathways that are affected by or modify the effects of diseaseassociated genes (Yuen et al. 2007, Deshpande et al. 2013, van Pel et al. 2013, Bian et al.
2014). Such studies provide valuable insight into disease mechanisms at the genetic level.
However, key post-transcriptional, translational and post-translational information can be
missed without investigation at the protein level.
For the present study, a collection of yeast EGFP-fusion strains (Huh et al. 2003) was employed
to develop a yeast screening system to explore proteins and molecular pathways that may be
associated with the pathological effects of TDP-43, FUS and mutant SOD1 in ALS. This
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collection was created by the integration of an EGFP at the C-terminus of the genomic locus
of each yeast gene, preserving the natural promoter of each gene to facilitate minimal
perturbation in the levels and activity of each encoded protein. Previously, most studies
utilising this collection have investigated the localisation of proteins and their alterations under
stress conditions using fluorescence microscopy (Huh et al. 2003, Breker et al. 2013, Breker
et al. 2014). The use of a fluorescent plate reader to quantify the expression of the yeast EGFPfusion proteins under different conditions has only recently emerged (Lichten et al. 2014). In
the face of extrinsic or intrinsic stimuli that disturb cellular homeostasis, cells respond by upregulating proteins that assist in maintaining a homeostatic state and down-regulating proteins
that impair the cellular ability to appropriately respond to the disturbance (Beyer et al. 2004,
Newman et al. 2006, Sigal et al. 2006, Erjavec et al. 2007, Sigal et al. 2007, Aragon et al.
2009, Frenkel-Morgenstern et al. 2010, Eden et al. 2011, Lee et al. 2011, Tkach et al. 2012,
Breker et al. 2013). Consequently, the measurement of protein abundance changes in cells
exposed to different stressors, such as the overexpression of disease-causing gene variants, can
provide insight into the proteins and molecular processes involved in the cellular response to
the specific stress. It was thus hypothesised that proteins found to have differential levels in
yeast expressing human TDP-43, FUS and mutant SOD1 may be critically involved in the
response of cells to these aberrant ALS-associated proteins.
There are no true homologues of TDP-43 and FUS in yeast (Johnson et al. 2008, Ju et al. 2011).
In previously described yeast models, the expression of human TDP-43WT and FUSWT without
the need for ALS specific mutation recapitulates key pathological features observed in human
tissue, mammalian cell culture and animal models. These features include a shift from
predominantly nuclear localisation to cytoplasmic sequestration and aggregation, and toxicity
(Johnson et al. 2008, Johnson et al. 2009, Fushimi et al. 2011, Ju et al. 2011, Kryndushkin et
al. 2011, Sun et al. 2011, Kim et al. 2014). Data gained from these and other yeast-based
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studies of neurodegenerative disease mechanisms have gone on to be validated in
neurologically relevant cellular and animal models, as well as in human tissue (Couthouis et
al. 2011, Couthouis et al. 2012, Kim et al. 2014). For instance, findings from a yeast genomewide screen were followed up using Drosophila melanogaster and mammalian cell culture
models of ALS and led to the discovery that dysfunction in SG dynamics contributes
significantly to toxicity caused by a pathological interaction between TDP-43 and ataxin-2
(Kim et al. 2014). Indeed, these findings from yeast led to the discovery of genetic association
between ataxin-2 and ALS, clearly demonstrating the relevance of yeast as a model system.
Furthermore, examining the findings from this yeast-based study in D. melanogaster led to the
discovery of a protein that is critical for the pathological TDP-43-ataxin-2 interaction,
polyadenylate-binding protein (PABP), and that this protein is present in cytoplasmic
inclusions in post-mortem spinal cord tissue from individuals with ALS (Kim et al. 2014).
Many of the early yeast-based studies into neurodegenerative disease mechanisms, and the
correlation of the reported findings with those documented in mammalian cell culture and
animal models, have been thoroughly reviewed elsewhere (Outeiro and Muchowski 2004).
As reviewed in Chapter I, while the mechanisms that have been postulated to contribute to ALS
pathogenesis are diverse, many of them link either directly or indirectly to disruptions in the
proteostasis network. There remains a need to further dissect these links to proteostasis
dysfunction and to decipher precisely how this dysfunction proceeds with regard to the cellular
response to ALS-causing pathological proteins. One way to gain such insight is to focus on the
molecular processes that have been implicated in ALS pathogenesis, including molecular
processes that are part of the proteostasis network, and examine whether any specific protein
components of these processes are differentially regulated in cells expressing ALS-causing
gene variants. Thus, to investigate the specific proteins that are involved in the cellular response
to pathological TDP-43, FUS and mutant SOD1 expression in yeast, the aims of the work
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described in this chapter were to:
(i)

collate a list of proteins involved in molecular processes that have been previously
implicated in ALS pathogenesis and

(ii)

using the EGFP-fusion yeast library, determine whether the levels of these proteins
are altered by the expression of the ALS-associated proteins TDP-43WT, FUSWT,
SOD1WT and mutant SOD1A4V.

It was hypothesised that some of these proteostasis-associated proteins will have differential
expression in the absence versus presence of TDP-43, FUS and mutant SOD1 and that these
will represent proteins with key roles in the cellular response to ALS-linked pathology.
Materials and methods
3.2.1

Materials and reagents

Bacto™ agar, Bacto™ peptone, Bacto™ tryptone and Bacto™ yeast extract were from BD
Biosciences (Becton, Dickinson and Co., San Jose, CA, USA). Sterile 384-well flat-bottom
µclear microplates and sterile 96-well flat-bottom crystal-clear microplates were from Greiner
Bio-One (Frickenhausen, Germany). Agarose (molecular biology grade, electrophoresis
grade), glycine and tris(hydroxymethyl)aminomethane were from Melford (Suffolk, UK). The
E.Z.N.A.® Plasmid DNA Mini Kit I was from Omega Bio-Tek, Inc. (Norcross, GA, USA).
The QIAquick® Gel Extraction Kit was from Qiagen (Hilden, Germany). D-(+)-galactose, D(+)-glucose, D-(+)-raffinose pentahydrate, glass beads (acid-washed), L-glutamic acid
monosodium salt hydrate, L-leucine, uracil and yeast nitrogen base without amino acids (YNB)
were from Sigma-Aldrich (St. Louis, MO, USA). Glycerol and sodium chloride (NaCl) were
from Thermo Fisher Scientific (Waltham, MA, USA).
3.2.2

Advanced Gateway® Cloning, plasmids and yeast transformation

The human SOD1WT and SOD1A4V open reading frames (ORFs) in pEGFP-N1 were sub-cloned
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into the pAG416GAL-ccdB-DsRed vector using the Advanced Gateway® BP and LR
recombination reactions, as per the manufacturer’s instructions (Figure 3.1, a). In order to carry
out the BP recombination reaction, site-specific attachment (attB) sites were first added to the
5’ and 3’ ends of the ORFs of SOD1WT and SOD1A4V in pEGFP-N1. PCR primers were
designed to add attB sites and isolate the SOD1WT and SOD1A4V ORFs from the backbone
sequence (Table 3.1). Manufacturing of the primers was outsourced to Sigma-Aldrich (UK).
The PCR procedure was carried out using VELOCITY DNA polymerase (Bioline, UK) as per
the manufacturer’s instructions. Following PCR, each reaction mixture was digested with 5
units of DpnI (New England BioLabs® Inc., MA, USA) at 37 °C for 1 h to remove any
remnants of the original plasmids.
Table 3.1. PCR primer sequences used to add attB sites to SOD1WT and SOD1A4V in pEGFP-N1.

Gene/vector
backbone

Purpose

Primer sequence

SOD1WT and
SOD1A4V in
pEGFP-N1.

To add attB1 and attB2 sites to
the 5’ and 3’ ends of the SOD1
ORFs and isolate them from
backbone sequence.

Forward: 5’GGGGACAAGTTTGTACAAA
AAAGCAGGCTCCATGGCGA
CGAAGGCCGTG-3’
Reverse: 5’GGGGACCACTTTGTACAAG
AAAGCTGGGTGCAATTGGG
CGATCCCAATTACAC-3’

To purify the PCR products from the reaction mixture, 50 µL of each reaction mixture was
mixed with 10 µL of 6× DNA loading dye and subjected to agarose gel electrophoresis. DNA
bands corresponding to human SOD1WT and SOD1A4V flanked with attB sites were then excised
from the agarose gel and purified using the QIAquick® Gel Extraction Kit (Qiagen, Hilden,
Germany). The purified attB-SOD1WT and attB-SOD1A4V PCR products were sub-cloned into
the pDONR™221 vector using the Advanced Gateway® BP recombination reaction, as per the
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manufacturer’s instructions but with the following modifications to scale down volumes: 0.4
µL of 5× BP Clonase™, 0.4 µL of 5× BP Clonase™ Reaction Buffer, 30 ng of pDONR™221,
30 ng of either attB-SOD1WT , attB-SOD1A4V PCR product or pEXP7-tet (positive control) and
TE buffer (pH 8.0) to a final volume of 2 µL, for a 1 h reaction at 25 °C. The reaction mixtures
were then treated with 0.2 µL of Proteinase K. The resulting pDONR™221-SOD1WT,
pDONR™221-SOD1A4V and positive control were then transformed into chemicallycompetent TOP10 E. coli using the heat-shock transformation protocol and incubated overnight
at 37 °C on LB agar plates supplemented with 50 µg/mL kanamycin. The following day, 3
single colonies from each transformation plate were picked and streaked onto new LB agarkanamycin plates followed by overnight incubation at 37 °C. Single colonies were isolated and
used to inoculate 2.5 mL of LB broth containing 50 µg/mL kanamycin for overnight incubation
at 37 °C with agitation.
Since the expression of human TDP-43WT and FUSWT in yeast recapitulates key pathological
features observed in human tissue, mammalian cell culture and animal models, these were used
to transform yeast rather than specific ALS-associated mutant isoforms of these genes. The
expression of SOD1WT in yeast, on the other hand, has no effect on the viability of yeast cells,
and serves as a suitable control to yeast strains expressing ALS-associated SOD1 mutations
(e.g. A4V and G93A) (Gunther et al. 2004, Bastow et al. 2016). Human TDP-43WT and FUSWT
in pDONR™221 (previously prepared by Dr. Daniel Bean, University of Cambridge, UK), and
SOD1WT and SOD1A4V in pDONR™221 were sub-cloned into the pAG416GAL-ccdB-DsRed
vector using the Advanced Gateway® LR recombination reaction, as per the manufacturer’s
instructions but with the following modifications to scale down volumes: 0.4 µL of 5× LR
Clonase™ II, 30 ng of the Entry Clone (pDONR™221 containing TDP-43 or FUS) and of the
Destination Vector (pAG416GAL-ccdB-DsRed), and TE buffer (pH 8.0) to a final volume of
2 µL, for a 1 hour reaction at 25 °C. The reaction mixture was then treated with 0.2 µL of
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Proteinase K. The resulting pAG416GAL-TDP-43WT-DsRed, pAG416GAL-FUSWT-DsRed,
pAG416GAL-SOD1WT-DsRed and pAG416GAL-SOD1A4V-DsRed expression clones were
then transformed into chemically-competent TOP10 E. coli using the heat-shock
transformation protocol. Plasmid DNA from successfully transformed single colonies was then
extracted from bacterial cells using the E. Z. N. A. Plasmid DNA Mini Kit I (VWR
International, Omega Bio-Tek, Inc., GA, USA) as per the manufacturer’s instructions.
Extracted plasmid DNA was then subject to restriction enzyme digestion and agarose gel
electrophoresis to verify that the recombinant plasmids had the correct backbone and insert
size. Colonies identified to contain the correct plasmid DNA were then used to prepare glycerol
stocks. Briefly, 2.5 mL aliquots of LB containing the appropriate antibiotic were inoculated
with the selected colonies and incubated overnight at 37 °C with agitation. The following day
these cultures were then diluted 1:1 with sterile 50% (v/v) glycerol solution and stored in sterile
cryogenic tubes at -80 °C for long-term storage.
3.2.3

Yeast strains, transformation, media and culturing

Yeast were cultured at 30 °C unless otherwise indicated. The haploid MATα strain of
Saccharomyces cerevisiae, Y7039 (MATα can1Δ::STE2pr-LEU2 lyp1Δ his3Δ1 leu2Δ0 ura3Δ0
LYS2+), was a gift from Prof. Charles Boone (University of Toronto, Canada). Y7039 cells
were grown in rich media (yeast extract-peptone-dextrose; YPD; 1% (w/v) yeast extract, 2%
(w/v) peptone, 2% (w/v) glucose) or in synthetic medium lacking leucine (0.67% (w/v) yeast
nitrogen base without amino acids, 0.0109% (w/v) adenine, 0.00725% (w/v) uracil, 0.00725%
(w/v) inositol, 0.000725% (w/v) para-aminobenzoic acid, 0.00725% (w/v) alanine, 0.00725%
(w/v) arginine, 0.00725% (w/v) asparagine, 0.00725% (w/v) aspartic acid, 0.00725% (w/v)
cysteine, 0.00725% (w/v) glutamic acid, 0.00725% (w/v) glutamine, 0.00725% (w/v) glycine,
0.00725% (w/v) histidine, 0.00725% (w/v) isoleucine, 0.00725% (w/v) lysine, 0.00725% (w/v)
methionine, 0.00725% (w/v) phenylalanine, 0.00725% (w/v) proline, 0.00725% (w/v) serine,
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0.00725% (w/v) threonine, 0.00725% (w/v) tryptophan, 0.00725% (w/v) tyrosine and
0.00725% (w/v) valine) containing 2% (w/v) glucose (SD/-Leu), 2% (w/v) raffinose (SRaf/Leu), or 2% (w/v) galactose (SGal/-Leu).
Cultures of Y7039 were transformed with the pAG416GAL-TDP-43WT-DsRed, pAG416GALFUSWT-DsRed,

pAG416GAL-SOD1WT-DsRed,

pAG416GAL-SOD1A4V-DsRed

and

pAG416GAL-ccdB-DsRed constructs using the PEG/lithium acetate method to create four
query strains and a control strain (Ito et al. 1983) (Figure 3.1, b). The pAG416GAL-ccdBDsRed vector contains the URA3 selectable marker and enables growth of transformed cells
on media lacking uracil. The Y7039 cultures transformed with pAG416GAL-TDP-43WTDsRed,

pAG416GAL-FUSWT-DsRed,

pAG416GAL-SOD1WT-DsRed,

pAG416GAL-

SOD1A4V-DsRed or the pAG416GAL-ccdB-DsRed vector were grown in synthetic medium
lacking leucine and uracil, supplemented with 2% (w/v) glucose (SD/-Leu/Ura), 2% (w/v)
raffinose (SRaf/-Leu/Ura, or 2% (w/v) galactose (SGal/-Leu/Ura).
The yeast EGFP-fusion collection (Huh et al. 2003) was grown on solid synthetic medium
lacking histidine (0.67% (w/v) yeast nitrogen base without amino acids, 0.0109% (w/v)
adenine, 0.00725% (w/v) uracil, 0.00725% (w/v) inositol, 0.000725% (w/v) paraaminobenzoic acid, 0.00725% (w/v) alanine, 0.00725% (w/v) arginine, 0.00725% (w/v)
asparagine, 0.00725% (w/v) aspartic acid, 0.00725% (w/v) cysteine, 0.00725% (w/v) glutamic
acid, 0.00725% (w/v) glutamine, 0.00725% (w/v) glycine, 0.00725% (w/v) isoleucine, 0.036%
(w/v) leucine, 0.00725% (w/v) lysine, 0.00725% (w/v) methionine, 0.00725% (w/v)
phenylalanine, 0.00725% (w/v) proline, 0.00725% (w/v) serine, 0.00725% (w/v) threonine,
0.00725% (w/v) tryptophan, 0.00725% (w/v) tyrosine and 0.00725% (w/v) valine) containing
2% (w/v) glucose, 2% (w/v) agar and supplemented with 100 µg/mL ampicillin (SD/-His +
Amp) in PlusPlates (Singer instruments, Somerset, UK). Single colonies from the 17× 384colony-dense plates of the yeast EGFP-fusion collection were picked using the Stinger modular
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extension of the ROTOR™ High-throughput Microbial Array Pinning Robot (Singer
Instruments, Somerset, UK) and inoculated onto new PlusPlates to prepare 4× 96-colony-dense
plates of customised arrays.
To prepare glycerol stocks of the full yeast EGFP-fusion collection and of the custom arrays,
the ROTOR™ was used to pin colonies from agar plates to 96-well plates containing 140
µL/well of SD/-His broth. Plates were incubated overnight at 30 °C with agitation. The
following day the cultures in each well were diluted with 60 µL of sterile 80% (v/v) glycerol
solution. Wells were sealed using pre-cut sheets of sterile multi-well plate sealing film and
stored at -80 °C for long-term storage.
3.2.4

Yeast mating procedure

The yeast mating procedure is illustrated schematically in Figure 3.1, c. Single colonies of
Y7039 transformed with either pAG416GAL-TDP-43WT-DsRed (GALTDP-43WT-DsRed),
pAG416GAL-FUSWT-DsRed
(GALSOD1WT-DsRed),

(GALFUSWT-DsRed),

pAG416GAL-SOD1A4V-DsRed

pAG416GAL-SOD1WT-DsRed
(GALSOD1A4V-DsRed)

or

pAG416GAL-ccdB-DsRed (GALDsRedempty; vector control) were inoculated into 10 mL of
SD/-Leu/Ura and grown overnight at 30 °C with agitation. The following morning the
overnight cultures were diluted into 30 mL of SD/-Leu/Ura and pinned in 96-colony density
format to PlusPlates containing YPD using the ROTOR™, 4 plates per query strain. The pinned
query strains were then grown for 48 h at 30 °C.
Each query strain and the control strain were crossed to an ordered 96-colony-dense array of a
selection of 128 haploid MATa strains from the EGFP-fusion collection of yeast strains. Each
EGFP-fusion ORF in this collection is tagged with the S. pombe his5+ gene which allows
growth on medium lacking histidine. The resulting heterozygous diploid strains were selected
by growing the cells on solid (agar) synthetic medium lacking histidine and uracil,
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supplemented with 2% (w/v) glucose (SD) – His/Ura), for 48 h at 30 °C (Figure 3.1, d).
Glycerol stocks of the diploid strains were prepared using the ROTOR™ to pin colonies from
agar plates to 96-well plates containing 140 µL/well of SD/-His/Ura broth. Plates were
incubated overnight at 30 °C with agitation. The following day the cultures in each well were
diluted with 60 µL of sterile 80% (v/v) glycerol solution. Wells were sealed using pre-cut sheets
of sterile multi-well plate sealing film and stored at -80 °C for long-term storage.
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Figure 3.1. Schematic representation of the generation of SOD1WT-DsRed, SOD1A4V-DsRed, TDP-43WTDsRed and FUSWT-DsRed yeast query strains, mating with the yeast EGFP-fusion collection and diploid
selection in preparation for screening experiments. (A) Human wild-type TDP-43 (TDP-43WT), FUSWT,
SOD1WT and SOD1A4V were cloned from a mammalian expression vector into pAG416GAL-ccdB-DsRed using
the Advanced Gateway® cloning system. (B) The resulting galactose-inducible pAG416GAL-TDP-43WT-DsRed,
pAG416GAL-SOD1WT-DsRed,
pAG416GAL-SOD1A4V-DsRed
and
pAG416GAL-FUSWT-DsRed,
pAG416GAL-ccdB-DsRed (vector control) expression clones were transformed into the haploid MATα yeast
strain Y7039 to create four query strains and a control strain. (C) Each query strain and the control strain were
crossed to an ordered array of a selection of 128 haploid MATa strains from the EGFP-fusion collection of yeast
strains (Huh et al. 2003). The EGFP-fusion strains were selected based on involvement in conserved proteostasis
pathways, other pathways suspected to be involved in ALS pathogenesis as well as the yeast orthologues of human
proteins that have been found colocalised in inclusions in ALS patients’ motor neurons. Each EGFP-fusion ORF
is tagged with the S. pombe his5+ gene and allows growth on medium lacking histidine. (D) The resulting
heterozygous diploid strains were selected by growing the cells on solid (agar) synthetic medium lacking histidine
and uracil (synthetic dextrose (SD) – His/Ura).

3.2.5

Spotting assays

Single colonies of the haploid MATα yeast query strains, generated through transformation of
Y7039 with pAG416GAL-TDP-43WT-DsRed (GALTDP-43WT-DsRed), pAG416GAL-FUSWTDsRed

(GALFUSWT-DsRed),

pAG416GAL-SOD1A4V-DsRed

pAG416GAL-SOD1WT-DsRed
(GALSOD1A4V-DsRed)

or

(GALSOD1WT-DsRed),

pAG416GAL-ccdB-DsRed

(GALDsRedempty; vector control) and grown on SD/-Ura agar plates, were picked and used to
inoculate 10 mL of SD/-Ura broth. Following overnight incubation at 30 °C with agitation, 125
µL of each culture was diluted into 2.5 mL of SRaf/-Ura broth and grown overnight at 30 °C
with agitation. The following day this dilution procedure was repeated for a second night of
growth in SRaf/-Ura broth. Cultures were then normalised for OD600, serial diluted, spotted
onto SD/-Ura or SGal/-Ura and incubated at 30 °C for 48 h. The incubated plates were then
scanned using a standard HP® scanner, and the sizes of the resulting colonies were
qualitatively examined for the diameter and density of yeast growth.
Spotting assays were also carried out following mating of haploid yeast query strains with
haploid MATa strains from the EGFP fusion collection of yeast strains, and consequent diploid
selection. The resulting diploid strains were prepared for spotting assays using the procedure
above, with the exception that SD/-His/Ura, SRaf/-His/Ura, and SGal/-His/Ura selective media
were used to grow the cultures.
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Query strains and diploid strains were grown in either galactose-supplemented media to induce
expression of DsRed-tagged FUSWT, TDP-43WT, SOD1WT, SOD1A4V or DsRed alone, or in
glucose-supplemented media to control for differences in growth between strains that were not
caused by expression of the DsRed-fusion genes.
3.2.6

DeltaVision OMX™ super resolution fluorescence microscopy

To characterise the localisation of TDP-43WT-DsRed, FUSWT-DsRed, SOD1WT-DsRed and
SOD1A4V-DsRed and the EGFP fusion proteins in diploid strains, the fluorescent proteins were
examined in cells using a DeltaVision OMX™ super resolution microscope (GE Healthcare
Life Sciences, Marlborough, MA, USA). Super resolution microscopy was necessary for these
experiments due to the size of the yeast cells; conventional microscopy would not provide the
resolution needed to examine the intracellular localisation patterns of the EGFP-fusion
proteins. To validate the use of diploid GALDsRedempty strains as control strains and to establish
the baseline cellular levels of the EGFP-fusion proteins screened, it was crucial to ensure that
the localisation of the EGFP-fusion proteins in the GALDsRedempty strains were comparable to
the localisation patterns previously reported for growth in control conditions (Huh et al. 2003,
Breker et al. 2013, Breker et al. 2014). Time limitations prevented the microscopic examination
of all diploid strains used in the present work, thus only several strains were selected for
microscopy. To microscopically examine a variety of localisation patterns, strains were
selected to include EGFP-fusion proteins that have been reported to be localised to different
macromolecular structures, organelles and to the cytosol. Slides were prepared for microscopy
by placing flat agarose pads of 1 cm diameter, made of SGal/-His/Ura containing 1.5% (w/v)
agarose, into the centre of each slide. To prepare diploid strains for microscopy, individual
colonies on 96-colony-dense SD/-His/Ura plates were picked and used to inoculate 2.5 mL of
SRaf/-His/Ura broth to grow overnight at 30 °C with agitation. The following day, 125 µL of
each culture was diluted into 2.5 mL of SRaf/-His/Ura broth and grown overnight at 30 °C with
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agitation. Following this second night of growth in SRaf/-His/Ura broth, 125 µL of each culture
was diluted into 2.5 mL of SGal/-His/Ura broth and grown overnight at 30 °C with agitation to
induce

expression

of

GAL

SOD1A4V-DsRed or

GAL

GAL

TDP-43WT-DsRed,

GAL

FUSWT-DsRed,

GAL

SOD1WT-DsRed,

DsRedempty. In the later rounds of microscopy, in which diploid

BMH1-EGFP, RPL40A-EGFP, RPN10-EGFP, TRS23-EGFP, MDJ1-EGFP, MGE1-EGFP,
PUB1-EGFP, XRN1-EGFP and UFD4-EGFP strains were imaged, cells were counterstained
with 0.8 µg/mL DAPI in PBS for 30 min at room temperature, followed by two washes in PBS
(each wash involved centrifugation of cells at 1,000 × g followed by resuspension in 1 mL of
PBS), centrifugation at 1,000 × g and resuspension in 1 mL of fresh SGal/-His/Ura broth.
Resuspended cells from each culture (5 µL) was then pipetted onto SGal/-His/Ura agarose pads
on prepared slides. Imaging was carried out using the 100× oil-immersion objective lens, with
EGFP fluorescence excited at 488 nm and DsRed fluorescence excited at 568 nm using
optically pumped, frequency-doubled vertical external cavity surface emitting lasers
(VECSELs). The localisation of the EGFP-fusion yeast proteins observed through microscopy
was compared with the localisation data documented on the Yeast GFP Fusion Localisation
Database (YGFLD) [https://yeastgfp.yeastgenome.org/ - (Huh et al. 2003)], the LoQAtE
database (Breker et al. 2013, Breker et al. 2014), the UniProt Database and the Saccharomyces
Genome Database (SGD).
It should be noted that for diploid RPL40A-EGFP, RPN10-EGFP, TRS23-EGFP, MDJ1EGFP, MGE1-EGFP, PUB1-EGFP, UFD4-EGFP and XRN1-EGFP strains, time restrictions
prevented the microscopic examination of all five corresponding diploid strains
(GALDsRedempty,

GAL

TDP-43WT-DsRed,

GAL

FUSWT-DsRed,

GAL

SOD1WT-DsRed

and

GAL

SOD1A4V-DsRed). However, the corresponding diploid EGFP-fusion/GALDsRedempty strain

was included as a control for microscopic examination of each diploid EGFP-fusion/GALTDP43WT-DsRed, EGFP-fusion/GALFUSWT-DsRed, EGFP-fusion/GALSOD1WT-DsRed and EGFP65

fusion/GALSOD1A4V-DsRed strain, for comparisons of protein localisation patterns. Time
limitations prevented the repetition of microscopy of each diploid strain, and thus the images
presented and the observations described in the Results section are representative of n = 1
experiment.
3.2.7

Measurement of EGFP-fusion protein levels in diploid yeast strains

The methods used to measure levels of EGFP-fusion proteins in diploid strains is illustrated
schematically in Figure 3.2. Each 96-colony-dense plate of diploid strains was pinned in
quadruplicate to a 384-well microtitre plate containing 100 µL per well of SRaf/-His/Ura using
the ROTOR™ and grown overnight at 30 °C with agitation (Figure 3.2, a). The following day
the 100 µL overnight cultures were pinned to black-walled 384-well µclear plates containing
100 µL per well of SGal/-His/Ura to induce expression of GALTDP-43WT-DsRed, GALFUSWTDsRed,

GAL

SOD1WT-DsRed,

GAL

SOD1A4V-DsRed or

GAL

DsRedempty. The absorbance (optical

density [OD] at 600 nm), EGFP (excitation 485/12 nm, emission collected at 510/20 nm) and
DsRed (excitation 580/10 nm, emission collected at 612 nm) fluorescence were then measured
in each plate of cells over 48 h using a FLUOstar® Optima plate reader (BMG LABTECH,
Ortenberg, Germany) set to incubate plates at 30 °C (Figure 3.2, b).
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Figure 3.2. Schematic representation of the analysis workflow used to identify yeast EGFP-fusion proteins
with altered levels in yeast expressing human SOD1WT-DsRed, SOD1A4V-DsRed, TDP-43WT-DsRed and
FUSWT-DsRed. (A) Each 96-colony-dense plate of diploid strains was pinned in quadruplicate to a 384-well
microtitre plate containing SRaf/-His/Ura using the ROTOR™ and grown overnight at 30 °C with agitation. The
following day the overnight cultures were pinned to black-walled 384-well µclear plates containing SGal/-His/Ura
to induce expression of GALTDP-43WT-DsRed, GALFUSWT-DsRed, GALSOD1WT-DsRed, GALSOD1A4V-DsRed or
GAL
DsRedempty (DsRed alone). (B) The absorbance (optical density [OD] at 600 nm), EGFP (excitation 485/12 nm,
emission collected at 510/20 nm) and DsRed (excitation 580/10 nm, emission collected at 612 nm) fluorescence
were then measured in each plate of cells over 48 h using a FLUOstar® Optima plate reader. (C) The EGFP
fluorescence intensity (F.I.) measured at 485 nm in each well of cells was normalised to the absorbance at each
time point to account for cell density in each well. The normalised EGFP values were used in subsequent analyses
to calculate yield of EGFP-fusion protein levels in cells expressing GALTDP-43WT-DsRed, GALFUSWT-DsRed,
GAL
SOD1WT-DsRed or GALSOD1A4V-DsRed relative to control cells expressing GALDsRedempty. Custom R scripts
were used to analyse the normalised EGFP F.I. values over the 48 h assay period. Calculations of the yield of
EGFP-fusion protein levels were based on the difference in normalised EGFP from mid-exponential growth phase
to stationary phase (monitored by the OD at 600 nm), when EGFP F.I. reached a maximum. (D) T tests were
carried out using a custom R script to determine the difference (fold change) in EGFP-fusion protein levels in
strains expressing GALTDP-43WT-DsRed, GALFUSWT-DsRed, GALSOD1WT-DsRed or GALSOD1A4V-DsRed
compared to strains expressing GALDsRedempty. (E) Strains exhibiting a significant differential in EGFP-fusion
protein levels (p < 0.05) were selected for repeat screening. EGFP-fusion proteins were ranked as having
differential levels in GALTDP-43WT-DsRed, GALFUSWT-DsRed, GALSOD1WT-DsRed or GALSOD1A4V-DsRed strains
based on those exhibiting both a fold change in EGFP-fusion protein levels of > 0.075 (arbitrary cut-off value)
and p < 0.05 relative to control GALDsRedempty strains. In the case of GALSOD1A4V-DsRed, ‘hits’ were selected
based on those exhibiting differential protein levels only in strains expressing GALSOD1A4V-DsRed but not in
strains expressing GALSOD1WT-DsRed.

3.2.8

Analysis of EGFP-fusion protein levels

Analyses of EGFP-fusion protein levels measured in each diploid strain are illustrated
schematically in Figure 3.2, c, d and e. R statistical computing software, Microsoft® Office
Excel and Graphpad Prism 5 (GraphPad Software Inc., La Jolla, CA, USA) were used for
subsequent data analyses. The EGFP fluorescence intensity (F.I.) (excitation 485/12 nm,
emission collected at 510/20 nm) measured in each well was normalised to the absorbance at
600 nm at each time point using Microsoft® Office Excel in order to account for cell density
in each well. Normalisation involved dividing the EGFP F.I. value by the absorbance at each
time point. The normalised EGFP values were used in subsequent analyses in R to calculate
yield and fold change in EGFP-fusion protein levels in cells expressing GALTDP-43WT-DsRed,
GAL

FUSWT-DsRed,

expressing

GAL

SOD1WT-DsRed or

GAL

SOD1A4V-DsRed relative to control cells

GAL

DsRedempty (DsRed alone). Custom R scripts (Appendix I) were originally

written by Dr. Daniel Bean (University of Cambridge, UK) for analyses of yeast growth curves
(absorbance) and modified in the present work for analyses of normalised EGFP F.I. values
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over the 48 h assay period. Calculations of the yield of EGFP-fusion protein levels were based
on the difference in normalised EGFP from mid-exponential growth phase to stationary phase,
when EGFP F.I. reached a maximum. T tests were carried out using a custom R script
(Appendix I) originally written by Ms Anastasiya Pachyna (University of Cambridge, UK) and
modified in the present work to determine the difference (fold change; ΔF) in EGFP-fusion
protein levels in strains expressing
DsRed or

GAL

TDP-43WT-DsRed,

GAL

GAL

SOD1A4V-DsRed compared to strains expressing

FUSWT-DsRed,

GAL

GAL

SOD1WT-

DsRedempty (DsRed alone),

across two replicates per strain. Strains exhibiting a significant change in EGFP-fusion protein
levels (p < 0.05) were selected for repeat screening (four replicates). EGFP-fusion proteins
were ranked as having differential levels in
GAL

SOD1WT-DsRed or

GAL

TDP-43WT-DsRed,

GAL

FUSWT-DsRed,

GAL

SOD1A4V-DsRed strains based on those exhibiting both a fold

change in EGFP-fusion protein levels of > 0.075 (arbitrary cut-off value) and p < 0.05 relative
to control GALDsRedempty strains. In the case of GALSOD1A4V-DsRed, ‘hits’ were selected based
on those exhibiting differential protein levels only in strains expressing

GAL

SOD1A4V-DsRed

but not in strains expressing GALSOD1WT-DsRed.
3.2.9

Analysis of protein-protein interaction networks

Interactions between yeast EGFP-fusion proteins that were identified to be present at altered
levels in diploid

GAL

TDP-43WT-DsRed,

relative to diploid control

GAL

FUSWT-DsRed or

GAL

SOD1A4V-DsRed strains

GAL

DsRedempty strains, ‘hits’, were analysed using the STRING

database (Szklarczyk et al. 2015, Szklarczyk et al. 2017) and Cytoscape 3.7.1 (National
Institute of General Medical Sciences (NIGMS) of the National Institutes of Health (NIH),
USA). Each set of hits for GALTDP-43WT-DsRed, GALFUSWT-DsRed and GALSOD1A4V-DsRed
was queried in STRING to identify interactions between the hits using co-expression, published
experiments and databases as sources of interaction data. STRING computes confidence scores
for all protein-protein interactions, and a high confidence cut-off (0.700) was used for the
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present analyses. No more than ten secondary interacting genes/proteins of the hits were
included in each interaction network. The resulting interaction network data was then imported
into Cytoscape to format the network to distinguish between the primary hits for each of
GAL

TDP-43WT-DsRed,

GAL

FUSWT-DsRed and

GAL

SOD1A4V-DsRed and the ten secondary

interactors connecting the hits to each other.
Although these yeast EGFP-fusion protein collection screens were pathway-focused, in that
only a selection of 128 strains from the full EGFP-fusion collection of strains were included,
this selection nevertheless covered a spectrum of molecular functions. It was thus useful to
examine the gene ontology (GO) functional enrichments of the hits for each of GALTDP-43WTDsRed, GALFUSWT-DsRed and GALSOD1A4V-DsRed against the background pathway-focused
selection of 128 EGFP-fusion proteins. GO analyses of each set of hits were carried out using
PANTHER GO Enrichment Analysis (version 14) (Ashburner et al. 2000, Mi et al. 2019, The
Gene Ontology Consortium 2019), with the pathway-focused selection of 128 EGFP-fusion
proteins set as the background reference list.
3.2.10 Data quality control analyses
To ensure that growth and expression of

GAL

TDP-43WT-DsRed,

GAL

FUSWT-DsRed,

GAL

SOD1WT-DsRed, GALSOD1A4V-DsRed and GALDsRedempty (DsRed alone) in diploid strains

assayed on the FLUOstar® Optima plate reader were consistent between wells within each
plate and between different plates in separate experiments, the raw absorbance (OD600) and
DsRed fluorescence data from each well were examined in GraphPad Prism. Specifically,
growth between strains and between replicates was evaluated by examining the distribution of
the OD600 yield (maximum OD600 – minimum OD600) and the maximum exponential rate of
change of OD600 (maximum growth rate; OD600/h) between wells. The expression of GALTDP43WT-DsRed,

GAL

FUSWT-DsRed,

GAL

SOD1WT-DsRed,

GAL

SOD1A4V-DsRed or

GAL

DsRedempty

(DsRed alone) between wells was assessed by comparing the distribution of the maximum
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DsRed F.I. (Fmax; maximum DsRed F.I. – minimum DsRed F.I.; relative fluorescence units,
RFU) and the maximum exponential rate of change of DsRed F.I. (maximum rate of DsRed
F.I. increase; RFU/h).
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Results
3.3.1

Collating the list of relevant EGFP-fusion yeast proteins to screen

The yeast EGFP-fusion collection comprises 4156 different strains (Huh et al. 2003). For the
purposes of the work described in this chapter, it was pertinent to collate a focused selection of
EGFP-fusion strains of relevance to human cellular biology in the context of ALS. Relevant
proteins and the corresponding EGFP-fusion yeast strains were selected based on (i)
involvement in conserved proteostasis pathways, (ii) other pathways suspected to be involved
in ALS pathogenesis, or (iii) the yeast orthologues of human proteins that have been found
colocalised in inclusions in ALS patients’ motor neurons (Ciryam et al. 2017). Literature
searches and online databases (Ensembl genome database, BioGRID, esyN, Kyoto
Encyclopedia of Genes and Genomes (KEGG), PubMed, Saccharomyces genome database
(SGD) and UniProt) were used to inform selection of the proteins of interest and to analyse
their function, localisation, expression and interaction data. It was crucial that expression of
the EGFP-fusion yeast genes could be reliably detected and measured using a fluorescent plate
reader. Therefore, in most cases proteins with known abundance levels greater than 1,500
molecules per cell were included for analysis (Ghaemmaghami et al. 2003). However, some
proteins (24) were included that had low cellular abundance (< 1,500 molecules/cell)
(Ghaemmaghami et al. 2003) (Table S3.2, Appendix I) or did not have direct human
orthologues (Table S3.3, Appendix I) because those proteins were particularly relevant to ALS
pathogenesis. The final selection consisted of 128 EGFP-fusion yeast strains (Table S3.1,
Appendix I). Of these, 19 have RNA metabolic functions, 13 have functions associated with
ribosomes and protein translation, 21 are involved in ubiquitin homeostasis and/or the UPS, 2
are ubiquitin-like modifier proteins, 15 are molecular chaperones, 15 are involved in regulating
ER proteostasis and/or responding to ER stress, 11 have functions in the endomembrane
system, ER-Golgi transport and Golgi function, 2 are components of the cytoskeleton, 2 are
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involved in autophagy, 1 is involved in aggresome function, 9 function in protein
phosphorylation, trafficking and signal transduction, 15 are involved in mitochondrial
homeostasis and antioxidant activity, 1 is a glutamine synthetase and 2 have functions in energy
metabolism.
Following selection of EGFP-fusion strains to cross with the GALTDP-43WT-DsRed, GALFUSWTDsRed,

GAL

SOD1WT-DsRed and

GAL

SOD1A4V-DsRed query strains and the

GAL

DsRedempty

(DsRed alone) control strain, it was found that 2 of the strains, UBP6-EGFP (YFR010W) and
EIF2A-EGFP (YGR054W), were unable to grow properly, even in rich YPD media. These
strains were thus excluded from the screens.
3.3.2

Characterisation of haploid query strains and diploid strains

To generate yeast models of SOD1, TDP-43 and FUS pathology, yeast centromeric galactoseinducible plasmids containing human SOD1WT, SOD1A4V, TDP-43WT and FUSWT with Cterminal DsRed tags were constructed and transformed into the haploid MATα yeast strain
Y7039. The resulting query strains along with a control strain transformed with the DsRed
backbone vector were tested for toxicity caused by expression of the human genes using
spotting assays (Figure 3.3). The untransformed Y7039 strain was included in the spotting
assays to confirm that it had normal growth patterns (Figure 3.3, a, i and ii). To ensure that any
differences in growth between strains were caused by expression of the DsRed-fusion human
genes and not by unknown variables, the haploid query strains and the diploid strains were
grown on glucose-supplemented plates (does not express DsRed-fusion human gene) in
parallel to galactose-supplemented plates (expresses DsRed-fusion human gene). Comparison
of the growth of each strain at each dilution on glucose-supplemented plates confirmed that
without expression of the DsRed-tagged human genes, viability was similar between each
haploid and diploid strain (Figure 3.3, b, ii and c, ii). Examining the growth of the haploid
query strains on galactose-supplemented plates showed that expression of
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GAL

TDP-43WT-

DsRed strikingly reduced yeast viability, while

GAL

FUSWT-DsRed,

GAL

SOD1WT-DsRed and

GAL

SOD1A4V-DsRed did not affect yeast viability relative to control yeast expressing

GAL

DsRedempty (DsRed alone) (Figure 3.3, b, i). The toxicity of

GAL

TDP-43WT-DsRed

expression was also evident in diploid yeast, as represented in the PUB1-EGFP/GALTDP-43WTDsRed strain, while no reduction in growth was observed in the PUB1-EGFP/GALSOD1WTDsRed and PUB1-EGFP/GALSOD1A4V-DsRed diploid strains relative to the diploid control
strain PUB1-EGFP/GALDsRedempty (Figure 3.3, c, i). Interestingly, while no reductions in cell
viability were observed for the haploid GALFUSWT-DsRed strain, a slight decrease in viability
was observed in diploid PUB1-EGFP/GALFUSWT-DsRed yeast compared to the diploid PUB1EGFP/GALDsRedempty strain.
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Figure 3.3. Viability of yeast expressing DsRed-tagged human SOD1WT, SOD1A4V, TDP-43WT, or FUSWT
relative to yeast expressing DsRed alone. Spotting assays of (A) the haploid MATα yeast strain, Y7039, (B)
Y7039 transformed with pAG416GAL-TDP-43WT-DsRed (GALTDP-43WT), pAG416GAL-FUSWT-DsRed
(GALFUSWT), pAG416GAL-SOD1WT-DsRed (GALSOD1WT), pAG416GAL-SOD1A4V-DsRed (GALSOD1A4V) or
pAG416GAL-ccdB-DsRed (GALDsRedempty; vector control (DsRed alone)) (haploid query strains) and (C)
representative diploid strains created by mating each haploid query strain with the haploid PUB1-EGFP strain
from the yeast EGFP fusion collection (Huh et al. 2003) and subsequent diploid selection. Yeast strains were
grown overnight in (A) YPD, (B, i) SGal/-Ura or (B, ii) SD/-Ura, (C, i) SGal/-His/Ura or (C, ii) SD/-His/Ura broth
at 30 °C with agitation. Cultures were then normalised for OD600, serial diluted, spotted onto solid (A) YPD, (B,
i) SGal/-Ura or (B, ii) SD/-Ura, (C, i) SGal/-His/Ura or (C, ii) SD/-His/Ura agar plates and incubated at 30 °C for
48 h. The incubated plates were then scanned using a standard HP® scanner, and the sizes of the resulting colonies
were qualitatively examined for the diameter and density of yeast growth. Query strains and diploid strains were
grown in either galactose-supplemented media to induce expression of DsRed-tagged GALFUSWT, GALTDP-43WT,
GAL
SOD1WT, GALSOD1A4V or GALDsRedempty (DsRed alone), or in glucose-supplemented media to control for
differences in growth between strains that were not caused by expression of the DsRed-tagged genes.

Prior to screening the levels of the EGFP-fusion proteins in each diploid strain using the
fluorescent plate reader, it was imperative to microscopically examine the localisation patterns
of both the DsRed-fusion proteins and a selection of the EGFP-fusion yeast proteins. This was
important to ensure that the localisation of the EGFP-fusion proteins in control GALDsRedempty
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strains did not deviate from those documented on the UniProt and SGD databases and as
previously reported for the EGFP-fusion strains grown in control conditions (Breker et al.
2013, Breker et al. 2014), and thus that the

GAL

DsRedempty strains could be used as valid

controls. For this purpose, several strains were selected for microscopy to include EGFP-fusion
proteins that have functions in different cellular compartments and thus diverse localisation
patterns; CDC48, ERV25, ENO1, BMH1, RPL40A, RPN10, TRS23, MDJ1, MGE1/GRPE,
PUB1, XRN1 and UFD4. The localisation patterns of TDP-43WT-DsRed, FUSWT-DsRed,
SOD1WT-DsRed and SOD1A4V-DsRed were also assessed. While the spotting assays
demonstrated that the expression of TDP-43WT-DsRed and FUSWT-DsRed was toxic in yeast,
it was necessary to confirm that TDP-43WT-DsRed and FUSWT-DsRed shifted from a
predominantly nuclear localisation to accumulate into cytoplasmic foci, and thus recapitulate
the mislocalisation observed in human tissue, mammalian cell culture and animal models. The
expression of SOD1A4V-DsRed did not impair the viability of yeast, in contrast to the toxicity
the SOD1A4V mutant causes in neuronal cells (data presented in Chapter IV; Figure 4.1, a), in
zebrafish, and the rapid disease progression in individuals with ALS who have this mutation
(Cudkowicz et al. 1997, Juneja et al. 1997, Lemmens et al. 2007). Because SOD1-positive
inclusions are a characteristic pathological feature observed in post-mortem spinal cord tissue
samples from SOD1-fALS patients (Shibata et al. 1996, Kato et al. 2000) and mutant SOD1
transgenic mouse models (Bruijn et al. 1997, Johnston et al. 2000, Watanabe et al. 2001, Wang
et al. 2002) it was of interest to examine whether SOD1A4V-DsRed aggregated into inclusions
in the diploid yeast strains.
Across all diploid strains examined, the expression of DsRed alone was observed to be
relatively low (Figures S3.1 to S3.12, Appendix I). In cells in which its fluorescence was
detectable, DsRed appeared to be localised to focal regions of the cell rather than more diffusely
distributed throughout the cytoplasm, as is usually seen with expression of the pEGFP-N1
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vector (EGFP alone) (data presented in Chapters IV and V). Both TDP-43WT-DsRed and
FUSWT-DsRed were predominantly localised to small cytoplasmic foci in most cells. In
contrast, SOD1WT-DsRed and SOD1A4V-DsRed exhibited a uniform distribution throughout
the cytoplasm and nucleus of all cells. Interestingly, SOD1A4V-DsRed was not observed to
aggregate into inclusions but had a similar localisation pattern to that of SOD1WT-DsRed.
The localisation patterns of the examined EGFP-fusion proteins (Figures S3.1 to S3.12,
Appendix I) are summarised in Table 3.2. Importantly, examination of the EGFP-fusion
proteins localisation patterns in diploid

GAL

DsRedempty strains confirmed that there was no

deviation from the localisation patterns that had previously been reported for the EGFP-fusion
strains grown under control conditions (Breker et al. 2013, Breker et al. 2014) and as
documented on the UniProt and SGD databases. Across the examined diploid strains
expressing TDP-43WT-DsRed, FUSWT-DsRed, SOD1WT-DsRed or SOD1A4V-DsRed, several of
the EGFP-fusion proteins exhibited differential localisation patterns. Although evaluation of
the localisation patterns of the EGFP-fusion proteins across the different diploid strains was
not a primary objective of the present study, and only a sub-selection of diploid strains were
examined out of the full selection screened in the plate reader-based assays, it is worth noting
the localisation changes that were observed in the microscopically examined diploid strains.
The localisation patterns of CDC48-EGFP, RPL40A-EGFP, RPN10-EGFP and PUB1-EGFP
were observed to be altered in yeast expressing TDP-43WT-DsRed compared to yeast
expressing DsRed alone. The localisation patterns of RPN10-EGFP and PUB1-EGFP were also
altered in yeast expressing FUSWT-DsRed. In diploid CDC48-EGFP/GALTDP-43WT-DsRed
yeast, CDC48-EGFP appeared to colocalise to the cytoplasmic foci formed by TDP-43WTDsRed (Figure S3.1, Appendix I). In diploid RPL40A-EGFP/GALDsRedempty and RPL40AEGFP/GALSOD1A4V-DsRed strains the EGFP-fusion protein was predominantly localised to
cell nuclei, whereas in the diploid RPL40A-EGFP/GALTDP-43WT-DsRed strain it was
77

distributed more evenly throughout the cytoplasm of cells (Figure S3.5, Appendix I). RPL40A
is a fusion protein that is proteolytically cleaved to produce ubiquitin and the L40 ribosomal
subunit protein (Finley et al. 1989). After cleavage, the L40 protein predominantly assembles
into mature cytoplasmic pre-60 S ribosomal subunits (Fernández-Pevida et al. 2012). The
cleaved ubiquitin forms a complex with ribosomal proteins and helps regulate translation
(Kobayashi et al. 2016). The ribosomal subunit protein is in the C terminal region of RPL40A,
to which EGFP is fused. It is unclear whether the pattern of EGFP fluorescence seen in cells
may reflect the localisation of uncleaved RPL40A or cleaved L40 protein. For instance, the
increased EGFP fluorescence intensity observed in the cytoplasm of RPL40A-EGFP/GALTDP43WT-DsRed cells could be due to increased association of L40 with cytoplasmic ribosomal
subunits.
In diploid RPN10-EGFP/GALTDP-43WT-EGFP and RPN10-EGFP/GALFUSWT-EGFP yeast,
cytoplasmic foci formed by TDP-43WT-DsRed and FUSWT-DsRed appeared to colocalise with
areas of increased cytoplasmic RPN10-EGFP fluorescence intensity (Figure S3.6, Appendix
I). RPN10 is one of the non-ATPase base subunits of the 19S regulatory particle of the
proteasome (Glickman et al. 1998, Verma et al. 2004). The observed regions of increased
RPN10-EGFP fluorescence intensity may indicate areas of higher concentration of assembled
proteasomes. The localisation of TDP-43WT-DsRed and FUSWT-DsRed foci to these regions
could be due to targeting of the foci for proteasomal degradation.
PUB1 is a poly (A)+ RBP involved in the regulation of translation and is an important
component of SGs (reviewed in Buchan and Parker (2009)). In both PUB1-EGFP/GALTDP43WT-DsRed and PUB1-EGFP/GALFUSWT-DsRed cells, a proportion of the cytosolic foci
formed by TDP-43WT-DsRed and FUSWT-DsRed colocalised with foci formed by PUB1-EGFP
(Figure S3.10, Appendix I). This is likely due to the association of these proteins in SGs. It is
possible that cytosolic foci formed by TDP-43WT-DsRed and FUSWT-DsRed that were not
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colocalised with PUB1-EGFP were cytosolic accumulations of the proteins into inclusions that
were distinct from SGs.
TRS23 is one of the core subunits of transport protein particle (TRAPP) complexes I-III and is
involved in ER-Golgi transport and autophagy (Sacher et al. 2001, Lynch-Day et al. 2010, Yip
et al. 2010). As such, it localises to the ER and Golgi apparatus in the cytoplasm of cells. In
diploid TRS23-EGFP/GALDsRedempty and TRS23-EGFP/GALTDP-43WT-DsRed cells, the
fluorescence of TRS23-EGFP was diffuse throughout the cytoplasm of cells, excluded from
cell nuclei and structures likely corresponding to vacuoles (Figure S3.7, Appendix I). There
were also small regions of increased EGFP fluorescence intensity surrounding cell nuclei and
the vacuoles. This was likely due to increased localisation of TRS23-EGFP to the ER, the Golgi
apparatus and to vacuoles that may be involved in autophagy. Interestingly, the pattern of
TRS23-EGFP fluorescence was strikingly different in TRS23-EGFP/GALSOD1A4V-DsRed
yeast. The overall fluorescence intensity of TRS23-EGFP was markedly reduced, there did not
appear to be vacuole-like structures excluding TRS23-EGFP, and in some cells there were
small EGFP fluorescent puncta.
In diploid UFD4-EGFP/GALFUSWT-DsRed, UFD4-EGFP/GALSOD1A4V-DsRed and UFD4EGFP/GALDsRedempty yeast cells, UFD4-EGFP was localised to distinct foci throughout the
cytoplasm (Figure S3.12, Appendix I). In UFD4-EGFP/GALFUSWT-DsRed yeast there were
numerous larger UFD4-EGFP foci than were observed in UFD4-EGFP/GALSOD1A4V-DsRed
and UFD4-EGFP/GALDsRedempty yeast cells, and these foci were colocalised with foci formed
by FUSWT-DsRed. UFD4 is an E3 ubiquitin ligase and has been reported to interact with
subunits of the 19S regulatory particle of the proteasome (Xie and Varshavsky 2000). Proteins
that have been conjugated to a few ubiquitin molecules by UFD4 are detected by the CDC48UFD1-NPL4 complex, which subsequently recruits the ubiquitin chain elongation factor (E4),
UFD2, to facilitate the extension of the polyubiquitin chain and direct substrate proteins to the
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proteasome (Koegl et al. 1999). The UFD4-EGFP foci observed in diploid cells may be sites
of ubiquitylation of proteins targeted for proteasomal degradation. This would suggest that
colocalisation of FUSWT-DsRed and UFD4-EGFP foci may be due to ubiquitylation and
targeting of misfolded FUSWT-DsRed to the proteasome for degradation.
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Table 3.2. Localisation patterns of selected EGFP-fusion proteins as observed through super-resolution fluorescence microscopy. Diploid strains were grown for 2
nights in SRaf/-His/Ura broth before being diluted 20× into SGal/-His/Ura broth and grown overnight at 30 °C with agitation to induce expression of GALTDP-43WT-DsRed,
GAL
FUSWT-DsRed, GALSOD1WT-DsRed, GALSOD1A4V-DsRed or GALDsRedempty (vector control; DsRed alone). The fluorescent proteins were examined in cells using the 100×
oil-immersion objective lens of a DeltaVision OMX™ super resolution microscope. Localisation patterns were compared with those documented on the UniProt and SGD
databases and as previously reported for the EGFP-fusion strains grown in control conditions (Breker et al. 2013, Breker et al. 2014).
Yeast
Systematic
Name

Yeast
Standard
Name

Supp.
figure
no.

GAL

TDP43WT-DsRed

GAL

FUSWTDsRed

GAL

SOD1WTDsRed

GAL

SOD1A4VDsRed

GAL

Published
localisation
(Breker et al.
2013, Breker et
al. 2014,
Saccharomyces
Genome
Database;
SGD, UniProt)

Description of yeast
orthologue
(Saccharomyces Genome
Database; SGD,
UniProt)

YDL126C

CDC48

S3.1

Decreased
diffuse
cytosolic F.I.;
colocalisation
with TDP43WT-DsRed
cytosolic foci

Cytosol and
nucleus

Cytosol and
nucleus

Cytosol and
nucleus

Cytosol and
nucleus

Cytosol

AAA ATPase; subunit of
polyubiquitin-selective
segregase complex
involved in ERAD;
subunit of complex
involved in mitochondriaassociated degradation, in
macroautophagy, PMN,
RAD, ribophagy (Ye et al.
2003, Heo et al. 2010).

YML012W

ERV25

S3.2

ER; reduced
F.I.

ER

ER

ER

ER

ER

Transport between the ER
and the Golgi apparatus as
a component of COPIIcoated ER-derived
transport vesicles (Belden
and Barlowe 1996).
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DsRedempty

YGR254W

ENO1

S3.3

Cytosol;
excluded from
vacuole-like
structures

Cytosol;
excluded
from vacuolelike structures

Cytosol;
excluded
from
vacuole-like
structures
Cytosol and
nucleus;
excluded
from
vacuole-like
structures
Not
examined

Cytosol;
excluded from
vacuole-like
structures

Cytosol;
excluded from
vacuole-like
structures

Cytosol

YER177W

BMH1

S3.4

Cytosol and
nucleus;
excluded from
vacuole-like
structures

Cytosol and
nucleus;
excluded
from vacuolelike structures

Cytosol and
nucleus;
excluded from
vacuole-like
structures

Cytosol and
nucleus;
excluded from
vacuole-like
structures

Cytosol

YIL148W

RPL40A

S3.5

Nucleus and
cytosol.
Predominantly
cytosolic

Not examined

Nucleus and
cytosol.
Predominantly
localised to
cell nuclei

Nucleus and
cytosol.
Predominantly
localised to
cell nuclei

Nucleus and
cytosol

YHR200W

RPN10

S3.6

Cytosol and
nucleus;
colocalisation
with TDP43WT-DsRed
cytosolic foci

Cytosol and
nucleus;
colocalisation
with FUSWTDsRed
cytosolic foci

Not
examined

Cytosol and
nucleus; small
defined
regions of
increased F.I.
throughout
cytosol

Cytosol and
nucleus; small
defined
regions of
increased F.I.
throughout
cytosol

Cytosol

YDR246W

TRS23

S3.7

Cytosol;
excluded from
vacuole-like
structures.
Small regions
of increased
F.I.
surrounding
cell nuclei and
vacuole-like
structures

Not examined

Not
examined

Reduced
cytosolic F.I.;
small
cytosolic
EGFPfluorescent
foci

Cytosol;
excluded from
vacuole-like
structures.
Small regions
of increased
F.I.
surrounding
cell nuclei and
vacuole-like
structures

Punctate in
cytosol; ER,
Golgi apparatus
and preautophagosomal
structures
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Phosphopyruvate
hydratase; involved in
glycolysis and
gluconeogenesis (Cohen et
al. 1987).
14-3-3 protein; diverse
functions including vesicle
transport and aggresome
formation (van Heusden et
al. 1992, Xu et al. 2013).
Fusion protein that is
proteolytically cleaved to
produce ubiquitin and the
L40 ribosomal subunit
protein (Finley et al.
1989).
Non-ATPase base subunit
of the 19S regulatory
particle of the proteasome
(Glickman et al. 1998).

Core subunit of transport
protein particle (TRAPP)
complexes I-III involved
in ER-Golgi transport and
autophagy (Sacher et al.
2001).

YFL016C

MDJ1

S3.8

Not examined

Mitochondria

Not
examined

Mitochondria

Mitochondria

Mitochondria

YOR232W

MGE1/
GRPE

S3.9

Not examined

Mitochondria
and
throughout
cytosol; low
F.I.

Not
examined

Mitochondria
and
throughout
cytosol

Mitochondria
and
throughout
cytosol

Cytosol and
mitochondria

YNL016W

PUB1

S3.10

Cytosol and
nucleus;
excluded from
vacuole-like
structures.
Colocalisation
with cytosolic
TDP-43WTDsRed foci

Cytosol and
nucleus;
excluded
from vacuolelike
structures.
Colocalisation
with cytosolic
FUSWTDsRed foci

Not
examined

Not examined

Cytosol and
nucleus;
excluded from
vacuole-like
structures

Cytosol

Poly (A)+ RBP involved
in translation regulation;
key component of SGs
(Matunis et al. 1993).

YGL173C

XRN1

S3.11

Cytosolic foci

Diffuse
throughout
cytosol, with
cytosolic foci

Not
examined

Not examined

Cytosolic foci

Cytosol and
cytosolic foci
(P-bodies)

5’ – 3’ exonuclease
involved in mRNA decay
(Larimer et al. 1992, Sheth
and Parker 2003).

YKL010C

UFD4

S3.12

Not examined

Cytosolic foci
colocalised
with FUSWTDsRed foci

Not
examined

Cytosolic foci

Cytosolic foci

Nucleus,
cytosol and
mitochondria

E3 ubiquitin ligase (Koegl
et al. 1999).
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HSP40 chaperone;
involved in protein folding
and refolding in the
mitochondrial matrix
(Rowley et al. 1994).
Mitochondrial matrix
cochaperone (Deloche et
al. 1997).

As noted above, the main objective of the work presented in this chapter was to screen for
alterations in the cellular levels of the ALS-relevant selection of 128 EGFP-fusion proteins,
rather than to examine whether the localisation patterns of this set of proteins were altered in
the presence of TDP-43, FUS and mutant SOD1. However, the documentation of the EGFPfusion proteins observed here to have altered localisation in response to TDP-43, FUS or
mutant SOD1 demonstrates that systematic evaluation of the localisation patterns of the full set
of 128 EGFP-fusion proteins across strains expressing TDP-43WT-DsRed, FUSWT-DsRed and
SOD1A4V-DsRed could provide valuable information about the cellular responses to the
expression of these ALS-linked genes.
3.3.3

Quality control analyses of FLUOstar® Optima plate reader data

There are various environmental and biological factors that can impact the growth of yeast
strains and result in growth variation between individual cultures of the same strain. This is
particularly important to consider for experiments involving the growth of yeast in 96- and
384-well microtitre plates, in which culture volumes are very small (< 200 µL). Variation in
temperature and aeration between wells across each multi-well plate can significantly affect
the activity and metabolism of yeast cells, as well as cause variation in rates of evaporation of
culture medium, leading to differences in culture volumes and further impacting yeast growth.
It was important to test that the expression of
GAL

SOD1WT-DsRed,

GAL

SOD1A4V-DsRed or

GAL

TDP-43WT-DsRed,

GAL

FUSWT-DsRed,

GAL

DsRedempty (DsRed alone) in diploid strains,

and that the growth of the strains, was consistent between wells within each plate and between
different plates in separate experiments. This was done by examining the distribution of the
raw absorbance (OD600) and DsRed F.I. data from each well in all plates of yeast that were
assayed for measurements of EGFP-fusion protein levels.
In diploid

GAL

TDP-43WT-DsRed strains and the corresponding

GAL

DsRedempty control strains,

the OD600 yield was reasonably consistent between replicates of the same strains as well as
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between the majority of the strains (Figure 3.4, a and b). A clear difference in the maximum
exponential rate of change of OD600 (maximum growth rate) between diploid

GAL

TDP-43WT-

DsRed strains and the corresponding GALDsRedempty control strains was evident, with GALTDP43WT-DsRed strains growing at a slower rate (Figure 3.4, c and d). This is consistent with the
reduced growth of haploid and diploid

GAL

TDP-43WT-DsRed strains observed in the spotting

assays (Figure 3.3, section 3.3.2). Several strains exhibited lower OD600 yields and/or
maximum growth rates than the majority of diploid GALTDP-43WT-DsRed and GALDsRedempty
strains. Accordingly, the lower numbers of cells and slower growth rates of these strains
corresponded with most of them exhibiting lower DsRed Fmax and slower rates of exponential
increase of DsRed F.I. (Figure 3.4, e, f, g and h). However, the DsRed Fmax and rates of
exponential increase of DsRed F.I. were also altered in individual replicates of several strains
that did not display reduced growth.
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Figure 3.4. Distribution of raw OD600 and DsRed fluorescence intensity data from FLUOstar® Optima plate
reader assays of diploid yeast EGFP-fusion strains expressing DsRed-fusion human TDP-43WT or DsRed
alone. Diploid strains were created by mating haploid Y7039 transformed with pAG416GAL-TDP-43WT-DsRed
(GALTDP-43WT) or pAG416GAL-ccdB-DsRed (GALDsRedempty; vector control) with haploid strains from the yeast
EGFP fusion collection (Huh et al. 2003). Duplicates of each diploid strain were grown in 384-well µclear plates
containing 100 µL per well of SGal/-His/Ura to induce expression of GALTDP-43WT or GALDsRedempty in a
FLUOstar® Optima plate reader. The absorbance (optical density [OD] at 600 nm), EGFP (excitation 485/12 nm,
emission collected at 510/20 nm) and DsRed (excitation 580/10 nm, emission collected at 612 nm) fluorescence
were measured over 48 h of yeast incubation at 30 °C. Raw data collected for each replicate were analysed to
calculate the OD600 yield (maximum OD600 – minimum OD600), the maximum exponential rate of change of OD600
(maximum growth rate; OD600/h), the maximum DsRed fluorescence intensity (Fmax) (maximum DsRed F.I. –
minimum DsRed F.I.; relative fluorescence units, R.F.U.) and the maximum exponential rate of change of DsRed
F.I. (maximum rate of DsRed F.I. increase; R.F.U./h). These data per replicate are presented as follows: (A) scatter
plot and (B) histogram displaying the OD600 yield; (C) scatter plot and (D) histogram showing the maximum
exponential rate of change of OD600 (maximum growth rate); (E) scatter plot and (F) histogram displaying the
DsRed Fmax; (G) scatter plot and (H) histogram displaying the maximum exponential rate of change of DsRed F.I.
(maximum rate of DsRed F.I. increase; R.F.U./h).

In diploid

GAL

FUSWT-DsRed strains and the corresponding GALDsRedempty control strains, the

OD600 yield was reasonably consistent between replicates of the same strains as well as between
the majority of strains (Figure 3.5, a and b). Unlike the diploid GALTDP-43WT-DsRed strains,
there were no differences in the maximum exponential rate of change of OD600 (maximum
growth rate) between diploid

GAL

FUSWT-DsRed strains and the corresponding

GAL

DsRedempty

control strains (Figure 3.5, c and d). Several diploid strains were observed to have reduced
growth compared to the majority of diploid strains. As was observed for the corresponding
diploid STI1-EGFP/GALTDP-43WT-DsRed strain, growth was much reduced in all replicates of
STI1-EGFP/GALFUSWT-DsRed and STI1-EGFP/GALDsRedempty. The DsRed Fmax and rate of
exponential increase of DsRed F.I. were reduced in all replicates of STI1-EGFP/GALFUSWTDsRed and STI1-EGFP/GALDsRedempty, and is in accordance with their reduced growth and
lower culture density (Figure 3.5, e, f, g and h). Several other diploid strains exhibited markedly
different DsRed Fmax and/or rate of exponential increase of DsRed F.I. compared to the majority
of diploid

GAL

FUSWT-DsRed and

GAL

DsRedempty strains. Notably, all replicates of the PRE3-

EGFP/GALFUSWT-DsRed and PRE3-EGFP/GALDsRedempty strains exhibited greater DsRed Fmax
and rates of exponential increase of DsRed F.I., as was observed for all replicates of the
corresponding PRE3-EGFP/GALTDP-43WT-DsRed strain.
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Figure 3.5. Distribution of raw OD600 and DsRed fluorescence intensity data from FLUOstar® Optima
plate reader assays of diploid yeast EGFP-fusion strains expressing DsRed-fusion human FUSWT or DsRed
alone. Diploid strains were created by mating haploid Y7039 transformed with pAG416GAL-FUSWT-DsRed
(GALFUSWT) or pAG416GAL-ccdB-DsRed (GALDsRedempty; vector control) with haploid strains from the yeast
EGFP fusion collection (Huh et al. 2003). Duplicates of each diploid strain were grown in 384-well µclear plates
containing 100 µL per well of SGal/-His/Ura to induce expression of GALFUSWT or GALDsRedempty in a FLUOstar®
Optima plate reader. The absorbance (optical density [OD] at 600 nm), EGFP (excitation 485/12 nm, emission
collected at 510/20 nm) and DsRed (excitation 580/10 nm, emission collected at 612 nm) fluorescence were
measured over 48 h of yeast incubation at 30 °C. Raw data collected for each replicate were analysed to calculate
the OD600 yield (maximum OD600 – minimum OD600), the maximum exponential rate of change of OD600
(maximum growth rate; OD600/h), the maximum DsRed fluorescence intensity (Fmax) (maximum DsRed F.I. –
minimum DsRed F.I.; relative fluorescence units, R.F.U.) and the maximum exponential rate of change of DsRed
F.I. (maximum rate of DsRed F.I. increase; R.F.U./h). These data per replicate are presented as follows: (A) scatter
plot and (B) histogram displaying the OD600 yield; (C) scatter plot and (D) histogram showing the maximum
exponential rate of change of OD600 (maximum growth rate); (E) scatter plot and (F) histogram displaying the
DsRed Fmax; (G) scatter plot and (H) histogram displaying the maximum exponential rate of change of DsRed F.I.
(maximum rate of DsRed F.I. increase; R.F.U./h).

The OD600 yield and maximum exponential rate of change of OD600 were similar amongst
replicates of diploid

GAL

SOD1WT-DsRed,

GAL

SOD1A4V-DsRed and the corresponding

GAL

DsRedempty control strains (Figure 3.6, a, b, c and d). However, several diploid strains were

observed to have variation in their growth relative to most of the diploid strains (Figure 3.6, a,
b, c and d). Across the plate reader assays of diploid EGFP-fusion/GALTDP-43WT-DsRed,
/GALFUSWT-DsRed, /GALSOD1WT-DsRed, /GALSOD1A4V-DsRed or /GALDsRedempty, several
EGFP-fusion strains were repeatedly observed to have variable growth amongst replicates;
HRP1-EGFP, UBC4-EGFP, BET3-EGFP, STI1-EGFP, YDJ1-EGFP, PUP1-EGFP, HSP82EGFP, ASC1-EGFP, SIL1-EGFP, HUL5-EGFP and TSA1-EGFP. Diploid

GAL

SOD1WT-

DsRed and GALSOD1A4V-DsRed strains exhibiting variable growth also, accordingly, exhibited
variable DsRed Fmax and differing rates of exponential increase of DsRed F.I. to the majority
of diploid strains (Figure 3.6, e, f, g, h). However, the DsRed Fmax and rate of exponential
increase of DsRed F.I. measured in some strains did not correlate with the yield of their growth
or with their growth rate, showing either increased or decreased DsRed Fmax or rates of increase
relative to the cell density of the culture.
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Figure 3.6. Distribution of raw OD600 and DsRed fluorescence intensity data from FLUOstar® Optima
plate reader assays of diploid yeast EGFP-fusion strains expressing DsRed-fusion human SOD1WT,
SOD1A4V or DsRed alone. Diploid strains were created by mating haploid Y7039 transformed with
pAG416GAL-SOD1WT-DsRed (GALSOD1WT), pAG416GAL-SOD1A4V-DsRed (GALSOD1A4V), or pAG416GALccdB-DsRed (GALDsRedempty; vector control) with haploid strains from the yeast EGFP fusion collection (Huh et
al. 2003). Duplicates of each diploid strain were grown in 384-well µclear plates containing 100 µL per well of
SGal/-His/Ura to induce expression of GALSOD1WT, GALSOD1A4V or GALDsRedempty in a FLUOstar® Optima plate
reader. The absorbance (optical density [OD] at 600 nm), EGFP (excitation 485/12 nm, emission collected at
510/20 nm) and DsRed (excitation 580/10 nm, emission collected at 612 nm) fluorescence were measured over
48 h of yeast incubation at 30 °C. Raw data collected for each replicate were analysed to calculate the OD600 yield
(maximum OD600 – minimum OD600), the maximum exponential rate of change of OD600 (maximum growth rate;
OD600/h), the maximum DsRed fluorescence intensity (Fmax) (maximum DsRed F.I. – minimum DsRed F.I.;
relative fluorescence units, R.F.U.) and the maximum exponential rate of change of DsRed F.I. (maximum rate of
DsRed F.I. increase; R.F.U./h). These data per replicate are presented as follows: (A) scatter plot and (B)
histogram displaying the OD600 yield; (C) scatter plot and (D) histogram showing the maximum exponential rate
of change of OD600 (maximum growth rate); (E) scatter plot and (F) histogram displaying the DsRed Fmax; (G)
scatter plot and (H) histogram displaying the maximum exponential rate of change of DsRed F.I. (maximum rate
of DsRed F.I. increase; R.F.U./h).

There are various factors that could have affected the expression of the galactose-inducible
DsRed-fusion genes carried in the centromeric plasmids. For instance, the CEN/ARS elements
in the plasmids may have interacted with DNA replication factors that were perhaps
differentially active in the specific EGFP-fusion strains listed above. However, the combination
of CEN and ARS sequences in yeast expression vectors are designed to provide greater stability
of plasmid copy numbers in yeast cells (Duina et al. 2014). The varied levels of the DsRedfusion proteins may also have been influenced by variation in the volume of growth media in
the wells, differential rates of evaporation of the media, or slight variations in temperature
across the 384-well plate. Each EGFP-fusion strain crossed with each different DsRed-fusion
gene plasmid had the same position in each plate between replicates. Thus, there may have
existed particular positions in the plates that resulted in a given well(s) being subject to
conditions that varied from other wells in the plate. This may account for the repeated
variability observed for some diploid strains.
Following analyses of EGFP-fusion protein levels and identification of EGFP-fusion proteins
showing altered levels in diploid
DsRed or

GAL

TDP-43WT-DsRed,

GAL

GAL

FUSWT-DsRed,

SOD1A4V-DsRed strains relative to control diploid

GAL

SOD1WT-

GAL

DsRedempty strains

(described in the following section 3.3.4), the corresponding diploid strains were analysed in
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repeated assays to confirm the observed alterations in EGFP-fusion protein levels. In these
repeated assays, the array of strains in each plate was changed to exclude strains that had not
exhibited alterations in EGFP-fusion protein levels, and strains, including the diploid STI1EGFP strains, that had consistently shown highly variable viability and growth. Each strain
was arrayed in quadruplicate wells of 384-well plates and a total of 8 plates were arrayed and
monitored using the FLUOstar® Optima. Examining the distribution of OD600 yield and the
maximum exponential rate of change of OD600 (maximum growth rate) across the 8 plates,
plate-to-plate variation in yeast growth was evident, including for the control

GAL

DsRedempty

strains (Figure S3.13, a, b, c and d, Appendix I). As was observed in the first round of assays
of diploid
between

GAL

TDP-43WT strains, there were clear differences in maximum growth rates

GAL

TDP-43WT strains and their corresponding

GAL

DsRedempty strains, again

highlighting the reduction in cell viability caused by expression of human TDP-43WT observed
in spotting assays (section 3.3.2.). In contrast,

GAL

FUSWT-DsRed,

GAL

SOD1WT-DsRed and

GAL

SOD1A4V-DsRed strains showed less deviation in growth relative to their corresponding

GAL

DsRedempty strains. The DsRed Fmax and the maximum exponential rate of change of DsRed

F.I. (maximum rate of DsRed F.I. increase) measured in diploid
greater than in the corresponding

GAL

TDP-43WT strains was

GAL

DsRedempty strains, despite the relatively greater growth

of the GALDsRedempty strains (Figure S3.13, e, f, g and h, Appendix I). The DsRed Fmax and the
maximum rate of DsRed F.I. increase was also greater in diploid GALSOD1A4V-DsRed strains
relative to the corresponding

GAL

DsRedempty strains. The expression of the

GAL

DsRedempty

plasmid (DsRed alone) resulted in a much lower DsRed F.I. than was seen in GALTDP-43WTDsRed, GALFUSWT-DsRed, GALSOD1WT-DsRed and GALSOD1A4V-DsRed strains when viewed
using a fluorescence microscope (section 3.3.2). Thus, the lower DsRed F.I. signal measured
using the fluorescent plate reader is in accordance with the observations made by fluorescence
microscopy.
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In the following section 3.3.4, the analyses of EGFP-fusion protein levels amongst the diploid
strains, it should be noted that any variation in growth between replicates of strains were
accounted for by normalising the EGFP F.I. of the EGFP-fusion proteins to the OD600 at each
measured time-point. Significant variations in normalised EGFP F.I. between replicates were
accounted for in statistical analyses, ensuring that strains exhibiting variation between
replicates would not be calculated to reach significance below the p value cut-off of 0.05.
3.3.4

Identification of yeast proteins with altered levels associated with the expression
of human TDP-43WT, FUSWT and mutant SOD1A4V

3.3.4.1 Expression of human TDP-43WT-DsRed is associated with alterations in the
levels of 24 yeast EGFP-fusion proteins
Out of the 128 diploid EGFP-fusion protein/GALTDP-43WT-DsRed strains screened, differential
levels of the EGFP-fusion proteins were observed in 24 strains (Figure 3.7 and Table 3.3). Of
these, 20 proteins had decreased levels compared to control diploid GALDsRedempty strains while
4 proteins had increased levels.

96

Figure 3.7. Expression of human TDP-43WT-DsRed in yeast causes alterations in the levels of 24 yeast
EGFP-fusion proteins. The absorbance and EGFP fluorescence of diploid EGFP-fusion protein/GALTDP-43WTDsRed strains grown in SGal/-His/Ura were measured over 48 h using a FLUOstar® Optima plate reader set to
incubate plates at 30 °C. Alterations in EGFP-fusion protein levels in diploid EGFP-fusion protein/GALTDP-43WTDsRed strains were identified based on a fold change of > ±0.075 (arbitrary cut-off) and p < 0.05 from t tests
comparing the mean normalised EGFP fluorescence intensity yield (yield from 0 to 48 h) relative to control diploid
EGFP-fusion protein/GALDsRedempty strains. These cut-offs are highlighted by dashed lines. Note that the y axis
displays the -log10 of the p values. Data points represent the ΔEGFP fluorescence and -log10 of the p value from t
tests comparing the differences in the means calculated from the average of quadruplicate samples. EGFP-fusion
proteins exhibiting altered levels are displayed in red.

97

Table 3.3. Yeast EGFP-fusion proteins with altered levels in diploid strains expressing human TDP-43WT-DsRed.
Major cellular
function/s

Glycolysis and
gluconeogenesis

Ubiquitin
homeostasis,
ubiquitinproteasome
system (UPS)

Yeast
orthologue

Human
orthologue

ENO1

ENO1,
ENO2, ENO3

TDH3

RPN10

TIF4631
Ribosomes and
protein
translation

GAPDHS

PSMD4

EIF4G1

Description of yeast orthologue
(Saccharomyces Genome Database; SGD,
UniProt)

Increased
Enolase I, a phosphopyruvate hydratase;
catalyses conversion of 2-phosphoglycerate to
phosphoenolpyruvate during glycolysis and the
reverse reaction during gluconeogenesis.
Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), isozyme 3; involved in glycolysis and
gluconeogenesis; tetramer that catalyses the
reaction of glyceraldehyde-3-phosphate to 1,3
bis-phosphoglycerate; detected in the cytoplasm
and cell wall.
Non-ATPase base subunit of the 19S regulatory
particle of the 26S proteasome; N-terminus plays
a role in maintaining the structural integrity of
the regulatory particle; binds selectively to
polyubiquitin chains.
Translation initiation factor eIF4G; subunit of
the mRNA cap-binding protein complex (eIF4F)
that also contains eIF4E (CDC33); interacts with
PAB1 and with eIF4A (TIF1); also has a role in
biogenesis of the large ribosomal subunit.
Interacts with CDC48.
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ΔF

0.204

0.126

0.13

0.102

p value

0.0416

0.0486

0.0454

0.0293

Connection to
ALS/Proteostasis
function(s)/Interaction with
relevant proteins (BioGRID)

Reference
for
gene/protein
with direct
connection
to ALS

ENO2 has been detected in
ubiquitin-immunoreactive
inclusions in SOD1-linked
fALS. Involved in glycolysis.

Kato et al.
1997

Transcription, RNA transport,
DNA replication, apoptosis.
Modulates cytoskeleton
organisation.

Proteasomal protein
degradation; components of the
19S regulatory particle have
been detected in nuclear
inclusions in sALS.

Seilhean et
al. 2004

Present in ubiquitinimmunoreactive inclusions in
FUS-linked fALS.

Dormann et
al. 2010

ADA2

GCN5

mRNA splicing,
transcription,
RNA
metabolism and
stress granules.

PBP1

PAB1

TADA2A/B

BAZ1A/B,
BAZ2A/B,
KAT2A/B,
CECR2,
BPTF
ATXN2

RBMS2,
RBMS3,
PABPC1

Decreased
Transcription coactivator, component of the
ADA and SAGA transcriptional adaptor/HAT
(histone acetyltransferase) complexes.
Catalytic subunit of ADA and SAGA histone
acetyltransferase complexes; modifies Nterminal lysines on histones H2B and H3;
acetylates RSC4, a subunit of the RSC
chromatin-remodelling complex, altering
replication stress tolerance; relocalises to the
cytosol in response to hypoxia.
Component of glucose deprivation induced stress
granules; involved in P-body-dependent granule
assembly; similar to human ataxin-2; interacts
with PAB1 to regulate mRNA polyadenylation.

-0.079

-0.089

-0.126

Poly(A) binding protein; part of the 3'-end RNAprocessing complex, mediates interactions
between the 5' cap structure and the 3' mRNA
poly(A) tail, involved in control of poly(A) tail
length, interacts with translation factor eIF-4G.
-0.124
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0.0392

0.0382

0.0339

3.10E05

Involved in chromatin
remodelling, transcription and
the UPR.
Involved in chromatin
remodelling, transcription and
the UPR.

PBP1 enhances TDP-43
toxicity; ATXN2 is present in
ubiquitin-immunoreactive
inclusions in sALS and FUSlinked fALS.

Elden et al.
2010; Farg et
al. 2013;
Kim et al.
2014

PAB1 suppresses FUS toxicity;
PABPC1 is present in
basophilic ubiquitinimmunoreactive inclusions in
sALS and FUS-linked fALS;
PABP is required for TDP-43
toxicity in Saccharomyces
cerevisiae; PABP mediates
interaction between TDP-43 and
ATXN2 in Drosophila
melanogaster.

Sun et al.
2011; Kim et
al. 2014

PUB1

Ribosomes and
protein
translation

SSB1

DSK2

TIA-1

HSPA13

UBQLN2

Ubiquitin
homeostasis,
ubiquitinproteasome
system (UPS)
CPR1

Molecular
chaperones,
protein folding

HSP82

PPIE, PPIF

HSP90AA1,
HSP90AB1

Poly (A)+ RNA-binding protein; abundant
mRNP-component protein that binds mRNA and
is required for stability of many mRNAs;
component of glucose deprivation induced stress
granules, involved in P-body-dependent granule
assembly; implicated in regulation of translation;
carries Q/N-rich domain at C- terminus,
identified as candidate prion; human homologue
TIA-1 is critical for normal synaptic plasticity.
Cytoplasmic ATPase that is a ribosomeassociated molecular chaperone; functions with
J-protein partner ZUO1; may be involved in
folding of newly-made polypeptide chains;
member of the HSP70 family.
Nuclear-enriched ubiquitin-like polyubiquitinbinding protein, required for spindle pole body
(SPB) duplication and for transit through the
G2/M phase of the cell cycle, involved in
proteolysis, interacts with the proteasome.

Cytoplasmic peptidyl-prolyl cis-trans isomerase
(cyclophilin); catalyses the cis-trans
isomerisation of peptide bonds N-terminal to
proline residues.

HSP90 chaperone; required for pheromone
signalling, negative regulation of HSF1; docks
with TOM70 for mitochondrial preprotein
delivery; promotes telomerase DNA binding,
nucleotide addition; contains two acid-rich
unstructured regions that promote solubility of
chaperone-substrate complexes.
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-0.09

-0.231

-0.174

-0.264

-0.398

Stress granule marker;
colocalises with TDP-43 in
stress granules.

Kim et al.
2014

HSP70 molecular chaperone
family.

Wolff,
Weissman &
Dillin, 2014
(review)

Present in ubiquitinimmunoreactive inclusions in
sALS and SOD1-, TARDBP-,
FUS-, OPTN-, UBQLN2- and
C9ORF72-linked fALS.
Mutations in UBQLN2 cause
some forms of fALS.

Deng et al.
2011; Mori
et al. 2013;
May et al.
2014

Member of the peptidyl-prolyl
cis-trans isomerase (PPIase;
cyclophilin) family. PPIases
have been detected in ubiquitinimmunoreactive inclusions in
SOD1-linked fALS.

Basso et al.
2009

Present in ubiquitinimmunoreactive inclusions in
SOD1-linked fALS.

Basso et al.
2009

0.0022

0.0023

0.0148

0.0018

9.68E05

DER1

CDC48

DERL1

VCP

ER stress, UPR,
ERAD

HAC1

XBP1

ER membrane protein that promotes export of
misfolded polypeptides; required for ERAD of
misfolded or unassembled proteins; initiates
export of aberrant polypeptides from ER lumen
by threading them into ER membrane and
routing them to HRD1 for ubiquitylation.

AAA ATPase; subunit of polyubiquitin-selective
segregase complex involved in ERAD, cell wall
integrity during heat stress, mitotic spindle
disassembly; subunit of complex involved in
mitochondria-associated degradation; role in
mobilising membrane bound transcription factors
by regulated ubiquitin/proteasome-dependent
processing, in macroautophagy, PMN, RAD,
ribophagy, homotypic ER membrane fusion,
disassembly of MET30 from SCF complex,
functional orthologue of human p97/VCP.
Basic leucine zipper (bZIP) transcription factor
(ATF/CREB1 homolog); regulates the UPR. ER
stress-induced splicing pathway facilitates
efficient HAC1 synthesis; translation initiation is
repressed under non-stress conditions; protein
abundance increases in response to DNA
replication stress.
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Involved in ERAD.

-0.121

-0.162

3.51E05

9.28E05

VCP mutations cause some
forms of ALS. VCP is present
in ubiquitin-immunoreactive
inclusions in SOD1-linked
fALS.

Involved in the UPR.

-0.173

0.0086

Johnson et
al. 2010;
Abramzon et
al. 2012;
Weisberg et
al. 2012

Nma111

ERV25
Endomembrane
system, ERGolgi transport

GEA2

ATG8

Autophagy

HTRA2
(HtrA2/Omi)

TMED10

GBF1

MAP1LC3
and
GABARAP
subfamilies

Serine protease and general molecular
chaperone; cleaves ROQ1, which modifies the
substrate specificity of the UBR1 ubiquitin
ligase, promoting the stress-induced
homeostatically-regulated protein degradation
(SHRED) of misfolded and native ER-membrane
and cytosolic proteins; chaperone activity
involved in the heat stress response; promotes
apoptosis through proteolysis of BIR1; role in
lipid homeostasis; mammalian Omi/HtrA2 serine
protease family member.
Member of the p24 family involved in ER to
Golgi transport; role in misfolded protein quality
control.
Guanine nucleotide exchange factor for ADP
ribosylation factors (ARFs); involved in
vesicular transport between the Golgi and ER,
Golgi organisation, and actin cytoskeleton
organisation.
Component of autophagosomes and Cvt vesicles;
regulator of ATG1, targets it to autophagosomes;
binds the ATG1-ATG13 complex, triggering its
vacuolar degradation; unique ubiquitin-like
protein whose conjugation target is lipid
phosphatidylethanolamine (PE); ATG8-PE is
anchored to membranes, is involved in
phagophore expansion, and may mediate
membrane fusion during autophagosome
formation; deconjugation of ATG8-PE is
required for efficient autophagosome biogenesis.
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Present in ubiquitinimmunoreactive inclusions in
sALS and SOD1-linked fALS.
-0.168

-0.155

-0.118

0.0197

0.026

0.0228

ER to Golgi transport; role in
misfolded protein quality
control.
Vesicular transport between the
Golgi and ER; Golgi
organisation.
Involved in autophagy.

-0.103

0.0078

Kawamoto
et al. 2010

SLT2

MAPK15

Protein
phosphorylation,
trafficking and
signal
transduction

SOD2

TSA1
Mitochondrial
homeostasis and
antioxidant
activity

TSA2

SOD2

PRDX1,
PRDX2,
PRDX3,
PRDX4

PRDX2

Serine/threonine MAP kinase; coordinates
expression of all 19S regulatory particle
assembly-chaperones (RACs) to control
proteasome abundance; involved in regulating
maintenance of cell wall integrity, cell cycle
progression, nuclear mRNA retention in heat
shock, septum assembly; required for mitophagy,
pexophagy; affects recruitment of mitochondria
to phagophore assembly site; regulated by the
PKC1-mediated signalling pathway.
Mitochondrial manganese superoxide dismutase;
protects cells against oxygen toxicity and
oxidative stress; human mitochondrial SOD2 can
complement a yeast null mutant and human
cytoplasmic SOD1 can also complement when
targeted to the mitochondrial matrix.
Thioredoxin peroxidase; acts as both ribosomeassociated and free cytoplasmic antioxidant; selfassociates to form high-molecular weight
chaperone complex under oxidative stress;
chaperone activity essential for growth in zinc
deficiency; required for telomere length
maintenance; binds and modulates CDC19
activity; protein abundance increases, forms
cytoplasmic foci during DNA replication stress.
Stress inducible cytoplasmic thioredoxin
peroxidase; cooperates with TSA1 in the
removal of reactive oxygen, nitrogen and sulphur
species using thioredoxin as hydrogen donor.
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-0.142

-0.229

-0.502

-0.125

0.0349

0.0169

0.0015

0.0223

Regulates proteasome
abundance. MAP kinases have
been detected in ubiquitinimmunoreactive inclusions in
SOD1-linked fALS and sALS.

Bendotti et
al. 2004;
Basso et al.
2009

Mitochondrial manganese
superoxide dismutase; involved
in antioxidant activity.

PRDX2 has been detected in
ubiquitin-immunoreactive
inclusions in SOD1-linked
fALS. Involved in antioxidant
activity.

Kato et al.
2004

Detected in ubiquitinimmunoreactive inclusions in
SOD1-linked fALS. Involved in
antioxidant activity.

Kato et al.
2004

STRING network analysis of protein-protein interactions amongst the hits identified several
interactions (Figure 3.8). Noticeably, CDC48 was a hub for several interacting proteins; DER1,
HSP82 and TIF4631 with its shared interactions with SSB1 and PAB1. Ten additional
interacting proteins connected CDC48 indirectly with DSK2 and RPN10; PRE4, PRE5, PRE8,
PRE9, RPT3, RPT4, RPT6, RPN5, RPN11 and RPN12.

Figure 3.8. Protein-protein interaction network for EGFP-fusion protein/GALTDP-43WT-DsRed screen hits.
The twenty-four yeast EGFP-fusion proteins with altered levels in diploid EGFP-fusion protein/GALTDP-43WTDsRed strains were queried in the STRING protein-protein interaction database (Szklarczyk et al. 2015,
Szklarczyk et al. 2017). Interactions between the hits were queried using co-expression, published experiments
and databases as sources of interaction data, and only interactions scored with high confidence were included. It
was selected that ten secondary interacting proteins would be included in the network analysis. The four upregulated proteins are displayed as pink circles, while the twenty down-regulated proteins are displayed as blue
circles. CDC48 is indirectly linked with DSK2 and RPN10 via a sub-network of ten secondary interactors,
displayed as pale grey/purple circles.

Analysis of the 24 primary hits and the 10 secondary interactors was carried out to identify any
GO term enrichment amongst the hits and interactors above the background pathway-focused
selection of 128 EGFP-fusion proteins. The specific functions that have been documented for
each of the 24 hits were additionally evaluated as collated in Table 3.3. GO term analysis
identified that there was no enrichment in any one biological process amongst the hits out of
the background set of 128 EGFP-fusion proteins. Nevertheless, the diverse functions that have
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been reported for each of the 24 hits (Table 3.3) reveal specific molecular alterations caused
by the expression of TDP-43WT-DsRed.
TDH3 and ENO1, two of the four yeast EGFP-fusion proteins measured to have increased
levels in diploid GALTDP-43WT-DsRed yeast, interact with each other and are both involved in
glycolysis. Seven of the hits have functions that are involved in gene expression regulation;
CPR1, ADA2, GCN5, PAB1, PBP1, PUB1 and TIF4631. With the exception of TIF4631, the
levels of each of these proteins were found to be decreased in diploid

GAL

TDP-43WT-DsRed

yeast (Table 3.3). In a study identifying the composition of RNA-processing complexes in
yeast, Krogan et al. (2004) detected an interaction between TIF4631 and CDC48. The levels
of CDC48 were decreased in diploid GALTDP-43WT-DsRed yeast (p = 9.28E-05). CDC48 was
indirectly linked with the hits DSK2 and RPN10 via ten additional interacting proteins. Each
of these secondary interactors are subunits of the 26S proteasome. In total, 13 of the primary
hits and all 10 secondary interactors have functions in misfolded protein quality control and
protein degradation mechanisms in different cellular compartments (Table 3.3). CDC48 and
DER1 are both required for the export of misfolded proteins from the ER for ERAD (Knop et
al. 1996, Ye et al. 2001). ADA2 and GCN5 are catalytic subunits of the SAGA histone
acetyltransferase complex that is involved in the transcriptional activation of ER-associated
molecular chaperones in the IRE1-mediated UPR signalling pathway (Welihinda et al. 1997,
Welihinda et al. 2000, Lew et al. 2015). HAC1 is essential in this pathway; the splicing of
HAC1 mRNA, mediated by IRE1 in response to an accumulation of unfolded or misfolded
proteins in the ER lumen, is necessary for transcriptional activation of ER-associated molecular
chaperones (Cox and Walter 1996, Mori et al. 1996, Ron and Walter 2007). SSB1, CPR1,
HSP82 and NMA111 are molecular chaperones with diverse functions in protein folding and
targeting substrate proteins for degradation (Borkovich et al. 1989, Haendler et al. 1989,
Nelson et al. 1992, Hasumi and Nishikawa 1993, Nathan et al. 1997, Dolinski et al. 1998,
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Lopez-Buesa et al. 1998, Pfund et al. 1998, Pfund et al. 2001, Gautschi et al. 2002, Picard
2002, Padmanabhan et al. 2009, Szoradi et al. 2018). SLT2, DSK2, RPN10, CDC48 and the
10 secondary interactors are required for functionality of the UPS (Funakoshi et al. 2002, Rao
and Sastry 2002, Saeki et al. 2002, Carmody et al. 2010, Stolz et al. 2011, Rousseau and
Bertolotti 2016). With the exception of RPN10, the levels of each of these proteins were found
to be decreased in diploid TDP-43WT-DsRed yeast. As well as their functions in proteasomal
degradation, DSK2 and CDC48 are also important in the autophagy pathway, in which another
hit, ATG8, has a key role (Kim and Klionsky 2000, Klionsky et al. 2003, Xie et al. 2008).
3.3.4.2 Alterations in the levels of 10 yeast EGFP-fusion proteins are associated with
the expression of human FUSWT-DsRed
In diploid EGFP-fusion protein/GALFUSWT-DsRed strains, 10 yeast EGFP-fusion proteins had
altered levels relative to their levels in control diploid EGFP-fusion protein/GALDsRedempty
strains (Figure 3.9 and Table 3.4). Of these, the levels of 9 proteins were increased, whilst 1
protein (MGE1) had decreased levels of expression.
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Figure 3.9. Expression of human FUSWT-DsRed in yeast causes alterations in the levels of 10 yeast EGFPfusion proteins. The absorbance and EGFP fluorescence of diploid EGFP-fusion protein/GALFUSWT-DsRed
strains grown in SGal/-His/Ura were measured over 48 h using a FLUOstar® Optima plate reader set to incubate
plates at 30 °C. Alterations in EGFP-fusion protein levels in diploid EGFP-fusion protein/GALFUSWT-DsRed
strains were identified based on a fold change of > ±0.075 (arbitrary cut-off) and p < 0.05 from t tests comparing
the mean normalised EGFP fluorescence intensity yield (yield from 0 to 48 h) relative to control diploid EGFPfusion protein/GALDsRedempty strains. These cut-offs are highlighted by dashed lines. Note that the y axis displays
the -log10 of the p values. Data points represent the ΔEGFP fluorescence and -log10 of the p value from t tests
comparing the differences in the means calculated from the average of quadruplicate samples. EGFP-fusion
proteins exhibiting altered levels are displayed in red.
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Table 3.4. Yeast EGFP-fusion proteins with altered levels in diploid strains expressing human FUSWT-DsRed.
Major cellular
function/s

mRNA splicing,
transcription,
RNA
metabolism and
stress granules.

Yeast
orthologue

Human
orthologue

PBP1

ATXN2

DSK2

UBQLN2

Ubiquitin
homeostasis,
ubiquitinproteasome
system (UPS)
HSF1
Molecular
chaperones,
protein folding

HSF1

Description of yeast orthologue (Saccharomyces
Genome Database; SGD, UniProt)

Increased
Component of glucose deprivation induced stress
granules; involved in P-body-dependent granule
assembly; similar to human ataxin-2; interacts with
PAB1 to regulate mRNA polyadenylation.
Nuclear-enriched ubiquitin-like polyubiquitin-binding
protein, required for spindle pole body (SPB) duplication
and for transit through the G2/M phase of the cell cycle,
involved in proteolysis, interacts with the proteasome.

Trimeric heat shock transcription factor; activates
multiple genes in response to highly diverse stresses,
including hyperthermia; recognises variable heat shock
elements (HSEs); monitors translational status of cell at
the ribosome through an RQC (Ribosomal Quality
Control)-mediated translation-stress signal; involved in
diauxic shift; posttranslationally regulated.
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ΔF

0.3332407

p value

0.0115777

0.1084386

0.0494203

0.1105651

0.0489443

Connection to
ALS/Proteostasis
function(s)/Interaction
with relevant proteins
(BioGRID)

Reference for
gene/protein
with direct
connection to
ALS

PBP1 enhances TDP-43
toxicity; ATXN2 is present
in ubiquitin-immunoreactive
inclusions in sALS and
FUS-linked fALS.

Elden et al.
2010; Farg et
al. 2013; Kim
et al. 2014

Present in ubiquitinimmunoreactive inclusions
in sALS and SOD1-,
TARDBP-, FUS-, OPTN-,
UBQLN2- and C9ORF72linked fALS. Mutations in
UBQLN2 cause some forms
of fALS.
Heat shock response.

Deng et al.
2011; Mori et
al. 2013; May
et al. 2014

UFD1

ER stress, UPR,
ERAD

Protein
phosphorylation,
trafficking and
signal
transduction

HAC1

PHO85

MDJ1

UFD1L

XBP1

CDK5

DNAJA3

Mitochondrial
homeostasis
RUB1
Miscellaneous

NEDD8

Substrate-recruiting cofactor of the CDC48-NPL4-UFD1
segregase; polyubiquitin binding protein that assists in
the dislocation of misfolded, ERAD substrates that are
subsequently delivered to the proteasome for
degradation; involved in regulated destruction of ER
membrane proteins such as HMG-CoA reductase
(HMG1/2) and cytoplasmic proteins (FBP1); involved in
mobilising membrane bound transcription factors by
regulated Ub/proteasome-dependent processing.
Basic leucine zipper (bZIP) transcription factor
(ATF/CREB1 homologue); regulates the unfolded
protein response, via UPRE binding, and membrane
biogenesis; ER stress-induced splicing pathway
facilitates efficient HAC1 synthesis; two functional
forms of HAC1 are produced; translation initiation is
repressed under non-stress conditions; protein abundance
increases in response to DNA replication stress.
Cyclin-dependent kinase; has ten cyclin partners;
involved in regulating the cellular response to nutrient
levels and environmental conditions and progression
through the cell cycle; human lissencephaly-associated
homologue CDK5 functionally complements null
mutation.
Co-chaperone that stimulates HSP70 protein SSC1
ATPase activity; involved in protein folding/refolding in
the mitochondrial matrix; required for proteolysis of
misfolded proteins; member of the HSP40 (DNAJ)
family of chaperones.
Ubiquitin-like protein with similarity to mammalian
NEDD8; conjugation (neddylation) substrates include
the cullins CDC53, RTT101, and CUL3; activated by
ULA1 and UBA3 (E1 enzyme pair); conjugation
mediated by UBC12 (E2 enzyme).
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ERAD pathway.

0.2240214

0.0489068

UPR pathway.

0.127716

0.1468222

0.0222142

0.0283158

Present in ubiquitinimmunoreactive inclusions
in SOD1-linked fALS.

Nakamura et
al. 1997

Mitochondrial HSP40
chaperone.
0.2038949

0.1287392

0.0163733

0.0028463

Present in ubiquitinimmunoreactive inclusions
in sALS and SOD1-linked
fALS.

Tanji et al.
2007

SMT3

MGE1/
GRPE
Mitochondrial
homeostasis and
antioxidant
activity

SUMO1

GRPEL1

Ubiquitin-like protein of the SUMO family; conjugated
to lysine residues of target proteins; associates with
transcriptionally active genes; regulates chromatid
cohesion, chromosome segregation, APC-mediated
proteolysis, DNA replication and septin ring dynamics;
human homologue SUMO1 can complement yeast null
mutant.

Decreased
Mitochondrial matrix cochaperone; nucleotide release
factor for SSC1 in protein translocation and folding; also
acts as cochaperone for SSQ1 in folding of Fe-S cluster
proteins; acts as oxidative sensor to regulate
mitochondrial SSC1; in presence of oxidative stress,
dimeric MGE1 becomes a monomer and unable to
regulate SSC1 function; homologue of E. coli GRPE and
human MGE1 (GRPEL1), which also responds to
oxidative stress.
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0.1283347

0.0177666

Sumoylation of Lys-75 in
SOD1 modulates SOD1
aggregation; aggregates
containing a spliced mutant
of TDP-43 have been found
to contain SUMO2/3; FUS
can function as a SUMO E3
ligase, and can itself be
sumoylated.
Mitochondrial protein
import; mitochondrial
chaperone binding.

-0.170056

0.0030688

Fei et al.
2006; Oh et
al. 2010;
Seyfried et al.
2010

GO term enrichment analysis of the hits against the background set of 128 EGFP-fusion
proteins showed that there was no enrichment in any of the biological process terms annotated
amongst the background set of proteins. However, evaluation of the specific functions reported
for the hits, as collated in Table 3.4, was important to identify the molecular processes that
were altered in cells expressing FUSWT-DsRed. Moreover, STRING network analysis revealed
interactions amongst the hits (Figure 3.10). Ten secondary interacting proteins link several of
the hits with each other in sub-networks that highlight their shared molecular pathways. A subnetwork linking HSF1, UFD1 and RUB1, each of which were up-regulated in diploid FUSWTDsRed yeast, included two secondary interactors; CDC48 and NPL4. CDC48, NPL4 and UFD1
form a polyubiquitin-selective segregase complex involved in ERAD (Ye et al. 2001).
STRING analysis inferred a functional interaction between NPL4 and RUB1 from interactions
that have been identified experimentally between their mammalian orthologues, rather than
directly between these proteins in Saccharomyces cerevisiae. HSF1 linked into this subnetwork via its interaction with CDC48. CDC48 has diverse functions in cells, one of which is
in the ribosome quality control (RQC) complex (Brandman et al. 2012). In this complex,
CDC48 signals to HSF1 under conditions of stress resulting from disruptions in protein
translation to elicit transcriptional activation of the heat shock response (HSR), leading to the
expression of diverse molecular chaperones. It is interesting to note that CDC48 was found to
be down-regulated in diploid GALTDP-43WT-DsRed yeast (section 3.3.4.1).
A sub-network linked MDJ1 and MGE1 with 2 secondary interactors, SSC1 and TIM44. MDJ1
is a HSP40 co-chaperone that activates the HSP70 ATPase, SSC1, which is involved in protein
folding and refolding in the mitochondrial matrix (Deloche et al. 1997, Kubo et al. 1999).
MGE1 is another mitochondrial matrix co-chaperone that assists SSC1 in its protein
translocation and folding functions. Interestingly, while the levels of MDJ1 were increased in
yeast expressing FUSWT-DsRed, the levels of MGE1 were decreased. Moreover, MGE1 was
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the only protein measured to have decreased levels in diploid FUSWT-DsRed yeast.
Three proteins that had been measured to have decreased levels in diploid

GAL

TDP-43WT-

DsRed yeast, HAC1, PBP1 and DSK2, were observed to have increased levels in diploid
GAL

FUSWT-DsRed yeast. Through STRING analysis, no interactions were identified between

these proteins and the other hits. The cyclin-dependent kinase, PHO85, and the ubiquitin-like
protein, SMT3, were also not identified to share interactions with the other hits. However, they
were connected to secondary interactors in their own distinct sub-networks.

Figure 3.10. Protein-protein interaction network for EGFP-fusion protein/GALFUSWT-DsRed screen hits.
The ten yeast EGFP-fusion proteins with altered levels in diploid EGFP-fusion protein/GALFUSWT-DsRed strains
were queried in the STRING protein-protein interaction database (Szklarczyk et al. 2015, Szklarczyk et al. 2017).
Interactions between the hits were queried using co-expression, published experiments and databases as sources
of interaction data, and only interactions scored with high confidence were included. It was selected that ten
secondary interacting proteins would be included in the network analysis. The nine up-regulated proteins are
displayed as pink circles, while the one down-regulated protein is displayed as a blue circle. The ten secondary
interacting proteins of the hits are displayed as pale grey/purple circles, showing sub-networks that link several
of the hits with each other.
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3.3.4.3 Expression of human SOD1A4V-DsRed is associated with changes in the levels of
7 yeast EGFP-fusion proteins
In the set of 128 diploid EGFP-fusion protein/GALSOD1A4V-DsRed yeast strains that were
examined, altered levels of the EGFP-fusion proteins were measured in 7 strains (Figure 3.11
and Table 3.5). Out of these, the levels of 5 proteins were increased relative to the
corresponding control diploid EGFP-fusion protein/GALDsRedempty strains and EGFP-fusion
protein/GALSOD1WT-DsRed strains, whilst 2 proteins had decreased levels.
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Figure 3.11. Expression of human SOD1A4V-DsRed in yeast causes alterations in the levels of 7 yeast EGFPfusion proteins. The absorbance and EGFP fluorescence of diploid EGFP-fusion protein/GALSOD1A4V-DsRed
strains grown in SGal/-His/Ura were measured over 48 h using a FLUOstar® Optima plate reader set to incubate
plates at 30 °C. Alterations in EGFP-fusion protein levels in diploid EGFP-fusion protein/GALSOD1A4V-DsRed
strains were identified based on a fold change of > ±0.075 (arbitrary cut-off) and p < 0.05 from t tests comparing
the mean normalised EGFP fluorescence intensity yield (yield from 0 to 48 h) relative to control diploid EGFPfusion protein/GALDsRedempty strains. These cut-offs are highlighted by dashed lines. Note that the y axis displays
the -log10 of the p values. Data points represent the ΔEGFP fluorescence and -log10 of the p value from t tests
comparing the differences in the means calculated from quadruplicate samples. Only EGFP-fusion proteins
exhibiting altered levels in diploid EGFP-fusion protein/GALSOD1A4V-DsRed strains but not in the corresponding
diploid EGFP-fusion protein/GALSOD1WT-DsRed strains were included in further analyses, and are displayed in
red.
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Table 3.5. Yeast EGFP-fusion proteins with altered levels in diploid strains expressing human SOD1A4V-DsRed.
Major cellular
function/s

mRNA
splicing,
transcription,
RNA
metabolism and
stress granules.

Yeast
orthologue

DCP2

ASC1

Human
orthologue

DCP2

RACK1

Ribosomes and
protein
translation
PRE2
Ubiquitin
homeostasis,
ubiquitinproteasome
system (UPS)

UBA1

Description of yeast orthologue (Saccharomyces
Genome Database; SGD, UniProt)

Increased
Catalytic subunit of the DCP1-DCP2 decapping enzyme
complex; removes the 5' cap structure from mRNAs
prior to their degradation; also enters the nucleus and
positively regulates transcription initiation; forms
cytoplasmic foci upon DNA replication stress; human
homologue DCP2 complements yeast DCP2
thermosensitive mutant.
An integral ribosomal protein; G-protein beta subunit
and guanine dissociation inhibitor for GPA2; orthologue
of RACK1 that inhibits translation; core component of
the small (40S) ribosomal subunit; regulates P-body
formation induced by replication stress.

PSMB5,
PSMB8,
PSMB11

Beta 5 subunit of the 20S proteasome; responsible for the
chymotryptic activity of the proteasome.

UBA1

Ubiquitin activating enzyme (E1); catalyses the first step
in ubiquitin conjugation to mark cellular proteins for
degradation through the ubiquitin-proteasome system.

ΔF

0.135671

0.1649825

0.0092441

0.0188575

Connection to
ALS/Proteostasis
function(s)/Interaction with
relevant proteins
(BioGRID)

Reference for
gene/protein
with direct
connection to
ALS

Reported to co-localise with
FUS in stress granules.
Native interactor of CDC48
(VCP). Involved in mRNA
degradation.

Sun et al.
2011

Involved in protein quality
control at ribosomes during
translation.

Wolff,
Weissman &
Dillin, 2014
(review)

Proteasomal protein
degradation.
0.2916613
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p value

0.0941485

0.00218

0.0479153

Ubiquitin homeostasis;
ubiquitin-proteasome system
(UPS).

UFD1

UFD1L

ER stress,
UPR, ERAD

Ubiquitin
homeostasis,
ubiquitinproteasome
system (UPS)

PRE3

Endoplasmic reticulumassociated degradation
(ERAD) pathway.
0.1193909

SOD1,
SOD3, CCS

0.0352671

Decreased
Beta 1 subunit of the 20S proteasome; responsible for
cleavage after acidic residues in peptides.

Proteasomal protein
degradation.
-0.205477

SOD1
Mitochondrial
homeostasis
and antioxidant
activity

PSMB6,
PSMB9

Substrate-recruiting cofactor of the CDC48-NPL4-UFD1
segregase; polyubiquitin binding protein that assists in
the dislocation of misfolded, ERAD substrates that are
subsequently delivered to the proteasome for
degradation; involved in regulated destruction of ER
membrane proteins such as HMG-CoA reductase
(HMG1/2) and cytoplasmic proteins (FBP1); involved in
mobilising membrane bound transcription factors by
regulated Ub/proteasome-dependent processing.

Cytosolic copper-zinc superoxide dismutase; detoxifies
superoxide; stabilizes YCK1 and YCK2 kinases in
glucose to repress respiration; phosphorylated by DUN1,
enters nucleus under oxidative stress to promote
transcription of stress response genes; human orthologue
SOD1 implicated in ALS complements a null allele;
localisation to mitochondrial intermembrane space is
modulated by MICOS complex.
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-0.081141

0.0008374

0.0081055

Mutations in SOD1 cause
~20% of fALS cases. SOD1
is present in ubiquitinimmunoreactive inclusions in
SOD1-linked fALS. Involved
in antioxidant activity;
scavenges free radicals in
cells.

Shibata et al.
1994; Kato et
al. 1997;
Benatar et al.
2006

GO term enrichment analysis of the hits against the background set of 128 EGFP-fusion
proteins showed that there was no enrichment in any biological process terms. STRING
network analysis, however, identified that several of the hits were connected in interaction subnetworks, linked through ten secondary interacting proteins (Figure 3.12). This revealed that
several of the hits and the majority of the secondary interactors shared a common interactor;
RPS31. RPS31 and eight of the ten secondary interactors are ribosomal subunits (RPS12,
RPS13, RPS15, RPS2, RPS20, RPS3, RPS31 and RPS5). RPS31 is one of two fusion proteins
that are proteolytically cleaved to yield ubiquitin and the S31 ribosomal subunit (Finley et al.
1989, Oh et al. 2013). Of the primary hits, ASC1, PRE3, UBA1 and UFD1 directly interact
with RPS31. ASC1 is a core component of the small (40S) ribosomal subunit. The levels of
ASC1 were increased in diploid

GAL

SOD1A4V-DsRed yeast (p = 0.0189). UFD1, which had

increased levels in yeast expressing SOD1A4V-DsRed (p = 0.0353), also had increased levels in
yeast expressing FUSWT-DsRed (see section 3.3.4.2). As described in section 3.3.4.2, UFD1
forms a polyubiquitin-selective segregase complex, together with NPL4 and CDC48, that is
involved in ERAD (Ye et al. 2001). UBA1 is the primary E1 ubiquitin-activating enzyme in
yeast, as is its orthologue in humans (Chiu et al. 2007, Jin et al. 2007, Pelzer et al. 2007). UBA1
levels were found to be increased in diploid GALSOD1A4V-DsRed yeast (p = 0.048). PRE3, the
levels of which were decreased in yeast expressing SOD1A4V-DsRed (p = 0.0008), is a β-subunit
of the 20S proteasome that catalyses cleavage after acidic residues in peptides. PRE3 interacts
with PRE2, another β-subunit of the 20S proteasome that is responsible for the chymotryptic
activity of the proteasome. The secondary interactors of these two proteins, PRE7 and PUP1,
are the β6 and β2 subunits of the 20S proteasome. Out of the 17 total primary hits and secondary
interactors, 6 are involved in ubiquitin-dependent protein degradation (PRE2, PRE3, UBA1,
UFD1, PRE7 and PUP1).
Two of the hits did not share interactions with the other hits or the secondary interactors; DCP2
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and SOD1. Yeast SOD1 was found to be down-regulated in yeast expressing human SOD1A4VDsRed (p = 0.0081). The heterologous expression of human SOD1 containing ALS-associated
mutations (G93A, G85R and K100G) in yeast has been shown to complement a null yeast SOD1
allele (Nishida et al. 1994). It is possible that the overexpression of human SOD1A4V-DsRed
was complementary to the activity of yeast SOD1, causing a decrease in the expression of yeast
SOD1. DCP2, which had increased levels in diploid GALSOD1A4V-DsRed yeast (p = 0.0092), is
a catalytic subunit of the DCP1-DCP2 decapping enzyme complex that removes the 5’ cap from
mRNAs before they are degraded (Dunckley and Parker 1999).

Figure 3.12. Protein-protein interaction network for EGFP-fusion protein/GALSOD1A4V-DsRed screen hits.
The seven yeast EGFP-fusion proteins with altered levels in diploid EGFP-fusion protein/GALSOD1A4V-DsRed
strains were queried in the STRING protein-protein interaction database (Szklarczyk et al. 2015, Szklarczyk et al.
2017). Interactions between the hits were queried using co-expression, published experiments and databases as
sources of interaction data, and only interactions scored with high confidence were included. It was selected that
ten secondary interacting proteins would be included in the network analysis. The five up-regulated proteins are
displayed as pink circles, while the two down-regulated proteins are displayed as blue circles. The ten secondary
interacting proteins of the hits are displayed as pale grey/purple circles, showing sub-networks that link several of
the hits with each other.
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3.3.4.4 Common hits and pathways differentially expressed in diploid EGFP-fusion
strains expressing human TDP-43WT, FUSWT or SOD1A4V
While there were no common hits between all three screens against TDP43, FUS and SOD1,
three hits (PBP1, HAC1 and DSK2) were common between the TDP-43 and FUS screens and
one hit (UFD1) was common between the FUS and SOD1 screens (Figure 3.13). The levels of
UFD1 were found to be increased both in yeast expressing SOD1A4V-DsRed and in yeast
expressing FUSWT-DsRed. As described in sections 3.3.4.2 and 3.3.4.3, UFD1 is one of the
three proteins that form a polyubiquitin-selective segregase complex, together with NPL4 and
CDC48, that is involved in ERAD (Ye et al. 2001). While the levels of HAC1, PBP1 and DSK2
were decreased in yeast expressing TDP-43WT-DsRed, their levels were increased in yeast
expressing FUSWT-DsRed. These three proteins are not reported to directly interact with one
another. DSK2 has several functions in proteolysis. It is a ubiquitin-like polyubiquitin-binding
protein involved in the UPS, autophagy as well as in the ERAD pathway (Funakoshi et al. 2002,
Saeki et al. 2002, Medicherla et al. 2004, Nolan et al. 2017). HAC1 is involved in the IRE1mediated UPR signalling pathway. It is a transcription factor that promotes the expression of
proteins important for ER quality control (Cox and Walter 1996, Mori et al. 1996, Ron and
Walter 2007). PBP1 also has roles in regulating gene expression, however it is specifically
involved in the maturation of pre-mRNAs for translation, mediating their polyadenylation
(Mangus et al. 1998). PBP1 also regulates the assembly of SGs and P-bodies (Buchan et al.
2008).
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Figure 3.13. Venn diagram illustrating the yeast EGFP-fusion proteins that were commonly altered by the
expression of human TDP-43WT-DsRed, FUSWT-DsRed and/or SOD1A4V-DsRed in diploid yeast strains.
Three proteins were altered both in yeast expressing TDP-43WT-DsRed and in yeast expressing FUSWT-DsRed;
PBP1, HAC1 and DSK2. The levels of UFD1 were increased both in yeast expressing FUSWT-DsRed and in yeast
expressing SOD1A4V-DsRed. PBP1 is involved in mRNA processing and stress granule dynamics and is the yeast
orthologue of ATXN2, polyglutamine repeat expansions in which are a genetic risk factor for ALS (Elden et al.
2010, Farg et al. 2013, Tazen et al. 2013). HAC1 is the major regulator of the unfolded protein response. DSK2 is
the yeast orthologue of UBQLN2, mutations in which are associated with ALS (Deng et al. 2011). UFD1 has
crucial functions in the endoplasmic reticulum-associated degradation pathway.

GO term enrichment analysis for the primary hits identified in each screen against the
background set of 128 EGFP-fusion proteins showed that there was no enrichment in any of the
biological processes that have been annotated for the background set of proteins. However,
several of the hits and secondary interactors identified in the screens of yeast expressing human
TDP-43WT-DsRed, FUSWT-DsRed and SOD1A4V-DsRed have functions in gene expression, SG
assembly and dynamics, ERAD and the UPS (Table 3.6). In the screens of yeast expressing
human TDP-43WT-DsRed or FUSWT-DsRed there were hits and interactors with molecular
chaperone functions and involvement in autophagy.
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Table 3.6. The common major categories of molecular processes that have been reported for the primary
hits and secondary interactors identified in the screens of diploid yeast EGFP-fusion strains expressing
human TDP-43WT-DsRed, FUSWT-DsRed or SOD1A4V-DsRed.
Molecular process
Gene expression;
transcription and
translation
Stress granules
Molecular
chaperone activity
Transport between
ER and Golgi

TDP-43WT-DsRed
screen
ADA2, GCN5, HAC1,
PAB1, PBP1, PUB1,
RPT3, RPT4, RPT6,
SLT2, TIF4631
PBP1, PUB1, TIF4631
CPR1, HSP82, SSB1,
TSA1, TSA2

FUSWT-DsRed screen

SOD1A4V-DsRed screen

PBP1, CKS1, HAC1,
HSF1, PHO80,
PHO85

DCP2, RPS12, RPS13,
RPS15, RPS2, RPS20,
RPS3, RPS31, RPS5

PBP1
MDJ1, MGE1, SSC1

DCP2

ATG8, ERV25, GEA2

ER stress, UPR,
ERAD

CDC48, DER1, DSK2,
HAC1, RPT3, RPT4,
RPT6, SLT2

CDC48, DSK2,
HAC1, NPL4, UFD1

UFD1

Ubiquitin
homeostasis, UPS

CDC48, HSP82, DSK2,
PRE4, PRE9, RPN10,
RPN11, RPN12, RPT3,
RPT4, RPT6, PRE5,
PRE8

CDC48, NPL4,
UFD1, DSK2

PRE2, PRE3, PRE7, PUP1,
UBA1, UFD1

Autophagy

ATG8, CDC48, DSK2,
GEA2, SLT2

CDC48, DSK2,
PHO80, PHO85

Mitochondrion
function
Antioxidant activity
Calcium-mediated
signalling

MDJ1, MGE1, SSC1,
TIM44
SOD2, TSA1, TSA2

SOD1
PHO80, PHO85

Discussion
Over the last two decades, the study of different neurodegenerative diseases, including PD, HD,
AD and ALS, has benefited from the use of Saccharomyces cerevisiae as a model organism
(Krobitsch and Lindquist 2000, Auluck et al. 2002, Outeiro and Lindquist 2003, Willingham et
al. 2003, Cooper et al. 2006, Johnson et al. 2008, Gitler et al. 2009, Johnson et al. 2009, Elden
et al. 2010, Sun et al. 2011, Treusch et al. 2011, Kim et al. 2014). Many conserved, fundamental
biological processes that are affected by the expression of disease-causing genes in humans can
be identified using yeast as a model system. In the present study, the effect of the heterologous
expression of TDP-43WT, FUSWT and SOD1A4V on the levels of a pathway-focused set of 128
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different yeast proteins was investigated. It was hypothesised that any proteins in this selection
that were found to have altered expression in the presence of TDP-43, FUS and mutant SOD1
may play a key role(s) in the cellular response to ALS-associated pathology. A comprehensive
list of conserved yeast proteins to include for screening was compiled, including proteins
involved in proteostasis mechanisms, other pathways suspected to be involved in ALS
pathogenesis (e.g. mitochondrial dysfunction, disruptions in energy metabolism), and
orthologues of human proteins that have been found colocalised in inclusions in post-mortem
spinal cord tissue from ALS patients (Ciryam et al. 2017). The result of this yeast screen was
the identification of 24, 10 and 7 yeast proteins found to have altered levels in yeast expressing
TDP-43WT-DsRed, FUSWT-DsRed and SOD1A4V-DsRed, respectively.
In future work it will be necessary to validate the hits from this yeast screen. The hits will first
need to be validated biochemically through immunoblotting of lysates prepared from each
diploid yeast strain. This could be done using an anti-EGFP antibody to probe for the EGFPfusion yeast protein in each diploid strain, to then compare the levels of each EGFP-fusion
protein between each diploid strain expressing the ALS gene relative to the corresponding
control strain expressing DsRed alone. It will also be important to confirm that the changes in
EGFP-fusion protein levels measured in the present study were of a magnitude that would have
functional effects. There is no available method or formula to calibrate the measured changes
in EGFP-fusion protein levels to an absolute quantity of the protein levels. This limits us from
comparing the changes in EGFP-fusion protein levels that were observed with data published
in the literature on protein expression level changes that would be sizeable enough to impact
molecular and cellular function. One approach to investigate this experimentally would involve
measuring the activity of molecular processes that are downstream from each hit, and
comparing between each diploid yeast strain expressing the ALS gene and the corresponding
control strain expressing DsRed alone. Differences in the activity of the targeted molecular
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process in cells expressing the ALS gene relative to control cells expressing DsRed alone would
provide evidence that the alterations in EGFP-fusion protein levels measured in the present
study were of an amplitude great enough to have functional effects.
All biochemically confirmed hits would then need to be validated using mammalian cell culture
models of SOD1, TDP-43 and FUS. Validation in these models would involve preparing cell
lysates from each cell culture model and using these to immunoblot for the endogenous
mammalian orthologue of each hit. As would be done for the yeast strains, the endogenous
levels of the protein hit that was probed for would be compared between cells expressing the
ALS gene mutant and corresponding control cells expressing GFP alone.
Beyond these proposed validation studies, it would be important to carry out knockdown studies
using siRNA targeted to each hit. Conversely, it would also be important to carry out studies to
examine the effects of overexpression of each hit. In these knockdown and overexpression
studies, measurement of the effect on the activity of known downstream targets of the hit, cell
viability, localisation of the ALS mutant and/or aggregation of the ALS mutant would provide
valuable mechanistic information on the role that the hit may play in the cellular response to
the expression of the ALS mutant.
3.4.1

Alterations in gene expression regulation may be common to ALS associated with
SOD1, TDP-43 and FUS

In the past decade, studies to characterise alterations in protein levels resulting from factors that
cause cellular stress have emerged as a way to gain insight into the molecular pathways involved
in disease and in the cellular response to harmful stimuli (Breker et al. 2013, D'Souza et al.
2014, Fesenko et al. 2016, Tangsongcharoen et al. 2019). Between all three screens conducted
as part of this work, the primary hits and secondary interactors identified have functions in
several common molecular processes of the proteostasis network; gene expression, ERAD and
the UPS. Of course, the set of 128 yeast EGFP-fusion strains included in the present study were
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selected based on their relevance to the molecular mechanisms suspected to be involved in
motor neuron dysfunction in ALS, particularly proteostasis. Thus, it is not surprising that
processes related to proteostasis were identified to be affected; however, it is important to gain
insight into commonly altered molecular processes in all three genetic screens, as well as any
changes that are unique to each. For instance, gene expression alterations and changes in SG
dynamics have been comprehensively investigated in the context of mutations in TARDBP and
FUS, both of which are involved in RNA metabolism. Up until very recently, these molecular
alterations had not received attention in relation to their association with mutations in SOD1.
However, a 2016 study revealed an interaction between mutant SOD1 and G3BP1, a protein
involved in SG dynamics (Gal et al. 2016). In the present work, the levels of the P-body and
SG-associated protein, DCP2, were up-regulated in yeast expressing SOD1A4V-DsRed. DCP2
is involved in gene expression through its function in mRNA degradation (Dunckley and Parker
1999). Some of the proteins identified in the SOD1A4V screen, ASC1 and its secondary
interactors, are components of the small 40S ribosomal subunit and therefore essential for
translation. One of these interactors, RPS31, was a central interactor linking ASC1 and the other
primary hits UFD1, UBA1 and PRE3. The up-regulation of DCP2 and ASC1 and the connection
between all seven primary hits of a ribosome subunit fusion protein, RPS31, suggest that there
may have been an increased need for gene expression regulation in yeast expressing SOD1A4V.
Gene expression alterations may thus not only be associated with TDP-43 and FUS in ALS, but
also altered in the presence of mutant SOD1.
Further to identifying that gene expression regulation, ERAD and the UPS were commonly
affected molecular processes in yeast modelling TDP-43, FUS and SOD1 pathology, three
specific proteins (PBP1, HAC1 and DSK2) were found to be commonly altered between the
TDP-43 and FUS yeast screens, and one common hit (UFD1) was identified between the FUS
and SOD1 yeast screens.
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3.4.2

The expression of TDP-43WT and FUSWT cause alterations in the IRE1-mediated
UPR signalling pathway in yeast

The expression of human TDP-43WT-DsRed was clearly toxic in yeast, as demonstrated through
spotting assays (see section 3.3.2), showing that critical processes were perturbed in these cells.
Several proteins involved in ER protein quality control and the ER stress response were found
to have decreased levels in yeast expressing TDP-43WT-DsRed; ERV25 has functions in
misfolded protein quality control in the ER (Copic et al. 2009), DER1 promotes the export of
misfolded proteins from the ER for ERAD (Knop et al. 1996, Hitt and Wolf 2004), CDC48 is
one of the three members of the polyubiquitin-selective segregase complex involved in ERAD
(Ye et al. 2001, Ye et al. 2003), and NMA111 promotes stress-induced homeostaticallyregulated protein degradation (SHRED) of misfolded and native ER-membrane proteins
(Szoradi et al. 2018). Potentially, the presence of human TDP-43WT-DsRed in yeast caused a
widespread dysregulation of ER proteostasis. Reduction in the capacity of cells to ameliorate
ER stress has previously been implicated to be involved in the pathogenic mechanisms of
mutant TDP-43 (Walker et al. 2013, Wang et al. 2015). Compounding this, the decreased levels
of HAC1 suggest that TDP-43WT-DsRed further caused disruption of the pathway that regulates
HAC1 translation, impairing the IRE1-mediated UPR signalling pathway that is triggered by
ER stress (Cox and Walter 1996, Sidrauski and Walter 1997, Ron and Walter 2007).
The increased levels of HAC1 in yeast expressing FUSWT-DsRed indicate that proteostasis in
the ER of cells was compromised, causing ER stress, leading to increased splicing of HAC1
mRNA and consequently up-regulation of HAC1. In line with this, there is evidence that the
expression of mutant FUS in NSC-34 cells causes ER stress (Farg et al. 2012).
Importantly, these findings suggest that functionality of the IRE1-mediated UPR signalling
pathway may be a key determinant of the cellular ability to respond to ER stress caused by
mislocalised TDP-43 and FUS. Moreover, dysregulation of HAC1 mRNA splicing may be a
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key mechanism of TDP-43 toxicity, impairing cellular ability to restore ER proteostasis that is
initially disrupted through the aberrant activity of mislocalised TDP-43.
3.4.3

Differential regulation of PBP1 reveals differences in the cellular response to
mislocalised, toxic TDP-43WT and FUSWT

PBP1 is the yeast orthologue of ATXN2. Intermediate expansions of a CAG trinucleotide repeat
in ATXN2 are correlated with an increased risk for ALS (Elden et al. 2010, Tazen et al. 2013).
ATXN2 has further been associated with ALS through discovery of its presence in ubiquitinimmunoreactive inclusions in tissue from patients with sALS and FUS-linked fALS (Farg et al.
2013, Tazen et al. 2013). In yeast expressing TDP-43WT-DsRed it was found that PBP1 was
down-regulated, whereas it was up-regulated in yeast expressing FUSWT-DsRed. Findings from
previous work investigating modifiers of TDP-43WT toxicity indicated that increased levels of
PBP1 enhance the toxicity caused by TDP-43WT (Kim et al. 2014). It was further identified that
polyadenylate-binding protein (PAB1) mediated interactions between TDP-43 and
ATXN2/PBP1 that resulted in toxicity (Kim et al. 2014). In the present work, PAB1 was found
to be down-regulated in yeast expressing TDP-43WT-DsRed. The expression of human TDP43WT-DsRed caused striking toxicity in yeast. If, as reported by Kim et al. (2014), increased
levels of PBP1 enhance the toxicity caused by TDP-43WT in yeast, and PAB1 is involved in an
aberrant interaction between PBP1 and TDP-43, then down-regulation of these proteins may
improve the fitness of yeast expressing TDP-43WT. The decreased levels of PBP1 and PAB1 in
yeast expressing TDP-43WT may thus be the result of selection for TDP-43WT-DsRedexpressing cells that expressed lower levels of these proteins over successive cell divisions.
PBP1 is involved in diverse RNA processing pathways that control gene expression, including
P-body-dependent SG assembly and the regulation of mRNA polyadenylation (Mangus et al.
1998, Buchan et al. 2008). The up-regulation of PBP1 in yeast expressing FUSWT-DsRed may
promote SG assembly and repression of translation as part of a cellular stress response to the
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toxicity of mislocalised FUSWT-DsRed. Indeed, as well as up-regulation of PBP1 in yeast
expressing FUSWT-DsRed, several other proteins with key functions in responding to
proteotoxic stress were up-regulated, including HAC1 (as discussed above), DSK2, UFD1,
SMT3, HSF1 and MDJ1.
3.4.4

Yeast differentially regulate DSK2 in response to proteotoxic stress caused by
mislocalised TDP-43WT and FUSWT

The third common hit identified in the TDP-43WT-DsRed and FUSWT-DsRed screens, DSK2, is
particularly interesting as it is the yeast orthologue of a protein that is closely associated with
ALS; UBQLN2. Mutations in UBQLN2 cause X-linked ALS and ALS/FTD (Deng et al. 2011,
Teyssou et al. 2017). It is a commonly detected protein component of several different types of
inclusions detected in ALS patients’ motor neurons. It is detected in skein-like p62-, TDP-43-,
FUS- and OPTN-positive inclusions in ALS patients with P497H or P506T mutations in
UBQLN2 and in patients with sALS and fALS patients with mutations in SOD1, TARDBP and
FUS (Deng et al. 2011). It is also detected in TDP-43-negative, poly-(Gly-Ala), -(Gly-Pro), (Gly-Arg) DPR-, p62- and ubiquitin-positive inclusions in patients with pathological
hexanucleotide repeat expansions in C9ORF72 (Mori et al. 2013, May et al. 2014). Both DSK2
and its mammalian orthologue have several functions in proteolysis. It is a ubiquitin-like
polyubiquitin-binding protein involved in the UPS, autophagy and ERAD (Funakoshi et al.
2002, Saeki et al. 2002, Medicherla et al. 2004, Nolan et al. 2017). Interestingly, as was the
case for the other two common hits, HAC1 and PBP1, DSK2 was down-regulated in yeast
expressing TDP-43WT-DsRed but up-regulated in yeast expressing FUSWT-DsRed. Alterations
in the levels of DSK2 indicate that downstream ubiquitin-dependent degradation pathways,
namely the UPS, autophagy and ERAD, may be implicated in the cellular response to TDP43WT-DsRed and FUSWT-DsRed. Indeed, as well as up-regulation of DSK2 in yeast expressing
FUSWT-DsRed, the other proteins found to be up-regulated have diverse functions that assist
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cells in responding to proteotoxic stress. Apart from PBP1 (discussed above) the up-regulation
of proteins involved in mitochondrial proteostasis (MDJ1), ERAD (DSK2, UFD1), the UPR
(HAC1), the UPS and autophagy (DSK2) and, critically, the major regulator of the cellular
response to proteotoxic stress (HSF1), indicate that the expression of FUSWT-DsRed caused
widespread proteostasis dysfunction in cells. Potentially, these proteins were up-regulated in an
attempt by the cell to deal with proteostasis disruption caused by mislocalised FUSWT-DsRed.
In yeast expressing TDP-43WT-DsRed, as well as decreased levels of DSK2, the levels of ATG8,
required for autophagosome membrane formation, and proteins involved in ERAD (CDC48,
DER1, HAC1 and NMA111) were similarly decreased. Regarding the UPS, the primary
proteasome-associated ubiquitin receptor, RPN10, was up-regulated in yeast expressing TDP43WT-DsRed. Moreover, the localisation of RPN10-EGFP was altered in yeast expressing TDP43WT-DsRed, observed to be colocalised with cytosolic TDP-43WT-DsRed foci (Table 3.2,
section 3.3.2 and Figure S3.6, Appendix I). RPN10 is an atypical component of the proteasome,
as a large proportion of it exists in a proteasome-unassociated pool in which it functions,
similarly to DSK2, as a ubiquitin/polyubiquitin shuttle factor (Fu et al. 1998). In a landmark
study, Matiuhin et al. (2008) discovered a unique interaction between DSK2 and RPN10:
through demonstrating that overexpression of DSK2 was toxic in yeast, they unravelled a
complex mechanism by which RPN10 competes with DSK2 for binding to the proteasome, and
that RPN10 attenuates the toxicity associated with dysregulated DSK2. The toxicity mediated
by dysregulated DSK2 results from its interference with the normal functioning of the UPS,
altering the ratio of Lys48 to Lys63 polyubiquitin chains in the cellular ubiquitin pool (Matiuhin
et al. 2008). The data reported by Matiuhin et al. (2008) suggests that the delivery of substrate
polyubiquitylated proteins to the proteasome requires stringent regulation by the polyubiquitin
shuttle proteins, particularly DSK2 and RPN10, for efficient proteolysis and prevention of
proteasomal ‘clogging’. In the present work, the down-regulation of DSK2 and up-regulation
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of RPN10 may be due to an increased demand for RPN10 in shuttling proteasomal substrates
for degradation. In this case, DSK2 may be down-regulated to prevent its interference with the
ubiquitin/polyubiquitin shuttling activity of RPN10. Moreover, the colocalisation of RPN10
with cytosolic TDP-43WT-DsRed foci may indicate an attempt to direct mislocalised, toxic
TDP-43WT-DsRed for proteasomal degradation. However, in the present work it was not
investigated whether the cytosolic TDP-43WT-DsRed foci were ubiquitylated. Microscopy of
diploid RPN10-EGFP/TDP-43WT-DsRed yeast immunostained for ubiquitin would be needed
to examine whether the cytosolic RPN10-EGFP/TDP-43WT-DsRed foci are ubiquitin-positive,
and thus whether the colocalisation of RPN10-EGFP to these foci may be due to its
ubiquitin/polyubiquitin shuttling activity.
3.4.5

UFD1 is up-regulated in the presence of mutant SOD1A4V and mislocalised
FUSWT in yeast

In both yeast expressing FUSWT-DsRed and yeast expressing SOD1A4V-DsRed, the levels of
UFD1 were found to be increased. UFD1 is a polyubiquitin binding protein that has a crucial
role in ERAD, forming a segregase complex with CDC48 and NPL4 that extracts misfolded
proteins from the ER and directs them to the proteasome for degradation (Ye et al. 2001). Three
different ALS-causing mutations in SOD1, A4V, G85R and G93A, have been shown to cause
disruptions in ER-Golgi trafficking and the secretory pathway, leading to ER stress (Atkin et
al. 2014). The up-regulation of UFD1 in yeast expressing SOD1A4V-DsRed may thus be due to
augmentation of the ERAD pathway in an attempt to ameliorate ER stress caused by SOD1A4VDsRed-mediated disruption of ER proteostasis.
Interestingly, UFD1 and the CDC48-NPL4-UFD1 complex have been implicated in the DNA
damage response (DDR) pathway. Nie et al. (2012) investigated SUMO-targeted ubiquitin
ligases (STUbLs) and SUMOylation of target proteins in the context of toxicity caused by the
accumulation of SUMOylated species in cells, and in the DDR pathway. SUMOylation and
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ubiquitylation of target proteins are important modulators of the DDR pathway (reviewed in
Jackson and Durocher (2013)). Using a proteomics approach Nie et al. (2012) discovered that
the CDC48-NPL4-UFD1 complex was highly enriched among SUMO-binding proteins in the
fission yeast Schizosaccharomyces pombe, revealing a role for the CDC48-NPL4-UFD1
complex as a STUbL cofactor which protects cells against SUMO chain-mediated toxicity.
Furthermore, a combination of ubiquitin and SUMO recognition motifs within UFD1 appear to
mediate the targeting of the CDC48-NPL4-UFD1 complex to SUMOylated and ubiquitylated
substrates (Nie et al. 2012). Intriguingly, in the present work SMT3, a protein of the SUMO
family, was also up-regulated in yeast expressing FUSWT-DsRed. In another study, in cells in
which the DDR pathway was activated, a mutation in UFD1 lead to an accumulation of
SUMOylated species in nuclear foci (Køhler et al. 2013). This supports a direct role for UFD1
in regulating SUMOylated species in the DDR pathway. The up-regulation of UFD1 and SMT3
in yeast expressing FUSWT-DsRed observed here may be indicative of dysregulation of the
DDR pathway. Indeed, several studies have demonstrated that FUS has important functions in
the DDR pathway, and that mutations in the NLS of FUS result in impairment of this pathway
(Wang et al. 2013, Higelin et al. 2016, Gong et al. 2017, Naumann et al. 2018). Further
investigation of changes in the activity of UFD1 and its downstream effects in neuronal cell
models of disease-associated FUS mutations may help elucidate a role for UFD1 in the DDR
in the context of FUS-linked ALS.
3.4.6

Expression of TDP-43WT in yeast is associated with decreased levels of two key
autophagy proteins

CDC48 is a particularly intriguing hit from the TDP-43WT-DsRed screen given that mutations
in the human orthologue of CDC48, VCP, account for 1-2% of fALS and <1% of sALS cases
(Johnson et al. 2010, Abramzon et al. 2012). Mutations in VCP also cause IBMPFD (Watts et
al. 2004). TDP-43-positive inclusions are a hallmark pathological feature both in IBMPFD
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patients’ muscle and brain tissue (Watts et al. 2004, Kimonis et al. 2008) and in diseased motor
neurons in ALS patients. It was previously hypothesised that SGs that persist abnormally in
diseased cells seed the formation of inclusions, including TDP-43 inclusions (Dewey et al.
2012, Parker et al. 2012). More recent work has demonstrated that SGs do not seed the
aggregation of TDP-43 into inclusions (Chen and Cohen 2019, Gasset-Rosa et al. 2019, Mann
et al. 2019), however they may indirectly promote the pathological accumulation of TDP-43
into inclusions by interfering with the autophagic clearance of TDP-43 aggregates (Chen and
Cohen 2019).
Importantly, CDC48/VCP has been reported to mediate the clearance of SGs through selective
autophagy (Buchan et al. 2013). This provides a key link in diseases that are associated with
VCP mutations between impaired VCP function and the occurrence of TDP-43-positive
inclusions, with impairment in the autophagy pathway perhaps playing an important pathogenic
role. Loss of VCP function may impair the autophagic clearance of TDP-43, and potentially
further promote the accumulation of aggregated TDP-43 into inclusions due to impaired
autophagic clearance of SGs. SGs that have escaped clearance may sequester proteins that have
key functions in autophagy (Chen and Cohen 2019), further impairing the ability of cells to
eliminate TDP-43 inclusions through autophagy. In the present work, the levels of CDC48 were
reduced in yeast expressing TDP-43WT-DsRed, as were the levels of the key autophagy-related
protein ATG8. Through confocal microscopy, TDP-43WT-DsRed was observed to form
cytosolic foci in yeast cells, and there was minimal colocalisation with the SG protein PUB1,
indicating that these TDP-43 foci likely represented pathological inclusions that were distinct
from SGs (Table 3.2, section 3.3.2 and Figure S3.10, Appendix I). The localisation of CDC48EGFP was unique in yeast expressing TDP-43WT-DsRed compared to control diploid CDC48EGFP/GALDsRedempty yeast; it was observed to colocalise with cytosolic TDP-43WT-DsRed foci.
This apparent colocalisation may have been due to sequestration of CDC48-EGFP into TDP131

43 inclusions. Pathologically mislocalised, aggregated TDP-43WT-DsRed may thus have
impaired CDC48 function by depleting its functional levels in cells. Moreover, the decreased
levels of CDC48 and ATG8 in yeast expressing TDP-43WT-DsRed further suggest that
pathological TDP-43WT-DsRed may have aberrantly interacted with these proteins,
consequently impairing their functions in autophagy. Potentially, TDP-43-mediated
impairment of the functions of CDC48 and ATG8 in autophagy may have further enabled
aggregated TDP-43WT-DsRed to escape autophagic clearance and to accumulate in cells. To
explore this hypothesis, immunocytochemistry to probe for ATG8 and other autophagy
markers, including the yeast orthologue of beclin-1, VPS30, in CDC48-EGFP/GALTDP-43WTDsRed yeast at several time points is required in order to measure autophagic flux and determine
if autophagy is impaired in yeast expressing TDP-43WT-DsRed.
3.4.7

Up-regulation of key UPS proteins is associated with an absence of SOD1A4V
toxicity in yeast

An intriguing observation in the work presented in this chapter is that the expression of human
SOD1 containing the ALS-causing A4V mutation did not cause toxicity in yeast, whereas this
mutation is associated with a rapidly progressive disease course in humans (Cudkowicz et al.
1997, Juneja et al. 1997). Coinciding with this distinct lack of toxicity in each of the diploid
EGFP-fusion/GALSOD1A4V-DsRed strains was up-regulation of three proteins with important
roles in ubiquitin-dependent protein degradation; UBA1, PRE2 and UFD1. The secondary
interactors of these proteins, PRE7 and PUP1, are β-subunits of the 20S proteasome complex,
as is the primary hit PRE2. Interestingly, another β-subunit of the 20S proteasome complex,
PRE3, was down-regulated in yeast expressing SOD1A4V-DsRed.
The down-regulation of PRE3 is surprising given the up-regulation of UBA1, PRE2 and UFD1
as each of these proteins have functions in the UPS. Specifically, this raises the question as to
why one key catalytic β-subunit of the proteasome was up-regulated (PRE2), while another key
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catalytic β-subunit was down-regulated (PRE3). Differential regulation of proteasome subunits
has been investigated in relation to the changes that occur throughout diverse processes
including neonatal development, aging, cellular stress responses, cellular replicative
senescence, and in response to targeted RNAi of specific proteasome subunits (Shibatani et al.
1996, Keller et al. 2000, Wójcik and DeMartino 2002, Chondrogianni et al. 2003, Claud et al.
2014). These findings demonstrate that differential regulation of specific proteasome subunits
can enable cells to fine-tune their responses to changes in the intracellular environment,
increasing their capacity to adapt. For instance, overexpression of catalytic β-subunits of the
20S proteasome complex can lead to augmentation of the specific catalytic activity of the
overexpressed β-subunit (Gaczynska et al. 1994, Gaczynska et al. 1996). Overexpression of the
β5 subunit in human fibroblasts has been reported to increase the replicative potential of cells
(Chondrogianni et al. 2005). In the present work, the increased levels of PRE2, the β5 subunit
of the 20S proteasome complex, in yeast expressing SOD1A4V-DsRed may indicate that cells
had an increased requirement for the catalytic chymotryptic activity of this subunit. Moreover,
there may be decreased demand for the catalytic activity of the PRE3 β-subunit in these cells,
and thus it was consequently down-regulated to further enable the up-regulation of PRE2. In
this case, the cellular levels of PRE2 β5 subunits may even be a critical determinant of
proteasome activity in cells expressing SOD1A4V-DsRed. It has been hypothesised that reduced
availability of β-subunits in cells is a rate-limiting factor in proteasome activity (Chondrogianni
et al. 2005). In the present work, as yeast expressing SOD1A4V-DsRed did not exhibit reduced
cellular viability, down-regulation of PRE3 in the context of up-regulated PRE2 was not
detrimental to the viability of yeast.
The up-regulation of UBA1, UFD1 and PRE2 suggest that UPS activity was increased in cells
expressing SOD1A4V-DsRed. Moreover, the common, central interactor of the primary hits and
secondary interactors, RPS31, is one of the two ubiquitin-ribosomal subunit fusion proteins that
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are conserved in eukaryotes (Finley et al. 1989, Oh et al. 2013). As such, it is one of four genes
that encode ubiquitin in yeast, as is its mammalian orthologue. Common between these primary
hits and secondary interactors (PRE7, PUP1 and RPS31) is that through their functions in cells
they influence the distribution of ubiquitin in the cellular ubiquitin pools. In particular, UBA1
is a key enzyme that modulates the activated ubiquitin pool. It functions at the apex of the UPS,
mediating ATP- and Mg2+-dependent activation of ubiquitin before it is transferred to one of
∼40 E2 enzymes which work in co-operation with one of > 600 E3 ligases to conjugate
ubiquitin to target proteins (Ayusawa et al. 1992, Cook and Chock 1992, Clague et al. 2015).

It is thus the key driver of the UPS. The increased levels of UBA1 and the other proteins of the
UPS, and the lack of toxicity of SOD1A4V-DsRed, suggest that yeast effected these changes in
response to SOD1A4V and this protected against the toxicity of SOD1A4V. Indeed, extensive
evidence suggests that dysfunction of the UPS contributes to motor neuron degeneration in
ALS. This includes, but is not limited to, the universal presence of ubiquitin and the frequent
detection of proteasome subunits in inclusions in ALS patients’ motor neurons (Leigh et al.
1991, Seilhean et al. 2004). It is thus warranted that the effect of increased levels and activity
of key UPS proteins be investigated in neuronal cell culture models to gain an understanding as
to whether increased UPS functionality can afford protection in neurons expressing ALScausing mutations.
3.4.8

Concluding statements

The complexity of molecular mechanisms that underlie ALS and other neurodegenerative
diseases make for an exceedingly challenging task in elucidating potential proteins and
molecular processes that could be targeted for the development of a therapy. However, yeast
represent a good model system to explore the fundamental molecular changes that are involved
in neurodegenerative diseases. This is because many of the molecular disturbances involved in
neurodegeneration occur in pathways of the proteostasis network that are well conserved
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amongst eukaryotic organisms. In the work presented in this chapter, the heterologous
expression of human TDP-43, FUS and SOD1A4V in 128 yeast strains from the EGFP-fusion
collection (Huh et al. 2003) led to the identification of processes that are potentially involved
in cellular responses to the pathogenic mechanisms that underlie ALS. Moreover, each of these
three ALS-associated proteins were found to have their own unique ‘fingerprint’ in terms of the
specific cellular response they elicited. Indeed, the pathways by which these three ALSassociated proteins aggregate in cells are distinct to each (Farrawell et al. 2015). Validation of
these findings in neuronal cell culture models will provide the basis for further studies into the
specific roles of the differentially-regulated proteins, and the pathways in which they function,
in ALS. Potentially, ALS linked to mutations in TARDBP, FUS and SOD1 may benefit from,
if not require, therapeutic targets that are specific to each.
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Chapter 4: Increased levels of UBA1 protect against
SOD1A4V toxicity in NSC-34 cells

136

Introduction
Ubiquitin is essential for the regulation of many aspects of cell biology. In the
neurodegeneration field, it is well known for its role in the degradation of misfolded proteins.
However, beyond tagging proteins for degradation, ubiquitylation is one of the most abundant
protein modifications in cellular signalling, controlling numerous cellular pathways such as
transcription, translation, vesicle transport and apoptosis (Winston et al. 1999, Deng et al. 2000,
Hoppe et al. 2000, Spence et al. 2000, Hoege et al. 2002, Haglund et al. 2003, Li et al. 2003,
Margottin-Goguet et al. 2003, Wertz et al. 2004, Carter et al. 2007, Kravtsova-Ivantsiv et al.
2009, Raiborg and Stenmark 2009, Boname et al. 2010, Dynek et al. 2010, Goto et al. 2010,
Ren and Hurley 2010, Gerlach et al. 2011, Ikeda et al. 2011). Ubiquitin labels substrate proteins
via a highly ordered multi-step enzymatic cascade, with specific differences in the length and
topology of poly-ubiquitin chains determining a range of signalling outcomes or proteolytic
degradation via the proteasome. In the nervous system, the UPS contributes to the regulation of
many aspects of neural function, such as neuronal growth and development, neuronal
excitability, neurotransmission, long-term potentiation (LTP) and synapse formation and
elimination (Mabb and Ehlers 2010, Kawabe and Brose 2011). Many factors can influence
ubiquitin homeostasis, and accumulation of ubiquitin in large misfolded protein deposits found
in ALS pathology may indirectly interfere with other essential ubiquitin-dependent cellular
processes (Farrawell et al. 2018). Indeed, neurons are sensitive to ubiquitin dyshomeostasis,
which if prolonged may lead to cell death (Tan et al. 2000, Tan et al. 2001). UPS function is
therefore central to neuronal health and neurodegenerative disease, and ubiquitylation is
emerging as a highly promising target for human therapy that remains to be fully exploited
(Jankowska et al. 2013). However, ubiquitin-dependent cellular processes are highly
interconnected, and there is a lack of systematic data on disease-related perturbations in these
systems. Therefore, it is critical to gain comprehensive insight into the ubiquitylation machinery
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in affected neurons and in response to therapeutic intervention.
Several of the genes implicated in fALS cohorts encode components and regulators of the UPS,
including VCP (Johnson et al. 2010, Abramzon et al. 2012), SQSTM1 (Fecto et al. 2011),
UBQLN2 (Deng et al. 2011, Teyssou et al. 2017), OPTN (Maruyama et al. 2010), CCNF
(Williams et al. 2016) and TBK1 (Cirulli et al. 2015). Defects in these genes are likely to lead
to perturbations in ubiquitin homeostasis, but the precise effect of these mutations on the
maintenance of ubiquitin homeostasis is currently unknown. Recent work using proteomics to
map the ubiquitin-modified proteome in NSC-34 cells showed significant changes in the
distribution of ubiquitin in mutant SOD1-expressing cells (Farrawell et al. 2018). Mutations in
genes such as TARDBP also lead to disruption of ubiquitin homeostasis. For example,
knockdown of the DUB, UBPY, exacerbated the toxicity of TDP-43 in Drosophila
melanogaster (Hans et al. 2014).
Ubiquitin regulates cellular concentrations of TDP-43 and SOD1 (Miyazaki et al. 2004, Scotter
et al. 2014) and their aberrant accumulation can be triggered by inhibition of the proteasome.
In human skin fibroblasts, significantly higher accumulation of a UPS reporter was observed in
ALS patient-derived cells compared to those from controls (Yang et al. 2015). Cell models of
CCNF-linked fALS were also found to have higher levels of the reporter compared to controls
(Williams et al. 2016), consistent with a compromised UPS in ALS. Similar reporters of UPS
function demonstrated UPS dysfunction in cultures of NSC-34 cells expressing mutant SOD1
(Crippa et al. 2010) and in the spinal motor neurons of mice with ALS caused by a SOD1
mutation (Basso et al. 2009). Indeed, proteasomal clearance of mutant SOD1 was reported to
be impaired uniquely in NSC-34 cells in contrast to muscle cells, which exhibited efficient
degradation of mutant SOD1 (Onesto et al. 2011). Recent work has shown that C9ORF72 poly(Gly-Ala) aggregates sequester a large proportion of the cell’s proteasomes and functionally
impair them (Guo et al. 2018). Moreover, motor neuron-specific knockdown of proteasome
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subunit RPT3 in the absence of an ALS genetic background can result in an ALS phenotype in
mice, including locomotor dysfunction, progressive motor neuron loss and mislocalisation of
TDP-43, FUS, UBQLN2, and OPTN (Tashiro et al. 2012). These data are consistent with a
reduction in UPS capacity being sufficient to drive ALS pathology in mice. Indeed, not even
overexpression of human mutant TDP-43 gives such an accurate reproduction of a human ALSlike phenotype in mice. The increased expression of components of the ubiquitin-dependent
proteolysis machinery were identified as a significant distinguishing factor in the transcriptome
of microdissected resistant oculomotor neurons compared to vulnerable motor neurons from
the human spinal cord (Brockington et al. 2013), suggesting increased UPS capacity is
protective in ALS.
In a screen for responses in the proteome to expression of SOD1A4V in yeast (Chapter III), the
E1 ubiquitin-activating enzyme UBA1 was found to be up-regulated relative to control cells.
The increased levels of UBA1 correlated with a distinct lack of SOD1A4V toxicity, which is in
contrast to the toxicity this SOD1 mutation causes in humans (Cudkowicz et al. 1997, Juneja et
al. 1997). UBA1 is the primary initiator of the UPS cascade, mediating ATP- and Mg2+dependent activation of ubiquitin before it is transferred to one of ∼40 E2 enzymes which work
in co-operation with one of > 600 E3 ligases to conjugate ubiquitin to target proteins. UBA1 is

fundamental to the UPS, and its downregulation attenuates UPS activity (Ciechanover et al.
1984, Ghaboosi and Deshaies 2007, Qin et al. 2016). It is known to be vital for motor neuron
health as mutations in UBA1 result in an infant onset motor neuron disease, X-linked spinal
muscular atrophy (XL-SMA; (Ramser et al. 2008)). XL-SMA represents a rare form of SMA,
however, notably, UBA1 is present at decreased levels in the majority of SMA cases caused by
mutations in SMN1 (Wishart et al. 2014, Powis et al. 2016). Increasing the levels of UBA1
restored motor performance and increased lifespan in mouse and zebrafish models of SMA
(Powis et al. 2016). Hence, work presented in this chapter was aimed at investigating the
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hypothesis that increased UBA1 expression is protective against cellular toxicity induced by
SOD1A4V. To investigate this hypothesis, the murine NSC-34 cell line was used as a mammalian
neuronal cellular model of SOD1A4V-ALS. The specific aims of the work presented in this
chapter were to:
(i)

compare the levels of endogenous UBA1 in mammalian neuronal cells
overexpressing SOD1A4V with cells overexpressing SOD1WT,
determine the effect of increased UBA1 expression on SOD1A4V-induced toxicity in

(ii)

NSC-34 cells and
(iii)

investigate the effect of increased UBA1 expression on SOD1A4V aggregation in
cells.

Materials and methods
Saponin (Saponin from Quillaja bark, Cat. No. S4521-10G) was from Sigma-Aldrich (St. Louis,
MO, USA).
4.2.1

Plasmid constructs for NSC-34 cells

The pEGFP-N1 vectors containing human SOD1WT (SOD1WT-EGFP) and SOD1A4V (SOD1A4VEGFP) were described in Chapter II. The pEGFP-N1 vector, which encodes for EGFP alone,
was used as a control for EGFP-tagged SOD1 expression. pCDNA3.1(+) constructs containing
murine wild-type UBA1 (UBA1WT) or a catalytically-inactive mutant C632S UBA1
(UBA1C632S) isoform were generated by sub-cloning murine UBA1WT from pET28-mE1
(Addgene plasmid 32534, provided by Jorge Eduardo Azevedo (Carvalho et al. 2012)) into
pCDNA3.1(+) and replacing Cys-632 with Ser, via GenScript’s customised cloning and sitedirected mutagenesis services. The pmCherry-C1 vector, which encodes mCherry alone, was
used as a control in place of UBA1WT and UBA1C632S in co-transfections with SOD1WT-EGFP
or SOD1A4V-EGFP. In these co-transfections the expression of mCherry alone was used to
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measure co-transfection efficiency and to account for cell viability in the absence of UBA1WT
and UBA1C632S.
4.2.2

Mammalian cell culture and transfections

NSC-34 cells (neuroblastoma × spinal cord hybrid) were maintained as described in Chapter II.
Cells were seeded at 1 × 105 cells/mL in DMEM/F-12/FBS into 6-well plates to prepare cell
lysates for immunoblot analyses, 8-well µ-Slides (Ibidi, Planegg-Martinsried, Germany) for
confocal microscopy, or 24-well plates for flow cytometry or IncuCyte® ZOOM imaging. Cells
were transfected 24 h later using Lipofectamine® 3000 (Invitrogen, USA) according to the
manufacturer’s instructions, with 0.2 µg DNA per well for 8-well µ-Slides, 0.5 μg DNA per
well for 24-well plates or 2.5 μg DNA per well for 6-well plates. For co-transfections the
amount of DNA was divided equally between constructs. Non-transfected cells were included
as controls in all experiments. For all experiments, a time-point of 48 h post-transfection was
used for cell lysis or fixing for confocal microscopy.
4.2.3

IncuCyte® ZOOM live cell imaging

IncuCyte® ZOOM live cell imaging and analysis was used to carry out two different measures
in NSC-34 cells transiently transfected with SOD1WT-EGFP, SOD1A4V-EGFP or EGFP alone,
or co-transfected with these constructs together with either UBA1WT, UBA1C632S or mCherry
alone. One of the experiments involved monitoring the relative population growth of transfected
cells (EGFP-positive cells) over 80 h. The net cell population growth (rate of cell division –
rate of cell death) was used as a measure of cell viability, on the basis that toxicity caused by
the overexpression of SOD1A4V-EGFP would impair cellular ability to proliferate and/or result
in the loss of cells relative to control cells overexpressing SOD1WT-EGFP or EGFP alone. NSC34 cells were transfected in 6-well plates and were re-plated at 24 h post-transfection at uniform
cell density (5 × 104 cells/mL) in 200 µL/well DMEM/F-12/FBS into 96-well plates and imaged
using the 10× objective lens of an IncuCyte® ZOOM over 70-90 h. To quantify the numbers of
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viable transfected cells, a processing definition in the IncuCyte® ZOOM software was
optimised to identify and count transfected cells based on a minimum level of EGFP
fluorescence, and viable cells based on a minimum size. Non-transfected controls were used to
account for and exclude background fluorescence and fluorescent artefacts, cell debris and
dying cells.
The second experiment quantified cells containing inclusions using a modification of a saponinpermeabilisation protocol described by Pokrishevsky et al. (2018). Saponin is a mild,
cholesterol-chelating detergent that creates pores in the plasma membrane of cells (Symons and
Mitchison 1991). These pores allow soluble intracellular proteins to diffuse out of the cell, while
trapping insoluble proteinaceous structures. NSC-34 cells were transfected with each
expression construct in quadruplicate in 96-well plates, and after 48 h were imaged using an
IncuCyte® ZOOM. These pre-permeabilisation images were used to measure the numbers of
cells that were transfected (EGFP-positive) in each well. After imaging, cells were incubated
with 0.03% (w/v) saponin in PBS for 10 min at RT to create pores in the cells’ plasma
membranes. Saponin-treated cells were then imaged again to measure the numbers of cells in
which non-diffusable, insoluble EGFP-positive material remained following permeabilisation.
The percentage of transfected cells containing insoluble EGFP-fusion proteins were then
calculated using the following formula:
% 𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑛𝑛𝑔𝑔 𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖 𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝
Equation 4.1.
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𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁 𝑜𝑜𝑜𝑜 𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝
� × 100
𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁 𝑜𝑜𝑜𝑜 𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝑝𝑝𝑝𝑝𝑝𝑝 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝

For all IncuCyte® experiments, the mean ± SEM was calculated across quadruplicate
replicates, and used for statistical analyses.
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4.2.4

Treatment with MG132

To test the susceptibility of cells to proteasome inhibition, NSC-34 cells transfected with each
of SOD1WT-EGFP, SOD1A4V-EGFP or EGFP alone were first replated at 24 h post-transfection
at uniform cell density and imaged in an IncuCyte® ZOOM. At 36 h post-transfection cells
were treated with 0, 0.5, 1, 1.5, 2, 2.5, 3.5 or 5 µM of the proteasome inhibitor MG132 and
imaging was continued for the next 50 h. Out of two independent experiments, for each
concentration of MG132, the numbers of cells at 48 h post-transfection were quantified and the
IC50 was calculated for cells transfected with SOD1WT-EGFP, SOD1A4V-EGFP or EGFP alone.
To compare the IC50 for cells expressing SOD1WT-EGFP, SOD1A4V-EGFP or EGFP alone, the
numbers of cells expressing SOD1A4V-EGFP or EGFP alone were normalised to the numbers
of cells expressing SOD1WT-EGFP.
4.2.5

Cell lysis, protein extraction and quantification

NSC-34 cells transfected with SOD1WT-EGFP, SOD1A4V-EGFP or EGFP alone and grown in
6-well plates were harvested at 48 h post-transfection using 0.05% trypsin-EDTA. Cells were
washed with PBS before being resuspended in RIPA buffer (50 mM Tris-HCl, pH 7.4
containing 0.5% (w/v) sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, 1% (v/v) Triton X100, 0.1% (w/v) SDS and Halt™ Protease Inhibitor Cocktail (Thermo Fisher Scientific,
Sydney, Australia)) and incubated overnight at 4 °C to promote cell lysis. Using 23 G needles,
each cell suspension was drawn up and down twelve times to ensure the nuclear membrane was
broken and the chromosomal DNA sheared. An aliquot was taken for total protein quantitation
by bicinchoninic acid (BCA) assay and the remainder of the samples stored at -80 °C.
4.2.6

Immunoblotting

The UBA1 antibody used in this study was a rabbit monoclonal to human UBA1, and had been
commercially tested for reactivity with mouse, rat and human UBA1. As a monoclonal
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antibody, it should have high specificity and minimal cross-reactivity, recognising a single
epitope at the C-terminus of UBA1. As this epitope is at the C-terminus of UBA1, this antibody
should react with both of the isoforms of UBA1 (UBA1a and UBA1b), which differ only at the
N-terminus (there are an additional 40 amino acids at the N-terminus of UBA1a) (Stephen et
al. 1997). For SDS-PAGE and immunoblotting, 100 µg of total cellular protein from NSC-34
lysates were prepared in appropriate volumes of 2× loading buffer (final concentrations: 2%
(w/v) SDS, 0.5 M Tris-HCl, 25% (w/v) glycerol, 0.01% (w/v) bromophenol blue, 5% (v/v) βmercaptoethanol). Samples were reduced and denatured by heating at 95 °C for 5 min before
being electrophoresed on a Mini-PROTEAN TGX Stain-Free Gel (Bio-Rad, USA) for 1.5 h at
100 V. Prior to transfer, the total protein loaded per lane on each gel was imaged using a
Criterion Stain-Free Imager (Bio-Rad, USA). Proteins were transferred onto a nitrocellulose
membrane (Pall Corporation, USA) at 20 V overnight at 4 °C. The membrane was blocked in
5% (w/v) skim milk powder in Tris-buffered saline (TBS) supplemented with 0.05% (v/v)
Tween-20 (TBS-T) overnight at 4 °C, followed by overnight incubation with rabbit monoclonal
antibody to E1 ubiquitin activating enzyme (ab181225, Abcam) at 1:10,000 dilution in 5%
(w/v) skim milk powder in TBS-T. The following day the membrane was washed three times
with TBS-T over 30 min before being incubated overnight at 4 °C with horseradish peroxidise
(HRP)-conjugated goat anti-rabbit antibody (A16104, Invitrogen) at 1:2,000 dilution in 5%
skim milk powder in TBS-T. The membrane was then washed three times with TBS-T over 45
min and visualised with WesternBright™ Sirius chemiluminescent HRP substrate (Advansta)
on an Amersham Imager 6600RGB. Four separate SDS-PAGE and immunoblotting
experiments were carried out on cell lysates prepared in four separate transfection experiments.
To measure the relative density of protein bands resolved in each immunoblotting experiment,
the density of each band and of the total protein loaded in the respective lane of the gel were
quantified using Image Studio™ software (LI-COR Biosciences, USA). The calculated density
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of each band was then normalised to the calculated total protein density in the respective gel
lane as is standard practice for immunoblots. The mean normalised relative band densities from
the four biological repeats were compared using one-way ANOVA with Tukey’s multiple
comparisons post-hoc test.
4.2.7

Fixing, permeabilising, immunolabelling and confocal microscopy

At 48 h post-transfection, NSC-34 cells transfected with SOD1WT-EGFP, SOD1A4V-EGFP or
EGFP alone, or co-transfected with these constructs as well as UBA1WT, UBA1C632S or mCherry
alone, were fixed in 4% (w/v) paraformaldehyde in PBS for 20 min at room temperature in
monolayers in 8-well µ-Slides for confocal microscopy. Cells were then washed three times
over 15 min with PBS (pH 7.4), and permeabilised with 1% (v/v) Triton X-100 in PBS for 30
min on crushed ice. Following permeabilisation, cells were washed twice over 10 min with PBS
and blocked for 1 h at room temperature with 5% (v/v) FBS, 1% (w/v) bovine serum albumin,
0.3% (v/v) Triton X-100 in PBS. After blocking, cells were washed twice over 10 min with
PBS and incubated for 16 h at 4 °C with rabbit monoclonal antibody to E1 ubiquitin activating
enzyme (ab181225, Abcam) or rabbit IgG monoclonal isotype control (ab172730, Abcam) at
1:200 dilution. Primary antibodies were diluted in 1% (w/v) bovine serum albumin, 0.1% (v/v)
Triton X-100 in PBS. The following day, cells were washed twice over 10 min with PBS and
incubated for 5 h at room temperature with Alexa Fluor™ 647 goat anti-rabbit IgG (H+L)
secondary antibody (ab150079, Abcam) at 1:500 dilution. Secondary antibodies were diluted
in 1% (w/v) bovine serum albumin, 0.1% (v/v) Triton X-100 in PBS. Cells were then washed
three times over 15 min in PBS.
Cells were imaged using a Leica TCS SP5 II confocal microscope with a 63× oil-immersion
objective lens (Leica Microsystems, Wetzlar, Germany). EGFP fluorescence was excited at 488
nm by an argon laser; mCherry fluorescence was excited at 561 nm by a DPS 561 laser.
Fluorescent emissions were acquired by sequential scanning using the Leica Application Suite
145

– Advanced Fluorescence (LAS-AF) software (version 3, Leica Microsystems, Wetzlar,
Germany).
Results
4.3.1

Endogenous UBA1 levels are unaffected by overexpression of SOD1A4V-EGFP in
NSC-34 cells

The A4V mutation in SOD1 causes one of the most aggressive forms of ALS (Cudkowicz et al.
1997, Juneja et al. 1997, Lemmens et al. 2007). In order to measure the effects of SOD1A4VEGFP overexpression on the viability of NSC-34 cells, live cell imaging on an IncuCyte®
ZOOM was used to monitor cells over a 70 h time period. In this assay, reduced net population
growth of cells overexpressing SOD1A4V-EGFP relative to control cells overexpressing
SOD1WT-EGFP or EGFP alone was considered to be a toxic effect of SOD1A4V-EGFP. Over the
imaging period the numbers of cells expressing SOD1WT-EGFP and EGFP alone steadily
increased, while the numbers of cells expressing SOD1A4V-EGFP increased at a slower rate
(Figure 4.1, a). At 48 h post-replating there were significantly lower numbers of cells expressing
SOD1A4V-EGFP than cells expressing SOD1WT-EGFP (p = 0.0151) or EGFP alone (p = 0.0435)
(Figure 4.1, b). This indicates that the overexpression of SOD1A4V-EGFP caused toxicity.
To characterise the appearance of transfected cells and the intracellular localisation of the
EGFP-fusion proteins, cells were imaged 48 h post-transfection using confocal microscopy.
While SOD1WT-EGFP was observed to have a relatively even distribution throughout the
cytoplasm and within nuclei, in a proportion of cells SOD1A4V-EGFP formed multiple large
inclusions in the cytoplasm (Figure 4.1, c).
Given that the heterologous expression of human SOD1A4V in yeast did not cause toxicity, that
there was an absence of SOD1A4V aggregation in yeast cells, and that these observations
coincided with increased levels of yeast UBA1 (Chapter III), the level of endogenous murine
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UBA1 in NSC-34 cells expressing SOD1A4V-EGFP, SOD1WT-EGFP or EGFP alone was
investigated. Immunoblot analysis showed that there were no differences in the levels of UBA1
(~118 kDa) between NSC-34 cells overexpressing SOD1A4V-EGFP, SOD1WT-EGFP and EGFP
alone (Figure 4.1, d).
Considerable evidence supports impaired proteasome activity as one of the downstream toxic
effects of mutant SOD1 expression in motor neurons (Urushitani et al. 2002, Allen et al. 2003,
Kabashi et al. 2004, Cheroni et al. 2009, Crippa et al. 2010, Onesto et al. 2011). In yeast
expressing human SOD1A4V the levels of PRE2, a key proteasome subunit, and UFD1, a protein
with important functions in ubiquitin-dependent protein degradation, were both increased
(Chapter III). Given these data, the susceptibility of NSC-34 cells expressing SOD1A4V-EGFP
to proteasome inhibition were tested. Cells overexpressing SOD1A4V-EGFP were more
sensitive to proteasome inhibition by MG132 than cells overexpressing SOD1WT-EGFP or
EGFP alone. This was evident through the IC50 for cells overexpressing SOD1A4V-EGFP being
markedly lower than for cells overexpressing SOD1WT-EGFP or EGFP alone (Figure 4.1, e).
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Figure 4.1. Endogenous UBA1 levels are unaffected by overexpression of SOD1A4V-EGFP in NSC-34 cells.
(A) Representative time-resolved plot from one of three experiments showing the numbers of NSC-34 cells
transiently transfected with either SOD1WT-EGFP, SOD1A4V-EGFP or EGFP alone. Over time, cells
overexpressing SOD1WT-EGFP or EGFP alone continued to proliferate while the numbers of cells overexpressing
SOD1A4V steadily plateaued after the initial imaging period. Cells were replated at 24 h post-transfection at uniform
cell density, before being imaged in an IncuCyte® ZOOM over 70 hours. (B) Comparison of the numbers of cells
expressing SOD1WT-EGFP, SOD1A4V-EGFP or EGFP alone 48 h after replating and imaging in the IncuCyte®
ZOOM. Graph represents the mean ± SEM from three independent experiments. Differences between the means
were determined using a one-Way ANOVA followed by Tukey’s multiple comparison test. * indicates p < 0.05.
(C) SOD1A4V-EGFP forms cytoplasmic aggregates in NSC-34 cells, while SOD1WT-EGFP is diffusely distributed
throughout the cell. Cells were imaged at 48 h post-transfection on a Leica TCS SP5 II confocal microscope. Scale
bar represents 10 µm. (D) The levels of endogenous UBA1 in NSC-34 cells are not altered in cells overexpressing
SOD1A4V. NSC-34 cells overexpressing SOD1WT-EGFP, SOD1A4V-EGFP or EGFP alone were lysed at 48 h posttransfection. 100 µg total protein from each lysate were run on a SDS-PAGE gel and immunoblotted for UBA1.
UBA1 band densities were normalised to total protein loaded in each gel lane. Total protein loading was assessed
by imaging stain-free gels prior to transfer. Representative immunoblot showing bands corresponding to UBA1
(~118 kDa). Graph represents the mean ± SEM from four immunoblots of four independent transfection
experiments. (E) NSC-34 cells overexpressing SOD1A4V-EGFP are more susceptible to proteasome inhibition than
cells overexpressing SOD1WT-EGFP or EGFP alone. Cells were replated at 24 h post-transfection at uniform cell
density, then treated with different concentrations (0, 0.5, 1, 1.5, 2, 2.5, 3.5 or 5 µM) of the proteasome inhibitor
MG132 at 36 h post-transfection and imaged in an IncuCyte® ZOOM over 50 hours. 48 h after MG132 treatment,
the concentration of MG132 required to cause half the number of cells overexpressing SOD1A4V-EGFP to die (IC50)
was lower than that of cells overexpressing SOD1WT-EGFP or EGFP alone. Graph represents the mean ± SEM
from two independent experiments.

4.3.2

UBA1 expression is similar in NSC-34 cells transfected with either pcDNA3.1(+)UBA1WT or pcDNA3.1(+)-UBA1C632S plasmids

To explore the effect of increasing the levels of UBA1 in NSC-34 cells overexpressing
SOD1A4V-EGFP, two plasmid constructs were generated; pcDNA3.1(+) containing murine
UBA1WT or UBA1C632S (UBA1 with mutation of Cys-632, the residue responsible for its E1
catalytic activity) (Hatfield and Vierstra 1992, Forrester et al. 2011, Yang et al. 2012). To
ensure that any effects observed in cells overexpressing UBA1WT were due to the enzymatic
capacity of UBA1 and not from differences in expression levels between pcDNA3.1(+)UBA1WT and pcDNA3.1(+)-UBA1C632S, endogenous and overexpressed UBA1 levels were
examined by immunocytochemistry and confocal microscopy. Visual inspection of the confocal
images showed that the anti-UBA1 immunostaining was stronger in cells transfected with
pcDNA3.1(+)-UBA1WT or pcDNA3.1(+)-UBA1C632S than in cells that were not transfected with
these constructs (Figure 4.2, a). UBA1 appeared to be localised throughout the cytoplasm and
within nuclei but staining was more intense in nuclei and in small foci throughout the
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cytoplasm. This localisation pattern aligns with findings from other studies showing that UBA1
is present in nuclei and throughout the cytoplasm, including localising at high concentrations
to several organelles (Schwartz et al. 1992, Moudry et al. 2012). Quantification of anti-UBA1
Alexa Fluor™ 647 fluorescence intensity confirmed that there were greater levels of UBA1 in
cells transfected with either of the two UBA1 constructs than in non-transfected cells
(pcDNA3.1(+)-UBA1WT, p = 0.0062; pcDNA3.1(+)-UBA1C632S, p = 0.0036) (Figure 4.2, b).
Importantly, UBA1WT and UBA1C632S were expressed at comparable levels in transfected cells,
with no significant differences calculated in the mean anti-UBA1 Alexa Fluor™ 647
fluorescence intensity between cells transfected with each of these two constructs.
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Figure 4.2. UBA1WT and UBA1C632S are expressed at the same levels in transfected NSC-34 cells. (A)
Representative images showing immunostaining for UBA1 in NSC-34 cells transiently co-transfected with
SOD1A4V-EGFP and to express either mCherry alone (‘control’), UBA1WT or UBA1C632S. Cells were fixed,
permeabilised and stained for UBA1 (Alexa Fluor™ 647) 48 h post-transfection. Scale bar represents 10 µm. (B)
Confocal images of the cells were analysed using a macro in Image J to quantify the fluorescence intensity (F.I.)
of the Alexa Fluor™ 647 α-UBA1 staining. Graph represents the mean ± SEM from 3 wells of cells prepared in 3
separate transfection experiments. Means were compared using one-way ANOVA with Tukey’s multiple
comparisons test. ** indicates p < 0.01.
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4.3.3

Overexpression of UBA1WT reduces the toxicity of SOD1A4V-EGFP in NSC-34
cells

To test the hypothesis that increased UBA1 expression protects the viability of cells
overexpressing mutant SOD1, NSC-34 cells were co-transfected with SOD1WT-EGFP,
SOD1A4V-EGFP or EGFP alone and either UBA1WT, UBA1C632S or mCherry alone, and the net
population growth of EGFP-positive cells monitored over 90 h using an IncuCyte® ZOOM. As
was observed for cells transfected with just SOD1WT-EGFP or SOD1A4V-EGFP (Figure 4.1, a),
the numbers of cells overexpressing SOD1WT-EGFP and either UBA1WT, UBA1C632S or
mCherry alone continued to increase over the 90 h of imaging (Figure 4.3, a). Within the first
~32 h of imaging, the population growth rate of cells co-expressing SOD1A4V-EGFP and
UBA1WT was greater than that of cells co-expressing SOD1A4V-EGFP and UBA1C632S or
mCherry alone, such that, 48 h post-transfection, the numbers of cells co-expressing SOD1A4VEGFP and UBA1WT were significantly greater than the numbers of cells co-expressing
SOD1A4V-EGFP and UBA1C632S (p = 0.0020) or mCherry alone (p = 0.0003) (Figure 4.3, b).
This suggests that the increased levels of catalytically active UBA1WT buffered against the
toxicity caused by SOD1A4V-EGFP overexpression. The sudden decrease in cell numbers after
the first 32 h of imaging may be due to a decrease in the availability of UBA1WT in the cells
over time, either due to dilution or degradation of the UBA1WT plasmid DNA, or to functional
saturation of the exogenous UBA1WT molecules in activating ubiquitin and initiating the
ubiquitylation cascade for target proteins.
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Figure 4.3. UBA1WT overexpression increases viability of NSC-34 cells overexpressing SOD1A4V-EGFP.(A)
Representative graph showing numbers of NSC-34 cells transiently co-transfected to express either SOD1WTEGFP, SOD1A4V-EGFP or EGFP and UBA1WT, the catalytically inactive mutant UBA1C632S or mCherry. Cells
were replated at 24 h post-transfection at uniform cell density, before being imaged in an IncuCyte® ZOOM over
90 h. (B) Numbers of co-transfected NSC-34 cells at 48 h post-transfection, normalised to cells co-transfected with
SOD1WT-EGFP and UBA1WT. Experiment was performed three times and the bar chart represents mean ± SEM.
Differences between the means were determined using one-Way ANOVA followed by Tukey’s multiple
comparison test. ** indicates p < 0.01, *** indicates p < 0.001.
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4.3.4

SOD1A4V-EGFP aggregation is unaffected by UBA1WT overexpression

After discovering that increased UBA1WT expression protected against the toxicity caused by
SOD1A4V-EGFP in NSC-34 cells, it was next explored whether this effect may be mediated by
inhibiting the accumulation of SOD1A4V-EGFP aggregates. To quantify the numbers of
transfected cells containing SOD1A4V-EGFP aggregates, an assay was used in which the plasma
membrane of transfected cells was permeabilised using saponin, allowing soluble intracellular
proteins to diffuse out of the cell while trapping insoluble protein material. Cells were imaged
pre- and post-permeabilisation with saponin, using an IncuCyte® ZOOM, to quantify numbers
of transfected cells and numbers of cells containing insoluble EGFP-fusion proteins.
Saponin-permeabilisation and imaging of NSC-34 cells co-transfected with SOD1WT-EGFP
and either UBA1WT, UBA1C632S or mCherry alone showed that there was no fluorescent signal
from cells overexpressing SOD1WT-EGFP or EGFP alone following plasma membrane
permeabilisation (Figure 4.4). In contrast, after permeabilisation, SOD1A4V-EGFP protein
remained in 8.82 ± 1.47%, 13.03 ± 2.31% and 14.3 ± 3.01% of SOD1A4V-EGFP cells coexpressing mCherry alone, UBA1WT and UBA1C632S, respectively, indicating that similar
amounts of insoluble, non-diffusable SOD1A4V-EGFP were present in cells under each
condition. These results indicate that increased levels of UBA1WT had no impact on the overall
numbers of SOD1A4V-EGFP aggregates that formed in cells.
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Figure 4.4. UBA1WT overexpression does not affect SOD1A4V-EGFP aggregation in NSC-34 cells. Percentages
of transfected cells containing insoluble EGFP-positive inclusions. NSC-34 cells were transiently co-transfected
to express either SOD1WT-EGFP, SOD1A4V-EGFP or EGFP alone and UBA1WT, the catalytically inactive mutant
UBA1C632S or mCherry alone. After 48 h, cells were imaged on an IncuCyte® ZOOM, followed by incubation with
0.03% (w/v) saponin in PBS for 10 min at room temperature, before being imaged again. Cells were transfected
in triplicate, and the experiment was performed three times. The data presented is the mean ± SEM of the
percentage of transfected NSC-34 cells containing insoluble EGFP-positive protein following permeabilisation
with saponin. The means were compared using one-Way ANOVA followed by Tukey’s multiple comparison test.

As well as the toxicity associated with the aggregation of SOD1A4V into insoluble inclusions,
several studies have also reported that soluble oligomeric species formed by SOD1A4V potently
reduce cell viability (Redler et al. 2014, Proctor et al. 2016, Zhu et al. 2018). Thus, it was
examined whether the protective effect of increased UBA1WT expression against SOD1A4VEGFP toxicity was associated with it reducing the levels of SOD1A4V-EGFP in cells.
Comparison of the mean EGFP fluorescence intensity of cells co-expressing SOD1A4V-EGFP
and UBA1WT, UBA1C632S or mCherry alone prior to permeabilisation by saponin showed that
there were no differences in SOD1A4V-EGFP levels in cells co-expressing UBA1WT relative to
cells co-expressing UBA1C632S or mCherry alone (Figure 4.5). Similarly, there were no
differences in the levels of SOD1WT-EGFP in cells co-expressing UBA1WT, UBA1C632S or
mCherry alone. These data demonstrate that increased expression of UBA1WT did not protect
against SOD1A4V-EGFP toxicity through reduction of the total levels of SOD1A4V-EGFP in
these cells.
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Figure 4.5. UBA1WT overexpression has no effect on the total levels of SOD1A4V-EGFP in NSC-34 cells. The
mean EGFP F.I. of SOD1A4V-EGFP and SOD1WT-EGFP in NSC-34 cells co-expressing UBA1WT, the catalytically
inactive mutant UBA1C632S or mCherry alone. NSC-34 cells were transiently co-transfected with either SOD1WTEGFP or SOD1A4V-EGFP and UBA1WT, UBA1C632S or mCherry alone. After 48 h, cells were imaged on an
IncuCyte® ZOOM, and the EGFP F.I. in cells was measured. Cells were transfected in triplicate, and the
experiment was performed three times. The data presented are the mean ± SEM of the EGFP F.I. in transfected
NSC-34 cells. The means were compared using one-Way ANOVA followed by Tukey’s multiple comparison test.
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Discussion
Extensive evidence implicates dysregulation of the UPS and ubiquitin homeostasis in the
pathogenesis of ALS. One of the strongest connections is that the hallmark pathological feature
of ALS-affected motor neurons is the presence of inclusions comprised of misfolded proteins
and ubiquitin (Leigh et al. 1991). This sequestration of ubiquitin likely influences its
distribution in the cellular pools in which it resides (Kaiser et al. 2011). In the pool comprised
of polyubiquitin chains, the function of ubiquitin in tagging and directing target proteins for
degradation through autophagy and through the UPS requires its activation by the E1 enzyme,
UBA1 (Ayusawa et al. 1992, Cook and Chock 1992, Clague et al. 2015). In screening the levels
of yeast proteins in response to the heterologous expression of human SOD1A4V (Chapter III),
the levels of UBA1 were found to be increased, coinciding with a distinct lack of SOD1A4V
toxicity. Because the A4V mutation in SOD1 results in rapid motor neuron degeneration and
ALS disease progression in humans (Cudkowicz et al. 1997, Juneja et al. 1997), it was
hypothesised that the increased levels of UBA1 in yeast enabled cells to respond to the toxic
mechanisms usually induced by the SOD1A4V protein, and thereby cell viability was not
impaired. To test this hypothesis, in the present chapter the NSC-34 cell line was used to
examine whether UBA1 was differentially regulated in NSC-34 cells overexpressing SOD1A4V
or SOD1WT, and to determine whether increased UBA1 expression was associated with
modulation of SOD1A4V aggregation and toxicity.
4.4.1

Increased UBA1WT expression protects against SOD1A4V toxicity

In the work presented in this chapter it was found that SOD1A4V-EGFP expression caused
striking toxicity in NSC-34 cells, consistent with the toxicity the A4V SOD1 mutation causes
in human motor neurons (Cudkowicz et al. 1997, Juneja et al. 1997). Importantly, in contrast
to yeast expressing SOD1A4V, there were no differences in the levels of endogenous murine
UBA1 in NSC-34 cells expressing SOD1A4V-EGFP relative to NSC-34 cells expressing
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SOD1WT-EGFP or EGFP alone. It should be noted that the levels of UBA1 were not normalised
to the transfection efficiency of SOD1, they were normalised to the total amount of protein
loaded into each lane of the gel as is standard practice for immunoblots. The transfection
efficiency of SOD1 was on average ~20%, thus, there would be a negligible effect on UBA1
levels as measured by immunoblot. Immunofluorescence, however, would be a suitable
alternative technique to use as a read-out.
Through confocal microscopy it was observed that SOD1A4V-EGFP formed multiple large
aggregates in NSC-34 cells. Furthermore, NSC-34 cells expressing SOD1A4V-EGFP were more
vulnerable to proteasome inhibition using MG132 compared to cells expressing SOD1WT-EGFP
or EGFP alone, suggesting that there was disruption of normal UPS activity in cells expressing
SOD1A4V-EGFP before cells were exposed to MG132-mediated proteasome inhibition. Indeed,
dysfunction of the UPS in motor neurons expressing mutant SOD1 has been reported in several
studies (Urushitani et al. 2002, Cheroni et al. 2009, Crippa et al. 2010, Onesto et al. 2011).
Moreover, impaired proteasome activity in cultured cells expressing mutant SOD1 has been
correlated with cellular toxicity (Matsumoto et al. 2005, Kitamura et al. 2014). Vulnerability
to mutant SOD1-mediated UPS dysfunction is potentially greater in spinal cord motor neurons
than in other cell types. Spinal cord motor neurons from mice have been found to be more
vulnerable to proteasome inhibition than non-motor neurons (Urushitani et al. 2002). A
transcriptomic study of populations of spinal motor neurons that succumb to degeneration in
ALS compared to resistant oculomotor neurons discovered that UPS genes were downregulated
in the spinal motor neurons (Brockington et al. 2013). Thus, it is logical to hypothesise that
increasing UPS capacity in motor neurons expressing ALS-causing mutations in SOD1 could
provide cellular protection.
When the levels of UBA1WT were increased through overexpression in NSC-34 cells expressing
SOD1A4V-EGFP, the toxicity caused by SOD1A4V-EGFP was reduced. This was dependent on
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the catalytic activity of UBA1, as the expression of UBA1C632S, an isoform with a mutation of
the catalytic cysteine residue, did not improve cell viability. UBA1 is the primary E1 ubiquitinactivating enzyme in mammalian cells (Schulman and Harper 2009, Ye and Rape 2009). It is
crucial for proper UPS functioning in eukaryotes. Severe UPS inhibition has been reported in
yeast cells harbouring a temperature-sensitive UBA1 allele, causing depletion of ubiquitin
conjugates (Ghaboosi and Deshaies 2007). Thus, in the present work, the increased levels of
UBA1 in NSC-34 cells may have led to augmented UPS activity.
4.4.2

UBA1WT-mediated protection against SOD1A4V toxicity is not associated with
suppression of SOD1A4V aggregation

With the improved viability of NSC-34 cells expressing SOD1A4V-EGFP resulting from
UBA1WT overexpression, it was hypothesised that this may have been mediated by improved
UPS function and therefore suppression of SOD1A4V-EGFP aggregation. It has long been
debated whether the accumulation of misfolded, aggregated proteins into inclusions is a cause
of cellular toxicity, a by-product of widespread proteostasis dysfunction in cells, or a protective
mechanism used to sequester toxic intermediate oligomeric protein species into isolated
compartments. Notably, mounting evidence shows that certain types of inclusions, such as the
JUNQ compartment, can serve protective functions in the cell by sequestering toxic misfolded
proteins, oligomeric species and aggregates (Kaganovich et al. 2008, Weisberg et al. 2012).
Through a saponin-permeabilisation assay the results presented in the present work indicate
that the overexpression of UBA1WT did not lead to suppression of SOD1A4V-EGFP aggregation.
Moreover, the total cellular levels of SOD1A4V-EGFP were not reduced in cells overexpressing
UBA1WT. Evidence from previous work has demonstrated that mutant SOD1G93A aggregates
can be toxic or nontoxic depending on whether they are localised to an active JUNQ (Weisberg
et al. 2012). Weisberg et al. (2012) found that SOD1G93A aggregates compartmentalised within
the JUNQ were able to sequester the functional pool of HSP70 and other protein quality control
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factors that reside inside the JUNQ. By sequestering and depleting the pool of chaperones, other
quality control substrates that required degradation could not be delivered to JUNQ-localised
proteasomes for degradation. Importantly, Weisberg et al. (2012) also showed that
overexpression of HSP70 significantly reduced SOD1G93A-mediated toxicity, thus
demonstrating that up-regulation of quality control components that have been sequestered by
aggregated SOD1G93A in the JUNQ can reverse this effect by increasing quality control capacity.
More recently it has been reported that aggregates formed by SOD1A4V-EGFP in NSC-34 cells
sequester free monomeric ubiquitin from the cytoplasm, depleting the free ubiquitin pool in
cells (Farrawell et al. 2018). Moreover, when the ubiquitin-modified proteome (the
‘ubiquitome’) was analysed and compared between NSC-34 cells expressing SOD1A4V-EGFP
and those expressing SOD1WT-EGFP, it was revealed that the expression of SOD1A4V-EGFP
caused widespread ubiquitin redistribution and consequent ubiquitin dyshomeostasis (Farrawell
et al. 2018).
As the primary ubiquitin-activating enzyme, disruption of the normal activity of UBA1 results
in ubiquitin dyshomeostasis in cells. In SMA linked to disruption of normal UBA1 activity,
ubiquitin homeostasis disturbances have been well documented (Aghamaleky Sarvestany et al.
2014, Powis et al. 2014, Wishart et al. 2014). In a mouse model of SMA, increasing the levels
of UBA1 through AAV9-mediated delivery led to increases in the levels of monoubiquitin and
polyubiquitin, restoration of ubiquitin homeostasis and amelioration of impaired UPS activity
(Powis et al. 2016). Moreover, AAV9-UBA1 treatment in these mice led to body weight
stabilisation, improved motor performance and increased survival (Powis et al. 2016). The
toxicity caused by SOD1A4V-EGFP expression in NSC-34 cells observed in the present work
may have been due, at least in part, to sequestration of free monomeric ubiquitin and depletion
of the free ubiquitin pool in NSC-34 cells. This, in turn, may have contributed to
dyshomeostasis of the cellular ubiquitin pools and disruption of downstream ubiquitin160

dependent molecular processes. Indeed, it was found that UPS activity was impaired in NSC34 cells expressing SOD1A4V-EGFP. Furthermore, if the SOD1A4V-EGFP inclusions observed
in NSC-34 cells represented localisation of SOD1A4V-EGFP to JUNQ compartments, this may
have disrupted the intra-JUNQ proteasomal degradation of ubiquitylated proteins. Thus,
increasing the levels of UBA1WT may have contributed to enhancement in the capacity of cells
to ubiquitylate other proteins that critically need to be degraded by the proteasome. This
hypothesised mechanistic pathway, however, remains to be explored through further
investigation. This could be tested by measuring free ubiquitin levels as described in Farrawell
et al. (2018).
Inhibiting UBA1 activity leads to interference of both excitatory and inhibitory synapses in
hippocampal neurons (Rinetti and Schweizer 2010). Similarly, loss of UBA1 in Drosophila
melanogaster causes defects in axon development (Watts et al. 2003). Additional work in
Drosophila melanogaster has shown that mutations that cause modest impairment of UBA1
expression and function cause a neurodegeneration phenotype (Pfleger et al. 2007), while yet
others have demonstrated that a UBA1 mutation causing partial loss of function is associated
with severe locomotion impairment and reduction in lifespan (Liu and Pfleger 2013). Of note,
increased UBA1 levels have been implicated in the mechanism of action of the slow Wallerian
degeneration mutation, which confers protection to synapses and axons in a range of traumatic
and disease-related degeneration contexts (Wishart et al. 2007, Wishart et al. 2008).
4.4.3 Concluding statements
Importantly, the work presented in this chapter adds to previous efforts implicating the
beneficial effects of increased UBA1 activity in neuronal cells. Moreover, the data from the
present study extends on findings reported by others to demonstrate that augmented UBA1
activity may have the capacity to ameliorate ubiquitin dyshomeostasis and UPS dysfunction
associated with SOD1A4V-mediated toxicity. Taking these previously-reported findings
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together with the work presented in this chapter, it is hypothesised that increasing the levels of
UBA1 in motor neurons may be able to improve cell viability by restoring ubiquitin
homeostasis. This may enable reestablishment of normal activity of the downstream ubiquitindependent molecular processes discussed above, including the UPS, that become dysfunctional
in motor neurons as a result of the expression of ALS-causing mutations in SOD1 and other
genes implicated in ALS.
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Chapter 5: A high-content screening system to
evaluate protein aggregation and proteostasis
capacity in cellular ALS models
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Introduction
Post-mortem examination of spinal cord tissue from ALS patients consistently reveal the
presence of TDP-43-, FUS- or SOD1- and ubiquitin-positive inclusions comprised of insoluble
proteinaceous material. Extensive research suggests that misfolded proteins, as abnormal
monomers and/or oligomeric precursors, possess cytotoxic properties (Bolognesi et al. 2010,
Proctor et al. 2016, Zhu et al. 2018) and that their aggregation into certain kinds of inclusions
may serve to protect cells and to assist in the clearance of these toxic species (Johnston et al.
1998, Kopito 2000, Kawaguchi et al. 2003, Arrasate et al. 2004, Kaganovich et al. 2008, Tan
et al. 2008, Treusch et al. 2009, Zhang and Qian 2011, Weisberg et al. 2012, Polling et al.
2014). However, the formation of protein inclusions is also indicative of dysregulated
proteostasis and the inability of the cell to properly monitor, refold or degrade non-native
proteins. Further, it has been suggested that the progressive spread of pathology in patients
could be due to the cell-to-cell propagation of protein misfolding and aggregation (Shaw 2002,
Brettschneider et al. 2014). Indeed, the uptake of preformed SOD1 aggregates into neuronal
cells from the surrounding cell culture media has been demonstrated in several studies (Munch
et al. 2011, Sundaramoorthy et al. 2013, Grad et al. 2014, Zeineddine et al. 2015). Inclusions
with distinct characteristics, and that have been formed through diverse pathways, are observed
in cellular models of ALS and human post-mortem tissue from patients with ALS and other
neurodegenerative disorders (Krobitsch and Lindquist 2000, Kamhi-Nesher et al. 2001, Huyer
et al. 2004, Matsumoto et al. 2005, Matsumoto et al. 2006, Kaganovich et al. 2008, Farrawell
et al. 2015); including aggresomes, JUNQ and IPOD inclusions. Aggresome-, JUNQ- and
IPOD-like inclusions can be distinguished based on their mobility, microtubule-dependence
and colocalisation with different components of protein quality control pathways, most notably
ubiquitin, but also with 26S proteasomes, molecular chaperones, and markers of autophagy and
ERAD (Taylor et al. 2003, Iwata et al. 2005, Kruse et al. 2006, Kaganovich et al. 2008). While
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the majority of the inclusions examined in ALS patient tissue are ubiquitin-positive, additional
types of inclusions that are ubiquitin-negative have also been reported (Forsberg et al. 2010).
The ubiquitylation dynamics of misfolded proteins plays a key role in determining the type of
inclusion they partition to (Kaganovich et al. 2008), however, the ubiquitylation dynamics of
ALS-associated proteins have largely remained unclear. Also remaining to be characterised are
the proteostasis disturbances that occur in motor neurons harbouring mutations in different
ALS-associated genes.
There is a vital need for the development of effective diagnostic tools and therapeutic strategies
for ALS. Given the heterogeneity of ALS, the ALS research field would benefit greatly from
the development of assays that can measure multiple phenotypic features in cellular ALS
models and extract rich, descriptive information of responses to candidate therapeutic
compounds and modifiers of ALS gene toxicity. Assays that utilise the principles of high
content screening (HCS) could help to address this investigative gap. In the past 20 years HCS
approaches have evolved to emerge as attractive options for researchers interested in obtaining
extensively descriptive phenotypic data through automated microscopy.
The overarching objective of the work presented in this chapter was to develop an experimental
system with HCS capacity that could be used to extract multiplexed phenotypic data from
cellular ALS models. The specific aims of this work were thus to:
(i) generate cellular models of SOD1-, TDP-43-, FUS-, CCNF-, VAPB-, VCP-, OPTNand UBQLN2-associated ALS
(ii) develop a HCS method with the potential to examine pathological features in cellular
ALS models
(iii) employ this system to examine proteostasis capacity in these ALS models.
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Materials and methods
5.2.1

Plasmids

In addition to SOD1WT-EGFP, SOD1A4V-EGFP, TDP-43WT-tGFP and TDP-43M337V-tGFP
(described in section 2.2, Chapter II), the plasmids used in the present work are detailed in Table
5.1. OPTNWT-EGFP, OPTNQ398X-EGFP and OPTNE478G-EGFP had previously been
transformed into chemically competent E. coli DH5-α cells, and were stored in glycerol at 80°C prior to plasmid DNA purification. Mammalian expression constructs comprised of the
pCMV6-AC-tGFP vector containing human WT FUS, VAPB, UBQLN2 and VCP were obtained
from OriGene Technologies (MD, USA). To obtain constructs containing ALS-associated
mutations in each gene, sequences were designed in-house according to mutant sequences
described in the literature, and site-directed mutagenesis was outsourced to GenScript.
Sequencing was carried out by GenScript as part of their service to confirm the correct full
sequence of each construct.
The pCIneo mammalian expression construct containing sequences encoding C-terminally
EGFP-tagged WT firefly luciferase (FlucWT-EGFP) and two conformationally destabilised
mutants (containing a single mutation (SM), FlucSM-EGFP or two mutations (double mutant;
DM), FlucDM-EGFP) were generously provided by Prof. Franz-Ulrich Hartl (Max Planck
Institute of Biochemistry, Planegg, Germany). For detailed information on the design and
construction of the destabilised Fluc-EGFP mutant plasmids see Gupta et al. (2011). Briefly,
WT luciferase from the American firefly (Photinus pyralis) was mutationally optimised, PCRamplified and sub-cloned into the pCIneo expression vector. Site-directed mutagenesis was
used to introduce either a single mutation (R188Q) or two mutations (R188Q and R261Q) to
generate increasingly destabilised forms of the protein. EGFP from pEGFP-N2 (Clontech) was
inserted at the 3’ end of luciferase in all three constructs to prepare EGFP-tagged versions.
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Table 5.1. List of plasmids used in the present chapter. The backbone vector, insert gene, any custom
modifications made, the in-text nomenclature used for each plasmid, the source of each plasmid and reference
publications detailing the construction of certain plasmids are detailed.
Backbone
vector

pEGFP-C3

Insert

Custom
modifications

OPTNWT

OPTNWT-EGFP

OPTNQ398X

OPTNQ398X-EGFP

OPTNE478G

OPTNE478G-EGFP

FUS

FUS

WT

WT

GenScript

FUSR521G

Site-directed
mutagenesis

FUSR521G-tGFP

GenScript

VAPBWT-tGFP

Cat. No. RG200517,
OriGene
Technologies, MD,
USA

VAPBP56S-tGFP

GenScript

UBQLN2WT-tGFP

Cat. No. RG209645,
OriGene
Technologies, MD,
USA

UBQLN2WT
UBQLN2P497H

Site-directed
mutagenesis

UBQLN2P497HtGFP

GenScript

UBQLN2P525S

Site-directed
mutagenesis

UBQLN2P525StGFP

GenScript

VCPWT-tGFP

Cat. No. RG211130,
OriGene
Technologies, MD,
USA

VCPWT

pcDNA3.1(+)

Cat. No. RG201808,
OriGene
Technologies, MD,
USA

FUSR495X-tGFP

Site-directed
mutagenesis

VCPR159H

Site-directed
mutagenesis

VCPR159H-tGFP

GenScript

VCPR191Q

Site-directed
mutagenesis

VCPR191Q-tGFP

GenScript

CCNFWTmCherry
CCNFS621GmCherry

Prof. Ian Blair,
Macquarie
University, NSW,
Australia

SOD1WT-tdT

Custom cloned using
GenScript

CCNFWT
CCNFS621G
SOD1WT
SOD1

A4V

pmRFP-ubiquitin (see
reference)

C-terminal
tdTomato tag

SOD1

A4V

-tdT

ubiquitin

mRFP

167

Reference

Assoc. Prof. Julie
Atkin, Macquarie
University, NSW,
Australia

Site-directed
mutagenesis

VAPBP56S

pmCherry-C1

-tGFP

Source

FUSR495X

VAPBWT

pCMV6-ACtGFP

In-text
nomenclature

Prof. Nico Dantuma,
Karolinska Institute,
Solna, Sweden
(Addgene plasmid
no. 11935)

Bergink et
al. 2006

pmRFP-C1

LC3

LC3

mRFP

TDP-43WT-tdTomato (see
reference)

TDP-43WT-tdT

WT firefly
luciferase

pCIneo

Firefly
luciferase
containing a
single
mutation
('single
mutant')
Firefly
luciferase
containing
two mutations
('double
mutant')

Kimura et
al. 2007

Yang et al.
2010

FlucWT-EGFP

C-terminal
EGFP tag

Fluc -EGFP
SM

Prof. Franz-Ulrich
Hartl, Max Planck
Institute of
Biochemistry,
Planegg, Germany

Gupta et al.
2011

Prof. Angus Lamond,
University of
Dundee, UK

Leung et al.
2004

FlucDM-EGFP

pBOS-H2B-ECFP-N1 (see
reference)

5.2.2

Prof. Tamotsu
Yoshimori, Osaka
University, Osaka,
Japan (Addgene
plasmid no. 21075)
Prof. Zuoshang Xu,
University of
Massachusetts, MA,
USA (Addgene
plasmid no. 28205)

Transient transfections and treatment with proteasome inhibitor

NSC-34 cells were seeded at 100,000 cells/mL in 10% (v/v) FBS in DMEM/F-12 into either 8well µ-Slides (Ibidi, Planegg-Martinsried, Germany) for confocal microscopy or 96-well plates
(Greiner Bio-One, Frickenhausen, Germany) for imaging using the Thermo Scientific™
Cellomics® ArrayScan™ VTI High Content Screening microscope. After overnight incubation
at 37 °C under 5% CO2/95% air, cells were either single-transfected, dual-transfected or tripletransfected using Lipofectamine® 2000 (Invitrogen, Waltham, USA) according to
manufacturer’s instructions. Briefly, per well, 0.3 µL or 0.6 µL of Lipofectamine® 2000 and a
total of 0.1 µg or 0.2 µg of plasmid DNA for the 96-well plate format or 8-well µ-Slide format,
respectively, were used to transfect NSC-34 cells. For dual and triple transfections, plasmids
were used at 1: 1 and 1: 1: 1 ratios, respectively. All transfection conditions were carried out in
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quadruplicate. For confocal microscopy experiments, NSC-34 cells were single-transfected or
dual-transfected. NSC-34 cells were single-transfected with SOD1WT-EGFP, SOD1A4V-EGFP,
TDP-43WT-tGFP,

TDP-43M337V-tGFP,

FUSWT-tGFP,

FUSR495X-tGFP,

FUSR521G-tGFP,

CCNFWT-mCherry, CCNFS621G-mCherry, the pEGFP-N1 vector (EGFP alone) or the
pmCherry-C1 vector (mCherry alone). NSC-34 cells were dual-transfected as detailed in Table
5.2. An additional dual transfection experiment was carried out with transfection of NSC-34
cells with (1) VCPWT-tGFP, VCPR159H-tGFP or VCPR191Q-tGFP and (2) TDP-43WT-tdTomato.
For these dual transfection experiments, mCherry alone was used as a control for the expression
of a RFP only, to ensure that the localisation patterns observed for mRFPLC3, mRFPubiquitin and
TDP-43WT-tdT were not a result of the RFP tag itself.
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Table 5.2. Plasmid combinations used in dual transfections. The localisation patterns of the EGFP-/tGFP
proteins, mRFPLC3, mRFPubiquitin and TDP-43WT-tdT, encoded in the plasmids listed here, were examined in dualtransfected NSC-34 cells using confocal microscopy.
mRFP

LC3 localisation microscopy

Plasmid 1

Plasmid 2

SOD1WT-EGFP

mRFP

SOD1A4V-EGFP

mRFP

TDP-43WT-tGFP

mRFP

TDP-43M337V-tGFP

mRFP

FUSWT-tGFP

mRFP

FUSR495X-tGFP

mRFP

FUSR521G-tGFP

mRFP

EGFP alone

mRFP

mRFP

LC3
LC3
LC3
LC3
LC3
LC3
LC3
LC3

ubiquitin localisation microscopy

Plasmid 1

Plasmid 2

VAPBWT-tGFP

mRFP

ubiquitin

VAPBP56S-tGFP

mRFP

OPTNWT-EGFP

mRFP

OPTNE478G-EGFP

mRFP

UBQLN2WT-tGFP

mRFP

UBQLN2P497H-tGFP

mRFP

VCPWT-tGFP

mRFP

VCPR159H-tGFP

mRFP

VCPR191Q-tGFP

mRFP

EGFP alone

mRFP

ubiquitin
ubiquitin
ubiquitin
ubiquitin
ubiquitin
ubiquitin
ubiquitin
ubiquitin
ubiquitin

TDP-43WT-tdT localisation
Plasmid 1

Plasmid 2

VCPWT-tGFP

TDP-43WT-tdT

VCPR159H-tGFP

TDP-43WT-tdT

VCPR191Q-tGFP

TDP-43WT-tdT
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For optimisation of the parameters used for automated imaging and image analysis using the
Thermo Scientific™ Cellomics® ArrayScan™ VTI High Content Screening microscope, NSC34 cells were triple-transfected as detailed in Table 5.3.
Table 5.3. Plasmid combinations used in triple transfections in preparation for HCS microscopy
optimisation. Triple-transfected NSC-34 cells were used for preliminary experiments to optimise the parameters
used for automated imaging and image analysis using a Cellomics® ArrayScan™ VTI HCS microscope.
Plasmid 1

Plasmid 2

Plasmid 3

SOD1WT-EGFP
SOD1A4V-EGFP
TDP-43WT-tGFP
TDP-43M337V-tGFP
FUSWT-tGFP
FUSR495X-tGFP
FUSR521G-tGFP
H2B-ECFP

VAPBWT-tGFP
VAPBP56S-tGFP

mCherry alone

OPTNWT-EGFP
OPTNE478G-EGFP
UBQLN2WT-tGFP
UBQLN2P497H-tGFP
VCPWT-tGFP
VCPR159H-tGFP
VCPR191Q-tGFP

Following optimisation of the parameters for automated imaging and image analysis, the
Cellomics® ArrayScan™ VTI HCS platform was employed for an experiment using FlucEGFP variants as sensors of changes in cellular protein quality control network capacity in
NSC-34 cells expressing mutant SOD1 or CCNF. For this experiment, NSC-34 cells were
triple-transfected as detailed in Table 5.4. As a positive control for cells under proteome stress,
quadruplicates of control cells expressing H2B-CFP, mCherry alone and the Fluc-EGFP
variants were treated with MG132 to inhibit proteasomal activity. MG132 was solubilised in
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DMSO at 20 mM and subsequently diluted to 5 µM in 10% (v/v) FBS in DMEM/F-12. The
prepared solution was added to cells at 30 h post-transfection and incubated for 18 h. For mock
treatment, 5 µM DMSO in 10% (v/v) FBS in DMEM/F-12 was instead added to cells. 48 h
following triple-transfections with the Fluc-EGFP variants, cells were fixed in 4% (w/v)
paraformaldehyde (PFA, pH 7.4) for 20 min at room temperature. Cells were then washed three
times with PBS before the addition of 100 µL of PBS to prepare for imaging on the Cellomics®
ArrayScan™ VTI High Content Screening microscope.
Table 5.4. Plasmid combinations used in triple transfections of NSC-34 cells in preparation for Fluc-EGFP
experiments.
Plasmid 1

Plasmid 2

Plasmid 3

Additional
treatment

FlucWT-EGFP
H2B-ECFP

FlucSM-EGFP

SOD1WT-tdT

FlucDM-EGFP

No treatment

EGFP alone
FlucWT-EGFP
H2B-ECFP

FlucSM-EGFP

SOD1A4V-tdT

FlucDM-EGFP

No treatment

EGFP alone
FlucWT-EGFP
H2B-ECFP

CCNF

WT

FlucSM-EGFP

-mCherry

FlucDM-EGFP

No treatment

EGFP alone
FlucWT-EGFP
H2B-ECFP

FlucSM-EGFP

CCNFS621G-mCherry

FlucDM-EGFP

No treatment

EGFP alone
FlucWT-EGFP
H2B-ECFP

FlucSM-EGFP

mCherry alone

FlucDM-EGFP
EGFP alone
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± MG132 treatment

5.2.3

Confocal microscopy live cell imaging

Prior to setting up the Thermo Scientific™ Cellomics® ArrayScan™ VTI HCS platform, the
localisation patterns of each EGFP- and mCherry-tagged WT and mutant ALS-associated
protein in transfected NSC-34 cells were characterised by imaging using a Leica TCS SP5 II
confocal microscope with a 63× oil-immersion objective lens (Leica Microsystems, Wetzlar,
Germany). Imaging was carried out 48 h post-transfection for single transfections and dual
transfections with

mRFP

LC3 and TDP-43WT-tdT, or 24, 48 and 72 h post-transfection for dual

transfections with mRFPubiquitin. EGFP fluorescence was excited at 488 nm by an argon laser;
RFP fluorescence was excited at 561 nm by a DPS 561 laser. Fluorescent emissions were
acquired by sequential scanning using the Leica Application Suite – Advanced Fluorescence
(LAS-AF) software (version 3, Leica Microsystems, Wetzlar, Germany). Across each set of
quadruplicate wells of cells for each transfection treatment, a minimum of 100 transfected cells
were imaged across 10-15 fields of view per replicate.
5.2.4

Confocal image analysis, inclusion characterisation and quantification

To characterise the localisation patterns of each EGFP-/tGFP- and mCherry-tagged ALSassociated protein in transfected NSC-34 cells and ensure that they corresponded with the
patterns recorded in the literature, the images acquired by confocal microscopy were manually
examined. To inform this characterisation, previous peer-reviewed studies revealing images of
post-mortem spinal cord tissue from ALS patients were used to establish the morphology and
size range of inclusions positive for mutant SOD1, TDP-43, FUS, VAPB, OPTN, UBQLN2
and VCP. This enabled a size minimum of 2 µm to be established for categorising fluorescent
foci as inclusions as opposed to associations of the fluorescent ALS proteins with other cellular
structures, granules (e.g stress or transport) or other irrelevant fluorescent debris and artefacts.
In order to quantify the percentage of VAPBWT-tGFP, VAPBP56S-tGFP, OPTNWT-EGFP,
OPTNE478G-EGFP, UBQLN2WT-tGFP, UBQLN2P497H-tGFP, VCPWT-tGFP, VCPR159H-tGFP
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and VCPR191Q-tGFP inclusions that were positive for

mRFP

ubiquitin in each dual transfection

treatment, the numbers of transfected cells and fluorescent protein-positive foci were manually
counted in each image acquired at 24, 48 and 72 h post-transfection. First, the numbers of
EGFP-positive transfected NSC-34 cells in each replicate across 10-15 fields of view were
counted. The numbers of these containing EGFP-fluorescent foci larger than 2 µm were then
recorded as inclusions positive for each EGFP-fusion ALS protein. RFP-fluorescent foci larger
than 2 µm were then counted as inclusions positive for mRFPubiquitin. The images collected in
the green and red channels were then merged and the numbers of inclusions positive for EGFP
and RFP fluorescence were counted as EGFP-fusion ALS protein inclusions positive for
mRFP

ubiquitin. Finally, the numbers of inclusions positive for EGFP and RFP fluorescence were

divided by the numbers of inclusions positive for each respective EGFP-fusion ALS protein,
and then multiplied by 100 to calculate the proportion of ALS protein inclusions that were
ubiquitin-positive. It should be noted that due to time limitations, the localisation patterns of
mRFP

ubiquitin with mutant VAPB, OPTN and UBQLN2, of mutant VCP with TDP-43WT-tdT

and of mutant SOD1, TDP-43 and FUS with

mRFP

LC3 observed here are each from n = 1

experiment and furthermore were not confirmed through immunocytochemistry. Thus, these
observations await confirmation by further experimentation.
5.2.5

IncuCyte® ZOOM live cell imaging and analysis

IncuCyte® ZOOM live cell imaging and analysis was used to carry out two different measures
in NSC-34 cells transiently transfected with each of the EGFP- and mCherry-tagged WT and
mutant ALS-associated proteins. Both experimental techniques are described in Chapter IV,
section 4.2.3. Briefly, the first experimental technique was used as a measure of cell viability
while the second technique was used to quantify numbers of transfected cells containing nondiffusable, insoluble EGFP- or mCherry-fusion proteins. For all IncuCyte® experiments, the
mean ± SEM was calculated across quadruplicate samples and used for statistical analyses.
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5.2.6

Developing a high content screening work flow for fluorescence-based analysis of
cellular ALS models

Following characterisation of the localisation patterns, the solubility and the effect on cell
viability of each EGFP-/tGFP-/mCherry-tagged WT and mutant ALS-associated gene in
transfected NSC-34 cells, a Cellomics® ArrayScan™ VTI HCS platform was established with
the overarching aim that it could be used for studies with each of these cellular ALS models.
The Thermo Scientific™ HCS Studio™ software uses image analysis algorithms, termed
BioApplications, designed to measure a range of different cellular features and biological
processes. These BioApplications initially detect cells or cellular objects using the fluorescence
in one channel, Channel 1/the primary channel, and then the fluorescence in up to another five
channels. In the primary channel, cell nuclei or other cellular regions can be fluorescently
labelled to serve as the primary object, defined by the algorithm using a mask for the first step
of identifying and selecting cells. The regions of the cell detected in each of the remaining
channels depend on the mask, or region, defined by the primary object. The masks in Channels
2-6 serve to enable measurement of different phenotypic features that report on cellular
responses to different conditions.
By transfecting NSC-34 cells with histone H2B-ECFP, the nuclei of cells could be detected
based on ECFP fluorescence in Channel 1 and served as the primary object in the analysis by
the Spot Detector BioApplications (Figure 5.1, b). As will be outlined in Section 5.2.6.3.2, for
each fluorescence channel imaged, the appropriate masks used by the Thermo Scientific™ HCS
Studio™ software to identify and select cells were carefully optimised to ensure that only cells
of interest were included for analysis. An NSC-34 cell line stably transfected with H2B-ECFP
was generated for future experiments with the HCS platform, as a cell line with constant
expression of a nuclear-localised ECFP-fusion protein that could be used for automated cell
identification and analysis. The intention was that this would aid in the efficiency of the HCS
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workflow. As time was limited for the development of this HCS platform, image processing
and analysis parameters in the Thermo Scientific™ HCS Studio™ software were optimised
concurrently with the generation of this stable cell line, which was instead frozen down as
stocks to use in future experiments.
5.2.6.1 Generation of an NSC-34 cell line stably transfected with H2B-ECFP
The algorithms used for automated image analysis in the Thermo Scientific™ HCS Studio™
software can use two different methods for automated identification of cells in each image; one
that is used for identifying bright objects/cells on a dark background (e.g. for a fluorescently
labeled cell nucleus in an unlabeled cell), and one that detects dark objects/cells on a bright
background (e.g. for an unlabeled cell nucleus in a labeled cytoplasm). For the present work it
was of interest to generate an NSC-34 cell line stably expressing a nuclear-localised fluorescent
protein-tagged protein that would enable automated identification of cells based on each cell
having a bright, fluorescent nucleus. Histone H2B tagged with ECFP (H2B-ECFP) was selected
for this purpose. H2B is a component of the histone protein core of nucleosomes and is thus
localised to the nucleus. ECFP was used due to the good separation of its excitation and
emission maxima from those of EGFP and RFP, enabling it to be used for co-expression with
the EGFP and RFP-tagged ALS-associated proteins used in this study. The pBOS-H2B-ECFPN1 construct contains the blasticidin antibiotic resistance gene. In order to generate an NSC-34
cell line stably transfected with pBOS-H2B-ECFP-N1, the optimal concentration of blasticidin
for selecting transfected NSC-34 cells was established by generating a kill curve. NSC-34 cells
were seeded at 100,000 cells/mL into 24-well plates in 10% (v/v) FBS in DMEM/F-12
containing blasticidin (CalBioChem, Cat. No. 203350) at the following concentrations: 0, 0.5,
1, 2, 4, 6, 8 and 10 µg/mL. Quadruplicate wells of cells were treated with each different
blasticidin concentration. Cells were imaged every 4 h for 1 week using an IncuCyte® ZOOM,
with the selective medium changed every 3 days. The numbers of cells grown at each blasticidin
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concentration were plotted against time to establish a kill curve. From this, a blasticidin
concentration of 6 µg/mL was established as the minimum concentration required to kill all
non-transfected cells over 1 week.
Following determination of the optimal blasticidin concentration to use, NSC-34 cells were
seeded at 100,000 cells/mL into two 100 mm × 20 mm (diameter × height) Corning® tissue
culture treated culture dishes (Cat. No. CLS430167, Corning, USA) and one 6-well plate in
10% (v/v) FBS in DMEM/F-12. After 24 h, cells in the 100 mm × 20 mm dishes were
transfected with 10 µg of pBOS-H2B-ECFP-N1 using 30 µL of Lipofectamine® 2000. Cells in
the 6-well plate were used as non-transfected control cells throughout the blasticidin-selection
process. At 48 h post-transfection, expression of H2B-ECFP in transfected cells was examined
by imaging using a Leica DM500 fluorescent microscope. After confirming H2B-ECFP
expression via nuclear-localised ECFP fluorescence, growth medium on cells in each dish and
three wells of the 6-well plate was exchanged for 6 µg/mL blasticidin in 10% (v/v) FBS in
DMEM/F-12. The remaining three wells of the 6-well plate were used as a no-antibiotic control.
Every 2-3 days, cell growth was examined and selective medium was replaced with fresh
selective medium. This continued until non-transfected control cells had been killed off, and
small colonies of transfected cells began to form. Once colonies had expanded and cells had
reached ~80% confluence, cells were passaged into two T-75 tissue culture flasks and grown to
~80% confluence. The generation of this polyclonal stable-transfected cell line was carried out
simultaneously to the experiments outlined in section 5.2.6.2, and time limitations prevented
the use of this cell line in any further experiments. Thus, stocks of the cell line were frozen
down in liquid N2 storage for use in future studies.
5.2.6.2 Imaging using a Cellomics® ArrayScan™ VTI High Content Screening
microscope
NSC-34 cells that were triple-transfected were either live-imaged at 24 h, 48 h and 72 h post177

transfection, or for triple-transfections with the Fluc-EGFP variants, cells were fixed 48 h posttransfection before imaging using the 20× objective lens of a Cellomics® ArrayScan™ VTI
High Content Screening microscope (Thermo Scientific, Waltham, USA). Fluorescence of
ECFP-, EGFP- and tdT/mCherry-fusion proteins was imaged using excitation filters of 386 nm,
485 nm and 549 nm, respectively. Phase contrast and fluorescent images from 20 fields of view
per well were acquired, with image analysis parameters optimised using the Spot Detector V4
BioApplication of the Thermo Scientific™ HCS Studio™ software, detailed in Section 5.2.6.3
and summarised in Figure 5.1. Modifications to this BioApplication were made for optimal
detection of transfected cells and inclusions containing the EGFP- and tdT/mCherry-fusion
proteins.
5.2.6.3 Optimisation of image processing and analysis parameters using the Cellomics®
Spot Detector BioApplication
5.2.6.3.1 Image pre-processing
In the Thermo Scientific™ HCS Studio™ software, the first stage of automated image analysis
is correction of background fluorescence in each image. A low pass filtration method was used
to compute and subtract background fluorescence, in which the local background around each
pixel is calculated, with the radius of the area sampled adjusted as determined by the user. The
optimised parameter settings for image pre-processing are summarised in Figure 5.1, a. A radius
value of 20 µm was found to adequately correct background fluorescence in the images of
transfected NSC-34 cells. For all images analysed, it was selected that each BioApplication
would reject any objects/cells lying on the image borders. The RejectBorderObjectsCh1
parameter controls this; a value of 1 sets the algorithm to exclude analysis of any objects/cells
located on the border of each image, while a value of 0 results in the algorithm including all
objects/cells in the image for analysis, including those on the image border. This parameter was
set to a value of 1 to reject all cells located on the border of each image (Figure 5.1, a, ii).
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Figure 5.1. Schematic of Cellomics® ArrayScan™ VTI High Content Screening (HCS) image processing
and analysis optimisation using Thermo Scientific™ HCS Studio™ software. To analyse the fluorescence
intensity of EGFP-/tGFP- and tdTomato (tdT)/mCherry-fusion proteins and quantify protein inclusions containing
EGFP-/tGFP-fusion proteins in NSC-34 cells, an image analysis algorithm designed to analyse fluorescent foci in
cells, termed the Cellomics® Spot Detector BioApplication, was optimised using the Thermo Scientific™ HCS
Studio™ software. Optimisation was carried out using images of NSC-34 cells triple-transfected to express H2BECFP, either SOD1WT-EGFP, SOD1A4V-EGFP, TDP-43WT-tGFP TDP-43M337V-tGFP, FUSWT-tGFP, FUSR495XtGFP, FUSR521G-tGFP, VAPBWT-tGFP, VAPBP56S-tGFP, OPTNWT-EGFP, OPTNE478G-EGFP, UBQLN2WT-tGFP,
UBQLN2P497H-tGFP, VCPWT-tGFP, VCPR159H-tGFP, VCPR191Q-tGFP or EGFP alone and (3) mCherry alone. Cells
were imaged at 48 h post-transfection using the 20× objective lens of a Cellomics® ArrayScan™ VTI HCS
microscope. (A) Raw images from Channels 1 (H2B-ECFP), 2 (EGFP-/tGFP-fusion proteins) and 3
(tdTomato/mCherry-fusion proteins) were first pre-processed to (i) remove background fluorescence, (ii) exclude
cells positioned on the border of each image from analysis and (iii) distinguish individual cells (‘object’
segmentation). (iv) Channel 1 images were additionally smoothed (blurred) to help reduce fluorescent noise that
could lead to the false inclusion of image artefacts in subsequent analyses. (B) Biological ‘objects’, in this case
cells, were identified using nuclear-localised H2B-ECFP fluorescence in Channel 1 images. (i) For detection of
ECFP-fluorescent nuclei, a fluorescence intensity threshold was set using the Isodata method, which derives the
threshold from the distribution of pixel intensities in each image. (ii) To select viable transfected cells for analysis
and exclude image artefacts, dead cells and cell debris, cells were selected based on the size and fluorescence
intensity of their ECFP-fluorescent nuclei. (C) The relevant measures for GFP fluorescence intensity and
fluorescent foci were measured in Channel 2 (i) within a circular analysis mask that expanded the mask derived in
Channel 1 by 7 µm. The green circular mask indicates cells selected for analysis, while yellow masks indicate
fluorescent foci/‘spots’ selected for analysis. A fluorescence intensity threshold was set for Channel 2 using the
Isodata method. An offset value of 1.11 enabled the image processing algorithm to correctly identify cells
expressing the GFP-fusion proteins. (ii) To ensure that cells with particularly low expression of GFP-fusion genes
were not included for analysis, GFP fluorescence intensity limits for CircAvgIntenCh2 were set to a minimum
intensity of 100 RFU and a maximum intensity of 3241 RFU. (iii) To detect and analyse fluorescent foci
corresponding to protein inclusions, upper and lower limits for size and fluorescence intensity were set. (D)
Channel 3 objects were identified using the same mask as Channel 2, after establishing the fluorescence intensity
threshold using the Isodata method with an offset value of 6.

To optimise the BioApplication’s ability to resolve individual objects, an object segmentation
method based on fluorescence intensity was used. This method separates objects/cells that are
touching based on fluorescence intensity peaks of each pixel. Cells expressing H2B-ECFP in
their nucleus exhibit a single, high intensity peak localised in the nucleus. Setting this
parameter, ObjectSegmentationCh1, to a negative value sets the segmentation method to the
Intensity method while a positive value sets it to the Geometric method based on the shape and
size of objects, relying on indentations lying at object/cell boundaries. For the Intensity method,
the absolute value selected governs the minimum relative height of the intensity peak to be used
for segmentation. A value of -19 relative fluorescence units (RFU) was found to optimally
separate touching fluorescent cells (Figure 5.1, a, iii). Object segmentation was further
improved by additionally smoothing the Channel 1 image. Smoothing was also opted for as it
helped to reduce noise that could lead to the false inclusion of image artefacts in subsequent
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analyses. Smoothing involves sampling the region surrounding each pixel and then replacing
the pixel using the average value of the pixels sampled. A SmoothFactorCh1 value of 1 pixel,
specifying the radius sampled, was determined to optimally smooth each image (Figure 5.1, a,
iv).
5.2.6.3.2 Identification and selection of cells for analysis
The optimised parameter settings for identification and selection of cells for analysis are
summarised in Figure 5.1, b. To identify H2B-ECFP-expressing NSC-34 cells using Channel
1, a fluorescence intensity threshold was set using the Isodata method. In the Isodata method,
the threshold is derived from the distribution of pixel intensities in each image and thus is
dependent on each image. This method was chosen to ensure that image-to-image variations in
H2B-ECFP intensity would not affect the analysis of cell features measured in the remaining
channels. The Isodata thresholding method can be optimised by setting an offset value that
alters the final threshold applied to each image. This user-defined offset alters the threshold that
is computed automatically from the pixel intensities in the image to set a final optimised
threshold that is then applied to each image. In the present work, an offset value of -0.164 was
found to be optimal for altering the final threshold that was used to identify fluorescent cells as
‘objects’ (Figure 5.1, b, i). The ‘objects’ that were identified were then filtered to select only
viable transfected cells for potential analysis in further image processing steps and exclude
image artefacts, dead cells and cell debris. Cells were selected based on the size and
fluorescence intensity of their ECFP-fluorescent nuclei. A nucleus size minimum of 61 µm2
and maximum of 628 µm2, and ECFP fluorescence intensity minimum of 227 RFU and
maximum of 1818 RFU, were found to be appropriate for selecting nuclei of viable transfected
cells (Figure 5.1, b, ii).
For Channel 2, the relevant measures for GFP fluorescence intensity and spots were measured
within a circular mask (‘Circ’ mask) that expanded the primary object mask by 7 µm
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(CircModifierCh2 = 7) (Figure 5.1, c, i). This setting ensured that data from the entire projected
area of the cell would be collected. To ensure that the only cells included for analyses were
those that were successfully transfected and expressing the GFP-fusion proteins in addition to
H2B-ECFP, a fluorescence intensity threshold was set for Channel 2 using the Isodata method.
An offset value of 1.11 enabled the image processing algorithm to correctly identify cells
expressing the GFP-fusion proteins while excluding cells exhibiting autofluorescence. To
ensure that cells with particularly low expression of EGFP-fusion genes were not included for
analysis, GFP fluorescence intensity limits for CircAvgIntenCh2 were set to a minimum
intensity of 100 RFU and a maximum intensity of 3241 RFU (Figure 5.1, c, ii).
5.2.6.3.3 Selection and analysis of intracellular fluorescent foci
To measure the presence of GFP-positive inclusions in cells, the Spot Detector BioApplication
was optimised using Channel 2. To detect and measure fluorescent foci of sizes corresponding
to protein inclusions, as established using confocal microscopy, a spot area minimum of 2 µm2
and maximum of 150 µm2 was set (Figure 5.1, c, iii). As inclusions are accumulations of high
concentrations of proteins, the concentrated fluorescence of GFP-tagged proteins in inclusions
allows them to be detected based on high fluorescence intensity. A spot average fluorescence
intensity minimum of 150 RFU was found to detect appropriate foci corresponding to GFPpositive inclusions. tdTomato/mCherry-tagged proteins were imaged in Channel 3. For assays
focused on examining the localisation patterns of GFP-tagged proteins and without in-depth
analysis of tdTomato/mCherry-tagged proteins, Channel 3 objects were simply identified using
the Isodata threshold method with an offset value of 6 (Figure 5.1, d).
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Results
5.3.1

Characterisation of cellular models of SOD1-, TDP-43-, FUS-, CCNF- VAPB-,
VCP-, OPTN-, and UBQLN2-associated ALS and optimisation of image analysis
parameters

Given the extraordinary molecular heterogeneity of ALS, it was of interest to create ALS
models that collectively would represent a diversity of fALS forms. Thus, models of SOD1-,
TDP-43-, FUS-, CCNF-, VAPB-, VCP-, OPTN- and UBQLN2-associated ALS using the
neuronal NSC-34 cell line and EGFP-/tGFP-/mCherry-fusion plasmids were generated. The
genetic mutations in these models were selected after careful consideration of the mutations
that segregate with ALS; SOD1A4V (Deng et al. 1993), TARDBPM337V (Tamaoka et al. 2010),
FUSR495X, FUSR521G (Kwiatkowski et al. 2009, Vance et al. 2009), CCNFS621G (Williams et al.
2016), UBQLN2P497H (Deng et al. 2011), OPTNE478G (Maruyama et al. 2010), VAPBP56S
(Nishimura et al. 2004), VCPR159H and VCPR191Q (Johnson et al. 2010, Abramzon et al. 2012,
Koppers et al. 2012).
Prior to using these NSC-34 models with the HCS platform, the localisation patterns of each
EGFP-/tGFP-/mCherry-fusion WT and mutant ALS-associated protein in transfected NSC-34
cells were characterised by imaging at 48 h post-transfection using confocal microscopy. As a
measure of toxicity caused by the expression of each fusion gene, live cell fluorescent imaging
was used to image and count the numbers of transfected cells (detected as EGFP-/tGFP- or
mCherry-positive cells) over 80 h. The solubility of each protein in NSC-34 cells was examined
using an assay to permeabilise the plasma membrane of transfected cells using saponin,
allowing soluble intracellular proteins to diffuse out of the cell while trapping insoluble protein
material. Cells were imaged pre- and post-permeabilisation with saponin to quantify numbers
of transfected cells and numbers of cells containing insoluble EGFP-/tGFP- and mCherryfusion proteins, respectively. To confirm that the fluorescent protein tags had little or no
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aggregation propensity themselves, in each experiment NSC-34 cells were also transfected with
empty vectors to express EGFP or mCherry alone. Confocal microscopy of cells transfected
with EGFP or mCherry alone demonstrated that the EGFP and mCherry proteins are diffusely
distributed throughout the cell and themselves do not aggregate (Figure 5.2, a, i and b, i). It was
also confirmed that the expression of EGFP or mCherry alone had no effect on the viability of
transfected cells. Numbers of cells expressing EGFP or mCherry alone steadily increased over
the 80 h imaging period (Figure 5.2, a, ii and b, ii).

Figure 5.2. Localisation patterns of EGFP and mCherry alone, and cell population growth over time of NSC34 cells expressing EGFP or mCherry alone. Live cell imaging of NSC-34 cells transiently transfected with (A)
the pEGFP-N1 vector (EGFP alone) or (B) the pmCherry-C1 vector (mCherry alone). (A, i and B, i) Representative
images of transfected cells taken using a Leica TCS SP5 II confocal microscope at 48 h post-transfection. Scale
bars represent 10 µm. (A, ii and B, ii) To measure viability of NSC-34 cells transiently transfected to express
EGFP or mCherry alone, cells were imaged in an IncuCyte® ZOOM and numbers of transfected cells (EGFP- or
mCherry-positive cells) were monitored over 80 h. Graphs represent the mean ± SEM of the numbers of EGFPor mCherry-positive transfected cells over 80 h.
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5.3.1.1 Localisation patterns and aggregation of SOD1A4V, TDP-43M337V, FUSR495X,
FUSR521G and CCNFS621G in NSC-34 cells
It was important to be able to distinguish inclusions of the fusion proteins from the appearance
of foci that could result from their normal colocalisation with other cellular structures and
organelles; e.g. TDP-43 and FUS with SGs, OPTN with the Golgi apparatus (0.1-2 µm) (Guil
et al. 2006, Maruyama et al. 2010). Inclusions of ALS-associated proteins are generally in the
range 2-20 µm in diameter in human post-mortem tissue (Leigh et al. 1991, Shibata et al. 1994,
Strong et al. 2005, Maruyama et al. 2010, Teyssou et al. 2013) and in cell culture models
(Johnston 2000, Matsumoto et al. 2005, Matsumoto et al. 2006, Cozzolino 2008, Kuijpers et
al. 2013, Zeineddine et al. 2015). A size minimum of 2 µm was thus established as suitable for
categorising fluorescent foci as inclusions. The foci formed by SOD1A4V-EGFP, TDP-43M337VtGFP, FUSR495X-tGFP, FUSR521G-tGFP and CCNFS621G-mCherry were manually examined in
images of cells and were consistently measured to be larger than 2 µm (Figures 5.3 and 5.4).
The localisation patterns and solubility of SOD1A4V-EGFP, and the toxicity caused by its
expression in NSC-34 cells, was assayed and is presented in Ch. IV (Figures 4.1 and 4.4).
TDP-43, in addition to FUS, are predominantly nuclear-localised RBPs with additional
cytoplasmic roles in the formation and dynamics of SGs. Imaging transfected NSC-34 cells
using confocal microscopy, it was observed that the tGFP-tagged WT proteins remained
localised to cell nuclei, while the TDP-43M337V, FUSR521G and FUSR495X mutants mislocalised
to the cytoplasm and formed large aggregates and smaller foci, as is observed in ALS patient
tissue (Figure 5.3, a, i and b, i) (Kwiatkowski et al. 2009, Vance et al. 2009, Tamaoka et al.
2010). Although TDP-43WT-tGFP was not observed to mislocalise and accumulate into
cytoplasmic inclusions when transfected cells were examined using confocal microscopy, after
permeabilising the plasma membrane of transfected cells and imaging using an IncuCyte TDP43WT-tGFP was found to remain inside 55% of transfected cells (Figure 5.3, a, ii). However, a
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significantly greater percentage of cells expressing TDP-43M337V-tGFP were tGFP-positive
following saponin permeabilisation (79%) when compared to cells expressing TDP-43WT-tGFP
(p = 0.0035). The large proportion of TDP-43WT-tGFP-expressing cells that remained tGFPpositive after saponin treatment may be due, in part, to the concentration of saponin solution
used, and the length of time that cells were incubated in saponin solution being insufficient to
permeabilise the nuclear membrane inside cells. Thus, TDP-43WT-tGFP that was localised
within nuclei may not have been released when cells were incubated with saponin solution. In
this case, the saponin-permeabilisation assay may not be appropriate for assaying the formation
of TDP-43 cytoplasmic inclusions, as it may not enable distinction between TDP-43 that is
localised to nuclei and TDP-43 that has accumulated into insoluble cytoplasmic inclusions.
Similarly, while FUSWT-tGFP was not observed to mislocalise and accumulate into cytoplasmic
inclusions when transfected cells were examined using confocal microscopy, the saponinpermeabilisation assay quantified that FUSWT-tGFP remained in 22.7% of transfected cells
following incubation with saponin solution (Figure, 5.3, b, ii). Moreover, the percentage of cells
expressing FUSR495X-tGFP that remained tGFP-positive following incubation with saponin
solution (26.2%) was similar to that of cells expressing FUSWT-tGFP. However, there was a
significantly greater percentage of cells expressing FUSR521G-tGFP that remained tGFP-positive
following incubation with saponin solution (52.4%) compared to both cells expressing FUSWTtGFP and cells expressing FUSR495X-tGFP (FUSWT-tGFP, p = 0.0012; FUSR495X-tGFP, p =
0.0023). As noted above, when cells expressing the FUS-tGFP constructs were examined using
confocal microscopy, there was extensive formation of small foci (< 2 µm) and large aggregates
by both FUS mutants (Figure 5.3, b, i). Thus, the similar percentages of cells expressing FUSWTtGFP and FUSR495X-tGFP that remained tGFP-positive after saponin-permeabilisation
compared to the marked differences in their localisation patterns indicates that the saponinpermeabilisation assay may not be appropriate for measuring the formation of insoluble
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cytoplasmic mutant FUS-tGFP inclusions.
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Figure 5.3. Characterising the localisation patterns and intracellular solubility of ALS-associated TDP43M337V, FUSR495X and FUSR521G. NSC-34 cells were transiently transfected with (A) TDP-43WT-tGFP or TDP43M337V-tGFP or (B) FUSWT-tGFP, FUSR495X-tGFP or FUSR521G-tGFP. After 48 h, transfected cells were either (A,
i and B, i) imaged using a Leica TCS SP5 II confocal microscope or (A, ii, iii and B, ii, iii) imaged on an IncuCyte®
ZOOM, followed by incubation with 0.03% (w/v) saponin in PBS for 10 min at room temperature, before being
imaged again on the IncuCyte. (A, i and B, i) Representative images from confocal microscopy, with white arrow
heads indicating inclusions formed by the tGFP-fusion proteins. Scale bars represent 10 µm. (A, ii and B, ii) Cells
were transfected in quadruplicate, and the data presented is the mean ± SEM of the percentage of transfected NSC34 cells containing insoluble tGFP-positive protein following permeabilisation with saponin. Differences between
the means were determined using Student’s t test or one-Way ANOVA followed by Tukey’s Multiple Comparison
Test. ** indicates p < 0.01. (A, iii and B, iii) Representative IncuCyte images of NSC-34 cells prior to
permeabilisation with saponin (pre-saponin) and immediately following permeabilisation with saponin (postsaponin), from which the graphs in A, ii and B, ii were derived. Scale bars represent 150 µm.

CCNF functions as a substrate recognition subunit of Skp1-Cul1-F-box (SCF) E3 ubiquitin
ligase complexes that mediate the ubiquitylation and proteasomal degradation of target proteins
(D'Angiolella et al. 2013). Since the identification of the S621G CCNF mutation in ALS and
FTD patients (Williams et al. 2016), the localisation patterns of the CCNFS621G mutant in motor
neurons have not been investigated in detail. However, Lee et al. (2018) carried out
immunofluorescence microscopy of CCNFS621G in Neuro-2A cells, in which CCNFS621G was
localised to inclusion-like structures in a proportion of cells while CCNFWT generally displayed
diffuse distribution throughout the cells. In the present work, mCherry-tagged CCNFWT
fluorescence was observed to have a diffuse distribution throughout the nucleus and cytoplasm
of all imaged cells (Figure 5.4, a). In contrast, CCNFS621G-mCherry formed into particularly
large amorphous aggregates ranging from 5 to > 10 µm. Interestingly, however, saponinpermeabilisation of the plasma membranes of cells expressing CCNFWT-mCherry and
CCNFS621G-mCherry revealed that both proteins formed extensively into insoluble structures,
with > 50% of both cells transfected with CCNFWT-mCherry and cells transfected with
CCNFS621G-mCherry containing insoluble mCherry-positive protein following permeabilisation
(Figure 5.4, b). Nevertheless, there were significantly more CCNFS621G-mCherry-expressing
cells containing insoluble mCherry-positive protein (67.8%) following permeabilisation than
there were of CCNFWT-mCherry cells (54.9%) (p = 0.0085).
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Figure 5.4. Characterising the localisation pattern and intracellular solubility of ALS-associated CCNFS621G.
NSC-34 cells were transiently transfected with CCNFWT-mCherry or CCNFS621G-mCherry. After 48 h, transfected
cells were either (A) imaged using a Leica TCS SP5 II confocal microscope or (B and C) imaged on an IncuCyte®
ZOOM, followed by incubation with 0.03% (w/v) saponin in PBS for 10 min at room temperature, before being
imaged again on the IncuCyte. (A) Representative images from confocal microscopy, with white arrow heads
indicating inclusions formed by CCNFS621G-mCherry. Scale bars represent 10 µm. (B) Cells were transfected in
quadruplicate, and the data presented is the mean ± SEM of the percentage of transfected NSC-34 cells containing
insoluble mCherry-positive protein following permeabilisation with saponin. Differences between the means were
determined using a Student’s t test. ** indicates p < 0.01. (C) Representative IncuCyte images of NSC-34 cells
prior to permeabilisation with saponin (pre-saponin) and immediately following permeabilisation with saponin
(post-saponin), from which the graph in B was derived. Scale bar represents 150 µm.

5.3.1.2 The expression of SOD1A4V, TDP-43M337V, FUSR495X, FUSR521G and CCNFS621G
cause toxicity in NSC-34 cells
Live cell imaging of cells expressing TDP-43WT-tGFP and TDP-43M337V-tGFP to monitor cell
population growth showed that the numbers of TDP-43M337V-tGFP expressing cells had a
significantly slower population growth rate compared to cells expressing TDP-43WT-tGFP (p <
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0.01) (Figure 5.5, a and b). The numbers of cells expressing TDP-43M337V-tGFP began to
plateau after ~48 h post-transfection (24 h post-replating) while the numbers of TDP-43WTtGFP expressing cells continued to increase steadily until ~72 h post-transfection (48 h postreplating). Comparison of the mean numbers of tGFP-positive transfected cells at 72 h posttransfection showed that there was a significantly greater number of cells expressing TDP43WT-tGFP than there was of cells expressing TDP-43M337V-tGFP (p < 0.001) (Figure 5.5, c).

Figure 5.5. ALS-associated TDP-43M337V causes toxicity in NSC-34 cells. NSC-34 cells were transiently
transfected with TDP-43WT-tGFP or TDP-43M337V-tGFP and imaged in an IncuCyte® ZOOM over 80 h. Graphs
represent the mean ± SEM of (A) numbers of tGFP-positive transfected cells over 80 h, (B) population growth
rates of transfected cells and (C, i) numbers of transfected cells at 48 h post-replating, in triplicate wells of cells.
(C, ii) Representative IncuCyte images of NSC-34 cells at 48 h post-replating, from which the graph in C, i, was
derived. Scale bar represents 150 µm. Differences between the means were determined using Student’s t tests. **
indicates p < 0.01, *** indicates p < 0.001.
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The expression of FUSR495X-tGFP and of FUSR521G-tGFP was observed to cause reduced
population growth of NSC-34 cells compared to FUSWT-tGFP (Figure 5.6). While the numbers
of cells expressing FUSWT-tGFP continued to increase steadily over the 80 h imaging period,
the numbers of both FUSR495X-tGFP and FUSR521G-tGFP cells began to plateau after ~40 h
(Figure 5.6, a). There was no difference in population growth rate between the two FUS
mutants, but both exhibited significantly reduced population growth compared to cells
expressing FUSWT-tGFP (FUSR495X-tGFP, p = 0.0019; FUSR521G-tGFP, p = 0.0041) (Figure 5.6,
b). At 72 h post-transfection there were significantly greater numbers of cells expressing
FUSWT-tGFP than there were of cells expressing either of the two mutants (FUSR495X-tGFP, p
= 0.0014; FUSR521G-tGFP, p = 0.0023) (Figure 5.6, c).
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Figure 5.6. ALS-associated FUSR495X and FUSR521G cause toxicity in NSC-34 cells. NSC-34 cells were
transiently transfected with FUSWT-tGFP, FUSR495X-tGFP or FUSR521G-tGFP and imaged in an IncuCyte® ZOOM
over 80 h. Graphs represent the mean ± SEM of (A) numbers of tGFP-positive transfected cells over 80 h, (B)
population growth rates of transfected cells and (C, i) numbers of transfected cells at 48 h post-replating, in
triplicate wells of cells. (C, ii) Representative IncuCyte images of NSC-34 cells at 48 h post-replating, from which
the graph in C, i, was derived. Scale bar represents 150 µm. Differences between the means were determined using
one-Way ANOVA followed by Tukey’s Multiple Comparison Test. ** indicates p < 0.01.

CCNFS621G-mCherry caused striking inhibition of cell population growth, with live cell imaging
revealing that the numbers of CCNFS621G-mCherry cells plateaued and dropped off steadily 28
h after replating (Figure 5.7, a). Analysis of the growth rates of the cell population expressing
the CCNF-mCherry constructs showed that the rate of growth of CCNFS621G-mCherry cells was
markedly slower than that of CCNFWT-mCherry cells (p < 0.0001) (Figure 5.7, b). At 72 h posttransfection the differences in growth between cells expressing CCNFWT-mCherry and
CCNFS621G-mCherry was clearly evident in the significantly lower numbers of CCNFS621G193

mCherry cells than CCNFWT-mCherry cells (p < 0.0001) (Figure 5.7, c).

Figure 5.7. ALS-associated CCNFS621G causes toxicity in NSC-34 cells. NSC-34 cells were transiently
transfected with CCNFWT-mCherry or CCNFS621G-mCherry and imaged in an IncuCyte® ZOOM over 80 h. Graphs
represent the mean ± SEM of (A) numbers of mCherry-positive transfected cells over 80 h, (B) population growth
rates of transfected cells and (C, i) numbers of transfected cells at 48 h post-replating, in triplicate wells of cells.
(C, ii) Representative IncuCyte images of NSC-34 cells at 48 h post-replating, from which the graph in C, i, was
derived. Scale bar represents 150 µm. Differences between the means were determined using Student’s t tests.
**** indicates p < 0.0001.

5.3.1.3 The expression of UBQLN2P497H, UBQLN2P525S, OPTNE478G, VAPBP56S,
VCPR159H and VCPR191Q cause toxicity in NSC-34 cells
Assaying cell population growth using live cell imaging over 80 h, expression of
UBQLN2P497H-tGFP and of UBQLN2P525S-tGFP was found to cause reductions in cell
population growth rates compared to the expression of UBQLN2WT-tGFP (UBQLN2P497HtGFP, p < 0.0001; UBQLN2P525S-tGFP, p < 0.001) (Figure 5.8, b). Interestingly, expression of
194

the UBQLN2P497H-tGFP mutant was observed to cause greater inhibition of cell population
growth compared to the UBQLN2P525S-tGFP mutant, with UBQLN2P497H-tGFP cells exhibiting
slower population growth rates (p = 0.0275) and dropping down to significantly lower numbers
by 72 h post-transfection (p = 0.0264) than UBQLN2P525S-tGFP cells (Figure 5.8, c).

Figure 5.8. ALS-associated UBQLN2P497H and UBQLN2P525S cause toxicity in NSC-34 cells. NSC-34 cells were
transiently transfected with UBQLN2WT-tGFP, UBQLN2P497H-tGFP or UBQLN2P525S-tGFP and imaged in an
IncuCyte® ZOOM over 80 h. Graphs represent the mean ± SEM of (A) numbers of tGFP-positive transfected cells
over 80 h, (B) population growth rates of transfected cells and (C, i) numbers of transfected cells at 48 h postreplating, in triplicate wells of cells. (C, ii) Representative IncuCyte images of NSC-34 cells at 48 h post-replating,
from which the graph in C, i, was derived. Scale bar represents 150 µm. Differences between the means were
determined using one-Way ANOVA followed by Tukey’s Multiple Comparison Test. * indicates p < 0.05, ***
indicates p < 0.001, **** indicates p < 0.0001.
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In NSC-34 cells expressing the VAPB-tGFP constructs, a clear reduction was observed in the
population growth of cells expressing VAPBP56S-tGFP compared to cells expressing VAPBWTtGFP (Figure 5.9). Although numbers of transfected cells were low due to low transfection
efficiency, total cell density was high, increasing from ~70% to ~95% over the 80 h imaging
period (data not shown). There was thus no potential effect of low total cell density on the
proliferation or loss of the VAPB-tGFP-expressing cells. Comparison of the numbers of VAPBtGFP cells in the first 20 h of imaging confirmed that VAPBP56S-tGFP significantly reduced the
population growth rate of cells (p = 0.0203) (Figure 5.9, b). The numbers of tGFP-positive cells
expressing VAPBP56S-tGFP at 48 h post-replating were significantly lower than cells expressing
VAPBWT-EGFP (p < 0.0001) (Figure 5.9, c), further highlighting the toxicity caused by
expression of the P56S mutation.
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Figure 5.9. ALS-associated VAPBP56S causes toxicity in NSC-34 cells. NSC-34 cells were transiently transfected
with VAPBWT-tGFP or VAPBP56S-tGFP and imaged in an IncuCyte® ZOOM over 80 h. Graphs represent the mean
± SEM of (A) numbers of tGFP-positive transfected cells over 80 h, (B) population growth rates of transfected
cells and (C, i) numbers of transfected cells at 48 h post-replating, in triplicate wells of cells. . (C, ii) Representative
IncuCyte images of NSC-34 cells at 48 h post-replating, from which the graph in C, i, was derived. Scale bar
represents 150 µm. Differences between the means were determined using Student’s t tests. * indicates p < 0.05,
**** indicates p < 0.0001.

The expression of OPTNE478G-EGFP reduced the population growth rate of transfected cells
compared to cells expressing OPTNWT-EGFP (Figure 5.10). In the first 20 h of imaging, the
population growth rate of OPTNE478G-EGFP-expressing cells was significantly slower than that
of OPTNWT-EGFP expressing cells (p = 0.0139) (Figure 5.10, b). Comparison of the numbers
of transfected cells at 48 h post-replating showed that there were significantly more viable
OPTNWT-EGFP-expressing cells than of OPTNE478G-EGFP-expressing cells (p < 0.001) (Figure
5.10, c), demonstrating that overexpression of the E478G mutant caused considerable toxicity
in NSC-34 cells.
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Figure 5.10. ALS-associated OPTNE478G causes toxicity in NSC-34 cells. NSC-34 cells were transiently
transfected with OPTNWT-EGFP or OPTNE478G-EGFP and imaged in an IncuCyte® ZOOM over 80 h. Graphs
represent the mean ± SEM of (A) numbers of EGFP-positive transfected cells over 80 h, (B) population growth
rates of transfected cells and (C, i) numbers of transfected cells at 48 h post-replating, in triplicate wells of cells.
(C, ii) Representative IncuCyte images of NSC-34 cells at 48 h post-replating, from which the graph in C, i, was
derived. Scale bar represents 150 µm. Differences between the means were determined using Student’s t tests. *
indicates p < 0.05, *** indicates p < 0.001.

Assaying the numbers of NSC-34 cells expressing the VCP-tGFP constructs over 80 h, it was
observed that both mutants significantly reduced the population growth rate of transfected cells
relative to VCPWT-tGFP (Figure 5.11). The population growth rate of cells expressing
VCPR191Q-tGFP was notably slower than that of cells expressing VCPR159H-tGFP (p = 0.004),
and 48 h after replating cells the numbers of viable VCPR191Q-tGFP-expressing cells were much
lower than the numbers of VCPR159H-tGFP cells (p = 0.0012) (Figure 5.11, b and c).
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Figure 5.11. ALS-associated VCPR159H and VCPR191Q cause toxicity in NSC-34 cells. NSC-34 cells were
transiently transfected with VCPWT-tGFP, VCPR159H-tGFP or VCPR191Q-tGFP and imaged in an IncuCyte® ZOOM
over 80 h. Graphs represent the mean ± SEM of (A) numbers of tGFP-positive transfected cells over 80 h, (B)
population growth rates of transfected cells and (C, i) numbers of transfected cells at 48 h post-replating, in
triplicate wells of cells. (C, ii) Representative IncuCyte images of NSC-34 cells at 48 h post-replating, from which
the graph in C, i, was derived. Scale bar represents 150 µm. Differences between the means were determined using
one-Way ANOVA followed by Tukey’s Multiple Comparison Test. ** indicates p < 0.01, *** indicates p < 0.001
and **** indicates p < 0.0001.

5.3.1.4 Characterisation of mutant UBQLN2, OPTN, VAPB and VCP solubility,
localisation and aggregation
The saponin-permeabilisation assay was next used to examine the mobility and solubility of
UBQLN2P497H-tGFP, UBQLN2P525S-tGFP, OPTNE478G-EGFP, VAPBP56S-tGFP, VCPR159H-tGFP
and VCPR191Q-tGFP in NSC-34 cells. In cells expressing the UBQLN2-tGFP constructs it was
found that UBQLN2WT-tGFP had a degree of immobility in cells, with 37% of transfected cells
quantified to contain tGFP-positive protein following permeabilisation of their plasma
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membranes (Figure 5.12, a). However, the two UBQLN2 mutants, UBQLN2P497H-tGFP and
UBQLN2P525S-tGFP, remained inside significantly more cells following permeabilisation;
65.1% (p = 0.002) and 68.1% (p = 0.0012), respectively. Interestingly, the saponinpermeabilisation assay quantified that ~35% of both cells expressing OPTNWT-EGFP and cells
expressing

OPTNE478G-EGFP

contained

insoluble

EGFP-positive

protein

following

permeabilisation (Figure 5.12, b). As OPTNWT can associate with proteins of the Golgi
apparatus (Sahlender et al. 2005, Maruyama et al. 2010), a proportion of OPTNWT-EGFP may
have been bound to the Golgi and thus immobile and unable to diffuse out of cells following
saponin treatment. Further experimentation is needed to determine the nature of this postpermeabilisation cell-bound OPTNWT-EGFP. Through saponin permeabilisation of cells
transfected with the VCP-tGFP constructs it was quantified that ~9.8% of cells transfected with
VCPWT-tGFP retained the tGFP-tagged protein following membrane permeabilisation (Figure
5.12, c). However, both VCPR191Q-tGFP and VCPR159H-tGFP remained cell-associated in
significantly greater percentages of transfected cells (VCPR191Q-tGFP, p = 0.0222; VCPR159HtGFP, p = 0.0111), indicating that both mutants were relatively less mobile and had reduced
solubility compared to VCPWT-tGFP.
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Figure 5.12. Analysis of the release of EGFP-/tGFP-fusion mutant UBQLN2, OPTN and VCP from NSC-34
cells following saponin-permeabilisation. NSC-34 cells were transiently transfected with (A) UBQLN2WT-tGFP,
UBQLN2P497H-tGFP or UBQLN2P525S-tGFP, (B) OPTNWT-EGFP or OPTNE478G-EGFP or (C) VCPWT-tGFP,
VCPR159H-tGFP or VCPR191Q-tGFP. After 48 h, cells were imaged on an IncuCyte® ZOOM, followed by incubation
with 0.03% (w/v) saponin in PBS for 10 min at room temperature, before being imaged again on the IncuCyte. (A,
i, B, i and C, i) Cells were transfected in quadruplicate, and the data presented in each graph is the mean ± SEM
of the percentage of transfected NSC-34 cells containing insoluble EGFP-/tGFP-positive protein following
permeabilisation with saponin. Differences between the means were determined using either Student’s t tests or
one-Way ANOVA followed by Tukey’s Multiple Comparison Test. * indicates p < 0.05, ** indicates p < 0.01.
(A, ii, B, ii and C, ii) Representative IncuCyte images of NSC-34 cells prior to permeabilisation with saponin (presaponin) and immediately following permeabilisation with saponin (post-saponin), from which the graphs in A, i,
B, i and C, i) were derived. Scale bars represent 150 µm.

Unfortunately, transfections with the VAPB-tGFP constructs for the IncuCyte-based assays
resulted in considerably low transfection efficiencies, as can be seen in the low numbers of
tGFP-positive transfected cells in Figure 5.9. The numbers of tGFP-positive cells at 48 h posttransfection detected pre- and post-permeabilisation with saponin for VAPBP56S-tGFP were thus
too low for analysis. This saponin-treatment experiment also may not have been appropriate for
VAPB, as it is an integral membrane protein and thus in its native localisation in cells is
immobile and unable to freely diffuse out of permeabilised cells.
The inclusion size cut-off of 2 µm established using confocal microscopy (section 5.3.1.1) was
used to examine the association of ubiquitin with inclusions formed by VAPBP56S-tGFP,
VCPR191Q-tGFP, VCPR159H-tGFP, OPTNE478G-EGFP and UBQLN2P497H-tGFP. Based on
previously published work showing that ubiquitylation of misfolded proteins can determine the
type of inclusion into which they are compartmentalised (Kaganovich et al. 2008), it was
hypothesised that the timing of ubiquitin association with inclusions may provide insight into
the aggregation pathways of each ALS-associated protein. At the time of the present work, the
dynamics of ubiquitin association with SOD1A4V-EGFP, TDP-43M337V-tGFP and FUSR495XtGFP inclusions were being characterised by Ms. N. Farrawell (University of Wollongong,
NSW, Australia) and have since been published (Farrawell et al. 2015). Thus, for this study,
the localisation patterns of ubiquitin and mutant VAPB, VCP, OPTN and UBQLN2 were
examined in NSC-34 cells co-expressing VAPBP56S-tGFP, VCPR191Q-tGFP, VCPR159H-tGFP,
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OPTNE478G-EGFP, or UBQLN2P497H-tGFP and

mRFP

ubiquitin over 72 h. UBQLN2-positive

inclusions in post-mortem spinal cord tissue from patients with ALS can have varying
morphologies, including round and compact, skein-like and large, amorphous inclusions (Deng
et al. 2011). In the present work, UBQLN2P497H-tGFP formed large cytoplasmic inclusions with
an amorphous appearance (Figure 5.13, b). UBQLN2P497H-tGFP inclusions were consistently
observed to colocalise with ubiquitin from 24 h through to 72 h post-transfection (Figure 5.13,
a), which was also observed for SOD1A4V-EGFP (Farrawell et al. 2015).
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Figure 5.13. The timing of ubiquitin colocalisation to inclusions differs between inclusions formed by mutant
VAPB, OPTN and UBQLN2. NSC-34 cells were transiently dual-transfected with VAPBP56S-tGFP, OPTNE478GEGFP or UBQLN2P497H-tGFP and mRFPubiquitin, and imaged at 24 h, 48 h and 72 h post-transfection by confocal
microscopy. (A) Percentages of inclusions containing the EGFP-/tGFP-fusion mutant proteins that were also
positive for mRFPubiquitin in dual-transfected NSC-34 cells at 24 h, 48 h and 72 h post-transfection. At each time
point 10-15 fields of view were imaged, with a minimum of 10 dual-transfected cells counted per field. Percentages
of EGFP-/tGFP-fusion mutant protein inclusions containing mRFPubiquitin at each time point is the mean ± SEM
from triplicate wells of dual-transfected cells, from n = 1 experiment. (B) Representative images of dualtransfected NSC-34 cells at (i) 24 h, (ii) 48 h and (iii) 72 h post-transfection. White arrow heads indicate inclusions
containing both the EGFP-/tGFP-fusion mutant proteins and mRFPubiquitin. Scale bars represent 10 µm.
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VAPB is a small type IV membrane protein found in the ER, in intracellular vesicle membranes
and in the plasma membrane (Soussan et al. 1999, Foster et al. 2000, Skehel et al. 2000,
Amarilio et al. 2005, Manford et al. 2012). The P56S mutation in VAPB causes the protein to
oligomerise and aggregate into distinct insoluble inclusions that have been ultrastructurally
characterised to contain ER-derived membranous tubules (Nishimura et al. 2004, Teuling et al.
2007, Tsuda et al. 2008, Papiani et al. 2012, Kuijpers et al. 2013). In the present work,
VAPBP56S-tGFP inclusions did not always colocalise with ubiquitin, in contrast to mutant
UBQLN2 inclusions, as was similarly the case for TDP-43M337V and FUSR495X inclusions
(Farrawell et al. 2015). At 24 h post-transfection ~60% of VAPBP56S-EGFP inclusions were
colocalised with ubiquitin, increasing to ~91% after 72 h (Figure 5.13, a).
Imaging cells co-transfected with OPTNWT-EGFP or OPTNE478G-EGFP and mRFPubiquitin using
confocal microscopy, OPTNE478G-EGFP cells were observed to contain small EGFP-positive
foci (< 2 µm) at 24 h post-transfection. These foci were not scored as inclusions as they could
not be distinguished from the potential association of OPTN with the Golgi apparatus and
related vesicular structures (Ying et al. 2010, Ying and Yue 2012). The use of
immunofluorescence staining for proteins of the Golgi apparatus and transport vesicles would
have enabled characterisation of the nature of these observed foci at 24 h post-transfection. At
48 h post-transfection, OPTNE478G-EGFP foci > 2 µm were observed, and were categorised as
inclusions (Figure 5.13, a and b, I and ii). At this time point, ~84% of inclusions colocalised
with mRFPubiquitin, increasing to ~93% after 72 h (Figure 5.13, a and b, ii and iii).
Interestingly, mutant VCP did not form inclusions when co-expressed with
however

mRFP

mRFP

ubiquitin,

ubiquitin inclusions were observed (Figure 5.14, a). As TDP-43-positive

inclusions are one of the hallmark features of ALS, it was next examined whether or not the
overexpression of WT or mutant VCP caused aggregation of TDP-43WT. NSC-34 cells were cotransfected with VCPWT-tGFP, VCPR191Q-tGFP or VCPR159H-tGFP and TDP-43WT-tdT, a
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construct previously generated and described by Yang et al. (2010), and imaged after 48 h of
incubation. Both VCP-tGFP variants as well as VCPWT-tGFP were observed to form inclusions
that colocalised with TDP-43WT-tdT in all cells that were imaged (Figure 5.14, b).

Figure 5.14. WT and mutant VCP do not aggregate into ubiquitylated inclusions, but are sequestered into
inclusions when co-expressed with TDP-43WT. NSC-34 cells were transiently dual-transfected with VCPWTtGFP, VCPR159H-tGFP or VCPR191Q-tGFP and (A) mRFPubiquitin or (B) TDP-43WT-tdTomato and imaged by
confocal microscopy 48 h later. Images shown are representative of 10-15 fields of view per well, and each dual
transfection was carried out in triplicate in n = 1 experiment. White arrow heads indicate inclusions formed by the
tGFP-, mRFP- and tdTomato-fusion proteins. Scale bars indicate 10 µm.

Time limitations prevented further investigation into these findings observed for UBQLN2,
VAPB, OPTN and VCP. Instead, the variable ubiquitin colocalisation timing found for
SOD1A4V, TDP-43M337V and FUSR495X inclusions obtained by Ms. N. Farrawell (University of
Wollongong, NSW, Australia) and described in Farrawell et al. (2015) was prioritised for
further investigation. It was tested whether inclusions negative for ubiquitin might colocalise
with

mRFP

LC3, a marker of autophagy. No observable relationship was observed between

SOD1A4V-EGFP inclusions and mRFPLC3 (Figure 5.15). TDP-43M337V-tGFP and FUSR495X-tGFP
inclusions, in contrast, were observed to be adjacent to
did not appear to be colocalised.
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mRFP

LC3-positive foci, although they

Figure 5.15. Mutant TDP-43M337V-tGFP and FUSR495X-tGFP inclusions are localised adjacent to mRFPLC3positive foci. NSC-34 cells were transiently dual-transfected with TDP-43M337V-tGFP, FUSR495X-tGFP or
SOD1A4V-EGFP and mRFPLC3 and imaged 48 h later using confocal microscopy. Images shown are representative
of 10-15 fields of view per well, and each dual transfection was carried out in triplicate in n = 1 experiment. White
arrows indicate mRFPLC3 foci localised adjacent to TDP-43M337V-tGFP and FUSR495X-tGFP inclusions. Scale bars
indicate 10 µm.

5.3.2

Firefly luciferase mutants report on proteostasis stress in NSC-34 cells expressing
SOD1A4V and CCNFS621G

The optimised HCS Spot Detector assay was used for an assay comparing the effect of the
overexpression of SOD1 and CCNF variants on the ability of the cellular protein quality control
network to prevent the aggregation of conformationally destabilised, aggregation-prone
mutants of firefly luciferase (Fluc). Fluc is a ~60 kDa multidomain protein that is known to be
chaperone-dependent for folding and refolding (Nimmesgern and Hartl 1993, Schroder et al.
1993, Frydman et al. 1994, Thulasiraman and Matts 1996, Gupta et al. 2011). It was reasoned
that reductions in the capacity of the protein quality control network would lead to increased
aggregation of the EGFP-tagged Fluc mutants, as has been shown before (Gupta et al. 2011).
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To ensure that the SpotDetector BioApplication was capable of identifying and analysing
transfected cells and fluorescent foci reliably and accurately, images from each experimental
condition were manually examined (Figure 5.16, a to d). While in some images transfected cells
were occasionally not detected by the BioApplication, > 90% of ECFP- and EGFP-positive
cells were detected (green circular masks). ‘Spot’ masks (yellow masks) were observed only
on large foci with high fluorescence intensity, corresponding to the inclusion size and
fluorescence intensity cut-offs established during assay optimisation.
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Figure 5.16. Optimised HCS SpotDetector BioApplication identifies and analyses transfected cells and FlucEGFP foci. Representative Cellomics® ArrayScan™ VTI images showing masks (first and third rows of each
panel) used to identify and select NSC-34 cells co-transfected with either (A) SOD1WT-tdTomato, (B) SOD1A4VtdTomato, (C) CCNFWT-mCherry or (D) CCNFS621G-mCherry and FlucWT-EGFP, FlucSM-EGFP or FlucDM-EGFP.
Cells were imaged at 48 h post-transfection. Green circular masks indicate cells selected for analysis, yellow masks
indicate ‘spots’ selected for analysis, representing aggregates. Images were acquired using a 20× objective lens.

Proteasome inhibition of cells expressing mCherry alone confirmed that increased proteome
stress results in increased aggregation of the Fluc-EGFP isoforms. Cells expressing mCherry
alone that were treated with MG132 developed significantly greater numbers of FlucWT-EGFP
(p < 0.0001), FlucSM-EGFP (p = 0.0001) and FlucDM-EGFP (p = 0.0021) aggregates compared
to untreated cells (Figure 5.17, a, i). MG132 treatment resulted in significantly higher numbers
of FlucWT-EGFP aggregates than FlucDM-EGFP aggregates (p = 0.0153). FlucWT-EGFP
aggregates were significantly smaller (p = 0.002) and more brightly fluorescent (p < 0.0001)
than FlucDM-EGFP aggregates (Figure 5.17, b, i and c, i). Aggregates of the Fluc-EGFP
isoforms were also detected in cells expressing SOD1-tdT, with a significant increase in the
numbers of aggregates formed in cells expressing mutant SOD1A4V-tdT compared to SOD1WTtdT (FlucWT-EGFP, p = 0.0331; FlucSM-EGFP, p = 0.0061; FlucDM-EGFP, p = 0.0042) (Figure
5.17, a, ii). There were also increases in the mean size of FlucDM-EGFP aggregates (p = 0.0430)
and fluorescence intensity of aggregates of FlucWT-EGFP (p < 0.0001), FlucSM-EGFP (p <
0.0001) and FlucDM-EGFP (p < 0.0001) in cells expressing mutant SOD1A4V-tdT compared to
SOD1WT-tdT (Figure 5.17, b, ii and c, ii). Interestingly, aggregation of FlucSM-EGFP and
FlucDM-EGFP was as extensive in cells expressing CCNFWT-mCherry as those expressing
CCNFS621G-mCherry (Figure 5.17, a, iii). Whilst aggregates of FlucWT-EGFP were also
detected, there were significantly lower numbers of cells containing them compared to the
numbers of cells containing aggregates of FlucSM-EGFP (p < 0.001) and FlucDM-EGFP (p <
0.0001), both in cells expressing CCNFWT-mCherry and in cells expressing CCNFS621GmCherry. There was also the same trend in the size of aggregates of the Fluc-EGFP isoforms
in cells expressing CCNFWT-mCherry and those expressing CCNFS621G-mCherry, with
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significantly larger aggregates of FlucDM-EGFP formed than aggregates of FlucWT-EGFP
(CCNFWT-mCherry, p = 0.0395; CCNFS621G-mCherry, p = 0.0328) (Figure 5.17, b, iii). There
was no significant difference in the mean fluorescence intensity of the Fluc-EGFP aggregates
of the Fluc-EGFP isoforms between cells expressing CCNFWT-mCherry and cells expressing
CCNFS621G-mCherry (Figure 5.17, c, iii).

211

212

Figure 5.17. Firefly luciferase mutants report on chaperone network activity in NSC-34 cells expressing
SOD1 and CCNF. (A) Numbers of Fluc-EGFP aggregates per 100 transfected cells, (B) mean size of Fluc-EGFP
aggregates (µm2) and (C) mean fluorescence intensity (FI) of Fluc-EGFP aggregates imaged at 48 h posttransfection in NSC-34 cells expressing (i) mCherry alone ± treatment with 5 µM MG132, (ii) SOD1WT-tdTomato
or SOD1A4V-tdTomato or (iii) CCNFWT-mCherry or CCNFS621G-mCherry. Treatment with MG132 was carried out
at 30 h post-transfection. For mock treatment, 5 µM DMSO was instead added to cells. Graphs represent the mean
± SEM from quadruplicate wells of cells in n = 1 experiment. Differences between the means were determined
using one-Way ANOVA followed by Tukey’s Multiple Comparison Test. * indicates p < 0.05, ** indicates p <
0.01, *** indicates p < 0.001, **** indicates p < 0.0001.

Discussion
The heterogeneity of ALS distinguishes it from most other neurodegenerative diseases that can
be linked to a single or a limited number of pathogenic mechanisms and phenotypes. The
mechanisms underlying the degeneration of motor neurons in ALS vary with the genetic
mutations involved and the various cellular insults and damage that accumulate in the CNS
throughout an individual’s lifetime. The ALS research field would benefit greatly from the use
of experimental systems with HCS capacity to help navigate through this complexity. To
address this, a project to develop a HCS methodology to use with cellular ALS models was
undertaken. The overall objective of this work was to develop a system that could be used to
collect descriptive phenotypic data from cellular ALS models that would enable (1)
characterisation of the inclusion formation pathways of different ALS-associated proteins, and
(2) the use of diverse markers of proteome stress and motor neuron dysfunction to assess
potential therapeutic compounds and genetic modifiers of ALS gene disease mechanisms and
toxicity.
5.4.1

Generation and characterisation of cellular models of SOD1-, TDP-43-, FUS-,
CCNF-, VAPB-, VCP-, OPTN- and UBQLN2-associated ALS

Upon generating NSC-34 models of SOD1-, TARDBP-, FUS-, CCNF-, VAPB-, VCP-, OPTNand UBQLN2-associated ALS, the localisation and aggregation patterns of each EGFP-/tGFP/mCherry fusion WT and mutant protein were examined by confocal microscopy. The solubility
and mobility of each protein in cells and the effect of each overexpressed protein on cell
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viability were assessed using IncuCyte-based live cell imaging assays. As each of these are
overexpression models, it was imperative to first confirm that the localisation patterns of each
WT protein were not divergent from those of the endogenous WT proteins characterised in
previous studies; SOD1 (Mackenzie et al. 2007, Tan et al. 2007), TDP-43 (Arai et al. 2006,
Neumann et al. 2006, Mackenzie et al. 2007, Tan et al. 2007, Ayala et al. 2008, Winton et al.
2008, Pamphlett et al. 2009), FUS (Kwiatkowski et al. 2009, Vance et al. 2009, Mackenzie et
al. 2011), UBQLN2 (Deng et al. 2011, Williams et al. 2012), OPTN (Maruyama et al. 2010),
VAPB (Nishimura et al. 2004, Kanekura et al. 2006, Teuling et al. 2007, Chen et al. 2010) and
VCP (Mizuno et al. 2003).
Although it was not tested in the present study, in any continued work utilising these NSC-34
cell models it would be valuable to compare the relative abundance of the exogenous ALSassociated mutants with the levels of the corresponding endogenous proteins. The vector
backbone of each plasmid used in this study utilised a constitutive cytomegalovirus (CMV)
promoter, a commonly used viral promoter for mammalian expression constructs. Incorporating
the same promoter across all ALS-associated mutant (and corresponding wild-type) plasmids
used in this study, in theory, enabled expression levels to be similar in each NSC-34 cell model.
This was important for enabling comparison between the effects of expression of each mutant
protein with the corresponding wild-type protein. The CMV promoter typically facilitates
robust expression of the encoded gene following transfection, however, it is important to note
that other molecular factors can affect the expression and turnover of exogenous proteins. This
means that the abundance of the exogenous protein in each cellular model cannot be predicted
with precision and requires measurement experimentally. This could be done through Western
blotting and immunocytochemistry. As transfections were transient, not stable, transfection
efficiency was variable. Thus, following transfection, cells would need to be sorted to isolate
the population of transfected cells. Otherwise, the exogenous protein would be diluted
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throughout the lysate of the whole cell population (i.e. all transfected and non-transfected cells).
Following cell sorting, cells would be lysed and Western blotted for the ALS-associated protein,
to then compare the relative abundance of the protein between transfected and non-transfected
cell populations. Immunocytochemistry could be used to complement the Western blots. This
would provide the added advantage of enabling examination and comparison of the localisation
patterns of the exogenous and endogenous ALS-associated protein between transfected and
non-transfected cells.
5.4.1.1 Localisation and aggregation patterns of SOD1, TDP-43 and FUS in NSC-34
cells
The localisation patterns of WT SOD1, TDP-43 and FUS and the ALS-associated SOD1A4V,
TDP-43M337V, FUSR521G and FUSR495X mutants are well characterised. In human post-mortem
tissue, mutant SOD1 is often detected in large perinuclear conglomerate inclusions (Chou et al.
1996). TDP-43 and FUS are predominantly nuclear-localised RBPs with additional cytoplasmic
roles in the formation and dynamics of SGs and RNA transport granules (Colombrita et al.
2009, Liu-Yesucevitz et al. 2010, Dewey et al. 2011, McDonald et al. 2011, Bentmann et al.
2012, Colombrita et al. 2012, Sama et al. 2013, Alami et al. 2014). Mutant TDP-43 and FUS
accumulate in cytoplasmic inclusions in patients with TARDBP or FUS mutations, respectively
(Arai et al. 2006, Neumann et al. 2006, Mackenzie et al. 2007, Tan et al. 2007, Ayala et al.
2008, Winton et al. 2008, Kwiatkowski et al. 2009, Pamphlett et al. 2009, Vance et al. 2009,
Mackenzie et al. 2011). These patterns were recapitulated in NSC-34 cells for each of the tGFPtagged mutant TDP-43 and FUS proteins (SOD1A4V-EGFP localisation, aggregation and
solubility was examined and is detailed in Chapter IV). The TDP-43M337V, FUSR521G and
FUSR495X mutants mislocalised to the cytoplasm and formed into large aggregates and smaller
foci. FUSR521G-tGFP predominantly accumulated into large numbers of small foci. It was found
that the saponin-permeabilisation assay was not suitable to compare the solubility and mobility
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of FUSWT-tGFP to the examined FUS-tGFP mutants, as it did not enable distinction between
FUS-tGFP that is localised within nuclei and FUS-tGFP that has accumulated into insoluble
cytoplasmic inclusions. However, using confocal microscopy it was observed that both FUStGFP mutants mislocalised from the nucleus and accumulated into cytoplasmic inclusions.
Thus, the saponin-permeabilisation assay was useful to compare the solubility and mobility of
cytoplasmic inclusions formed by FUSR495X-tGFP and FUSR521G-tGFP. A significant difference
was found between the solubilities of the two FUS mutants. The data from the saponinpermeabilisation assay suggests that the aggregates formed by the two FUS mutants may have
differing structural properties, with aggregates formed by the FUSR521G-tGFP mutant largely
becoming insoluble, while under these conditions the solubility of FUSR495X-tGFP was
indistinguishable from that of FUSWT-tGFP. Both TDP-43 and FUS contain low sequence
complexity prion-like domains that mediate their assembly into reversible, dynamic, nonmembrane-bound hydrogel droplets that associate with RNA granule-like structures, as well as
their assembly into irreversible fibrous prion-like aggregates (Han et al. 2012, Kato et al. 2012,
King et al. 2012, Li et al. 2018). Whether or not the aggregates formed by FUSR495X-tGFP
observed in the present work develop into insoluble structures over a longer of period of time
remains to be investigated.
5.4.1.2 Differential timing of ubiquitin association with UBQLN2P497H, OPTNE478G and
VAPBP56S inclusions
Ubiquitylation is a key factor governing the fate of misfolded proteins in cells (Kawaguchi et
al. 2003, Tan et al. 2008, Kraft et al. 2010, Zhang and Qian 2011). Ubiquitylation is associated
with the formation of certain types of inclusions, such as the JUNQ, that serve protein quality
control functions in cells (Kaganovich et al. 2008, Weisberg et al. 2012). To gain an
understanding of the aggregation pathways followed by mutant UBQLN2, OPTN, VAPB and
VCP, their association with ubiquitin was examined by confocal microscopy using a mRFP216

tagged ubiquitin. Through this work,

mRFP

ubiquitin was observed to colocalise to inclusions

containing UBQLN2P497H-tGFP, OPTNE478G-EGFP and VAPBP56S-tGFP, with the timing of
colocalisation differing for each mutant protein. In contrast, inclusions containing mRFPubiquitin
were observed at all time points in NSC-34 cells expressing VCPR191Q-tGFP or VCPR159H-tGFP,
however there was no localisation of mutant VCP to these inclusions.
In cells expressing UBQLN2P497H-tGFP,

mRFP

ubiquitin colocalisation to UBQLN2P497H-tGFP

inclusions was observed at all imaging time points. This is consistent with previous studies
detecting UBQLN2 in the ubiquitylated inclusions in sALS and fALS patients with UBQLN2
mutations as well as mutations in SOD1, TARDBP, FUS and hexanucleotide repeat expansions
in C9ORF72 (Deng et al. 2011, Brettschneider et al. 2012, Williams et al. 2012). UBQLN2 is
a member of the ubiquilin family of ubiquitin-like proteins that function in both autophagy and
the UPS (Kleijnen et al. 2000, Ko et al. 2004, N'Diaye et al. 2009). In the UPS, UBQLN2
delivers ubiquitylated proteins to the proteasome for degradation via its N-terminal UBL and
C-terminal UBA domains (Kleijnen et al. 2000, Walters et al. 2002, Walters et al. 2004, Zhang
et al. 2008). The presence of mRFPubiquitin in all observed UBQLN2P497H-tGFP inclusions from
early on (24 h post-transfection) could be indicative of aberrant interactions between misfolded
UBQLN2 and polyubiquitylated proteins. It may also suggest that UBQLN2P497H-tGFP was
sequestered into protein quality control compartments, for instance, in JUNQ inclusions, as a
protective mechanism (Figure 5.18, a). Examining UBQLN2P497H-tGFP inclusions for the
presence of other quality control components such as 26S proteasomes and chaperones, using
time-resolved imaging, would help in determining the formation pathway of these inclusions.
For example, detection of quality control components in addition to the presence of ubiquitin
in these inclusions may provide indication that UBQLN2P497H-tGFP was directed to JUNQ-like
inclusions. Both UBQLN2 mutants were observed to cause significant growth inhibition of
NSC-34 cells, suggesting that they impaired cellular viability. Thus, sequestration of mutant
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UBQLN2 in JUNQ inclusions could serve protective functions in cells. Indeed, evidence
indicates that JUNQ inclusions function to sequester toxic misfolded protein species away from
the cytosol, and that ubiquitylation is essential to maintain solubility of misfolded proteins for
refolding or proteasomal degradation in the JUNQ (Kaganovich et al. 2008, Weisberg et al.
2012).
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Figure 5.18. Summary of proposed dynamics of ubiquitin association with inclusions formed by
UBQLN2P497H, VAPBP56S and OPTNE478G. The localisation patterns of mRFPubiquitin and (A) UBQLN2P497HtGFP, (B) VAPBP56S-tGFP or (C) OPTNE478G-EGFP in NSC-34 cells were tracked using live-cell imaging at 24 h,
48 h and 72 h post-transfection. (A) mRFPubiquitin was observed to be associated with all UBQLN2P497H-tGFP
inclusions from early on (24 h post-transfection). Ubiquitin may have been involved in sequestration of
UBQLN2P497H-tGFP into protein quality control compartments, for instance, JUNQ inclusions, in a protective
mechanism. (B) mRFPubiquitin was not associated with all VAPBP56S-tGFP inclusions at the earliest imaging time
point, suggesting that a proportion of VAPBP56S-tGFP inclusions did not represent quality control compartments.
Rather, mutant VAPB molecules may have aggregated together to form inclusions. (C) Not all inclusions formed
by OPTNE478G-EGFP at an intermediate time point (48 h post-transfection) were associated with mRFPubiquitin,
indicating that their formation was not ubiquitin-dependent. Ubiquitin may have been aberrantly sequestered into
inclusions formed by VAPBP56S-tGFP and OPTNE478G-EGFP over time.
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In contrast to cells expressing UBQLN2P497H-tGFP,

mRFP

ubiquitin did not colocalise with all

observed VAPBP56S-tGFP inclusions at an early stage (24 h post-transfection), but its association
with the inclusions did increase over time. The association of

mRFP

ubiquitin with VAPBP56S-

tGFP inclusions is consistent with previous work in Drosophila melanogaster, transgenic mice
and mammalian cell culture models of VAPBP56S-ALS in which VAPBP56S inclusions are
ubiquitylated (Kanekura et al. 2006, Ratnaparkhi et al. 2008, Papiani et al. 2012, Kuijpers et
al. 2013, Larroquette et al. 2015). There is evidence to suggest that VAPB inclusions are a
unique type of ERAD quality control compartment. VAPBP56S inclusions have been reported to
contain ER tubules and proteins involved in ERAD, including VCP, Derlin-1 and BAP31
(Teuling et al. 2007, Kuijpers et al. 2013). Kuijpers et al. (2013) found that the presence of
VAPB inclusions was not associated with neuronal toxicity in transgenic mice. In a separate
study on VAPBP56S transgenic mice by Qiu et al. (2013), they observed VAPBP56S inclusions in
the spinal cord of the mutant mice, but a distinct lack of neurodegeneration. Aliaga et al. (2013)
interestingly documented that, while they observed VAPBP56S inclusions in corticospinal and
spinal motor neurons of transgenic mice, the effects of VAPBP56S on these two populations of
motor neurons differed. There was upregulation of the UPR and ER stress, and of pro-apoptotic
factors in both populations of motor neurons, but there was only degeneration of the
corticospinal motor neurons, not of the spinal motor neurons. The ability of cells to generate
potential ERAD quality control compartments, and thus the toxicity of VAPBP56S expression,
appear to be variable between cell types and between different models. This could be due to
differing expression levels of the mutant protein in different models. In the present work, the
expression of VAPBP56S-tGFP reduced the viability of transfected NSC-34 cells. If VAPBP56S
inclusions do represent an ERAD quality control compartment, the toxicity observed in
transfected NSC-34 cells and in other cell culture and animal models in previous studies (Chen
et al. 2010, Aliaga et al. 2013, Larroquette et al. 2015) may be the result of higher relative
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expression levels. Higher expression levels could result in overloading of the cellular ability to
sequester VAPBP56S into potential ERAD quality control compartments, thus overwhelming this
protective cellular strategy. Indeed, the observation in the present work that ubiquitin was not
associated with all VAPBP56S-tGFP inclusions at the earliest imaging time point suggests that at
least a proportion of the observed inclusions did not represent quality control compartments
(Figure 5.18, b).
Similarly to VAPBP56S-tGFP, not all observed OPTNE478G-EGFP inclusions were colocalised
with

mRFP

ubiquitin at all imaging time points. OPTNE478G-EGFP foci were not categorised as

inclusions until 48 h post-transfection as they were consistently smaller than the inclusion size
cut-off of 2 µm that had been established. OPTN is involved in vesicular trafficking,
autophagosome maturation and it associates with proteins of the Golgi apparatus (Sahlender et
al. 2005, del Toro et al. 2009), thus the small foci may have represented the localisation of
OPTN to these structures. Indeed, OPTNWT has been documented to form granular structures
that are closely associated with the Golgi apparatus (Maruyama et al. 2010). OPTNWT has also
been detected on LC3-positive autophagosomes under basal autophagy conditions (Tumbarello
et al. 2012). In the present work, the association of OPTNWT-EGFP with these structures may
also have reduced its mobility and solubility, thus rendering the saponin permeabilisation assay
unsuitable for examining the mobility and solubility of mutant OPTN inclusions.
Overexpression of OPTNWT has been found to decrease the numbers of mutant huntingtin
inclusions in Neuro2A cells through K63-linked polyubiquitin-mediated autophagy (Shen et al.
2015). The E478G mutation in OPTN alters its ubiquitin-binding domain. Shen et al. (2015)
observed that OPTNE478G retained an ability to bind to OPTNWT and colocalised with
polyubiquitylated mutant huntingtin inclusions, suggesting that its association with the
polyubiquitylated inclusions occurred indirectly through its interaction with OPTNWT. In the
present work, examination of the large (> 2 µm) inclusions formed by OPTNE478G-EGFP
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showed that their association with mRFPubiquitin increased from 48 h to 72 h post-transfection.
The observation that not all of the inclusions formed by OPTNE478G-EGFP at an intermediate
time point (48 h post-transfection) were associated with

mRFP

ubiquitin suggests that their

formation was not ubiquitin-dependent. Rather, over time ubiquitin may have been aberrantly
sequestered into these inclusions from the cytoplasm (Figure 5.18, c). Moreover, the data
reported by Shen et al. (2015) suggested that OPTNE478G causes toxicity through a dominantnegative mechanism by binding to and inhibiting the activity of OPTNWT in autophagosome
maturation, thereby inhibiting the clearance of misfolded proteins and inclusions by autophagy.
In the present work, the expression of OPTNE478G-EGFP caused significant growth inhibition
of NSC-34 cells, suggesting that cell viability was reduced. In these OPTNE478G-EGFPtransfected NSC-34 cells, the potential of a dominant-negative mechanism of OPTNE478G could
be explored using various methods. For example, interaction between OPTNE478G and OPTNWT
and alterations in autophagy could be examined by fluorescence microscopy of NSC-34 cells
co-transfected with RFP-tagged OPTNWT and EGFP-tagged OPTNE478G, coupled with
immunocytochemistry for autophagy markers such as LC3I and LC3II, p62, beclin-1 and
Lamp2a. Alterations in autophagy could also be investigated by examination of autophagic flux
using multiple complementary techniques in parallel studies (thorough review of methods for
studying autophagy in Klionsky et al. (2016)). Notwithstanding, accumulating evidence
indicates that OPTNWT is broadly involved in ALS, with its detection in inclusions in spinal
cord tissue of patients with non-OPTN-fALS and sALS in several studies (Maruyama et al.
2010, Deng et al. 2011, Osawa et al. 2011).
5.4.1.3 WT and mutant VCP associate with TDP-43WT in cytoplasmic inclusions
It was interesting to observe that, when co-expressed with

mRFP

ubiquitin, neither VCPR191Q-

tGFP nor VCPR159H-tGFP exhibited altered localisation patterns to that of VCPWT-tGFP.
Inclusions containing

mRFP

ubiquitin were present, however there was no colocalisation of the
222

tGFP-tagged VCP mutants or VCPWT to these inclusions. The saponin permeabilisation assay
showed that VCPWT-tGFP was retained in about a tenth of transfected cells while both VCPtGFP mutants were retained in significantly greater proportions of transfected cells. This
retention of the tGFP-tagged proteins suggests that VCPWT can be present in immobile and
insoluble forms in cells. VCP is essential for various cellular processes, including Golgi
apparatus and ER assembly, ERAD and autophagosome maturation (Song et al. 2003, Halawani
and Latterich 2006, Ju et al. 2009, Tresse et al. 2010, Meyer et al. 2012). The mobility of
VCPWT would thus be reduced when it is associated with these membrane structures in cells.
Moreover, VCPWT has been observed to localise to aggresomes in viable, functional cells and
to dynamically associate with other aggregated structures while mutant VCP persists in
immobile forms in these structures (Ju et al. 2008). Additionally, VCPWT has been reported to
colocalise with insoluble inclusions containing different disease-associated mutant proteins in
Machado-Joseph disease (MJD), HD and PD (Kawaguchi et al. 1994, Hirabayashi et al. 2001,
Mizuno et al. 2003, Ishigaki et al. 2004).
As the presence of TDP-43 in inclusions is a typical feature of most non-SOD1- and non-FUSrelated ALS cases, it was explored whether there was any association of VCP with TDP-43WT
in transfected cells. When co-expressed with TDP-43WT-tdT, VCPWT-tGFP as well as both VCP
mutants formed inclusions that colocalised with TDP-43WT-tdT in all cells that were imaged.
Unfortunately, time limitations prevented these observations being confirmed with repeat
experiments. Nevertheless, the association between VCP and TDP-43 in neurodegenerative
diseases has been investigated in several studies. As well as in ALS, mutations in VCP manifest
as a plethora of different degenerative disorders, including hereditary spastic paraplegia (de Bot
et al. 2012), parkinsonism (Kimonis et al. 2008), PD (Spina et al. 2013), Charcot-Marie-Tooth
Type 2 (Gonzalez et al. 2014) and the multisystem degenerative disorder referred to as IBMPFD
(Watts et al. 2004). In IBMPFD, the pathology is characterised by inclusions containing
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ubiquitin and TDP-43, similarly to ALS pathology (Forman et al. 2006, Neumann et al. 2007).
Notably, as mutant VCP is not detected in these inclusions, it has been suggested that alterations
in VCP function lead to disrupted protein degradation pathways and impaired metabolism of
TDP-43 (Forman et al. 2006, Neumann et al. 2007). Interestingly, ALS-associated mutations
in VCP have been linked with impaired autophagic clearance of TDP-43-, FUS-, hnRNPA1and hnRNPA2B1-positive SGs and pathogenic ribonucleoprotein (RNP) granules (Buchan et
al. 2013). Given that TDP-43 has important roles in SG dynamics, this raises the possibility
that one of the mechanisms by which VCP mutations lead to motor neuron dysfunction and
degeneration is through disrupted clearance of SGs. In a study using a Drosophila melanogaster
model of IBMPFD, disease-causing VCP mutations led to a genetic interaction between TDP43 and VCP that enhanced degeneration (Ritson et al. 2010). TDP-43WT redistribution to the
cytoplasm was enough to cause degeneration in this model, and toxicity was further enhanced
through overexpression of the ALS-causing TARDBPM337V mutation with mutant VCP.
The mechanisms by which mutations in VCP lead to neurodegeneration are likely to be
multifaceted, but the findings from these previous studies indicate that mutant VCP disease
mechanisms involve, to some extent, alterations in the activity of TDP-43. These alterations in
TDP-43 activity could result from loss of VCP functions in SG clearance and protein
degradation via the UPS and autophagy (Kwon et al. 2007, Ju et al. 2008, Buchan et al. 2013).
Although a preliminary finding from n = 1 experiment, the mutant VCP overexpression model
used in this study recapitulates the hallmark accumulation of ubiquitin and TDP-43WT in
cytoplasmic inclusions observed in ALS patient tissue and diverse ALS models. Taken together,
the reports from the literature discussed here and the preliminary finding of VCP colocalisation
with TDP-43WT in inclusions emphasise the importance of investigating the interactions
between mutant VCP and TDP-43 that lead to neurodegeneration.

224

5.4.2

Development of an HCS assay to measure chaperone network activity in cellular
ALS models

The NSC-34 models of ALS generated here were examined for the localisation patterns, the
mobility and solubility of the EGFP-/tGFP- and mCherry-fusion proteins, and for toxicity
caused by expression of the mutant proteins. The aim of these studies was to establish disease
phenotypes that could be used in an experimental system with HCS capacity for further studies
into disease mechanisms, and potentially for evaluation of candidate therapeutics. This
experimental system was generated using the Cellomics® ArrayScan™ VTI HCS platform.
Time limitations prevented multiple image analysis algorithms, BioApplications, from being
optimised for studies that could utilise different markers of proteome stress and motor neuron
dysfunction. Nevertheless, optimisation of the Spot Detector BioApplication was achieved for
investigation into reductions in cellular protein folding/re-folding capacity caused by WT and
mutant SOD1 and CCNF. Analysis of protein folding/re-folding capacity was facilitated by coexpression of conformationally destablised Fluc-EGFP mutants (Gupta et al. 2011) with WT
and mutant SOD1 and CCNF. It was hypothesised that dysregulation of proteostasis
mechanisms that may be exacerbated by ALS-associated mutations in SOD1 and CCNF would
overload cellular proteostasis capacity, resulting in inability of the cellular pool of molecular
chaperones to prevent aggregation of the Fluc-EGFP mutants. The optimised Spot Detector
BioApplication enabled quantification of the numbers, the mean size and fluorescence intensity
of aggregates formed by the Fluc-EGFP isoforms.
The ability of the Fluc-EGFP mutants to report on proteome stress was confirmed through
proteasome inhibition of cells expressing mCherry alone with the Fluc-EGFP isoforms. As well
as reduced stability of the single and double Fluc-EGFP mutants, increased proteome stress also
results in reduced stability of FlucWT-EGFP (Gupta et al. 2011). In MG132-treated cells,
FlucWT-EGFP aggregates that formed were smaller than the aggregates formed by FlucSM225

EGFP and FlucDM-EGFP, perhaps indicating that less of the WT protein misfolded and
accumulated into the aggregates that did form. Without exogenous proteome stress induced by
proteasome inhibition, there was negligible aggregation of the Fluc-EGFP isoforms,
demonstrating that they were able to report on increased proteome stress.
The overexpression of SOD1A4V-tdT resulted in increased numbers, size and fluorescence
intensity of aggregates of the Fluc-EGFP isoforms compared to overexpression of SOD1WTtdT. The numbers and size of the analysed aggregates correlated with the instability of the FlucEGFP isoforms, with FlucDM-EGFP forming greater numbers of larger aggregates than FlucSMEGFP, and more still than FlucWT-EGFP. Previous studies have reported evidence suggesting
an association between the expression of mutant SOD1 and impaired chaperone activity
(Bruening et al. 1999, Takeuchi et al. 2002, Tummala et al. 2005). The data from the present
work demonstrates that the optimised HCS assay using the Fluc-EGFP isoforms is able to report
on reduced activity of the cellular network of chaperones resulting from the expression of
SOD1A4V. The formation of Fluc-EGFP aggregates was similar between cells expressing
CCNFWT-mCherry and mutant CCNFS621G-mCherry. As was observed in SOD1A4V-tdTexpressing cells, a correlation was observed between relative stability of each Fluc-EGFP
isoform and extent of aggregation. The overexpression of CCNFWT-mCherry caused the same
extent of Fluc-EGFP aggregation as CCNFS621G-mCherry, indicating that mutant CCNF did not
differentially affect the folding/re-folding activity of chaperones in cells compared to CCNFWT.
CCNF is an important protein in the UPS, as a mediator of protein ubiquitylation (D'Angiolella
et al. 2013). Ubiquitylation of target proteins is altered in cells expressing mutant CCNF,
causing aberrant accumulation of ubiquitylated proteins and consequent stress on the
proteostasis network (Williams et al. 2016). The data obtained from the Fluc-EGFP HCS assay
developed in the present work suggests that proteostasis disruption caused by mutant CCNF in
cells does not involve impairment of the protein folding/re-folding activity of cellular
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chaperones.
The Fluc-EGFP isoforms were designed to act as sensors of cellular protein folding/re-folding
capacity that would themselves have minimal biological impact in most of the commonly used
cellular and animal models (Gupta et al. 2011). In the present work it was demonstrated that
they are suitable for use in a HCS assay format to report on disruptions in the activity of the
cellular chaperone network. The extent of aggregation of the Fluc-EGFP isoforms can be easily
measured using complementary readouts from a HCS microscope, including Fluc-EGFP
aggregate size, density (fluorescence intensity) and overall numbers in cells. The ability to
generate these HCS readouts enables higher resolution information to be obtained from the
Fluc-EGFP isoforms about the extent of protein folding/re-folding impairment in cells. In future
work it would be useful to optimise a HCS assay that utilises changes in luminescence activity
of the Fluc-EGFP isoforms (Gupta et al, 2011) as an additional measure of protein folding/refolding capacity in cells.
In addition to the use of this Fluc-EGFP HCS assay to examine cellular models of SOD1A4V
and CCNFS621G, it would be useful in future work to utilise this assay to examine protein
folding/re-folding capacity in the cellular models of mutant TDP-43, FUS, UBQLN2, OPTN,
VAPB and VCP generated in this work. Beyond establishing ALS-associated mutant proteins
that impair the activity of the chaperone network in cells, this HCS assay could have potential
for application in studies to screen for drugs that ameliorate chaperone activity impairment.
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Ch 6

Ch 6

Chapter 6: Research significance and conclusions
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Overview
Accumulating evidence from in vitro and in vivo models, and from post-mortem spinal cord
tissue from ALS patients, suggests that alterations in the mechanisms that maintain proteostasis
in motor neurons may be a common molecular feature of the different genetic forms of ALS.
The overall objective of the work presented in this thesis was to investigate the role of
proteostasis disruption in the pathogenesis of ALS caused by mutations in different ALSassociated genes. As the number of genes and molecular pathways implicated in ALS
pathogenesis continues to grow, there may be value in identifying common mechanisms, and
those distinct for each genetic mutation, that underlie the decline of motor neuron health and
subsequent degeneration.
The exact processes that normally maintain proteostasis but that are uniquely disturbed in motor
neurons expressing different genetic mutations, and the processes that are commonly disturbed
amongst these diverse genetic contexts, remain to be established. Obtaining a better
understanding of proteostasis disruption in association with different ALS-causing mutations
may identify novel therapeutic targets and strategies for ALS patients. In this work, two main
experimental approaches were developed to investigate proteostasis disturbances caused by the
expression of several ALS-causing gene variants. A yeast genetic screen was developed to
identify differentially regulated proteins and molecular pathways associated with SOD1, TDP43 and FUS pathology. This approach was validated through confirmation of the relevance of
one of the hits from the SOD1 yeast screen, UBA1, a protein that plays a critical role in
maintaining ubiquitin homeostasis, by demonstrating that its overexpression can protect against
SOD1A4V-mediated toxicity in neuronal NSC-34 cells. A second experimental system was
developed that exploited a HCS platform to examine dysregulated proteostasis in neuronal cell
culture models of ALS-causing gene variants. In this chapter the key findings of this PhD
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research are summarised, and the significance of these findings to the study and understanding
of ALS pathogenesis is discussed.
A novel approach using Saccharomyces cerevisiae to identify proteostasis
disturbances caused by ALS-associated proteins
The use of Saccharomyces cerevisiae to study complex neurodegenerative diseases is well
established as many of the key molecular processes affected in these diseases are highly
conserved and thus can be investigated in this simple eukaryote. Although many of these studies
have provided significant insight into genes that interact with the examined disease genes,
established high-throughput techniques have not previously been exploited to examine the
pathological changes that occur at the protein level. Thus, to test the hypothesis that proteins
found to have altered levels in the presence of pathological TDP-43, FUS or SOD1 are involved
in the cellular response to these ALS genes, a fluorescent plate reader-based screening system
using the yeast EGFP-fusion strain collection (Huh et al. 2003) was developed. By employing
an established collection of yeast strains in which an EGFP had been integrated into the Cterminus of the genomic locus of each yeast gene, the natural promoter of each gene was
preserved, enabling the examination of endogenous yeast proteins in a minimally perturbed
biological system. This approach also bypassed the need to introduce extrachromosomal
plasmid constructs containing yeast genes fused to fluorophores, and enabled the levels of
endogenous yeast proteins to be quantified in high-throughput format using a fluorescent plate
reader.
A subset of the yeast EGFP-fusion collection was selected to focus on proteins of relevance to
pathological changes in proteostasis pathways that have previously been implicated in ALS
(Figure 6.1, a). The collation of this subset of EGFP-fusion yeast proteins/strains is significant
as they can now be employed in future investigations to examine proteostasis disruptions caused
by other ALS-associated gene variants, for instance, CCNF, UBQLN2, VAPB and VCP variants.
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Such efforts would be valuable to provide insight into the conserved proteins and molecular
processes that are commonly and uniquely disrupted amongst different ALS-associated gene
variants, beyond TDP-43, FUS and SOD1. However, a major caveat of screening only against
this pathway-focused subset is the inherent bias of this approach. Albeit, the objective of this
approach was to identify specific proteins within this subset that may be involved in the cellular
response to mislocalised TDP-43, FUS and mutant SOD1. Yet there may be value in further
screening the full collection of 4156 EGFP-fusion yeast strains to remove this bias to (1)
identify other proteins that may be involved in the cellular response to different ALS gene
variants and (2) examine if there is enrichment in any biological process GO terms that have
not previously been associated with ALS gene variants.
The high-throughput plate reader-based approach used in the present study was appropriate for
the purposes of this investigation as it enabled information on the mean response of populations
of cells to the expression of each ALS gene mutant to be obtained. However, this approach was
limited as information at the single-cell level on cell-to-cell variation in expression levels was
lost. It would be interesting to follow up this screen with a microscopy approach in which
single-cell information was obtained, to observe how variation in expression of TDP-43, FUS
or mutant SOD1 between cells correlates with variation in the levels of the yeast EGFP-fusion
proteins. It may also be beneficial to systematically examine the localisation patterns of the full
collection of EGFP-fusion yeast proteins in cells expressing different ALS gene variants, using
an automated microscopy approach similar to that described in Breker et al. (2013).
Identification of proteins with altered localisation patterns could provide valuable information
about the cellular response to each ALS gene variant. Such work may identify novel proteins
and their associated molecular processes that could be targeted for the treatment of ALS.
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6.2.1

Distinct disruptions in proteostasis caused by mutant SOD1 and mislocalised
TDP-43 and FUS

Employing the pathway-focused selection of 128 EGFP-fusion yeast strains and measuring the
levels of the EGFP-fusion proteins in yeast expressing TDP-43WT, FUSWT or SOD1A4V enabled
the identification of specific proteins that were involved in responses to the proteotoxic burden
of these three ALS-linked proteins (Figure 6.1, b).
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Figure 6.1. Summary of the proteostasis components and processes found in this PhD research to be affected
by expression of pathological TDP-43, FUS and SOD1. (A) The molecular processes that comprise the
proteostasis network in eukaryotes (processes that regulate RNA metabolism, gene expression and protein quality
control), and in which disruptions have previously been implicated in the pathogenesis of ALS. Errors in RNA
metabolism, gene expression and protein quality control processes enable the production of misfolded proteins,
which can subsequently oligomerise and aggregate. Misfolded, oligomeric and aggregated forms of proteins have
all been shown to disrupt the protective actions of ubiquitin, molecular chaperones, and proteasomal and
autophagic protein degradation. However, under normal physiological conditions cells are able to buffer against
these aberrant protein forms through ubiquitylation and the action of different molecular chaperones. Misfolded
proteins can be re-folded into their native conformations, toxic aggregates can be directed for autophagic
degradation or disaggregated and degraded by the proteasome, or alternatively these aberrant protein forms can be
sequestered into protein quality control compartments (e.g. aggresomes). (B) In yeast, the heterologous expression
of human TDP-43WT, FUSWT or SOD1A4V adds proteotoxic burden to the proteostasis network. Up-regulated
proteins identified in yeast expressing TDP-43WT, FUSWT or SOD1A4V may be involved in augmenting the
degradation of these aberrant ALS-linked proteins and/or other compensatory processes to restore proteostasis.
Down-regulated proteins may be involved in aberrant interactions with pathological TDP-43, FUS or SOD1. They
may thus have been directly disrupted through these aberrant interactions. Figure adapted from Ciryam et al. 2017.

Gene expression alterations and changes in SG dynamics have been comprehensively
investigated in relation to TDP-43 and FUS. Both proteins have functions in transcription
regulation, pre-mRNA splicing, mRNA stabilisation and RNA transport (Buratti et al. 2001,
Buratti et al. 2004, Mercado et al. 2005, Strong et al. 2007, Colombrita et al. 2009) and each
have several thousand mRNA targets (Hoell et al. 2011, Polymenidou et al. 2011, Tollervey et
al. 2011). Importantly, a key finding in this work was that alterations in processes that regulate
gene expression were not only associated with TDP-43 and FUS, but were also altered in the
presence of mutant SOD1. As the expression of SOD1A4V in yeast did not impact cell viability,
contrasting to the toxicity of SOD1A4V expression in neuronal (NSC-34) cells, it is possible that
the up-regulation of proteins involved in gene expression regulation (DCP2 and ASC1), along
with proteins involved in the UPS and ERAD (UBA1, PRE2 and UFD1), provided cells with
an enhanced capacity to manage the proteotoxic burden of mutant SOD1A4V. Moreover, this
suggests that dysregulation of RNA metabolism and alterations in gene expression regulation
may be common molecular disturbances associated with mutant TDP-43, FUS and SOD1 in
ALS (Figure 6.1, b).
The regulation of RNA metabolism and gene expression are necessary for maintenance of the
proper levels of proteins in cells, and thus they form core processes of the proteostasis network.
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Closely connected to these processes in the proteostasis network are the diverse mechanisms
that manage protein quality control. These include mechanisms of protein folding, re-folding,
the prevention of protein oligomerisation and aggregation, maintenance of mitochondrial
proteostasis and ER proteostasis, protein ubiquitylation and the targeting of aberrant proteins
for proteolytic degradation (Figure 6.1, a). The expression of TDP-43WT, FUSWT and SOD1A4V
in yeast were each a source of proteotoxic burden to cells, and cells enacted distinct responses
by differentially regulating key proteins involved in protein quality control mechanisms (Figure
6.1, b). While the expression of SOD1A4V in yeast did not impair cell viability, FUSWT caused
moderate growth inhibition and TDP-43WT markedly reduced the growth of yeast, indicating
reduced cell viability.
Most notable amongst the differentially-regulated proteins identified between the yeast screens
was that up-regulation of UFD1, a key protein in maintaining ER proteostasis, correlated with
suppression of SOD1A4V toxicity and potentially increased cellular capacity to manage
pathological FUS. Moreover, HAC1 (IRE1 UPR signalling pathway) (Ron and Walter 2007)
and DSK2 (ubiquitin-dependent protein degradation, including ERAD, autophagy and the UPS)
(Medicherla et al. 2004) abundance changes formed two of three key differentials (PBP1 being
the third) between the TDP-43WT and FUSWT screens, with both HAC1 and DSK2 found to be
down-regulated in TDP-43WT-expressing yeast and up-regulated in FUSWT-expressing yeast.
The increased abundance of HAC1 in FUSWT-expressing yeast, resulting from increased IRE1mediated splicing of HAC1 mRNA, and the increased abundance and activity of DSK2, may
have augmented cellular capacity to restore ER proteostasis. Importantly, abnormal ER
morphology and ER stress have been frequently observed pathological features in studies of
post-mortem spinal cord tissue from sALS patients and murine models of mutant SOD1G93Alinked ALS (Dal Canto and Gurney 1995, Oyanagi et al. 2008, Sasaki 2010, Lautenschlaeger
et al. 2012). Moreover, the IRE1 and ATF6 UPR signalling pathways have been reported to be
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up-regulated in post-mortem spinal cord tissue from ALS patients (Montibeller and de
Belleroche 2018). From these observations, it stands to reason that disruption of ER proteostasis
and UPR signalling pathways are potentially key pathological processes that occur in the motor
neurons of individuals with ALS. Hence, the findings made in Chapter III further suggest that
disruptions in ER proteostasis and UPR signalling pathways could be common to different
genetic forms of ALS. As prolonged UPR signalling can lead to induction of apoptosis
(Schroder and Kaufman 2005), further studies into the mechanisms by which ALS proteins
cause disruptions in ER proteostasis in neuronal cells are warranted.
DSK2 is the yeast orthologue of UBQLN2, a protein that is genetically implicated in ALS.
UBQLN2 is a frequently detected component of inclusions in people with sALS, fALS linked
to mutations in SOD1, TARDBP, FUS and C9ORF72 and in fALS patients with UBQLN2
mutations (Deng et al. 2011, Mori et al. 2013, May et al. 2014). The common theme of
UBQLN2-positive inclusions in the motor neurons of people with diverse forms of fALS and
sALS suggests that disruption of its functions in ubiquitin-dependent protein degradation, and
the downstream consequences of this disruption, may be prominent features that lead to decline
of motor neuron viability in ALS. Indeed, the decreased levels of DSK2 in yeast expressing
TDP-43WT (and decreased levels of several other proteins with key protective functions in cells),
correlating with markedly reduced cellular viability, support the hypothesis that disruptions in
DSK2/UBQLN2 and the conserved functions of these orthologues in conserved ubiquitindependent protein degradation are detrimental in the face of the proteotoxic burden of a
pathological protein.
The research work of Chapter III demonstrates the utility of yeast as a simple eukaryote with
the capacity to model the pathology caused by ALS-associated gene variants, and as a screen
system. The key findings discussed here provide the foundation for continued investigation of
the molecular pathways found to be commonly disturbed in the presence of ALS-associated
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TDP-43, FUS and SOD1. Proteins were identified that were commonly affected by the
expression of both TDP-43WT and FUSWT (PBP1, HAC1 and DSK2), and by FUSWT and
SOD1A4V (UFD1). However, it will be necessary to confirm that the mammalian orthologues
(XBP1, ATXN2, UBQLN2 and UFD1L) of these common protein hits are involved in the
cellular response to mutant TDP-43, FUS and SOD1 in neuronal cells. Moreover, although
proteins were identified that may be involved in the cellular response to mislocalised TDP-43,
FUS and mutant SOD1, the mechanisms of their involvement were not examined. Hence, it will
be important to determine the specific mechanisms by which these proteins are involved in the
response to mutant TDP-43, FUS and SOD1 in neuronal cell culture models. This work could
be carried out using the neuronal cell culture models of SOD1A4V, TDP-43M337V and
FUSR495X/FUSR521G generated in Chapters IV and V. As numerous mutations in the genes
encoding these proteins have been identified in people with ALS, in future mechanistic studies
it would be beneficial to examine the common protein hits in motor neuron models generated
from induced pluripotent stem cells (iPSCs) derived from ALS patients with different TARDBP,
FUS and SOD1 mutations.
Increased levels of UBA1 reduce SOD1A4V toxicity but do not suppress SOD1A4V
aggregation
A particularly intriguing observation made in Chapter III was that the expression of human
SOD1A4V did not cause toxicity in yeast cells, which is in stark contrast to the severity of ALS
in people carrying this mutation (Cudkowicz et al. 1997, Juneja et al. 1997). The distinct lack
of SOD1A4V toxicity in yeast coincided with up-regulation of UBA1, PRE2 and UFD1, proteins
with key roles in the UPS, indicating that UPS activity was augmented in yeast expressing
SOD1A4V. UPS dysfunction is a critical occurrence that can lead to disastrous downstream
disturbances in the cell (Yerbury et al. 2016). The UPS is responsible for the co-ordinated
degradation of myriad regulatory short-lived proteins, and it heavily influences the distribution
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of ubiquitin in the cellular ubiquitin pools. Ubiquitin also has the essential responsibility of
modifying target proteins to control diverse pathways such as transcription, translation, vesicle
transport and apoptosis (Carlson et al. 1987, Palombella et al. 1994, Mimnaugh et al. 1997,
Ciechanover 1998, Terrell et al. 1998, Hoppe et al. 2000, Lucero et al. 2000, Nakatsu et al.
2000, Roth and Davis 2000, Katzmann et al. 2001, Muratani and Tansey 2003, de Napoles et
al. 2004, Wang et al. 2004, Baarends et al. 2005, Ciechanover 2006, Ikeda et al. 2011). Thus,
efficient UPS activity, and maintenance of ubiquitin homeostasis, is essential for normal
cellular activity.
UBA1 functions at the apex of the ubiquitin-activation and conjugation cascade and thus has
significant responsibility in modulating the cellular distribution of ubiquitin (Ayusawa et al.
1992, Cook and Chock 1992, Clague et al. 2015). Discovering that its levels were increased in
yeast expressing SOD1A4V was an important finding in light of evidence from previous studies
implicating its potentially protective role in another motor neuron disease, XL-SMA (Ramser
et al. 2008, Wishart et al. 2014, Powis et al. 2016). Taking these findings together led to the
hypothesis that the increased levels of UBA1 in SOD1A4V yeast formed part of a protective
response against SOD1A4V, which was then tested (Chapter IV) using the murine NSC-34 cell
line as a mammalian neuronal cellular model of SOD1A4V-ALS.
Work presented in Chapter IV confirmed that the expression of SOD1A4V in NSC-34 cells
caused disruption of normal UPS activity (Figure 4.1, e, Chapter IV), and this correlated with
cellular toxicity. SOD1A4V aggregation into large inclusions was a prominent feature in these
cells (Figure 4.1, c, Chapter IV). Remarkably, increasing the levels of catalytically-active
UBA1 (but not an inactive mutant) in these cells improved cell viability (Figure 4.3, Chapter
IV). This is significant as it demonstrates that UBA1 has the capacity to confer a protective
effect in neuronal cells beyond the genetic context of SMA. The protective mechanism of
increased UBA1 activity did not involve suppression of SOD1A4V aggregation. It has previously
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been shown that aggregates formed by SOD1 variants can promote cellular toxicity by
sequestering ubiquitin and components of the protein quality control network, diminishing
proteostasis capacity and causing ubiquitin dyshomeostasis (Weisberg et al. 2012, Farrawell et
al. 2018). Hence, it is likely that increasing the levels of UBA1 in SOD1A4V-EGFP-expressing
NSC-34 cells helped to ameliorate SOD1A4V-mediated deficiency of the activated ubiquitin
pools (Figure 6.2). By increasing the capacity of the activated ubiquitin pools, augmented
UBA1 activity may have therefore contributed to the restoration of downstream ubiquitindependent molecular processes, including the UPS, that become severely impaired in motor
neurons as a result of the expression of ALS-causing mutations in SOD1. In this theoretical
model, the improved viability of SOD1A4V-EGFP-NSC-34 cells overexpressing UBA1 resulted
from re-establishment of downstream ubiquitin-dependent molecular processes and efficient
UPS activity, deficiencies in which lead to lethal impairment of normal cellular function.
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Figure 6.2. Proposed mechanism by which increased levels of UBA1 protect against SOD1A4V-mediated
toxicity. (A) Mutations in SOD1 lead to the production of aberrant, misfolded SOD1 in cells. Mutant SOD1
oligomerises to form toxic oligomeric species, which are able to further aggregate. Misfolded, oligomeric and
aggregated forms of SOD1 sequester ubiquitin, disrupting homeostasis of the cellular ubiquitin pools, including
the activated ubiquitin pool. Dyshomeostasis of the cellular ubiquitin pools leads to impairment of downstream
ubiquitin-dependent molecular processes, including the UPS, causing further disruption of normal cellular activity
and eventually leading to loss of cell viability. (B) Increasing the levels of the major E1 ubiquitin-activating
enzyme, UBA1, helps to restore SOD1A4V-mediated deficiency of the activated ubiquitin pools and to re-establish
ubiquitin homeostasis. By helping to restore ubiquitin homeostasis, increased UBA1 activity may therefore
contribute to restoration of downstream ubiquitin-dependent molecular processes, thereby re-establishing normal
cellular activity and improving cell viability.
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As ubiquitin homeostasis may be disrupted in diverse forms of ALS due to the sequestration of
ubiquitin into inclusions, increasing the levels of UBA1 may be beneficial in the context of
other genetic mutations associated with ALS. Importantly, the present work adds to previous
efforts investigating the role of UBA1 in SMA, demonstrating that modulating the expression
or activity of this key enzyme may have therapeutic potential for motor neurons beyond SMA,
specifically in the context of SOD1A4V-associated ALS. Indeed, as post-mitotic, exceptionally
large cells with long neurites, motor neurons have higher demands for stringent maintenance of
proteostasis throughout the far reaches of the cytoplasm than most other cell types, including
non-motor neurons (Urushitani et al. 2002, Onesto et al. 2011, Yerbury et al. 2016). Moreover,
a unique subset of the motor neuron proteome encompasses metastable, aggregation-prone
(‘supersaturated’) proteins, amounting to an exceptionally challenging environment for the
proteostasis network (Ciryam et al. 2017).
In future research it will be important to examine whether UBA1 expression changes occur in
the motor neurons of ALS patients carrying mutations in SOD1 or other ALS-associated genes,
which could be carried out using ALS patient-derived iPSC-motor neurons. It could further be
tested if the protective effect of UBA1 observed in NSC-34 cells expressing SOD1A4V extends
to iPSC-motor neuron models of different SOD1 mutants and other ALS-associated gene
variants. To test this, human UBA1WT and UBA1C632S cloned into lentiviral vectors could be used
to generate ALS patient-derived iPSC-motor neurons stably overexpressing UBA1WT and
UBA1C632S. It will be important to identify the mechanism of UBA1-mediated protection in
SOD1A4V-NSC-34 cells, or indeed in human iPSC-motor neurons from ALS patients. To
evaluate the state of ubiquitin homeostasis after increasing UBA1 levels in these cellular
models, orthogonal approaches should be employed. For example, ubiquitome analysis, first
described in Nagarajan et al. (2017), has previously been used to show that the expression of
SOD1A4V in NSC-34 cells causes widespread ubiquitin redistribution and dyshomeostasis
241

(Farrawell et al. 2018). In future work this technique could be used to compare the ubiquitomes
of SOD1A4V-NSC-34 cells overexpressing UBA1WT or UBA1C632S. This could be paired with
experiments to compare the activated ubiquitin pools in these cells, using a technique described
by Gavin et al. (2012). As the objective of these future studies would be to examine the potential
of UBA1 as a target for gene therapy in ALS patients, there are important implications to
consider. It would be crucial to examine potential side effects resulting from increased UBA1
activity in cells. In particular, dysregulated protein ubiquitylation and UPS activity are
implicated in some cancers, e.g. multiple myeloma and mantle cell lymphoma (Popovic et al.
2014, Weathington and Mallampalli 2014). For instance, overactive ubiquitylation and
degradation of the tumour suppressor, p53, may be implicated in the transformation of cells into
a cancerous state (Scheffner et al. 1990, Michael and Oren 2003, Ciechanover and Schwartz
2004). Thus, analysis of the ubiquitylated state of p53 and other tumour suppressors could be
used as a way to monitor if increased UBA1 expression causes off-target effects that promote
oncogenesis in cell culture models. Beyond these potential studies in cell culture models, any
significant findings would need to be examined and validated using animal models. For
example, viral-delivery of UBA1 into transgenic mouse models of mutant SOD1 could be used
to (1) confirm the protective effect of UBA1 against mutant SOD1 in the context of a
functioning CNS and (2) examine potential off-target effects, including ubiquitylation of p53
and other markers of oncogenesis.
A high content imaging system to examine proteostasis capacity in neuronal cell
culture models of ALS-causing gene variants
A HCS system was developed with the aim of examining proteostasis capacity in NSC-34 cell
culture models of ALS-causing mutations in TARDBP, FUS, CCNF, VAPB, VCP, OPTN and
UBQLN2 in addition to the SOD1A4V NSC-34 cell model used in Chapter IV. The NSC-34 cell
models of SOD1A4V and CCNFS621G were further used in developing an assay to examine if the
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expression of these mutations caused changes in the activity of the protein quality control
network of chaperones.
As discussed in Chapter V, it was demonstrated that the Fluc-EGFP isoforms can be used in
high-throughput format as a tool to measure cellular protein folding/re-folding capacity in
cellular models of ALS-associated mutants. Applying this assay in high-throughput format
provides the advantage of speed, combined with the capacity to gain single-cell resolution
information about cellular phenotype using multiple readouts from the HCS platform. Although
time did not permit the use of this novel HCS assay to examine whether there were alterations
in the protein folding environment in the NSC-34 models of TARDBP-, FUS-, VAPB-, VCP-,
OPTN- and UBQLN2-linked ALS, these experiments can now be readily carried out in a future
research project. Furthermore, for ALS-associated mutant proteins that do cause reductions in
the protein quality control capacity of neuronal cells, as is the case for SOD1A4V, this HCS assay
has the potential to be applied in drug and genetic screening studies to identify candidate
compounds that are able to ameliorate this deficiency. Furthermore, in future work it would be
beneficial to develop HCS assays that could be used to explore the findings made in Chapter
III, using the generated NSC-34 cell culture models of ALS. Extension of this work may aid in
elucidating the specific proteostasis disturbances caused by ALS-associated mutations in
SOD1, TARDBP, FUS, VAPB, VCP, OPTN and UBQLN2 in the context of neuronal cells. The
HCS assays developed in this process could then be used to screen for candidate drugs that have
the potential to target the identified proteostasis deficiencies.
Concluding statements
With the accelerating progression of ALS research since the first report of SOD1 mutations in
ALS patients (Rosen et al. 1993), there has been a steady increase in the number of genes and
molecular processes associated with this devastating neurodegenerative disease. However,
extensive evidence indicates that proteostasis dysfunction may underlie the dysfunction and
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degeneration of motor neurons in ALS. Elucidating the proteostasis disturbances caused by
different ALS-associated mutant proteins is therefore a necessary step towards understanding
the pathogenic mechanisms that are unique to each gene variant and those that are common to
all. While disturbances in the proteostasis network in ALS have been a major focus of research
in the past two decades, there has been a lack of systematic approaches to examine multiple
ALS-associated gene variants in parallel. This represents a significant disadvantage in the ALS
research field since systematic, high-throughput approaches have the potential to fast-track the
identification of therapeutic targets that are relevant to the diverse genetic contexts of people
with ALS.
The work presented in this PhD thesis describes the development and use of two novel highthroughput methodologies to investigate proteostasis disturbances caused by diverse ALScausing mutations. By using yeast as a model system amenable to high-throughput screens,
common alterations in the proteostasis network caused by pathological TDP-43, FUS and
SOD1 were identified, laying the groundwork for further research. Based on this screening
approach, the therapeutic potential of UBA1 to suppress the toxicity associated with mutant
SOD1 expression in neuronal cells was uncovered. Moreover, this work adds to previous efforts
investigating the relevance of ubiquitin dyshomeostasis in SOD1-linked ALS. Finally, a HCS
assay was developed to further investigate the protein quality control sub-network of the
proteostasis network. This HCS assay furthermore has potential for drug screening applications.
Continued development of HCS assays that can measure the identified deficiencies in the
proteostasis network found through the yeast screens, utilising the neuronal cell culture models
that were generated, will be valuable in the search for therapeutic targets. Overall, this work
provides substantial foundation for further investigation into the specific proteostasis
components that could be potent targets for therapeutic intervention in ALS.
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R scripts
R script to fit plate reader absorbance (optical density), EGFP and DsRed fluorescence
data:
###
# Plate reader curve fitting and plotting
# Function to fit fluorescence and absorbance data
###
localMaxima <- function(x) {
# Use -Inf instead if x is numeric (non-integer)
y <- diff(c(-.Machine$integer.max, x)) > 0L
rle(y)$lengths

}

y <- cumsum(rle(y)$lengths)
y <- y[seq.int(1L, length(y), 2L)]
if (x[[1]] == x[[2]]) {
y <- y[-1]
}
y

localMinima <- function(x) {
# Use -Inf instead if x is numeric (non-integer)
y <- diff(c(.Machine$integer.max, x)) > 0L
rle(y)$lengths
y <- cumsum(rle(y)$lengths)
y <- y[seq.int(1L, length(y), 2L)]
if (x[[1]] == x[[2]]) {
y <- y[-1]
}
y
}
#fits a single curve i.e. a vector
robustfit <- function(data, time, name="NA", smoothing=0.7, upto=65 ){
#set up output
out <- list(min.fit.x = NA, min.fit.y = NA, max.fit.x = NA, max.fit.y = NA, exp.rate = NA,
lag = NA, max.before.chosen.time = NA, rate.before.chosen.time = NA)
#time must be a numeric vector
time <- as.numeric(time)
#fit
y.spl <- smooth.spline(x = time, y= as.numeric(data), spar = smoothing)
xrange<-c(min(c(min(time),min(y.spl$x))), max(c(max(time),max(y.spl$x))))
yrange<-c(min(c(min(data),min(y.spl$y))), max(c(max(data),max(y.spl$y))))
plot(xrange,yrange,type='n', main=name)
lines(y.spl$x, y.spl$y,type="l", col="red")
points(time,as.numeric(data))
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#get the gradient through each point
dydt.spl <- predict(y.spl, time, deriv = 1) #using predict.smooth.spline
index <- which.max(dydt.spl$y)
t.max <- dydt.spl$x[index]
dydt.max <- max(dydt.spl$y)
y.max <- y.spl$y[index]
mu.spl <- dydt.max
b.spl <- y.max - dydt.max * t.max
lambda.spl <- -b.spl/mu.spl #this is the old method
#calculate lambda
#if it grew exponentially from the start, what time would it have reached y.max
#use the first 10 timepoints to establish a baseline
t.st <- (y.max-mean(as.numeric(data[c(1:10)])))/dydt.max
t.lam <- t.max - t.st
abline(v=t.lam, col="brown")
#intercept baseline and exp.slope
bl = mean(as.numeric(data[c(1:10)])) #we use the mean of the first 10 timepoints as a
baseline
const = y.max - (dydt.max * t.max)
t.int = (bl-const)/dydt.max
abline(v=t.int, col="green")
if(t.int < 0){
cat("Warning: improved lag negative for: ",name,"\n")
}
#save
#positive.y <- y.spl$y[y.spl$y >= 0]
y.above.t.int <- y.spl$y[which(y.spl$x > t.int)]
positive.y <- ifelse(sum(y.above.t.int > 0) == 0, y.above.t.int[y.above.t.int < 0],
y.above.t.int[y.above.t.int > 0])
out$min.fit.y <- positive.y[which.min(positive.y)]
out$min.fit.x <- y.spl$x[which(out$min.fit.y == y.spl$y)]
out$max.fit.x <- y.spl$x[which.max(y.spl$y)]
out$max.fit.y <- y.spl$y[which(out$max.fit.x == y.spl$x)]
out$exp.rate <- mu.spl
out$lag <- t.int
local_maximas = y.spl$y[localMaxima(y.spl$y)]
out$second.max.y = ifelse(length(local_maximas) >=2, local_maximas[2],
local_maximas[1])
out$second.max.x = y.spl$x[which(out$second.max.y == y.spl$y)]
points(out$max.fit.x, out$max.fit.y, col="grey", pch=19)
points(out$second.max.x, out$second.max.y, col="purple", pch=19)
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local_minimas = y.spl$y[localMinima(y.spl$y)]
out$second.min.y = ifelse(length(local_minimas) >=2, local_minimas[2], local_minimas[1])
out$second.min.x = y.spl$x[which(out$second.min.y == y.spl$y)]
points(out$min.fit.x, out$min.fit.y, col="blue", pch=19)
points(out$second.min.x, out$second.min.y, col="pink", pch=19)
#add parameter A to plot
abline(h=out$max.fit.y, col='orange')
#add the maximum exponential rate to plot
mu <- mu.spl
lambda <- lambda.spl
bla <- y.spl$x * mu
bla <- bla + (-mu * lambda)
lines(y.spl$x, bla, lw = 2, lty = 2, col="blue")
########## get max and rate up to the given timepoint
out$max.before.chosen.time <- max(y.spl$y[c(1:upto)])
out$rate.before.chosen.time <- max(dydt.spl$y[c(1:upto)])
abline(h=out$max.before.chosen.time, col='orange',lty=2)
return(out)
}
#wraps robustfit to call it on every row of a matrix
#this is just for convenience
#returns a list of fit results, one entry per row in the same order as the input
#name is a vector of strings
RFall <- function(data, time, name="NA", smoothing=0.7, upto=65){
#set up output
out <- NULL
for(i in 1:dim(data)[1]){
n <- name[i] #otherwise all plots get all the names, even if you subset in the function call
cat(n, '\n')
out[[i]] <- robustfit(data[i,], time, n, smoothing, upto)
}
}

return(out)

#overview plot
#use sample positions to interpret layout in the plate
#positions are the row and column
#all wells are plotted on the same scale
plot96 <- function(data, times, positions){
#save original settings
mar <- par()$mar
mfrow <- par()$mfrow
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par(mfrow=c(8,12))
par(mar=c(0,0,0,0))
xrange <- range(times)
yrange <- range(data)
column <- 1 #the current column in the plate
rows <- c("A", "B", "C", "D", "E", "F", "G", "H") #use to convert between out numeric
index and the alphabetical one used on the plates
row <- 1
i <- 1 #the plot we're currently working on
plotnumber <- 0
while(plotnumber < 96){
plot(xrange, yrange, type="n", xaxt="n", yaxt="n")
if(i < dim(data)[1]){
if(positions[i,1] == column && positions[i,2] == rows[row]){
#plot data
lines(times, data[i,])
i <- i+1
column <- column + 1
} else {
#move on to the next column
column <- column + 1
}
} else {
#all the rest of the columns will be blank from this point, there are no rows left in the
input data
#move on to the next column
column <- column + 1
}

}

}

plotnumber <- plotnumber + 1
if(column == 13){
column <- 1 #we reached the end of a row, go back to the start
row <- row + 1 #row only ever increases
}

#reset plot parameters
par(mfrow=mfrow)
par(mar=mar)

#overview plot for any number of channels
#data must be a list of arrays with samples in rows
#use sample positions to interpret layout in the plate
#positions are the row and column
#if scale == TRUE, all wells are plotted on the same scale, otherwise the axes are rescaled for
every list element - i.e. every dataset has it's own scale but within datasets the scale is the
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same
plot96_all <- function(data, times, positions, scale, colours = 'auto'){
#save original settings
mar <- par()$mar
mfrow <- par()$mfrow
par(mfrow=c(8,12))
par(mar=c(0,0,0,0))
xrange <- range(times)
yranges <- NULL
if(scale == TRUE){
#set the y range using ALL of the input data, so the scale is the same for all datasets
for(i in 1:length(data)){
yranges[[i]] <- range(data)
}
} else {
#set the y range once per dataset
for(i in 1:length(data)){
yranges[[i]] <- range(data[[i]])
}
}
#colours
if(colours == 'auto'){
colours <- rainbow(length(data))
}
column <- 1 #the current column in the plate
rows <- c("A", "B", "C", "D", "E", "F", "G", "H") #use to convert between out numeric
index and the alphabetical one used on the plates
row <- 1
i <- 1 #the plot we're currently working on
plotnumber <- 0
while(plotnumber < 96){
if(i < dim(data[[1]])[1]){
if(positions[i,1] == column && positions[i,2] == rows[row]){
#plot data
for(j in range(1:length(data))){
plot(xrange, yranges[[j]], type="n", xaxt="n", yaxt="n")
lines(times, data[[j]][i,], col = colours[j])
if(j != length(data)){
par(new=TRUE) #to put different axes on one plot. Don't want to set this the last
time.
}
}
i <- i+1
column <- column + 1
} else {
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#move on to the next column
column <- column + 1
plot(xrange, yranges[[1]], type="n", xaxt="n", yaxt="n")

}
} else {
#all the rest of the columns will be blank from this point, there are no rows left in the
input data
#move on to the next column
column <- column + 1
plot(xrange, yranges[[1]], type="n", xaxt="n", yaxt="n")
}

}

}

plotnumber <- plotnumber + 1
if(column == 13){
column <- 1 #we reached the end of a row, go back to the start
row <- row + 1 #row only ever increases
}

#reset plot parameters
par(mfrow=mfrow)
par(mar=mar)
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R script to run t tests to:
Calculate

difference,

between

fusion/GALFUSWT-DsRed,

diploid

EGFP-fusion/GALTDP-43WT-DsRed,

EGFP-fusion/GALSOD1WT-DsRed,

EGFP-

EGFP-fusion/GALSOD1A4V-

DsRed and the corresponding control EGFP-fusion/GALDsRedempty strains, of the yield of
normalised EGFP fluorescence intensity from mid-exponential to stationary growth phase:
setwd("insert directory location of data file")
fitsn <- read.delim("output_A_GFP.csv", sep=",", header=T, stringsAsFactors=F)
fitsn <- fitsn[,-1]
rate <- as.numeric(fitsn[5, ])
lag <- as.numeric(fitsn[6, ])
max2 <- as.numeric(fitsn[9, ])
yield <- as.numeric(fitsn[15, ])#yield_to_use (DEFAULT min.fit.y to second.max.y)
#minfitmax2_yield <- as.numeric(fitsn [17, ])#second.max_norm.GFP_yield (min.fit.y &
second.max.y)
#min2max2_yield <- as.numeric(fitsn [18, ]) #second.min.2ndmax.norm.GFP_yield
#min2maxfit_yield <- as.numeric(fitsn[19, ]) #second.min.max.fit.norm.GFP_yield
#mid_yield <- as.numeric(fitsn [21, ])
p <- c()
p_yield <- c()
t_yield <- c()
p_max2 <- c()
t_max2 <- c()
#estimate_yield <- c()
#conf.int_yield <- c()
#p_minfitmax2_yield <- c()
#p_min2max2_yield <- c()
#p_min2maxfit_yield <- c()
p_rate <- c()
p_lag <- c()
growth_dif <- c()
#p_mid_yield <- c()
#These sequences combined run t tests of ONLY galactose-grown samples (for GLUC: (i in
seq(1+k,20+k,2)))
for (k in seq(1, 161, 80)) {
for (i in seq(0+k,19+k,2)) {
t_yield[i] = t.test(c(yield[i],yield[i+1],yield[i+20],yield[i+21]), c(yield[i+40], yield[i+41],
yield[i+60], yield[i+61]))$statistic
p_yield[i] = t.test(c(yield[i],yield[i+1],yield[i+20],yield[i+21]), c(yield[i+40], yield[i+41],
yield[i+60], yield[i+61]))$p.value
t_max2[i] = t.test(c(max2[i],max2[i+1],max2[i+20],max2[i+21]), c(max2[i+40],
max2[i+41], max2[i+60], max2[i+61]))$statistic
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p_max2[i] = t.test(c(max2[i],max2[i+1],max2[i+20],max2[i+21]), c(max2[i+40],
max2[i+41], max2[i+60], max2[i+61]))$p.value
p_rate[i] = t.test(c(rate[i], rate[i+1], rate[i+20], rate[i+21]), c(rate[i+40], rate[i+41],
rate[i+60], rate[i+61]))$p.value
p_lag[i] = t.test(c(lag[i], lag[i+1], lag[i+20], lag[i+21]), c(lag[i+40], lag[i+41], lag[i+60],
lag[i+61]))$p.value
#p_mid_yield[i] = t.test(c(mid_yield[i],mid_yield[i+20]), c(mid_yield[i+40],
mid_yield[i+60]))$p.value

}

}

#growth_dif[i] = log(mean(c(yield[i],yield[i+20]))/mean(c(yield[i+40], yield[i+60])))

#Trying to figure out sequences for the for loop:
#a.vector <- c(1:240)
#a.element <- c()
#for (k in seq(1, 161, 80)) {
# for (i in seq(0+k,19+k,2)) {
# a.element[i] <- a.vector[i]
# }
#}
#tidy up
keep = !is.na(p_yield)
p_yield = p_yield[keep]
t_yield = t_yield[keep]
p_max2 = p_max2[keep]
t_max2 = t_max2[keep]
p_rate = p_rate[keep]
p_lag = p_lag[keep]
layout.GFP <- read.delim("NAMES_REP_8_t tests.csv",sep=",",header=F,stringsAsFactors
= F)
#calculate combined score for p-values of mid.point yield and total yield
#X <- c()
#p_combined <- c()
#for (i in c(1:60)) {
# X[i] <- -2*(log(p_mid_yield[i])+log(p_yield[i]))
# p_combined[i] <- pchisq(X[i],df=4,lower.tail=FALSE)
#}
p_values_revised = cbind(c(t(layout.GFP)), t_max2, p_max2, t_yield,p_yield,p_rate, p_lag)
write.table(p_values_revised,"p_values_revised.txt",sep="\t",quote=F, row.names = FALSE)
write.csv(p_values_revised,file="p_values_revised.csv")
significant_yield_0.05 <- p_values_1[which(p_yield < 0.05)]
#significant_minfitmax2_yield_0.05 <- p_values_1[which(p_minfitmax2_yield < 0.05)]
#significant_min2max2_yield_0.05 <- p_values_1[which(p_min2max2_yield < 0.05)]
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#significant_min2maxfit_yield_0.05 <- p_values_1[which(p_min2maxfit_yield < 0.05)]
#significant_rate_dif_0.05 <- layout2[which(p_rate < 0.05)]
#significant_lag_dif_0.05 <- layout2[which(p_lag < 0.05)]
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Supplementary data from Deltavision OMX™ super resolution microscopy
of diploid strains
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Figure S3.1. Characterising the localisation of yeast CDC48-EGFP and DsRed-tagged human TDP-43WT,
FUSWT, SOD1WT and SOD1A4V in diploid strains. Representative images showing the localisation of each
DsRed-fusion protein and CDC48-EGFP in the respective diploid strains. Diploid strains were grown for 2 nights
in SRaf/-His/Ura broth before being diluted 20× into SGal/-His/Ura broth and grown overnight at 30 °C with
agitation to induce expression of GALTDP-43WT-DsRed, GALFUSWT-DsRed, GALSOD1WT-DsRed, GALSOD1A4VDsRed or GALDsRedempty (‘empty’ vector control (DsRed alone); EV). The fluorescent proteins were examined in
cells using the 100× oil-immersion objective lens of a DeltaVision OMX™ super resolution microscope. Outlines
of cells are indicated by white dashed lines. Scale bars represent 5 µm.
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Figure S3.2. Characterising the localisation of yeast ERV25-EGFP and DsRed-tagged human TDP-43WT,
FUSWT, SOD1WT and SOD1A4V in diploid strains. Representative images showing the localisation of each
DsRed-fusion protein and ERV25-EGFP in the respective diploid strains. Diploid strains were grown for 2 nights
in SRaf/-His/Ura broth before being diluted 20× into SGal/-His/Ura broth and grown overnight at 30 °C with
agitation to induce expression of GALTDP-43WT-DsRed, GALFUSWT-DsRed, GALSOD1WT-DsRed, GALSOD1A4VDsRed or GALDsRedempty (‘empty’ vector control (DsRed alone); EV). The fluorescent proteins were examined in
cells using the 100× oil-immersion objective lens of a DeltaVision OMX™ super resolution microscope. Outlines
of cells are indicated by white dashed lines. Scale bars represent 5 µm.
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Figure S3.3. Characterising the localisation of yeast ENO1-EGFP and DsRed-tagged human TDP-43WT,
FUSWT, SOD1WT and SOD1A4V in diploid strains. Representative images showing the localisation of each
DsRed-fusion protein and ENO1-EGFP in the respective diploid strains. Diploid strains were grown for 2 nights
in SRaf/-His/Ura broth before being diluted 20× into SGal/-His/Ura broth and grown overnight at 30 °C with
agitation to induce expression of GALTDP-43WT-DsRed, GALFUSWT-DsRed, GALSOD1WT-DsRed, GALSOD1A4VDsRed or GALDsRedempty (‘empty’ vector control (DsRed alone); EV). The fluorescent proteins were examined in
cells using the 100× oil-immersion objective lens of a DeltaVision OMX™ super resolution microscope. Outlines
of cells are indicated by white dashed lines. Scale bars represent 5 µm.
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Figure S3.4. Characterising the localisation of yeast BMH1-EGFP and DsRed-tagged human TDP-43WT,
FUSWT, SOD1WT and SOD1A4V in diploid strains. Representative images showing the localisation of each
DsRed-fusion protein and BMH1-EGFP in the respective diploid strains. Diploid strains were grown for 2 nights
in SRaf/-His/Ura broth before being diluted 20× into SGal/-His/Ura broth and grown overnight at 30 °C with
agitation to induce expression of GALTDP-43WT-DsRed, GALFUSWT-DsRed, GALSOD1WT-DsRed, GALSOD1A4VDsRed or GALDsRedempty (‘empty’ vector control (DsRed alone); EV). The fluorescent proteins were examined in
cells using the 100× oil-immersion objective lens of a DeltaVision OMX™ super resolution microscope. Outlines
of cells are indicated by white dashed lines. Scale bars represent 5 µm.
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Figure S3.5. Characterising the localisation of yeast RPL40A-EGFP and DsRed-tagged human TDP-43WT
and SOD1A4V in diploid strains. Representative images showing the localisation of each DsRed-fusion protein
and RPL40A-EGFP in the respective diploid strains. Diploid strains were grown for 2 nights in SRaf/-His/Ura
broth before being diluted 20× into SGal/-His/Ura broth and grown overnight at 30 °C with agitation to induce
expression of GALTDP-43WT-DsRed, GALSOD1A4V-DsRed or GALDsRedempty (‘empty’ vector control (DsRed alone);
EV). The fluorescent proteins were examined in cells using the 100× oil-immersion objective lens of a DeltaVision
OMX™ super resolution microscope. Outlines of cells are indicated by white dashed lines. Scale bars represent 5
µm.
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Figure S3.6. Characterising the localisation of yeast RPN10-EGFP and DsRed-tagged human TDP-43WT,
FUSWT and SOD1A4V in diploid strains. Representative images showing the localisation of each DsRed-fusion
protein and RPN10-EGFP in the respective diploid strains. Diploid strains were grown for 2 nights in SRaf/His/Ura broth before being diluted 20× into SGal/-His/Ura broth and grown overnight at 30 °C with agitation to
induce expression of GALTDP-43WT-DsRed, GALFUSWT-DsRed, GALSOD1A4V-DsRed or GALDsRedempty (‘empty’
vector control (DsRed alone); EV). The fluorescent proteins were examined in cells using the 100× oil-immersion
objective lens of a DeltaVision OMX™ super resolution microscope. Outlines of cells are indicated by white
dashed lines. Scale bars represent 5 µm.
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Figure S3.7. Characterising the localisation of yeast TRS23-EGFP and DsRed-tagged human TDP-43WT
and SOD1A4V in diploid strains. Representative images showing the localisation of each DsRed-fusion protein
and TRS23-EGFP in the respective diploid strains. Diploid strains were grown for 2 nights in SRaf/-His/Ura broth
before being diluted 20× into SGal/-His/Ura broth and grown overnight at 30 °C with agitation to induce
expression of GALTDP-43WT-DsRed, GALSOD1A4V-DsRed or GALDsRedempty (‘empty’ vector control (DsRed alone);
EV). The fluorescent proteins were examined in cells using the 100× oil-immersion objective lens of a DeltaVision
OMX™ super resolution microscope. Outlines of cells are indicated by white dashed lines. Scale bars represent 5
µm.
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Figure S3.8. Characterising the localisation of yeast MDJ1-EGFP and DsRed-tagged human FUSWT and
SOD1A4V in diploid strains. Representative images showing the localisation of each DsRed-fusion protein and
MDJ1-EGFP in the respective diploid strains. Diploid strains were grown for 2 nights in SRaf/-His/Ura broth
before being diluted 20× into SGal/-His/Ura broth and grown overnight at 30 °C with agitation to induce
expression of GALFUSWT-DsRed, GALSOD1A4V-DsRed or GALDsRedempty (‘empty’ vector control (DsRed alone);
EV). The fluorescent proteins were examined in cells using the 100× oil-immersion objective lens of a DeltaVision
OMX™ super resolution microscope. Outlines of cells are indicated by white dashed lines. Scale bars represent 5
µm.
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Figure S3.9. Characterising the localisation of yeast MGE1-EGFP and DsRed-tagged human FUSWT and
SOD1A4V in diploid strains. Representative images showing the localisation of each DsRed-fusion protein and
MGE1-EGFP in the respective diploid strains. Diploid strains were grown for 2 nights in SRaf/-His/Ura broth
before being diluted 20× into SGal/-His/Ura broth and grown overnight at 30 °C with agitation to induce
expression of GALFUSWT-DsRed, GALSOD1A4V-DsRed or GALDsRedempty (‘empty’ vector control (DsRed alone);
EV). The fluorescent proteins were examined in cells using the 100× oil-immersion objective lens of a DeltaVision
OMX™ super resolution microscope. Outlines of cells are indicated by white dashed lines. Scale bars represent 5
µm.
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Figure S3.10. Characterising the localisation of yeast PUB1-EGFP and DsRed-tagged human TDP-43WT
and FUSWT in diploid strains. Representative images showing the localisation of each DsRed-fusion protein and
PUB1-EGFP in the respective diploid strains. Diploid strains were grown for 2 nights in SRaf/-His/Ura broth
before being diluted 20× into SGal/-His/Ura broth and grown overnight at 30 °C with agitation to induce
expression of GALTDP-43WT-DsRed, GALFUSWT-DsRed or GALDsRedempty (‘empty’ vector control (DsRed alone);
EV). The fluorescent proteins were examined in cells using the 100× oil-immersion objective lens of a DeltaVision
OMX™ super resolution microscope. Outlines of cells are indicated by white dashed lines. Scale bars represent 5
µm.
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Figure S3.11. Characterising the localisation of yeast XRN1-EGFP and DsRed-tagged human TDP-43WT
and FUSWT in diploid strains. Representative images showing the localisation of each DsRed-fusion protein and
XRN1-EGFP in the respective diploid strains. Diploid strains were grown for 2 nights in SRaf/-His/Ura broth
before being diluted 20× into SGal/-His/Ura broth and grown overnight at 30 °C with agitation to induce
expression of GALTDP-43WT-DsRed, GALFUSWT-DsRed or GALDsRedempty (‘empty’ vector control (DsRed alone);
EV). The fluorescent proteins were examined in cells using the 100× oil-immersion objective lens of a DeltaVision
OMX™ super resolution microscope. Outlines of cells are indicated by white dashed lines. Scale bars represent 5
µm.
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Figure S3.12. Characterising the localisation of yeast UFD4-EGFP and DsRed-tagged human FUSWT and
SOD1A4V in diploid strains. Representative images showing the localisation of each DsRed-fusion protein and
UFD4-EGFP in the respective diploid strains. Diploid strains were grown for 2 nights in SRaf/-His/Ura broth
before being diluted 20× into SGal/-His/Ura broth and grown overnight at 30 °C with agitation to induce
expression of GALFUSWT-DsRed, GALSOD1A4V-DsRed or GALDsRedempty (‘empty’ vector control (DsRed alone);
EV). The fluorescent proteins were examined in cells using the 100× oil-immersion objective lens of a DeltaVision
OMX™ super resolution microscope. Outlines of cells are indicated by white dashed lines. Scale bars represent 5
µm.
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Supplementary data from quality control analyses of FLUOstar® Optima plate reader data
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Figure S3.13. Distribution of raw OD600 and DsRed fluorescence intensity data from repeats of the FLUOstar®
Optima plate reader assays of diploid yeast EGFP-fusion strains expressing DsRed-fusion human TDP-43WT,
FUSWT, SOD1WT, SOD1A4V or DsRed alone. Diploid strains were created by mating haploid Y7039 transformed with
pAG416GAL-TDP-43WT-DsRed (GALTDP-43WT), pAG416GAL-FUSWT-DsRed (GALFUSWT), pAG416GAL-SOD1WTDsRed (GALSOD1WT), pAG416GAL-SOD1A4V-DsRed (GALSOD1A4V), or pAG416GAL-ccdB-DsRed (GALDsRedempty;
vector control) with haploid strains from the yeast EGFP fusion collection (Huh et al. 2003). After first screening 128
different strains from the yeast EGFP fusion collection, EGFP-fusion proteins exhibiting altered levels in GALTDP-43WT,
GAL
FUSWT, GALSOD1WT or GALSOD1A4V relative to GALDsRedempty strains were re-assayed to confirm the altered levels.
Quadruplicates of each diploid strain were grown in 384-well µclear plates containing 100 µL per well of SGal/-His/Ura
to induce expression of GALTDP-43WT, GALFUSWT, GALSOD1WT, GALSOD1A4V or GALDsRedempty in a FLUOstar® Optima
plate reader. The absorbance (optical density [OD] at 600 nm), EGFP (excitation 485/12 nm, emission collected at 510/20
nm) and DsRed (excitation 580/10 nm, emission collected at 612 nm) fluorescence were measured over 48 h of yeast
incubation at 30 °C. Raw data collected for each replicate were analysed to calculate the OD600 yield (maximum OD600 –
minimum OD600), the maximum exponential rate of change of OD600 (maximum growth rate; OD600/h), the maximum
DsRed fluorescence intensity (Fmax) (maximum DsRed F.I. – minimum DsRed F.I.; relative fluorescence units, R.F.U.)
and the maximum exponential rate of change of DsRed F.I. (maximum rate of DsRed F.I. increase; R.F.U./h). These data
per replicate are presented as follows: (A) scatter plot and (B) histogram displaying the OD600 yield; (C) scatter plot and
(D) histogram showing the maximum exponential rate of change of OD600 (maximum growth rate); (E) scatter plot and
(F) histogram displaying the DsRed Fmax; (G) scatter plot and (H) histogram displaying the maximum exponential rate of
change of DsRed F.I. (maximum rate of DsRed F.I. increase; R.F.U./h).
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